title,url,time_published,summary,ticker,relevance_score,ticker_sentiment_score,ticker_sentiment_label
Bristol Myers Squibb  ( BMY )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2037592/bristol-myers-squibb-bmy-outpaces-stock-market-gains-what-you-should-know,2023-01-10 22:50:21,"Bristol Myers Squibb (BMY) closed the most recent trading day at $71.65, moving +0.9% from the previous trading session.",BMY,0.642187,0.285406,Somewhat-Bullish
Halozyme Provides 2023 Financial Guidance and Outlook,https://www.prnewswire.com/news-releases/halozyme-provides-2023-financial-guidance-and-outlook-301717757.html,2023-01-10 22:15:00,2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from Royalties Projected to Grow by >20% to $445 to $455 Million 2023 EBITDA Projected to Grow by >30% Year-Over-Year to $415 to $440 Million,BMY,0.02668,0.079527,Neutral
Bayer flags new blood thinner as $5 bln-plus opportunity,https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-flags-new-blood-thinner-5-bln-plus-opportunity-2023-01-10/,2023-01-10 13:06:14,"FRANKFURT, Jan 10 ( Reuters ) - Bayer predicted on Tuesday its experimental drug against dangerous blood clots could make more than 5 billion euros ( $5.4 billion ) in peak annual sales, as the company seeks to revive a share price that has drawn interest from activist investors.",BMY,0.077845,0.101351,Neutral
Should Investors Worry About AbbVie's Dividend?,https://www.fool.com/investing/2023/01/10/should-investors-worry-about-abbvie-dividend/,2023-01-10 10:31:00,"The risks are real, but they're decreasing over time.",BMY,0.056674,0.023096,Neutral
Is Alexandria Real Estate Equity a Buy?,https://www.fool.com/investing/2023/01/10/is-alexandria-real-estate-equity-a-buy/,2023-01-10 10:00:00,"It's a great stock, but investors dislike the sector.",BMY,0.115509,0.025857,Neutral
"SK Inc. hosts ""SK Bio Night"" in San Francisco to expand global partnerships",https://www.prnewswire.com/news-releases/sk-inc-hosts-sk-bio-night-in-san-francisco-to-expand-global-partnerships-301716343.html,2023-01-09 23:00:00,"SK Inc. hosts ""SK Bio Night"" in San Francisco to expand global ... PR ...",BMY,0.049221,0.100146,Neutral
"Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin  ( Luvelta ) , Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer - Sutro Biopharma  ( NASDAQ:STRO ) ",https://www.benzinga.com/pressreleases/23/01/g30340459/sutro-biopharma-announces-update-from-stro-002-luveltamab-tazevibulin-luvelta-phase-1-dose-expansi,2023-01-09 21:05:00,"- Results from the STRO-002 ( luvelta ) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg -",BMY,0.028089,0.04365,Neutral
"Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin  ( Luvelta ) , Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer",https://www.globenewswire.com/news-release/2023/01/09/2585663/0/en/Sutro-Biopharma-Announces-Update-from-STRO-002-Luveltamab-Tazevibulin-Luvelta-Phase-1-Dose-Expansion-Study-and-Registrational-Plans-in-Advanced-Ovarian-Cancer.html,2023-01-09 21:05:00,"- Results from the STRO-002 ( luvelta ) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of ...",BMY,0.020995,0.045579,Neutral
Why Editas Medicine Stock Is Sliding Today,https://www.fool.com/investing/2023/01/09/why-editas-medicine-stock-is-sliding-today/,2023-01-09 16:59:38,The gene-editing pioneer announced a big shake-up with its research and development programs.,BMY,0.145145,-0.012614,Neutral
BMY: 3,https://stocknews.com/news/bmy-cah-kt-3-strong-buy-stocks-you-dont-want-to-miss-out/,2023-01-09 14:06:34,"The Federal Reserve has been aggressively increasing the interest rates to curb the multi-decade high inflation. It has indicated continuing the hikes at a slower pace until inflation falls below 2%. Moreover, Morgan Stanley expects monetary policy to remain the primary driver of asset prices.",BMY,0.413992,0.327005,Somewhat-Bullish
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization,https://www.globenewswire.com/news-release/2023/01/09/2585226/0/en/Editas-Medicine-Announces-Strategic-Updates-and-Portfolio-Reprioritization.html,2023-01-09 13:15:00,Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing ...,BMY,0.034882,0.111731,Neutral
3 Dividend Stocks You Can Invest Confidently in Right Now,https://www.fool.com/investing/2023/01/08/3-dividend-stocks-you-can-invest-confidently-in-ri/,2023-01-08 12:12:00,"These stocks offer the hallmarks of confident investing: healthy earnings, stable outlooks, and superior credit ratings.",BMY,0.036926,0.263242,Somewhat-Bullish
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income,https://www.zacks.com/stock/news/2036195/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income,2023-01-06 14:10:03,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.210274,0.117238,Neutral
Is Trending Stock Bristol Myers Squibb Company  ( BMY )  a Buy Now?,https://www.zacks.com/stock/news/2036191/is-trending-stock-bristol-myers-squibb-company-bmy-a-buy-now,2023-01-06 14:00:06,"Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",BMY,0.100099,0.036011,Neutral
"Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors",https://www.prnewswire.com/news-releases/blueprint-medicines-appoints-john-tsai-md-to-its-board-of-directors-301715456.html,2023-01-06 14:00:00,"CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation ( NASDAQ: BPMC ) today announced the appointment of John Tsai, M.D., to its board of directors.",BMY,0.058759,0.042,Neutral
"Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive - Century Therapeutics  ( NASDAQ:IPSC ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/01/30307246/century-therapeutics-announces-internal-portfolio-prioritization-analyst-views-it-a,2023-01-06 13:23:24,Century Therapeutics IPSC revealed an internal portfolio prioritization and capital allocation strategy that is expected to extend the cash runway into 2026. The company will deprioritize investment in CNTY-103 for glioblastoma and a discovery program in hematologic malignancies.,BMY,0.327366,0.157785,Somewhat-Bullish
JNJ: 1 Dividend Stock to Buy Now and Retire on Later,https://stocknews.com/news/jnj-nvo-pfe-bmy-1-dividend-stock-to-buy-now-and-retire-on-later/,2023-01-06 13:03:07,"Record-high inflation, the Fed's hawkish stance, geopolitical turbulence, and growing recession fears kept the stock market highly volatile last year. However, Johnson & Johnson ( JNJ ) has been able to survive the market turmoil due to the defensive nature of its business and solid fundamentals.",BMY,0.105604,0.085233,Neutral
"CRISPR, Genetics And AI - Why 2023 Could Be Biotech's Year",https://www.investors.com/news/technology/biotech-stocks-how-crispr-genetics-and-ai-could-drive-a-2023-inflection/,2023-01-06 13:00:00,"Biotech Stocks: How CRISPR, Genetics And AI Could Drive A 2023 ... Investor's Business Daily ...",BMY,0.028155,-0.042845,Neutral
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA,https://www.prnewswire.com/news-releases/casi-pharmaceuticals-and-cleave-therapeutics-announce-clinical-trial-application-approval-for-cb-5339-in-patients-with-multiple-myeloma-in-china-301715199.html,2023-01-06 12:00:00,CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ... PR ...,BMY,0.065506,-0.059346,Neutral
"Salesforce Customers Not Swayed by Slack, Analysts Say",https://www.wsj.com/articles/salesforce-customers-not-swayed-by-slack-analysts-say-11672964706,2023-01-06 00:25:00,"When Salesforce bought Slack for $27.7 billion almost two years ago, it said it would transform how people work. Corporate technology buyers so far aren't impressed, analysts said.",BMY,0.045482,-0.064569,Neutral
"CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics - CytomX Therapeutics  ( NASDAQ:CTMX ) , Moderna  ( NASDAQ:MRNA ) ",https://www.benzinga.com/pressreleases/23/01/g30301606/cytomx-and-moderna-announce-strategic-research-collaboration-for-mrna-based-conditionally-activate,2023-01-05 21:05:00,"Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments",BMY,0.04476,-0.026954,Neutral
Healthcare Stocks Had a Strong 2022. It Isn't Too Late to Buy.,https://www.barrons.com/articles/healthcare-stocks-defensive-buy-51672951649,2023-01-05 20:49:00,"Healthcare stocks held their ground in 2022 when the rest of the market was getting crushed. Some still look cheap enough to considering buying. The Health Care Select Sector SPDR ETF ( XLV ) dropped only 3.5% in 2022. That isn't bad at all, considering the S&P 500 's 19% drop.",BMY,0.210274,0.154172,Somewhat-Bullish
Biking the Globe for C2C4C,https://investingnews.com/biking-the-globe-for-c2c4c/,2023-01-05 20:48:45,"""A bicycle ride around the world begins with a single pedal stroke."" A handful of inspirational words from author Scott Stoll served as the rallying cry for more than 350 Bristol Myers Squibb employees representing 23 nations who successfully trained and participated in four regional bicycle ...",BMY,0.269776,0.148171,Neutral
Why Investors Need to Take Advantage of These 2 Medical Stocks Now,https://www.zacks.com/stock/news/2035607/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now,2023-01-05 13:50:07,Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.,BMY,0.38489,0.35244,Bullish
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/01/30281863/looking-at-bristol-myers-squibbs-recent-unusual-options-activity,2023-01-05 13:27:30,"Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.810034,0.396091,Bullish
Hestia Insight Inc. Appoints Advisory Board Member to Assist in Company Growth,https://www.globenewswire.com/news-release/2023/01/05/2583502/0/en/Hestia-Insight-Inc-Appoints-Advisory-Board-Member-to-Assist-in-Company-Growth.html,2023-01-05 12:00:00,"NEW YORK, NY, Jan. 05, 2023 ( GLOBE NEWSWIRE ) -- via NewMediaWire - Hestia Insight Inc. ( OTCQB: HSTA ) ( ""Hestia Insight"" and the ""Company"" ) , a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and ...",BMY,0.050894,0.195412,Somewhat-Bullish
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors,https://www.globenewswire.com/news-release/2023/01/04/2583300/0/en/MacroGenics-Announces-Appointment-of-Dr-Margaret-Liu-and-Meenu-Chhabra-Karson-to-Board-of-Directors.html,2023-01-04 21:30:00,"ROCKVILLE, MD, Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- MacroGenics, Inc. ( NASDAQ: MGNX ) , a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A.",BMY,0.030918,0.08884,Neutral
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors - Macrogenics  ( NASDAQ:MGNX ) ,https://www.benzinga.com/pressreleases/23/01/g30283535/macrogenics-announces-appointment-of-dr-margaret-liu-and-meenu-chhabra-karson-to-board-of-director,2023-01-04 21:30:00,"ROCKVILLE, MD, Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- MacroGenics, Inc. MGNX, a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A.",BMY,0.030602,0.087755,Neutral
Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors - Oncternal Therapeutics  ( NASDAQ:ONCT ) ,https://www.benzinga.com/pressreleases/23/01/g30282525/oncternal-therapeutics-announces-the-appointment-of-jill-desimone-to-the-board-of-directors,2023-01-04 21:05:00,"SAN DIEGO, Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- Oncternal Therapeutics, Inc. ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors.",BMY,0.054857,-0.072947,Neutral
Investors Should Consider This Warren Buffett Advice in 2023,https://www.fool.com/investing/2023/01/04/investors-should-consider-this-warren-buffett-advi/,2023-01-04 15:07:00,"If investors wait too long to buy stocks, they're in danger of missing out on the inevitable rally.",BMY,0.116631,0.100676,Neutral
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar,https://www.zacks.com/stock/news/2035069/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar,2023-01-04 13:50:07,The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.,BMY,0.263942,0.316785,Somewhat-Bullish
The J.M. Smucker Co. Names Rebecca Scheidler Senior Vice President and General Manager of Consumer Foods,https://www.prnewswire.com/news-releases/the-jm-smucker-co-names-rebecca-scheidler-senior-vice-president-and-general-manager-of-consumer-foods-301713362.html,2023-01-04 13:30:00,The J.M. Smucker Co. Names Rebecca Scheidler Senior Vice ... PR ...,BMY,0.080458,0.151866,Somewhat-Bullish
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/01/04/2582844/0/en/Sutro-Biopharma-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,2023-01-04 13:00:00,"SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) ( NASDAQ: STRO ) , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced that Bill Newell, Chief Executive ...",BMY,0.110973,0.056697,Neutral
Aurobindo Pharma trades in red despite FDA nod to Eugia Pharma injection,https://www.moneycontrol.com/news/business/stocks/aurobindo-pharma-trades-in-red-despite-fda-nod-to-eugia-pharma-injection-9809671.html,2023-01-04 07:51:33,"Aurobindo Pharma's wholly owned subsidiary company, Eugia Pharma Specialities Limited received a final approval from the US Food Drug Administration ( USFDA ) to manufacture and market Azacitidine for Injection, 100 mg single-dose vial.",BMY,0.199037,0.100038,Neutral
Eugia Pharma Specialities receives USFDA approval for Azacitidine for Injection,https://www.business-standard.com/article/news-cm/eugia-pharma-specialities-receives-usfda-approval-for-azacitidine-for-injection-123010400322_1.html,2023-01-04 05:39:00,Eugia Pharma Specialities receives USFDA approval for Azacitidine ... Business Standard ...,BMY,0.769861,0.13926,Neutral
Auro Pharma's subsidiary get US FDA nod for MDS treatment drug,https://www.business-standard.com/article/news-cm/auro-pharma-s-subsidiary-get-us-fda-nod-for-mds-treatment-drug-123010400305_1.html,2023-01-04 05:27:00,Auro Pharmas subsidiary get US FDA nod for MDS treatment drugs Business Standard ...,BMY,0.159569,0.0,Neutral
Bristol Myers Squibb  ( BMY )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2034837/bristol-myers-squibb-bmy-gains-as-market-dips-what-you-should-know,2023-01-03 22:50:24,"Bristol Myers Squibb (BMY) closed the most recent trading day at $72.26, moving +0.43% from the previous trading session.",BMY,0.686288,0.193245,Somewhat-Bullish
Congressman Sells Stocks At End Of 2022 And Retires From Office: Taking Profits Or Warning Sign? - SPDR S&P 500  ( ARCA:SPY ) ,https://www.benzinga.com/news/23/01/30263009/congressman-sells-stocks-at-end-of-2022-and-retires-from-office-taking-profits-or-warning-sign,2023-01-03 21:44:25,A member of Congress sold out of his positions in several stocks at the end of 2022. The move came as he finished his term serving the state of Texas and announced his retirement.,BMY,0.220809,0.0,Neutral
Will Bristol Myers  ( BMY )  Beat Estimates Again in Its Next Earnings Report?,https://www.zacks.com/stock/news/2034728/will-bristol-myers-bmy-beat-estimates-again-in-its-next-earnings-report,2023-01-03 17:10:10,Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,BMY,0.166743,0.033476,Neutral
Cancer Vaccines Drug Pipeline Market will surpass USD 20.2 billion by 2030 : GreyViews,https://www.benzinga.com/pressreleases/23/01/g30260619/cancer-vaccines-drug-pipeline-market-will-surpass-usd-20-2-billion-by-2030-greyviews,2023-01-03 17:00:00,"Pune India, Jan. 03, 2023 ( GLOBE NEWSWIRE ) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa.",BMY,0.025113,-0.008569,Neutral
Anti-Cancer Drug Market is expected to grow from USD 150.6 billion in 2022 to USD 266.5 billion by 2030 : GreyViews,https://www.benzinga.com/pressreleases/23/01/g30259586/anti-cancer-drug-market-is-expected-to-grow-from-usd-150-6-billion-in-2022-to-usd-266-5-billion-by,2023-01-03 16:00:00,"Pune India, Jan. 03, 2023 ( GLOBE NEWSWIRE ) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the Anti-Cancer drug market is operating and is ...",BMY,0.023838,0.040191,Neutral
PFE: 1 Stock That Would Be an Excellent Addition to Your Portfolio for Years to Come,https://stocknews.com/news/pfe-jnj-nvo-bmy-1-stock-that-would-be-an-excellent-addition-to-your/,2023-01-03 13:56:39,PFE: 1 Stock That Would Be an Excellent Addition to Your Portfolio ... ...,BMY,0.08282,0.078603,Neutral
ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics,https://www.prnewswire.com/news-releases/zielbio-appoints-alan-bash-ceo-as-company-advances-oncology-therapeutics-301712159.html,2023-01-03 13:00:00,ZielBio Appoints Alan Bash CEO as Company Advances Oncology ... PR ...,BMY,0.064973,-0.077664,Neutral
Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare Conference,https://investingnews.com/bristol-myers-squibb-to-present-at-j-p-morgan-s-41st-annual-healthcare-conference/,2023-01-03 12:26:48,"Bristol Myers Squibb ( NYSE: BMY ) today announced that the company will present at J.P. Morgan's 41 st Annual Healthcare Conference on Monday, January 9, 2023. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will make a formal presentation and answer questions about the company ...",BMY,0.841981,0.176485,Somewhat-Bullish
"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York",https://investingnews.com/bristol-myers-squibb-completes-sale-of-manufacturing-facility-in-syracuse-new-york/,2023-01-03 12:26:48,"Bristol Myers Squibb ( NYSE: BMY ) has completed the previously announced sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS. The divestiture is part of Bristol Myers Squibb's ongoing evolution of its manufacturing network to support its product portfolio.",BMY,0.598621,-0.122461,Neutral
Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight,https://www.prnewswire.com/news-releases/propulsion-of-pancreatic-cancer-pipeline-as-novel-and-extensive-170-therapies-likely-to-enter-in-the-treatment-domain--delveinsight-301711743.html,2023-01-02 15:30:00,Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive ... PR ...,BMY,0.033351,-0.015509,Neutral
Biopharmaceutical Executive Eric Strati joins Gift of Life Biologics as Chief Executive Officer,https://www.benzinga.com/pressreleases/23/01/g30250368/biopharmaceutical-executive-eric-strati-joins-gift-of-life-biologics-as-chief-executive-officer,2023-01-02 15:00:00,"BOCA RATON, Fla., Jan. 02, 2023 ( GLOBE NEWSWIRE ) -- Gift of Life Biologics announced today that accomplished biopharmaceutical leader Eric Strati, Pharm.D. MBA has joined the firm as its Chief Executive Officer.",BMY,0.070105,0.111144,Neutral
LG Chem Completes Acquisition of AVEO Oncology,https://www.benzinga.com/pressreleases/23/01/g30493360/lg-chem-completes-acquisition-of-aveo-oncology,2023-01-19 21:35:03,"SEOUL, South Korea, Jan. 19, 2023 ( GLOBE NEWSWIRE ) -- LG Chem, Ltd. ( ""LG Chem"" ) ( KOSPI: 051910 ) today announced that it has completed its previously announced acquisition of AVEO Oncology ( ""AVEO"" ) , a commercial stage, oncology-focused biopharmaceutical company committed to delivering ...",BMY,0.047092,0.036659,Neutral
LG Chem Completes Acquisition of AVEO Oncology,https://www.globenewswire.com/news-release/2023/01/19/2592164/0/en/LG-Chem-Completes-Acquisition-of-AVEO-Oncology.html,2023-01-19 21:35:00,AVEO to Become the U.S. Foundation for LG Chem Life Sciences' Oncology Division AVEO to Become the U.S. Foundation for LG Chem Life Sciences' Oncology Division ...,BMY,0.04882,0.037762,Neutral
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million,https://investingnews.com/the-robert-a-winn-diversity-in-clinical-trials-award-program-established-by-the-bristol-myers-squibb-foundation-to-expand-with-amgen-s-commitment-of-8-million/,2023-01-19 13:49:51,Amgen Joins Gilead Sciences as a Program Supporter Applications Now Open for Physicians and Medical Students The Robert A.,BMY,0.156055,0.222553,Somewhat-Bullish
5 Stocks You Can Confidently Invest $500 in Right Now,https://www.fool.com/investing/2023/01/19/stocks-you-can-confidently-invest-500-in-right-now/,2023-01-19 10:49:00,Any investor with $500 can buy these stocks with conviction.,BMY,0.075754,-0.044546,Neutral
JNJ: 3 Stocks to Buy Right Now if You Want to Retire Early,https://stocknews.com/news/jnj-pfe-bmy-3-stocks-to-buy-right-now-if-you-want-to/,2023-01-18 17:01:25,"The U.S. inflation eased in December, supporting a moderation in the Fed's rate hikes for the upcoming months. Buoyed by the December jobs report and signs of a slowdown in inflation, investors are eyeing a 25-basis-point hike at the Fed's next policy meeting.",BMY,0.231057,0.17028,Somewhat-Bullish
"Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen",https://www.benzinga.com/general/biotech/23/01/30462022/neurodegenerative-diseases-focused-company-goes-public-via-wilbur-ross-backed-spac-joins-alzheime,2023-01-18 15:10:09,"Neurodegenerative diseases-focused Aprinoia Therapeutics has announced a business combination with Ross Acquisition Corp II ROSS, a special-purpose acquisition company founded by former Commerce Secretary Wilbur Ross, at an equity value of $280 million.",BMY,0.241684,0.372014,Bullish
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2040672/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks,2023-01-18 14:10:03,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.209365,0.116843,Neutral
"Stablix Appoints Douglas Williams, Ph.D., to Board of Directors",https://www.benzinga.com/pressreleases/23/01/g30458105/stablix-appoints-douglas-williams-ph-d-to-board-of-directors,2023-01-18 12:00:47,"NEW YORK, Jan. 18, 2023 ( GLOBE NEWSWIRE ) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization ( TPS ) as a novel therapeutic modality, today announced the appointment of Douglas E. Williams, Ph.D. to its Board of Directors.",BMY,0.063425,-0.038049,Neutral
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases,https://www.prnewswire.com/news-releases/aprinoia-therapeutics-and-ross-acquisition-corp-ii-announce-business-combination-agreement-to-create-publicly-listed-company-focused-on-neurodegenerative-diseases-301724108.html,2023-01-18 11:50:00,APRINOIA Therapeutics and ROSS Acquisition Corp II Announce ... PR ...,BMY,0.014462,0.111884,Neutral
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases,https://www.benzinga.com/pressreleases/23/01/n30457858/aprinoia-therapeutics-and-ross-acquisition-corp-ii-announce-business-combination-agreement-to-crea,2023-01-18 11:50:00,"ROSS SPAC will issue $280 million of stock for APRINOIA Therapeutics Precision Neurology Company Focused on Developing a Pipeline of Highly Specific Central Nervous System ( ""CNS"" ) Diagnostics and Therapeutics, including CNS Protein Degraders",BMY,0.014401,0.110941,Neutral
"Apprentice.io CEO, Angelo Stracquatanio, Invited to the Join Forbes Technology Council",https://www.benzinga.com/pressreleases/23/01/g30457112/apprentice-io-ceo-angelo-stracquatanio-invited-to-the-join-forbes-technology-council,2023-01-18 11:00:00,"JERSEY CITY, N.J., Jan. 18, 2023 ( GLOBE NEWSWIRE ) -- Angelo Stracquatanio, CEO and Co-founder of Apprentice.io, a technology company that helps pharma manufacturers get medicine to patients faster, was recently welcomed as a member of the Forbes Technology Council.",BMY,0.058188,0.215008,Somewhat-Bullish
Bristol Myers Squibb  ( BMY )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2040403/bristol-myers-squibb-bmy-dips-more-than-broader-markets-what-you-should-know,2023-01-17 22:50:23,"Bristol Myers Squibb (BMY) closed at $72.31 in the latest trading session, marking a -0.28% move from the prior day.",BMY,0.670305,0.187882,Somewhat-Bullish
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference,https://www.benzinga.com/pressreleases/23/01/g30450762/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conferen,2023-01-17 21:05:00,"SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the B.",BMY,0.157483,-0.053591,Neutral
ABBV: The #1 Pharma Stock to Buy in January 2023,https://stocknews.com/news/abbv-jnj-pfe-bmy-the-no-1-pharma-stock-to-buy-in-january-2023/,2023-01-16 13:20:02,ABBV: The No. 1 Pharma Stock to Buy in January ...,BMY,0.099271,0.168077,Somewhat-Bullish
Prothena  ( PRTA )  Stock Gains 88.5% in 6 Months: What Lies Ahead?,https://www.zacks.com/stock/news/2039265/prothena-prta-stock-gains-885-in-6-months-what-lies-ahead,2023-01-13 19:47:00,Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.,BMY,0.076847,-0.050801,Neutral
"Drug companies plan to raise prices on vital medicines to fund R&D, but they already spend more on shareholder returns",https://www.marketwatch.com/story/drug-companies-plan-to-raise-prices-on-vital-medicines-to-fund-r-d-but-they-already-spend-more-on-shareholder-returns-11673626340,2023-01-13 16:12:00,Drug companies say they need to raise prices on cancer drugs and other treatments to fund research. But they already spend more on stock buybacks and dividends.,BMY,0.102013,0.125176,Neutral
"The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Honeywell, Sony, Airbnb and Republic Services",https://www.zacks.com/stock/news/2038832/the-zacks-analyst-blog-highlights-bristol-myers-squibb-honeywell-sony-airbnb-and-republic-services,2023-01-13 10:00:00,"Bristol-Myers Squibb, Honeywell, Sony, Airbnb and Republic Services are included in this Analyst Blog.",BMY,0.137671,0.0,Neutral
"Top Stock Reports for Bristol-Myers Squibb, Honeywell International & Sony",https://www.zacks.com/research-daily/2038448/top-stock-reports-for-bristol-myers-squibb-honeywell-international-sony,2023-01-12 15:16:00,"Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb Company (BMY), Honeywell International Inc. (HON) and Sony Group Corporation (SONY).",BMY,0.177584,0.182292,Somewhat-Bullish
Here's Why Bristol Myers Squibb  ( BMY )  is a Strong Value Stock,https://www.zacks.com/stock/news/2038493/heres-why-bristol-myers-squibb-bmy-is-a-strong-value-stock,2023-01-12 14:40:06,"Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",BMY,0.33514,0.352442,Bullish
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2038428/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks,2023-01-12 14:10:02,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.207571,0.116065,Neutral
BMY: The No. 1 Stock to Keep an Eye on in 2023,https://stocknews.com/news/bmy-nvo-pfe-rdy-the-no-1-stock-to-keep-an-eye-on-in/,2023-01-11 16:23:11,BMY: The No. 1 Stock to Keep an Eye on in ...,BMY,0.678102,0.402679,Bullish
"Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More",https://www.zacks.com/stock/news/2037977/biotech-stock-roundup-regn-down-on-eylea-data-cinc-surges-on-azn-offer-more,2023-01-11 16:10:00,Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.,BMY,0.043186,0.064399,Neutral
"HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024",https://www.prnewswire.com/news-releases/halozyme-therapeutics-inc-announces-redemption-of-1-25-convertible-senior-notes-due-2024--301718785.html,2023-01-11 13:30:00,"HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION ... PR ...",BMY,0.055236,0.084034,Neutral
3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off,https://www.fool.com/investing/2023/01/11/3-supercharged-dividend-stocks-to-buy-if-theres-a/,2023-01-11 12:50:00,"These three healthcare stocks all deliver dependable dividends, with yields of 3% or more.",BMY,0.102888,0.11794,Neutral
"Down 14.5%, Is Pfizer Stock a Screaming Buy?",https://www.fool.com/investing/2023/01/30/down-145-is-pfizer-stock-a-screaming-buy/,2023-01-30 21:00:00,Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock.,BMY,0.130926,0.0,Neutral
"Global Pharmaceutical Drug Delivery Market worth $2,206.5 billion by 2026 - Exclusive Report by MarketsandMarkets™",https://www.benzinga.com/pressreleases/23/01/g30622827/global-pharmaceutical-drug-delivery-market-worth-2-206-5-billion-by-2026-exclusive-report-by-marke,2023-01-30 14:30:00,"Chicago, Jan. 30, 2023 ( GLOBE NEWSWIRE ) -- According to the new market research report ""Pharmaceutical Drug Delivery Market Size, Growth by Route of Administration ( Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes ) , Application ( Cancer, Diabetes ) , ...",BMY,0.087503,0.021576,Neutral
3 Top Dividend Stocks to Maximize Your Retirement Income,https://www.zacks.com/stock/news/2046228/3-top-dividend-stocks-to-maximize-your-retirement-income,2023-01-30 14:10:03,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.213048,0.118444,Neutral
How Will Bristol Myers Squibb Stock Trend Post Q4 Results?,https://www.forbes.com/sites/greatspeculations/2023/01/30/how-will-bristol-myers-squibb-stock-trend-post-q4-results/,2023-01-30 12:00:52,"A decline in Revlimid sales will likely more than offset sales growth for Eliquis, Opdivo, and Reblozyl.",BMY,0.699089,0.214845,Somewhat-Bullish
"With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028",https://www.benzinga.com/pressreleases/23/01/g30618366/with-14-1-cagr-monoclonal-antibody-therapy-market-size-worth-usd-451-89-billion-by-2028,2023-01-30 10:54:18,"Pune, India, Jan. 30, 2023 ( GLOBE NEWSWIRE ) -- The global monoclonal antibody therapy market size was USD 157.33 billion in 2020. The market is projected to grow from USD 178.50 billion in 2021 to USD 451.89 billion in 2028 at a CAGR of 14.1% in the 2021-2028 period.",BMY,0.035983,0.353198,Bullish
"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",https://www.benzinga.com/news/earnings/23/01/30616031/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among,2023-01-29 22:25:32,"With a full week of earnings behind us, it's time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. Some of the big tech names that fell short are Intel Corp. INTC and Texas Instruments, Inc.",BMY,0.054114,0.0,Neutral
2 Top Dividend Stocks to Buy in 2023 and Hold Forever,https://www.fool.com/investing/2023/01/29/2-dividend-stocks-to-buy-in-2023-and-hold-forever/,2023-01-29 13:53:00,These companies are established leaders in their respective fields.,BMY,0.114137,0.223038,Somewhat-Bullish
"Investing Action Plan - January Wrap: Apple, OPEC, Exxon And The Fed",https://www.investors.com/research/investing-action-plan/stock-market-investing-action-plan-january-wrap-apple-opec-exxon-and-the-fed/,2023-01-27 23:20:00,"Investing Action Plan - January Wrap: Apple, OPEC, Exxon And ... Investor's Business Daily ...",BMY,0.032916,0.047876,Neutral
Bristol Myers Squibb  ( BMY )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2045715/bristol-myers-squibb-bmy-stock-sinks-as-market-gains-what-you-should-know,2023-01-27 22:45:18,"Bristol Myers Squibb (BMY) closed at $72.45 in the latest trading session, marking a -0.74% move from the prior day.",BMY,0.634884,0.277949,Somewhat-Bullish
Bristol-Myers  ( BMY )  to Report Q4 Earnings: What's in Store?,https://www.zacks.com/stock/news/2045584/bristol-myers-bmy-to-report-q4-earnings-whats-in-store,2023-01-27 16:28:00,"Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.",BMY,0.232661,0.201387,Somewhat-Bullish
"Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent Beta Thalassemia",https://investingnews.com/bristol-myers-squibb-receives-positive-chmp-opinion-for-reblozyl-r-for-adult-patients-with-anemia-associated-non-transfusion-dependent-beta-thalassemia/,2023-01-27 12:27:10,Approval by the European Commission would expand the indications of Reblozyl for treatment of anemia in adults with beta thalassemia in Europe,BMY,0.190117,0.028277,Neutral
3 Healthcare Stocks to Buy and Hold for the Next 10 Years,https://www.fool.com/investing/2023/01/27/3-healthcare-stocks-buy-and-hold-for-next-10-years/,2023-01-27 11:50:00,These companies have the therapies to boost revenue for a decade.,BMY,0.090474,0.0,Neutral
Earnings Preview: Bristol Myers Squibb  ( BMY )  Q4 Earnings Expected to Decline,https://www.zacks.com/stock/news/2044805/earnings-preview-bristol-myers-squibb-bmy-q4-earnings-expected-to-decline,2023-01-26 15:01:16,Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.087985,-0.010523,Neutral
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors,https://investingnews.com/ivexsol-r-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors/,2023-01-26 13:43:02,iVexSol® Closes $23.8M Series A-3 Financing. Funds to Revolutionize the Production of Lentiviral Vectors Investing News Network ...,BMY,0.172713,0.044294,Neutral
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia,https://investingnews.com/bristol-myers-squibb-announces-transcend-cll-004-trial-of-breyanzi-r-met-primary-endpoint-of-complete-response-rate-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia/,2023-01-26 12:29:54,"Bristol Myers Squibb ( NYSE: BMY ) today announced topline results from TRANSCEND CLL 004, a Phase 1/2, open-label, single-arm, multicenter study evaluating Breyanzi ( lisocabtagene maraleucel ) in adults with relapsed or refractory ( R/R ) chronic lymphocytic leukemia ( CLL ) or small ...",BMY,0.236828,0.005573,Neutral
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific  ( TCB )  Collaboration with Astellas,https://www.globenewswire.com/news-release/2023/01/26/2595893/37704/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-Probody-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html,2023-01-26 12:00:00,-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to ...,BMY,0.068209,-0.02641,Neutral
3 Buffett-Type Stocks to Buy Right Now,https://www.fool.com/investing/2023/01/25/3-buffett-type-stocks-to-buy-right-now/,2023-01-25 14:37:00,These stocks are good value buys for the long haul.,BMY,0.159218,0.186885,Somewhat-Bullish
Johnson & Johnson  ( JNJ )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/01/24/johnson-johnson-jnj-q4-2022-earnings-call-transcri/,2023-01-24 21:30:21,"JNJ earnings call for the period ending December 31, 2022.",BMY,0.009203,0.028174,Neutral
4 Cancer Stocks to Consider in 2023,https://www.fool.com/investing/stock-market/market-sectors/healthcare/cancer-stocks/,2023-01-24 16:14:16,"Despite significant progress, cancer continues to be a big problem. Over 1.9 million new cases of cancer are likely to be diagnosed in the U.S. alone this year. More than 600,000 deaths are expected from cancer in 2022.There's also a huge financial cost that's growing rapidly.",BMY,0.173084,-0.082144,Neutral
3 Top Dividend Stocks to Maximize Your Retirement Income,https://www.zacks.com/stock/news/2043235/3-top-dividend-stocks-to-maximize-your-retirement-income,2023-01-24 14:10:03,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.211652,0.117837,Neutral
Bristol Myers Squibb  ( BMY )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2042906/bristol-myers-squibb-bmy-stock-sinks-as-market-gains-what-you-should-know,2023-01-23 22:50:21,"Bristol Myers Squibb (BMY) closed the most recent trading day at $73.26, moving -1.2% from the previous trading session.",BMY,0.670305,0.32203,Somewhat-Bullish
Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma,https://www.globenewswire.com/news-release/2023/01/23/2592873/0/en/Ultimovacs-Announces-Completed-Patient-Recruitment-in-NIPU-Phase-II-Clinical-Trial-of-UV1-in-Mesothelioma.html,2023-01-23 07:00:00,"Oslo, 23 January 2023: Ultimovacs ASA ( ""Ultimovacs"" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces the completed recruitment of 118 patients with pleural mesothelioma in the NIPU trial.",BMY,0.075397,-0.064231,Neutral
2 Top Biotech Stocks to Buy Right Now,https://www.fool.com/investing/2023/02/09/2-top-biotech-stocks-to-buy-right-now/,2023-02-09 14:37:00,These two companies each pay market-beating dividends to shareholders.,BMY,0.136499,0.0,Neutral
"2023 CALIFORNIA CONFERENCE FOR WOMEN TO FOCUS ON LEADERSHIP, CONNECTION, AND BEING A FORCE FOR CHANGE",https://www.benzinga.com/pressreleases/23/02/n30821811/2023-california-conference-for-women-to-focus-on-leadership-connection-and-being-a-force-for-chang,2023-02-08 20:29:00,"SANTA CLARA, Feb. 8, 2023 /PRNewswire/ -- Leaders from corporate America, the media, sports, arts, and Hollywood will come together this Women's History Month to discuss women leading together to be a force for positive change in 2023. They include the former CEO of IBM Ginny Rometty.",BMY,0.051551,0.15847,Somewhat-Bullish
BMY: Start 2023 out Right. Add These 2 Stocks to Your Portfolio Today,https://stocknews.com/news/bmy-gm-start-2023-out-right-add-these-2-stocks-to-your/,2023-02-08 16:59:06,"Wall Street ended 2022 with the biggest annual decline since 2008. Following last year's dismal performance, stocks have had an encouraging start to 2023, with the Nasdaq Composite and S&P 500 gaining about 11% and 6%, respectively, in the past month.",BMY,0.395579,0.443366,Bullish
2 Top Biotech Stocks to Buy in February,https://www.fool.com/investing/2023/02/08/feb3-2-top-biotech-stocks-to-buy-in-february/,2023-02-08 14:45:00,Biotech stocks aren't all created equal -- these two are the best of the bunch.,BMY,0.165788,0.087261,Neutral
Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results,https://www.globenewswire.com/news-release/2023/02/08/2603812/0/en/Purple-Biotech-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html,2023-02-08 12:12:00,Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in ...,BMY,0.017742,0.028993,Neutral
ZTS: 1 Medical Stock to Get Bullish on Right Now,https://stocknews.com/news/zts-nvo-nvs-bmy-1-medical-stock-to-get-bullish-on-right-now/,2023-02-07 16:00:57,"Medical stock Zoetis Inc. ( ZTS ) has gained 11.7% over the past month. Moreover, it has gained 23.4% over the past three months to close the last trading session at $164.93. Wall Street analysts expect the stock to hit $204.33 in the near term, indicating a potential upside of 23.9%.",BMY,0.13459,0.096671,Neutral
"2028 Immuno-Oncology Market Report Puts Limelight on Market Size, Share, Growth Opportunities, Factors and Trends Influencing the Industry | Xcellent Insights",https://www.benzinga.com/pressreleases/23/02/g30764491/2028-immuno-oncology-market-report-puts-limelight-on-market-size-share-growth-opportunities-factor,2023-02-07 14:19:55,"Pune, Feb. 07, 2023 ( GLOBE NEWSWIRE ) -- The global Immuno-Oncology Market Size was USD 43698.02 million in 2021 and is expected to register a robust revenue CAGR of 15.05% during the forecast period.",BMY,0.041181,0.0,Neutral
Overhaul Acquires SensiGuard to Become Largest In-Transit Supply Chain Cargo Security Provider,https://www.newswire.ca/news-releases/overhaul-acquires-sensiguard-to-become-largest-in-transit-supply-chain-cargo-security-provider-855223084.html,2023-02-07 14:00:00,Overhaul Acquires SensiGuard to Become Largest In-Transit Supply ... Canada ...,BMY,0.05339,0.036999,Neutral
Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/02/30735248/big-pharma-bristol-myers-returns-475m-il-12-oncology-asset-to-dragonfly,2023-02-06 17:41:14,"Bristol-Myers Squibb & Co BMY has returned the exclusive rights to Dragonfly Therapeutics' IL-12 oncology candidate. In 2020, BMS handed out $475 million in near-term and upfront payments deal to license the interleukin-12 ( IL-12 ) immunotherapy program, dubbed DF6002.",BMY,0.678673,0.347358,Somewhat-Bullish
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?,https://www.fool.com/investing/2023/02/06/could-this-indication-lift-bristol-myers-stock/,2023-02-06 14:00:00,Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union.,BMY,0.107255,0.178877,Somewhat-Bullish
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings,https://www.fool.com/investing/2023/02/06/1-company-bucks-the-office-reit-trend-with-higher/,2023-02-06 12:46:00,Life sciences companies may be more immune to work-from-home shifts.,BMY,0.128478,0.073705,Neutral
Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?,https://www.fool.com/investing/2023/02/04/will-these-3-potential-blockbuster-drugs-lift-bris/,2023-02-04 14:26:00,Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff.,BMY,0.104683,0.130498,Neutral
"Market Rally Powers Higher On Tame Fed, Meta: Weekly Review",https://www.investors.com/news/market-rally-powers-higher-on-tame-fed-meta-earnings-apple-google-amazon/,2023-02-03 18:43:00,"The stock market rally marched higher as the Fed took a slightly more dovish stance, even though it said rate hikes will continue. Friday's superhot jobs report failed to derail the uptrend. Big earnings or guidance continued to be mixed, but Meta Platforms ( META ) skyrocketed on cost cuts, ...",BMY,0.040864,-0.021831,Neutral
PFE: The Safest Stock to Buy on Wall Street Right Now,https://stocknews.com/news/pfe-jnj-abbv-bmy-the-safest-stock-to-buy-on-wall-street-right-now/,2023-02-03 16:59:24,"While a 25-bps interest-rate hike announced on Wednesday by the Federal Reserve Chair Jerome Powell hardly came as a surprise, market participants seem to have gone overboard over a simple acknowledgment that inflation ""has eased somewhat"" and ""the disinflationary process"" had started.",BMY,0.080188,0.0,Neutral
"Company News for Feb 3, 2023",https://www.zacks.com/stock/news/2049525/company-news-for-feb-3-2023,2023-02-03 14:11:00,"Companies in The news Are: META, BMY, PH, CAH.",BMY,0.576289,0.636212,Bullish
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference,https://investingnews.com/bristol-myers-squibb-to-participate-in-the-guggenheim-healthcare-talks-2023-oncology-conference/,2023-02-03 12:25:19,"Bristol Myers Squibb ( NYSE: BMY ) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023. Chris Boerner , Ph.D., Executive Vice President, Chief Commercialization Officer, will answer questions ...",BMY,0.866386,0.057797,Neutral
"Bristol-Myers  ( BMY )  Q4 Earnings Top, Revlimid Generic Impact Sales",https://www.zacks.com/stock/news/2049110/bristol-myers-bmy-q4-earnings-top-revlimid-generic-impact-sales,2023-02-02 19:59:00,"Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.",BMY,0.157483,0.158963,Somewhat-Bullish
"Golden Cross Hints 10% S&P 2023 Return; Apple, Google, Amazon On Deck; GM Breaks Out",https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-meta-surges-teslas-china-production-ramps-up-apples-post-earnings-stock-performance-record/,2023-02-02 19:05:00,"Dow Jones Falls, Nasdaq Rockets. Golden Cross Hints 10% 2023 ... Investor's Business Daily ...",BMY,0.157827,0.009788,Neutral
Bristol-Myers Squibb  ( BMY )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/02/02/bristol-myers-squibb-bmy-q4-2022-earnings-call-tra/,2023-02-02 19:00:21,"BMY earnings call for the period ending December 31, 2022.",BMY,0.018486,0.190073,Somewhat-Bullish
"Compared to Estimates, Bristol Myers  ( BMY )  Q4 Earnings: A Look at Key Metrics",https://www.zacks.com/stock/news/2048618/compared-to-estimates-bristol-myers-bmy-q4-earnings-a-look-at-key-metrics,2023-02-02 17:58:00,"While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",BMY,0.072876,-0.091636,Neutral
Economic Data Deluge,https://www.zacks.com/stock/news/2048524/economic-data-deluge,2023-02-02 16:04:00,"This morning, we see really terrific numbers on Q4 Productivity - the key to a strong economy outside employment levels, etc. It's a first read, so subject to revisions in the future, but for now we'll take it: +3.0% is half a percentage point higher than expected, and more than double the ...",BMY,0.157483,0.044076,Neutral
Goldilocks Econ Data Presides Over Pre-Market,https://www.zacks.com/stock/news/2048497/goldilocks-econ-data-presides-over-pre-market,2023-02-02 15:39:00,"We haven't thrown around the term ""Goldilocks"" too much lately, but this morning, the shoe fits.",BMY,0.147366,0.038371,Neutral
AZN: 3 Pharma Stocks to Buy in 2023 and Hold for Decades,https://stocknews.com/news/azn-bmy-gsk-3-pharma-stocks-to-buy-in-2023-and-hold-for/,2023-02-02 15:31:06,"COVID-19 continues to have a significant impact on the pharmaceutical industry. Vaccines are expected to increase the net cumulative pharmaceutical market to $500 billion by 2027. As per the report from IQVIA Institute, total spending and global demand for medicines could reach approximately ...",BMY,0.265089,0.252202,Somewhat-Bullish
"Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range",https://www.benzinga.com/general/biotech/23/02/30687807/revlimid-generic-competition-hurts-bristol-myers-q4-earnings-issues-annual-outlook-within-expecte,2023-02-02 14:05:33,"Bristol Myers Squibb & Co BMY said that its Q4 sales of $11.41 billion fell 5% Y/Y as generic competition impacted sales of its blockbuster cancer drug Revlimid in the U.S. and foreign exchange impacts, partially offset by in-line products ( primarily Opdivo ) and new product portfolio ( ...",BMY,0.585687,0.024598,Neutral
"Bristol Myers Stock Pops On Quarterly Beat, Strong Earnings Guide",https://www.investors.com/news/technology/bmy-stock-bristol-myers-earnings-q4-2022/,2023-02-02 13:55:00,"BMY Stock Pops On Fourth-Quarter Beat, Strong Earnings Outlook ... Investor's Business Daily ...",BMY,0.854693,0.48221,Bullish
Bristol Myers Squibb  ( BMY )  Q4 Earnings and Revenues Surpass Estimates,https://www.zacks.com/stock/news/2048225/bristol-myers-squibb-bmy-q4-earnings-and-revenues-surpass-estimates,2023-02-02 13:15:11,"Bristol Myers (BMY) delivered earnings and revenue surprises of 6.43% and 2.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",BMY,0.137671,0.095454,Neutral
Bristol Myers Profit Tops Estimates but Revenue Falls on Lower Revlimid Sales,https://www.barrons.com/articles/bristol-myers-stock-earnings-revlimid-sales-51675341530,2023-02-02 12:39:00,Bristol Myers Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates ...,BMY,0.807885,-0.163947,Somewhat-Bearish
Bristol-Myers Squibb Guides FY23 Adj. EPS In Line; Q4 Results Top Estimates,https://markets.businessinsider.com/news/stocks/bristol-myers-squibb-guides-fy23-adj-eps-in-line-q4-results-top-estimates-1032062561,2023-02-02 12:29:07,Bristol-Myers Squibb Guides FY23 Adj. EPS In Line. Q4 Results Top Estimates ...,BMY,0.521465,0.40369,Bullish
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022,https://investingnews.com/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2022/,2023-02-02 12:25:36,"Bristol Myers Squibb ( NYSE:BMY ) today reports results for the fourth quarter and full year of 2022, which reflect robust growth of the in-line and new product portfolios, driven by strong commercial execution and continued progress of the company's pipeline.",BMY,0.110416,0.213897,Somewhat-Bullish
Bristol Myers Q4 earnings sag on lower Revlimid sales,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-q4-earnings-sag-lower-revlimid-sales-2023-02-02/,2023-02-02 12:00:50,"[1/2] Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration",BMY,0.261117,-0.162105,Somewhat-Bearish
"Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?",https://www.benzinga.com/news/earnings/23/02/30684282/nasdaq-futures-fly-as-meta-keeps-tech-earnings-buoyancy-intact-will-apple-amazon-alphabet-toe-in-li,2023-02-02 11:34:23,"The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. Meta Platform Inc's META strong earnings could set the tempo for the market mood as traders wait to hear from some of its big tech peers after the close.",BMY,0.093836,-0.062628,Neutral
"Tech Futures Jump As Meta Spikes; Apple, Amazon, Google Due",https://www.investors.com/market-trend/stock-market-today/tech-futures-jump-on-meta-spike-after-gratifying-fed-rally-apple-amazon-google/,2023-02-02 11:30:00,Tech Futures Jump As Meta Spikes. Powell Spurs' Gratifying' Rally Investor's Business Daily ...,BMY,0.065387,-0.091937,Neutral
Fed Chief Triggers 'Gratifying' Rally; Meta Spikes On Earnings,https://www.investors.com/market-trend/stock-market-today/fed-chief-powell-triggers-gratifying-market-rally-meta-stock-spikes-on-earnings/,2023-02-01 21:57:00,Fed Chief Triggers 'Gratifying' Rally. Meta Spikes On Earnings Investor's Business Daily ...,BMY,0.04677,-0.082605,Neutral
Bristol-Myers Squibb Unusual Options Activity For February 01,https://www.benzinga.com/markets/options/23/02/30672257/bristol-myers-squibb-unusual-options-activity-for-february-01,2023-02-01 18:28:00,"Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.722509,0.144147,Neutral
WMT: Owning These 3 Stocks Could Make You Rich in 10 Years,https://stocknews.com/news/wmt-bmy-cvs-owning-these-3-stocks-could-make-you-rich-in-10/,2023-02-01 16:45:18,"With the steady stream of optimistic economic data, the stock market achieved a strong start this year. Despite widespread concern that the economy might be on the brink of a recession, the market closed off the first month with healthy gains.",BMY,0.220809,0.167288,Somewhat-Bullish
An Increase In Investments In The R&D Of Autoimmune Disease Drugs Is Expected To Drive The Autoimmune Treatment Market As Per The Business Research Company's Autoimmune Treatment Global Market Report 2023,https://www.benzinga.com/pressreleases/23/02/g30671480/an-increase-in-investments-in-the-r-d-of-autoimmune-disease-drugs-is-expected-to-drive-the-autoimm,2023-02-01 16:30:00,"LONDON, Feb. 01, 2023 ( GLOBE NEWSWIRE ) -- The Business Research Company's research on the ""Autoimmune Treatment Market"" forecasts the global autoimmune treatment market size to grow from $6 billion in 2022 to $6.8 billion in 2023 at a compound annual growth rate ( CAGR ) of more than 12%.",BMY,0.050572,-0.049564,Neutral
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate,https://www.benzinga.com/general/biotech/23/02/30669139/prothena-touts-encouraging-data-from-early-stage-alzheimers-candidate,2023-02-01 15:48:47,Prothena Corporation plc PRTA announced topline data from the Phase 1 single ascending dose ( SAD ) study for PRX005 for Alzheimer's disease. PRX005 is one of three global neuroscience research and development programs in collaboration between Prothena and Bristol Myers Squibb & Co BMY.,BMY,0.345674,0.0,Neutral
"Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others",https://www.zacks.com/stock/news/2047789/drugbiotech-stocks-q4-earnings-due-on-feb-2-gild-mrk-others,2023-02-01 15:44:00,Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.,BMY,0.172404,0.034539,Neutral
Qiagen  ( QGEN )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?,https://www.zacks.com/stock/news/2047014/qiagen-qgen-expected-to-beat-earnings-estimates-can-the-stock-move-higher,2023-01-31 15:01:00,Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.087503,0.039072,Neutral
"Global Cytotoxic Drugs Market Predicted to Generate a Revenue of $14,885.2 Million and Grow at a CAGR of 1.2% during the Analysis Timeframe from 2021 to 2028 [202-Pages] | Issued by Research Dive",https://www.benzinga.com/pressreleases/23/01/g30643164/global-cytotoxic-drugs-market-predicted-to-generate-a-revenue-of-14-885-2-million-and-grow-at-a-ca,2023-01-31 14:02:00,"New York, USA, Jan. 31, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research Dive, the global cytotoxic drugs market is anticipated to generate a revenue of $14,885.2 million and rise at a CAGR of 1.2% over the estimated timeframe from 2021 to 2028.",BMY,0.059341,0.0,Neutral
Flagship Pioneering Announces Appointment of Christian Schade as Growth Partner,https://www.prnewswire.com/news-releases/flagship-pioneering-announces-appointment-of-christian-schade-as-growth-partner-301733853.html,2023-01-31 12:00:00,Flagship Pioneering Announces Appointment of Christian Schade ... PR ...,BMY,0.054857,-0.016984,Neutral
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later,https://www.fool.com/investing/2023/02/18/3-dirt-cheap-stocks-to-buy-sooner-rather-than-late/,2023-02-18 13:14:00,These pharmaceutical stocks probably won't stay so attractively valued for too much longer.,BMY,0.256538,0.172595,Somewhat-Bullish
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,https://www.globenewswire.com/news-release/2023/02/17/2610961/0/en/Sutro-Biopharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2023-02-17 21:01:00,"SOUTH SAN FRANCISCO, Calif., Feb. 17, 2023 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) ( NASDAQ: STRO ) , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced that on February 15, 2023, the ...",BMY,0.076602,0.050821,Neutral
Bristol Myers' Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/02/30963196/bristol-myers-opdivo-shows-improved-clinical-benefits-in-bladder-cancer-at-three-years,2023-02-17 17:45:11,Bristol-Myers Squibb Co BMY announced three-year follow-up results from the Phase 3 CheckMate -274 Phase 3 trial of Opdivo compared to placebo for muscle-invasive urothelial carcinoma at a high risk of recurrence after radical resection.,BMY,0.514619,-0.179257,Somewhat-Bearish
Bladder Cancer Drugs Global Market Report 2023,https://www.prnewswire.com/news-releases/bladder-cancer-drugs-global-market-report-2023-301749125.html,2023-02-17 16:50:00,"NEW YORK, Feb. 17, 2023 /PRNewswire/ --Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International and Johnson & Johnson.",BMY,0.031529,-0.124665,Neutral
These 2 Biotech Stocks Could Soar in the Next Bull Market,https://www.fool.com/investing/2023/02/17/these-2-biotech-stocks-could-soar-in-the-next-bull/,2023-02-17 15:23:00,They're both at the cutting edge of gene-editing technology.,BMY,0.057907,0.159997,Somewhat-Bullish
"Adjuvant Opdivo Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial",https://investingnews.com/adjuvant-opdivo-continues-to-provide-significant-durable-clinical-benefits-for-patients-with-radically-resected-high-risk-muscle-invasive-urothelial-carcinoma-after-three-years-in-checkmate-274-trial/,2023-02-17 15:21:47,"Bristol Myers Squibb ( NYSE: BMY ) today announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo ( nivolumab ) for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive ...",BMY,0.082772,0.038537,Neutral
Why Bristol Myers Squibb  ( BMY )  is a Top Value Stock for the Long-Term,https://www.zacks.com/stock/news/2055894/why-bristol-myers-squibb-bmy-is-a-top-value-stock-for-the-long-term,2023-02-17 14:40:06,"Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",BMY,0.362065,0.369474,Bullish
The Patent Cliff Is Coming For Bristol Myers - Here's What It's Planning For 2023,https://www.investors.com/news/technology/bmy-stock-can-its-new-products-fill-the-looming-patent-cliff-gap/,2023-02-17 13:00:00,BMY Stock: Can Its New Products Fill The Looming Patent-Cliff Gap? Investor's Business Daily ...,BMY,0.280386,-0.055651,Neutral
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation and its Symptoms,https://investingnews.com/basketball-legend-kareem-abdul-jabbar-joins-no-time-to-wait-campaign-to-raise-awareness-of-atrial-fibrillation-and-its-symptoms/,2023-02-16 12:28:36,"Approximately 9.5 million people in the U.S. are projected to have AFib in 2023, with the number expected to rise to approximately 12.1 million by 2030; many ignore their symptoms, not realizing that AFib increases their risk of stroke by about five times",BMY,0.402501,0.095892,Neutral
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update,https://www.globenewswire.com/news-release/2023/02/16/2609348/0/en/Ultimovacs-ASA-Reports-Fourth-Quarter-2022-Financial-Results-and-Provides-General-Business-Update.html,2023-02-16 07:00:00,"Oslo, February 16, 2023: Ultimovacs ASA ( ""Ultimovacs"" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its fourth quarter 2022 results today.",BMY,0.02922,-0.030894,Neutral
KO: 4 Great Stocks to Buy Now for Under $100,https://stocknews.com/news/ko-bmy-cah-bvh-4-great-stocks-to-buy-now-for-under-100/,2023-02-15 17:28:51,KO: 4 Great Stocks to Buy Now for Under ...,BMY,0.106659,0.13565,Neutral
"Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical",https://www.globenewswire.com/news-release/2023/02/15/2608712/0/en/Cellectar-Biosciences-Hires-Dr-Andrei-Shustov-as-New-Senior-Vice-President-Medical.html,2023-02-15 13:30:00,"FLORHAM PARK, N.J., Feb. 15, 2023 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ: CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has hired Andrei ...",BMY,0.042346,-0.021395,Neutral
JNJ: 2 Stocks to Help You Sail Through This Volatile Market,https://stocknews.com/news/jnj-bmy-2-stocks-to-help-you-sail-through-this-volatile-market/,2023-02-15 13:16:54,"The Feds chose a less aggressive stance and dialed down rate hikes to 0.25 percentage points. This revived investor optimism. However, inflation reaccelerated in January, as the Consumer Price Index ( CPI ) rose 0.5% in January, translating to a 6.4% annual gain.",BMY,0.411176,0.311168,Somewhat-Bullish
"Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer - Exelixis  ( NASDAQ:EXEL ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/02/30898035/bristol-myers-squibb-exelixis-highlight-three-year-follow-up-data-from-opdivo-cabometyx-combo-the,2023-02-14 14:40:33,Bristol Myers Squibb & Co BMY and Exelixis Inc EXEL announced three-year follow-up results from the Phase 3 CheckMate -9ER Phase 3 trial evaluating Opdivo ( nivolumab ) plus Cabometyx ( cabozantinib ) in renal cancer.,BMY,0.382925,0.0,Neutral
"Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial",https://www.globenewswire.com/news-release/2023/02/14/2607476/0/en/Purple-Biotech-Announces-First-Patient-Dosed-in-Open-Label-Randomized-Part-of-CM24-Phase-2-Clinical-Trial.html,2023-02-14 12:01:00,"REHOVOT, Israel, Feb. 14, 2023 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( ""Purple Biotech"" or ""the Company"" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune ...",BMY,0.030799,0.02704,Neutral
Opdivo® in Combination with CABOMETYX® Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma,https://investingnews.com/opdivo-r-in-combination-with-cabometyx-r-shows-durable-survival-with-over-three-years-of-follow-up-in-the-checkmate-9er-trial-in-first-line-advanced-renal-cell-carcinoma/,2023-02-13 22:25:05,These three-year data with a median follow-up of 44 months from CheckMate -9ER represent the longest reported follow-up in any Phase 3 trial with an immunotherapy-tyrosine kinase inhibitor regimen in this population,BMY,0.080557,0.033179,Neutral
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma - Ipsen  ( OTC:IPSEY ) ,https://www.benzinga.com/pressreleases/23/02/g30889414/cabometyx-in-combination-with-nivolumab-shows-durable-survival-benefits-at-over-three-years-follow,2023-02-13 22:00:00,Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless of IMDC risk score1,BMY,0.013409,-0.014743,Neutral
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma,https://www.globenewswire.com/news-release/2023/02/13/2607168/0/en/Cabometyx-in-combination-with-nivolumab-shows-durable-survival-benefits-at-over-three-years-follow-up-in-first-line-advanced-renal-cell-carcinoma.html,2023-02-13 22:00:00,"PARIS, FRANCE Ipsen ( Euronext: IPN. ADR: IPSEY ) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® ( cabozantinib ) in combination with nivolumab provides survival and response rate benefits after three-years in ...",BMY,0.013342,-0.017511,Neutral
The 8 leading biotechs using AI to upend how drugs are discovered,https://www.businessinsider.com/list-top-ai-biotech-companies-recursion-schrodinger-abcellera,2023-02-13 18:51:07,"List of Top AI Biotech Innovators: Recursion, Schrödinger, AbCellera - Business Insider ...",BMY,0.038101,-0.001942,Neutral
A Bearish Sign Appears On Bristol-Myers Squibb's Chart - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/23/02/30878178/a-bearish-sign-appears-on-bristol-myers-squibbs-chart,2023-02-13 14:47:41,"If history is any guide, there may be trouble ahead for shares of Bristol-Myers Squibb BMY. A so-called ""death cross"" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions.",BMY,0.561184,-0.458171,Bearish
"Regenerative Medicine Market to Surpass USD 153.05 Billion by 2029, With 26.3% CAGR",https://www.benzinga.com/pressreleases/23/02/g30874563/regenerative-medicine-market-to-surpass-usd-153-05-billion-by-2029-with-26-3-cagr,2023-02-13 12:45:47,"Pune, India, Feb. 13, 2023 ( GLOBE NEWSWIRE ) -- The regenerative medicine market size was valued at USD 23.65 billion in 2021. The market is expected to grow from USD 29.86 billion in 2022 to USD 153.05 billion by 2029 with a CAGR of 26.3% during the forecast period.",BMY,0.039548,0.083153,Neutral
"Global Outlook for Antacids Market | Growth rate at 4.5 percent during the forecast period, Regional Insights and Key Players",https://www.benzinga.com/pressreleases/23/02/g30872081/global-outlook-for-antacids-market-growth-rate-at-4-5-percent-during-the-forecast-period-regional-,2023-02-13 09:57:44,"NEW YORK, Feb. 13, 2023 ( GLOBE NEWSWIRE ) -- Maximize Market research, a global Healthcare market research firm, has published a competitive intelligence and market research report on the ""Antacids Market"".",BMY,0.03319,-0.009406,Neutral
"Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients - 2seventy bio  ( NASDAQ:TSVT ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/02/30858501/bristol-myers-2seventy-partnered-abecma-cuts-risk-of-disease-progression-death-by-51-in-pretreate,2023-02-10 17:28:27,Bristol-Myers Squibb & Co BMY and 2seventy bio Inc TSVT announced the first publication and presentation of results from the KarMMa-3 Phase 3 study evaluating Abecma ( idecabtagene vicleucel ) in The New England Journal of Medicine.,BMY,0.456884,0.0,Neutral
Abecma Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study,https://investingnews.com/abecma-reduced-the-risk-of-disease-progression-or-death-by-51-versus-standard-regimens-in-earlier-lines-of-therapy-for-relapsed-and-refractory-multiple-myeloma-based-on-results-from-phase-3-karmma-3-s/,2023-02-10 16:35:40,Data published in The New England Journal of Medicine and presented at the EBMT and the European Hematology Association's 5 th European CAR T-cell Meeting,BMY,0.160166,0.024882,Neutral
NVO: 1 Pharma Stock That Could Help You Become a Millionaire,https://stocknews.com/news/nvo-nvs-bmy-alpmy-1-pharma-stock-that-could-help-you-become-a-millionaire/,2023-02-10 15:46:42,"Every investor is on a quest to find a stock that can create immense wealth. Wealth creation happens when an investor capitalizes on trends early on. Danish pharma major Novo Nordisk A/S ( NVO ) reported a solid end to fiscal 2022, with its sales rising 26% in the Danish kroner ( Kr. ) and by 16% ...",BMY,0.060388,0.140013,Neutral
United in the Fight Against Colorectal Cancer,https://www.benzinga.com/pressreleases/23/03/g31145199/united-in-the-fight-against-colorectal-cancer,2023-03-01 22:42:36,"Springfield, Mo., March 01, 2023 ( GLOBE NEWSWIRE ) -- On the heels of the White House declaring March as Colorectal Cancer Awareness Month, urging the public to get screened, national advocacy organization Fight Colorectal Cancer ( Fight CRC ) is bringing awareness to D.C. and beyond through ...",BMY,0.070935,-0.003072,Neutral
CytomX Therapeutics to Present at Upcoming March Investor Conferences - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/pressreleases/23/02/g31103016/cytomx-therapeutics-to-present-at-upcoming-march-investor-conferences,2023-02-28 21:05:00,"SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor ...",BMY,0.165031,-0.037087,Neutral
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates,https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-updates-301758465.html,2023-02-28 21:01:00,Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 ... PR ...,BMY,0.021484,0.0,Neutral
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference,https://www.globenewswire.com/news-release/2023/02/28/2616969/0/en/Ikena-Oncology-to-Participate-in-Cowen-43rd-Annual-Health-Care-Conference.html,2023-02-28 13:00:00,"BOSTON, Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- Ikena Oncology, Inc. ( Nasdaq: IKNA, ""Ikena"" ) , a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a Targeted Oncology Panel at the Cowen 43rd Annual Health Care ...",BMY,0.061159,0.043349,Neutral
Bristol Myers Squibb to Participate in Cowen's 43rd Annual Health Care Conference,https://investingnews.com/bristol-myers-squibb-to-participate-in-cowen-s-43rd-annual-health-care-conference/,2023-02-28 12:24:34,"Bristol Myers Squibb ( NYSE: BMY ) today announced that the company will take part in a fireside chat at Cowen's 43rd Annual Health Care Conference on Tuesday, March 7, 2023. Samit Hirawat , M.D., Executive Vice President, Chief Medical Officer, Head of Development, will answer questions about ...",BMY,0.851762,0.179049,Somewhat-Bullish
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo ....,https://investingnews.com/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-supplemental-biologics-license-application-and-european-medicines-agency-validates-application-for-opdivo/,2023-02-28 12:24:34,Bristol Myers Squibb ( NYSE: BMY ) today announced that the U.S.,BMY,0.07877,0.019596,Neutral
Changes in the governance of NFL Biosciences,https://www.globenewswire.com/news-release/2023/02/27/2616365/0/en/Changes-in-the-governance-of-NFL-Biosciences.html,2023-02-27 16:45:00,"Changes in the governance of NFL Biosciences NFL BIOSCIENCES ( Euronext Growth Paris - FR0014003XT0 - ALNFL ) , a biopharmaceutical company developing botanical drugs for the treatment of addictions, and in particular NFL-101, its drug candidate for smoking cessation, announces the appointment of ...",BMY,0.083833,0.034712,Neutral
PFE: 1 High-Value Stock to Keep in Your Portfolio Forever,https://stocknews.com/news/pfe-bmy-tak-alpmy-1-high-value-stock-to-keep-in-your-portfolio-forever/,2023-02-27 14:05:03,"With value investing gaining traction amid volatile market conditions, investors could consider adding attractively valued shares of fundamentally strong, profitable businesses. At the current price level, I think Pfizer Inc. ( PFE ) is one of the best value stocks for reasons explained ...",BMY,0.072,0.007108,Neutral
JNJ: 1 Dividend Stock to Buy for Passive Income in 2023,https://stocknews.com/news/jnj-nvo-bmy-nvs-1-dividend-stock-to-buy-for-passive-income-in-2023/,2023-02-27 14:02:34,JNJ: 1 Dividend Stock to Buy for Passive Income in ...,BMY,0.105604,0.080898,Neutral
Viatris names Scott Smith as CEO ahead of planned divestiture of certain businesses,https://www.reuters.com/business/healthcare-pharmaceuticals/viatris-names-scott-smith-ceo-ahead-planned-divestiture-certain-businesses-2023-02-27/,2023-02-27 14:01:00,Viatris names Scott Smith as CEO ahead of planned divestiture of ... ...,BMY,0.275867,0.0,Neutral
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology,https://investingnews.com/bristol-myers-squibb-to-present-data-supporting-its-cardiovascular-portfolio-at-the-american-college-of-cardiology-annual-scientific-session-together-with-world-congress-of-cardiology/,2023-02-27 12:26:58,"Bristol Myers Squibb ( NYSE: BMY ) today announced the presentation of research supporting the company's cardiovascular franchise at the American College of Cardiology ( ACC ) Annual Scientific Session & Expo together with the World Congress of Cardiology ( WCC ) , taking place in-person and ...",BMY,0.243295,0.001876,Neutral
Compugen Reports Fourth Quarter and Full Year 2022 Results,https://www.prnewswire.com/news-releases/compugen-reports-fourth-quarter-and-full-year-2022-results-301756395.html,2023-02-27 12:00:00,"On track to dose the first patients in MSS CRC and PROC triple combination proof of concept studies in Q1 2023 and Q2 2023, respectively, with the combination of potential first-in-class anti-PVRIG, COM701, potential best-in-class anti-TIGIT, COM902 and pembrolizumab",BMY,0.020335,0.0,Neutral
This Big Pharma Stock Is a Clear Buy,https://www.fool.com/investing/2023/02/26/this-big-pharma-stock-is-a-clear-buy/,2023-02-26 12:40:00,This drugmaker is one of the most well-known in the world.,BMY,0.128822,0.146352,Neutral
Global Cell & Gene Therapy Business and Investment Opportunities Q1 2023 Update: An Expanding CGT Pipeline Bodes Well for Growth,https://www.prnewswire.com/news-releases/global-cell--gene-therapy-business-and-investment-opportunities-q1-2023-update-an-expanding-cgt-pipeline-bodes-well-for-growth-301755634.html,2023-02-24 18:20:00,Global Cell & Gene Therapy Business and Investment Opportunities ... PR ...,BMY,0.018787,0.044196,Neutral
KO: 3 Stocks to Safeguard Your Portfolio in 2023,https://stocknews.com/news/ko-bmy-syy-3-stocks-to-safeguard-your-portfolio-in-2023/,2023-02-24 17:41:31,KO: 3 Stocks to Safeguard Your Portfolio in ...,BMY,0.268,0.127967,Neutral
Prothena  ( PRTA )  Q4 Earnings and Revenues Beat Estimates,https://www.zacks.com/stock/news/2058859/prothena-prta-q4-earnings-and-revenues-beat-estimates,2023-02-24 16:36:00,Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.,BMY,0.118064,-0.049304,Neutral
Why Nektar Therapeutics  ( NKTR )  Stock Is Plunging Today - Nektar Therapeutics  ( NASDAQ:NKTR ) ,https://www.benzinga.com/general/biotech/23/02/31045182/why-nektar-therapeutics-stock-is-plunging-today,2023-02-24 13:23:12,Nektar Therapeutics NKTR announced topline data from a Phase 2 study of rezpegaldesleukin ( LY3471851 or REZPEG ) in adults with moderately-to-severely active systemic lupus erythematosus ( SLE ) .,BMY,0.303175,-0.327328,Somewhat-Bearish
International Myeloma Foundation  ( IMF )  Launches #MYelomaSTORY Campaign for Myeloma Action Month in March 2023,https://www.benzinga.com/pressreleases/23/02/g31027448/international-myeloma-foundation-imf-launches-myelomastory-campaign-for-myeloma-action-month-in-ma,2023-02-23 13:45:00,"STUDIO CITY, Calif., Feb. 23, 2023 ( GLOBE NEWSWIRE ) -- With the International Myeloma Foundation ( IMF ) at the forefront, Myeloma Action Month is held every year for the whole month of March to encourage individuals and groups to take actions that positively impact the myeloma community.",BMY,0.034332,0.225632,Somewhat-Bullish
AZN: 1 Pharma Stock Poised for a Promising 2023,https://stocknews.com/news/azn-nvo-bmy-nvs-1-pharma-stock-poised-for-a-promising-2023/,2023-02-23 11:10:58,AZN: 1 Pharma Stock Poised for a Promising ...,BMY,0.075754,0.131488,Neutral
Bristol Myers Squibb to invest Rs 800 cr for drug development in Hyderabad,https://www.business-standard.com/article/current-affairs/bristol-myers-squibb-to-invest-rs-800-cr-for-drug-development-in-hyderabad-123022300326_1.html,2023-02-23 06:12:00,Bristol Myers Squibb to invest Rs 800 cr for drug development in ... Business Standard ...,BMY,0.29234,0.431142,Bullish
Breast Cancer Therapeutics Market Exhibits 13.1% CAGR to hit USD 55.27 Billion by 2027,https://www.benzinga.com/pressreleases/23/02/g31021654/breast-cancer-therapeutics-market-exhibits-13-1-cagr-to-hit-usd-55-27-billion-by-2027,2023-02-23 05:45:35,"Pune, India, Feb. 23, 2023 ( GLOBE NEWSWIRE ) -- The global Breast Cancer Therapeutics Market size was valued at USD 21.58 billion in 2019. The market is projected to grow USD 55.27 billion by 2027, exhibiting a CAGR of 13.1% during the forecast period.",BMY,0.040145,0.0,Neutral
This Recession-Proof Company Has a Best-in-Class Dividend,https://www.fool.com/investing/2023/02/22/this-recession-proof-company-has-a-best-in-class-d/,2023-02-22 12:30:00,"Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group.",BMY,0.139265,-0.114321,Neutral
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates,https://www.globenewswire.com/news-release/2023/02/22/2612962/0/en/Editas-Medicine-Announces-Fourth-Quarter-and-Full-Year-2022-Results-and-Business-Updates.html,2023-02-22 11:15:00,"Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter ...",BMY,0.023767,0.07168,Neutral
A top-5% fund manager shares 4 reasons why he's getting optimistic about the economy after hiding nearly half of his assets in cash last summer - and details 6 of his favorite stocks to buy now,https://www.businessinsider.com/investing-stock-picks-to-buy-recession-risk-outlook-inflation-rates-2023-2,2023-02-22 10:05:00,6 Stock Picks to Buy As Recession Risk Falls: Top-5% Fund Manager - Business Insider ...,BMY,0.070207,0.21546,Somewhat-Bullish
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS,https://www.prnewswire.com/news-releases/halozyme-reports-fourth-quarter-and-full-year-2022-financial-and-operating-results-301752201.html,2023-02-21 21:01:00,HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 ... PR ...,BMY,0.027876,0.060903,Neutral
BMY: Is Bristol-Myers a Good Dividend Stock to Pick up Right Now?,https://stocknews.com/news/bmy-nvo-nvs-alpmy-is-bristol-myers-a-good-dividend-stock-to-pick-up-right/,2023-02-21 14:02:29,"Leading pharma company Bristol-Myers Squibb Company ( BMY ) has 33 consecutive years of dividend payments and six consecutive years of dividend growth. The company paid a quarterly dividend of $0.57 per share on February 1, 2023, representing an increase of 5.6% over its previous quarterly ...",BMY,0.645887,0.330744,Somewhat-Bullish
"Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline",https://investingnews.com/merck-to-present-new-data-for-sotatercept-and-mk-0616-at-acc-23-wcc-demonstrating-significant-progress-in-advancing-its-innovative-cardiovascular-pipeline/,2023-02-21 12:17:51,"Merck ( NYSE: MRK ) , known as MSD outside of the United States and Canada, today announced the presentation of clinical data from its broad and advancing cardiovascular pipeline and portfolio at the upcoming American College of Cardiology's 72 nd Annual Scientific Session together with World ...",BMY,0.024572,0.169237,Somewhat-Bullish
PFE: 4 Pharma Stocks to Buy Now for the Long Haul,https://stocknews.com/news/pfe-azn-bmy-zts-4-pharma-stocks-to-buy-now-for-the-long-haul/,2023-02-20 14:53:40,"The pharmaceutical sector has thrived in recent years and is anticipated to reach $1.5 trillion this year. The integration of innovative technologies has opened a new world of possibilities for the industry. Moreover, customized medicine should potentially bolster the healthcare sector, ...",BMY,0.182113,0.145778,Neutral
Pancreatic Cancer Treatment Market Exhibits 15.7% CAGR to Hit USD 6.85 Billion by 2029,https://www.benzinga.com/pressreleases/23/02/g30975762/pancreatic-cancer-treatment-market-exhibits-15-7-cagr-to-hit-usd-6-85-billion-by-2029,2023-02-20 12:04:21,"Pune, India, Feb. 20, 2023 ( GLOBE NEWSWIRE ) -- The global pancreatic cancer treatment market size was worth USD 2.15 billion in 2021 and is slated to rise from USD 2.48 billion in 2022 to USD 6.85 billion by 2029, at 15.7% CAGR during forecast period.",BMY,0.031446,0.0,Neutral
"Buy these 16 dividend stocks to collect consistent cash payments while inflation stays high, according to a fund manager who outperformed 95% of his peers last year",https://www.businessinsider.com/investing-dividend-stocks-to-buy-inflation-outlook-federal-reserve-rates-2023-2,2023-02-20 10:30:00,16 Dividend Stocks to Buy As Inflation Persists: Top 5% Fund Manager - Business Insider ...,BMY,0.121241,0.057974,Neutral
Nasdaq Bear Market: 5 Stunning Growth Stocks You'll Regret Not Buying on the Dip,https://www.fool.com/investing/2023/03/11/nasdaq-bear-market-5-growth-stocks-regret-not-buy/,2023-03-11 10:06:00,A 33% plunge in the previously high-flying Nasdaq Composite is the perfect time for growth investors to pounce on some amazing deals.,BMY,0.026155,0.151409,Somewhat-Bullish
Should Investors Buy Bristol Myers or CVS Stock Near 52-week Lows?,https://www.zacks.com/stock/news/2064430/should-investors-buy-bristol-myers-or-cvs-stock-near-52-week-lows,2023-03-11 00:40:00,Investors are often on the lookout for strong companies that may be undervalued and present lucrative long-term opportunities.,BMY,0.345674,0.292008,Somewhat-Bullish
"Diffuse large B-cell lymphoma  ( DLBCL )  therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio",https://www.prnewswire.com/news-releases/diffuse-large-b-cell-lymphoma-dlbcl-therapeutics-market-size-to-increase-by-usd-2-061-88-million-between-2022-and-2027-growth-driven-by-increasing-approval-of-therapeutics---technavio-301768024.html,2023-03-10 22:30:00,Diffuse large B-cell lymphoma ( DLBCL ) therapeutics market size to ... PR ...,BMY,0.0378,0.00862,Neutral
Bristol Myers Squibb  ( BMY )  Stock Moves -1.19%: What You Should Know,https://www.zacks.com/stock/news/2064390/bristol-myers-squibb-bmy-stock-moves--119-what-you-should-know,2023-03-10 21:45:22,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $65.72, marking a -1.19% move from the previous day.",BMY,0.659949,0.260509,Somewhat-Bullish
Natco Pharma launches additional strengths of Revlimid generic in US,https://www.business-standard.com/article/news-cm/natco-pharma-launches-additional-strengths-of-revlimid-generic-in-us-123031000127_1.html,2023-03-10 03:17:00,Natco Pharma launches additional strengths of Revlimid generic in ... Business Standard ...,BMY,0.24289,0.0,Neutral
How Is The Market Feeling About Bristol-Myers Squibb? - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/23/03/31283341/how-is-the-market-feeling-about-bristol-myers-squibb,2023-03-09 18:45:46,"Bristol-Myers Squibb's BMY short percent of float has fallen 14.29% since its last report. The company recently reported that it has 17.72 million shares sold short, which is 0.84% of all regular shares that are available for trading.",BMY,0.221819,0.083071,Neutral
JNJ: 1 Stock to Buy for Safety in This Volatile Market,https://stocknews.com/news/jnj-nvo-bmy-nvs-1-stock-to-buy-for-safety-in-this-volatile-market/,2023-03-09 14:17:57,"Earlier this week, Fed Chair Jerome Powell cautioned that interest rates would likely rise higher than the central bank policymakers expected. As renewed recession fears will keep the stock market under pressure, investors looking for a safe stock may consider Johnson & Johnson ( JNJ ) .",BMY,0.066691,0.136341,Neutral
Anti-Viral Therapies Market Growth  ( $82.92 Billion by 2028 )  Driven by Branded Drugs Segment during  ( 2022-2028 )  - Global Report by The Insight Partners,https://www.benzinga.com/pressreleases/23/03/g31276388/anti-viral-therapies-market-growth-82-92-billion-by-2028-driven-by-branded-drugs-segment-during-20,2023-03-09 13:46:17,"New York, March 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Generic Drugs and Branded Drugs ) , Mechanism of Action ( Nucleotide Polymerase ...",BMY,0.02493,0.067196,Neutral
"Cancer Vaccines Market Size Expected to Hit USD 19.12 Billion by 2029, exhibiting a CAGR of 14.7%",https://www.benzinga.com/pressreleases/23/03/g31274832/cancer-vaccines-market-size-expected-to-hit-usd-19-12-billion-by-2029-exhibiting-a-cagr-of-14-7,2023-03-09 12:50:51,"Pune, India, March 09, 2023 ( GLOBE NEWSWIRE ) -- The global cancer vaccines market size was valued at USD 6.43 billion in 2021. The market is expected to grow from USD 7.32 billion in 2022 to USD 19.12 billion by 2029, exhibiting a CAGR of 14.7% during the forecast period.",BMY,0.040691,-0.073003,Neutral
"Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023",https://investingnews.com/bristol-myers-squibb-to-report-results-for-first-quarter-2023-on-april-27-2023/,2023-03-09 12:29:25,"Bristol Myers Squibb ( NYSE: BMY ) will announce results for the first quarter of 2023 on Thursday, April 27, 2023. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date.",BMY,0.686739,0.177026,Somewhat-Bullish
Aurobindo Pharma arm gets USFDA nod for cancer drug,https://www.business-standard.com/article/news-cm/aurobindo-pharma-arm-gets-usfda-nod-for-cancer-drug-123030800258_1.html,2023-03-08 04:49:00,"The pharmaceutical company on Wednesday announced that its wholly owned subsidiary, Eugia Pharma Specialities has received a final approval from the US Food & Drug Administration ( USFDA ) to manufacture and market Lenalidomide Capsules.",BMY,0.200688,0.106881,Neutral
AZN: The Best Stock to Buy for Under $100 Right Now,https://stocknews.com/news/azn-nvs-bmy-tak-the-best-stock-to-buy-for-under-100-right-now/,2023-03-07 19:50:51,"Amid macroeconomic turbulence regarding persistent inflation and the increasing threat of a Fed-induced recession, investing in shares of fundamentally strong, time-tested, and profitable businesses with resilient demand and margins, such as AstraZeneca PLC ( AZN ) , could ensure consistent, ...",BMY,0.075043,-0.053451,Neutral
BMY: 2 Dividend Stocks That Could Pay You for the Rest of Your Life,https://stocknews.com/news/bmy-gild-jnj-2-dividend-stocks-that-could-pay-you-for-the-rest/,2023-03-07 17:23:48,"Investors' confidence has taken a hit due to macroeconomic issues. As bear-market risks remain, I think it is ideal to invest in quality dividend stocks, Bristol-Myers Squibb Company ( BMY ) and Gilead Sciences, Inc. ( GILD ) , that can ensure a steady income source.",BMY,0.372448,0.156846,Somewhat-Bullish
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2062538/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks,2023-03-07 14:10:03,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.216376,0.119894,Neutral
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal,https://www.globenewswire.com/news-release/2023/03/07/2622063/0/en/SELLAS-Announces-Publication-of-Positive-GPS-Clinical-Data-in-Ovarian-Cancer-in-Peer-Reviewed-Journal.html,2023-03-07 13:30:00,Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti-PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer in the Post-Salvage Setting ...,BMY,0.034233,0.014261,Neutral
PFE: 4 Stocks to Buy in Any Market Climate,https://stocknews.com/news/pfe-bmy-amgn-elv-jnj-azn-4-stocks-to-buy-in-any-market-climate/,2023-03-07 12:18:04,"The stock market remains volatile ahead of Fed chair Jerome Powell's Semiannual Monetary Policy Report delivery to Congress. Moreover, as recessionary fears are high, quality healthcare stocks Pfizer Inc. ( PFE ) , Bristol-Myers Squibb Company ( BMY ) , Amgen Inc. ( AMGN ) , and Elevance Health ...",BMY,0.237668,0.065774,Neutral
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results,https://www.prnewswire.com/news-releases/inhibrx-reports-fourth-quarter-and-fiscal-year-2022-financial-results-301763574.html,2023-03-06 21:05:00,"SAN DIEGO, March 6, 2023 /PRNewswire/ -- Inhibrx, Inc. ( Nasdaq: INBX ) ( ""Inhibrx"" or the ""Company"" ) , a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2022.",BMY,0.035555,0.01958,Neutral
Ikena Oncology  ( Nasdaq: $IKNA )  Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma,https://www.investorideas.com/news/2023/biotech/03061NASDAQ-IKNA.asp,2023-03-06 20:11:35,Ikena Oncology ( Nasdaq: $IKNA ) Receives FDA Fast Track ... ...,BMY,0.082535,0.020985,Neutral
"Victories And failures Of Roche, Bristol Myers, and Merck And Why It's Worth Investing In Immunotherapy Now - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/23/03/31224493/victories-and-failures-of-roche-bristol-myers-and-merck-and-why-its-worth-investing-in-immunotherapy,2023-03-06 19:37:40,"The discovery of immune checkpoint proteins was a breakthrough in cancer immunotherapy. Today, Merck, Roche, and Bristol Myers are leading the immuno-oncology race, with Merck's Keytruda dominating. Bristol Myers's Opdivo is one step behind, while Roche is still looking for its niches after ...",BMY,0.091684,0.042644,Neutral
Merck's Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy,https://investingnews.com/merck-s-investigational-activin-signaling-inhibitor-sotatercept-improved-six-minute-walk-distance-by-40-8-meters-at-week-24-versus-placebo-in-adults-with-pulmonary-arterial-hypertension-on-background-/,2023-03-06 17:38:04,"Merck ( NYSE: MRK ) , known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, Merck's novel investigational activin signaling inhibitor biologic, in combination with stable background therapy for the ...",BMY,0.027925,0.104585,Neutral
Bristol Myers  ( BMY )  Gets EU Nod for Anemia Drug Reblozyl,https://www.zacks.com/stock/news/2062273/bristol-myers-bmy-gets-eu-nod-for-anemia-drug-reblozyl,2023-03-06 16:56:00,"Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.",BMY,0.439786,0.09155,Neutral
My brother was a first-generation immigrant who died in police custody. Now I'm a doctor dedicated to addressing health disparities.,https://africa.businessinsider.com/health/my-brother-was-a-first-generation-immigrant-who-died-in-police-custody-now-im-a/5tex5y0,2023-03-04 10:45:00,My brother was a first-generation immigrant who died in police ... - Business Insider Africa ...,BMY,0.063763,-0.016088,Neutral
Investing Action Plan: Feeling March Momentum,https://www.investors.com/research/investing-action-plan/stock-market-investing-action-plan-from-powell-to-payrolls-a-busy-week/,2023-03-03 23:23:00,"Stock Market Investing Action Plan: From Powell To Payrolls, A Busy ... Investor's Business Daily ...",BMY,0.059785,0.079999,Neutral
Bristol Myers Squibb Announces Dividend,https://investingnews.com/bristol-myers-squibb-announces-dividend-2659499099/,2023-03-03 21:50:52,"Bristol Myers Squibb ( NYSE: BMY ) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ( $0.57 ) per share on the $.10 par value common stock of the company. The dividend is payable on May 1, 2023, to stockholders of record at the close of business ...",BMY,0.851762,0.337068,Somewhat-Bullish
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia,https://investingnews.com/bristol-myers-squibb-receives-european-commission-approval-of-reblozyl-r-for-anemia-in-adult-patients-with-non-transfusion-dependent-beta-thalassemia/,2023-03-03 12:55:07,"Bristol Myers Squibb ( NYSE: BMY ) today announced that the European Commission ( EC ) has granted full Marketing Authorization for Reblozyl ® ( luspatercept ) , a first-in-class therapeutic option, for treatment in adult patients of anemia associated with non-transfusion-dependent ( NTD ) beta ...",BMY,0.129284,0.007295,Neutral
NVS: 3 Best Stocks to Own for Passive Income in 2023,https://stocknews.com/news/nvs-bmy-caj-3-best-stocks-to-own-for-passive-income-in-2023/,2023-03-03 12:12:40,NVS: 3 Best Stocks to Own for Passive Income in ...,BMY,0.255641,0.160144,Somewhat-Bullish
5 High-Yield Mutual Funds to Buy as Inflation Protection,https://www.zacks.com/stock/news/2061379/5-high-yield-mutual-funds-to-buy-as-inflation-protection,2023-03-03 11:28:00,"Invest in high dividend-paying mutual funds like DRRIX, MLPEX, EQTIX, MENYX and ENHRX to generate income.",BMY,0.036365,0.045604,Neutral
"The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor",https://investingnews.com/the-bristol-myers-squibb-janssen-collaboration-launches-pivotal-phase-3-librexia-clinical-trial-program-evaluating-milvexian-an-investigational-oral-factor-xia-inhibitor/,2023-03-02 12:21:15,"Bristol Myers Squibb ( NYSE: BMY ) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson ( Janssen ) today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa ( FXIa ) ...",BMY,0.216376,0.061703,Neutral
AZN: 2 Pharma Stocks to Buy Right Now and 1 You Might Want to Consider Selling,https://stocknews.com/news/azn-bmy-sndl-amgn-2-pharma-stocks-to-buy-right-now-and-1-you/,2023-03-02 11:23:37,AZN: 2 Pharma Stocks to Buy Right Now and 1 You Might Want to ... ...,BMY,0.20506,0.032723,Neutral
Does Bristol Myers Squibb Stock Have More Room For Growth?,https://www.forbes.com/sites/greatspeculations/2023/03/02/does-bristol-myers-squibb-stock-have-more-room-for-growth/,2023-03-02 11:00:53,"Bristol Myers Squibb stock (NYSE: BMY) has seen a fall of 3% in a month, compared with -4% returns for the broader S&P500 index.",BMY,0.687109,0.166024,Somewhat-Bullish
"Thousands of Women, Dozens of Top Employers Gather in Silicon Valley to Discuss Women in the Workplace",https://www.benzinga.com/pressreleases/23/03/n31151581/thousands-of-women-dozens-of-top-employers-gather-in-silicon-valley-to-discuss-women-in-the-workpl,2023-03-02 02:47:00,"SANTA CLARA,Calif., March 1, 2023 /PRNewswire/ -- Amid layoffs, economic headwinds, and backsliding on women's rights in many parts of the world, thousands of people from dozens of top employers gathered today to address women in the workplace at the 2023 California Conference for Women.",BMY,0.076602,0.161138,Somewhat-Bullish
Immatics Announces Full Year 2022 Financial Results and Corporate Update,https://www.globenewswire.com/news-release/2023/03/21/2631188/0/en/Immatics-Announces-Full-Year-2022-Financial-Results-and-Corporate-Update.html,2023-03-21 11:31:00,"Tuebingen, Germany and Houston, TX, March 21, 2023 - Immatics N.V. ( NASDAQ: IMTX. ""Immatics"" ) , a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for ...",BMY,0.085426,0.042318,Neutral
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/03/20/2630825/0/en/Eterna-Therapeutics-Reports-Financial-Results-for-Fourth-Quarter-and-Full-Year-2022-and-Recent-Business-Highlights.html,2023-03-20 20:10:00,- Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell ( iPSC ) -derived therapies for multiple neurology indications ...,BMY,0.058188,0.135016,Neutral
"Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says - Takeda Pharmaceutical  ( OTC:TKPHF ) , Takeda Pharmaceutical  ( NYSE:TAK ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31419385/takedas-highest-dose-psoriasis-candidate-can-potentially-beat-bristol-myers-approve,2023-03-20 14:21:15,Takeda Pharmaceutical Co Ltd TAK announced results from a Phase 2b clinical trial of TAK-279 ( NDI-034858 ) in patients with moderate-to-severe plaque psoriasis.,BMY,0.241684,0.265309,Somewhat-Bullish
Apprentice.io raises $65M for life sciences manufacturing,https://www.axios.com/pro/health-tech-deals/2023/03/20/apprenticeio-65m-life-sciences-manufacturing,2023-03-20 13:48:11,Why it matters: The advent of new drug classes - as well as increased outsourcing - has spiked demand for a tech update in pharmaceutical manufacturing.,BMY,0.080188,0.127235,Neutral
3 Top Dividend Stocks to Maximize Your Retirement Income,https://www.zacks.com/stock/news/2067903/3-top-dividend-stocks-to-maximize-your-retirement-income,2023-03-20 13:10:04,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.214937,0.120902,Neutral
JNJ: The Best Medical Stock That Money Can Buy,https://stocknews.com/news/jnj-nvo-bmy-nvs-the-best-medical-stock-that-money-can-buy/,2023-03-20 11:42:41,"Amid a volatile macroeconomic environment and heightened recessionary fears, medical stock Johnson and Johnson ( JNJ ) , with a history of stable dividend payments, could be a wise choice for investors to safeguard themselves against market downturns. Let us delve deeper to find more.",BMY,0.091335,0.111284,Neutral
Wall Street Is Bullish on GE HealthCare as It Invests in AI,https://www.fool.com/investing/2023/03/20/wall-street-is-bullish-on-ge-healthcare-as-it-inve/,2023-03-20 11:15:00,The stand-alone company that spun off from GE in January is off to a good start.,BMY,0.059049,0.007013,Neutral
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,https://www.globenewswire.com/news-release/2023/03/17/2629720/0/en/Sutro-Biopharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,2023-03-17 20:01:00,"SOUTH SAN FRANCISCO, Calif., March 17, 2023 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) ( NASDAQ: STRO ) , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced that on March 1, 2023, the ...",BMY,0.072435,0.051525,Neutral
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Sutro Biopharma  ( NASDAQ:STRO ) ,https://www.benzinga.com/pressreleases/23/03/g31403826/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4,2023-03-17 20:01:00,"SOUTH SAN FRANCISCO, Calif., March 17, 2023 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) STRO, a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced that on March 1, 2023, the Compensation Committee ...",BMY,0.068306,0.047247,Neutral
Two Biotech Stocks Hit In Medicare Negotiation Crossfire,https://www.investors.com/research/ibd-industry-themes/regn-stock-halo-stock-tumble-on-cms-negotiation-confusion/,2023-03-17 14:50:45,"REGN Stock, HALO Stock Tumble On CMS Negotiation Confusion ... Investor's Business Daily ...",BMY,0.127795,0.0,Neutral
"SNDL: If You Own This Drug Manufacturer Stock, It's Time to Sell",https://stocknews.com/news/sndl-bmy-nvs-jnj-if-you-own-this-drug-manufacturer-stock-its-time-to/,2023-03-17 14:16:43,"Canada-based medical and adult-use cannabis producer SNDL Inc. ( SNDL ) has been struggling to grow and make profits. While SNDL has made several acquisitions to support its growth, in this piece, I will discuss why the stock is still not worth buying now.",BMY,0.087185,0.088554,Neutral
2 Top Healthcare Stocks to Buy for the Long Haul,https://www.fool.com/investing/2023/03/17/2-top-healthcare-stocks-to-buy-for-the-long-haul/,2023-03-17 14:15:00,Both companies have outperformed the market over the past year.,BMY,0.087824,0.228028,Somewhat-Bullish
Bristol Myers Squibb  ( BMY )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2066994/bristol-myers-squibb-bmy-stock-sinks-as-market-gains-what-you-should-know,2023-03-16 21:50:20,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $67.10, marking a -0.56% move from the previous day.",BMY,0.523451,0.263103,Somewhat-Bullish
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/03/16/2629195/0/en/SELLAS-Life-Sciences-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,2023-03-16 20:11:00,Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late ...,BMY,0.025272,0.013609,Neutral
Two Biotech Stocks Hit In Medicare Negotiation Crossfire,https://www.investors.com/news/technology/regn-stock-halo-stock-tumble-on-cms-negotiation-confusion/,2023-03-16 16:05:45,"REGN Stock, HALO Stock Tumble On CMS Negotiation Confusion Investor's Business Daily ...",BMY,0.1331,0.0,Neutral
"Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows",https://www.fool.com/investing/2023/03/16/got-5000-these-2-high-yielding-dividend-stocks-are/,2023-03-16 13:15:00,These are blue chip stocks you can hold in your portfolio for many years.,BMY,0.20997,0.213825,Somewhat-Bullish
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2023/03/16/2628530/0/en/Century-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Updates.html,2023-03-16 11:30:00,- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway ...,BMY,0.028937,0.081343,Neutral
StockNews.com Begins Coverage on Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.defenseworld.net/2023/03/16/stocknews-com-begins-coverage-on-bristol-myers-squibb-nysebmy.html,2023-03-16 06:48:47,StockNews.com Begins Coverage on Bristol-Myers Squibb ( NYSE ... Defense World ...,BMY,0.752347,0.400757,Bullish
U.S. issues initial Medicare drug price negotiation guidance,https://www.reuters.com/business/healthcare-pharmaceuticals/us-issues-initial-medicare-drug-price-negotiation-guidance-2023-03-15/,2023-03-15 21:07:00,"WASHINGTON, March 15 ( Reuters ) - The U.S. government will select the Medicare program's 10 costliest prescription medicines based on gross spending for negotiating price cuts that will go into effect in 2026, the U.S. Centers for Medicare and Medicaid Services ( CMS ) said on Wednesday",BMY,0.083833,0.067467,Neutral
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments,https://investingnews.com/bristol-myers-squibb-announces-progress-toward-long-term-inclusion-diversity-goals-and-health-equity-commitments/,2023-03-15 17:38:10,- Commitments demonstrate leadership in advancing health equity and workforce representation to better serve patients and communities - $10 million in 2023 grant funding to 17 U.S. organizations focused on addressing social determinants of health,BMY,0.447528,0.335121,Somewhat-Bullish
PFE: The Smartest Stock to Buy for Under $50 Now,https://stocknews.com/news/pfe-nvo-bmy-nvs-sgen-the-smartest-stock-to-buy-for-under-50-now/,2023-03-15 12:12:45,"Stronger-than-expected macroeconomic data combined with the Fed's hawkish comments have increased investor anxiety. However, the pharma sector tends to be more resilient to economic downturns compared to others, as the demand for pharmaceutical products is generally not affected by macroeconomic ...",BMY,0.073098,0.006089,Neutral
BMY: 1 Stock to Buy This Week and Hold for the Next 20 Years,https://stocknews.com/news/bmy-nvo-nvs-alpmy-1-stock-to-buy-this-week-and-hold-for-the/,2023-03-14 14:14:56,Pharmaceutical companies enjoy almost inelastic demand for their products irrespective of economic cycles. This makes them an attractive long-term investment option. I believe Bristol-Myers Squibb Company ( BMY ) could be the perfect stock to buy and hold for the next twenty years.,BMY,0.611103,0.367157,Bullish
"Global Antiviral Therapies Market Predicted to Generate a Revenue of $66,016.5 Million, Growing at a CAGR of 3.1% over the 2020-2027 Timeframe [208-Pages] | Explicated by Research Dive",https://www.benzinga.com/pressreleases/23/03/g31339569/global-antiviral-therapies-market-predicted-to-generate-a-revenue-of-66-016-5-million-growing-at-a,2023-03-14 13:05:00,"New York, USA, March 14, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research Dive, the global antiviral therapies market is projected to garner a revenue of $66,016.5 million and rise at a CAGR of 3.1% throughout the estimated period from 2020 to 2027.",BMY,0.068502,0.0,Neutral
"Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/03/31324057/best-selling-drugs-by-bristol-myers-pfizer-abbvie-likely-candidates-for-us-price-negotiation,2023-03-13 17:18:58,"Bristol Myers Squibb & Co's BMY Eliquis, Pfizer Inc's PFE Ibrance, and AbbVie Inc's ABBV Imbruvica are expected to be among the ten top-selling drugs subject to U.S. price negotiations for 2026.",BMY,0.294093,0.0,Neutral
JNJ: This Big Pharma Stock Is a Clear Buy in 2023,https://stocknews.com/news/jnj-nvo-bmy-nvs-abmd-this-big-pharma-stock-is-a-clear-buy-in-2023/,2023-03-13 15:56:47,JNJ: This Big Pharma Stock Is a Clear Buy in ...,BMY,0.080055,0.138465,Neutral
3 Top Dividend Stocks to Maximize Your Retirement Income,https://www.zacks.com/stock/news/2064669/3-top-dividend-stocks-to-maximize-your-retirement-income,2023-03-13 13:10:06,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.207571,0.114473,Neutral
"Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation",https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-pfizer-abbvie-drugs-likely-face-us-price-negotiation-2023-03-13/,2023-03-13 10:09:00,"[1/3] A pharmacist holds a bottle of the drug Eliquis, made by Bristol Myers Squibb and Pfizer, at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey",BMY,0.088964,0.0,Neutral
DIA: Better To Be Bullish Or Bearish? Being Both Is The Best Approach,https://stocknews.com/news/better-to-be-bullish-or-bearish-being-both-is-the-62287653/,2023-03-13 00:17:01,"After a rip-roaring start to 2023, stocks have come crashing back to pretty much unchanged on the year. The NASDAQ 100 ( QQQ ) still is up nicely so far in 2023 at a little over 8%, but that is more than a 50% drop from the highs in early February.",BMY,0.424058,0.132185,Neutral
Bristol-Myers Squibb Unusual Options Activity For March 31 - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/03/31613906/bristol-myers-squibb-unusual-options-activity-for-march-31,2023-03-31 17:31:36,A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 19 strange trades.,BMY,0.699089,0.056918,Neutral
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy,https://investingnews.com/bristol-myers-squibb-receives-positive-chmp-opinion-for-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-large-b-cell-lymphoma-after-one-prior-therapy/,2023-03-31 12:31:16,Bristol Myers Squibb ( NYSE: BMY ) today announced the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has recommended approval of Breyanzi ( lisocabtagene maraleucel ) for the treatment of adult patients with diffuse large B-cell lymphoma ( DLBCL ...,BMY,0.257593,0.055294,Neutral
"Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells",https://www.globenewswire.com/news-release/2023/03/31/2638581/0/en/Nexcella-an-Immix-Biopharma-Subsidiary-Announces-2023-Haematologica-Editorial-Highlighting-NXC-201-Efficacy-In-The-Context-of-U-S-Food-And-Drug-Administration-Approved-BCMA-CAR-T-C.html,2023-03-31 12:00:00,"LOS ANGELES, March 31, 2023 ( GLOBE NEWSWIRE ) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. ( Nasdaq: IMMX ) ( ""ImmixBio"", ""Company"", ""We"" or ""Us"" ) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was ...",BMY,0.025845,0.055979,Neutral
"Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update",https://www.globenewswire.com/news-release/2023/03/30/2638285/0/en/Molecular-Templates-Inc-Reports-Fourth-Quarter-2022-Financial-Results-and-Business-Update.html,2023-03-30 22:10:00,"Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to BMS collaboration, and related workforce reduction Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, ...",BMY,0.050044,0.056472,Neutral
"Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones",https://www.globenewswire.com/news-release/2023/03/30/2638228/0/en/Sutro-Biopharma-Reports-Full-Year-2022-Financial-Results-Business-Highlights-and-Select-Anticipated-Milestones.html,2023-03-30 20:30:00,- Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter ...,BMY,0.016832,0.065729,Neutral
Bristol Myers' Flagship Opdivo Shows Long Term Durable Benefits In Lung Cancer Patients - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/03/31586246/bristol-myers-flagship-opdivo-shows-long-term-durable-benefits-in-lung-cancer-patients,2023-03-30 16:18:04,Bristol Myers Squibb & Co BMY announced three-year follow-up results from the Phase 3 CheckMate -816 trial of Opdivo ( nivolumab ) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small-cell-lung-cancer.,BMY,0.433523,0.132465,Neutral
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies - Bolt Biotherapeutics  ( NASDAQ:BOLT ) ,https://www.benzinga.com/general/biotech/23/03/31584214/bolt-biotherapeutics-says-phase-1-data-supports-advancing-into-phase-2-studies,2023-03-30 15:16:11,"Bolt Biotherapeutics Inc BOLT reported topline data from the dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies. BDC-1001 was well tolerated at all dose levels and schedules evaluated, both as monotherapy and combined with Bristol ...",BMY,0.368773,0.19972,Somewhat-Bullish
"Neoadjuvant Opdivo with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial",https://investingnews.com/neoadjuvant-opdivo-with-chemotherapy-demonstrates-long-term-durable-clinical-benefits-for-patients-with-resectable-non-small-cell-lung-cancer-at-three-years-in-the-checkmate-816-trial/,2023-03-30 13:41:15,"Bristol Myers Squibb ( NYSE: BMY ) today announced three-year follow-up results from the Phase 3 CheckMate -816 trial, demonstrating sustained clinical benefits with three cycles of Opdivo ( nivolumab ) in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients ...",BMY,0.079317,0.003114,Neutral
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings,https://www.zacks.com/stock/news/2072320/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings,2023-03-30 12:50:08,The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.,BMY,0.257668,0.275089,Somewhat-Bullish
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It,https://www.fool.com/investing/2023/03/30/2-reasons-to-sell-editas-stock-and-1-reason-to-buy/,2023-03-30 12:45:00,Editas Medicine is a high-risk stock with the potential of a big reward.,BMY,0.052112,0.118539,Neutral
"Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors",https://www.globenewswire.com/news-release/2023/03/30/2637531/16626/en/Zevra-Therapeutics-Appoints-Biopharma-Veteran-Wendy-Dixon-Ph-D-to-Board-of-Directors.html,2023-03-30 11:30:00,"CELEBRATION, Fla., March 30, 2023 ( GLOBE NEWSWIRE ) -- Zevra Therapeutics ( NasdaqGS: ZVRA ) ( ""Zevra"" or the ""Company"" and formerly KemPharm, Inc. ) , a rare disease therapeutics company, today announced that it has appointed Wendy L. Dixon, Ph.D., to the Company's Board of Directors ( the ...",BMY,0.066139,0.070237,Neutral
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/03/29/2637157/0/en/Bolt-Biotherapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,2023-03-29 20:15:00,"REDWOOD CITY, Calif., March 29, 2023 ( GLOBE NEWSWIRE ) -- Bolt Biotherapeutics, Inc. ( Nasdaq: BOLT ) , a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December ...",BMY,0.043898,0.046457,Neutral
NVO: Stay Forever Young With These 3 Pharmaceutical Stocks,https://stocknews.com/news/nvo-bmy-tak-stay-forever-young-with-these-3-pharmaceutical-stocks/,2023-03-29 15:52:21,"Although several macroeconomic headwinds marred the overall economy, the pharmaceutical companies fared comparatively well due to the inelastic demand for its products.",BMY,0.239174,0.161887,Somewhat-Bullish
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar,https://www.zacks.com/stock/news/2071754/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar,2023-03-29 12:50:08,Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.,BMY,0.376194,0.425214,Bullish
"Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run",https://www.fool.com/investing/2023/03/29/up-463-this-sizzling-growth-stock-could-have-a-lot/,2023-03-29 11:45:00,Viking Therapeutics stock might in the midst of a historic run.,BMY,0.047278,0.05616,Neutral
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update - Abeona Therapeutics  ( NASDAQ:ABEO ) ,https://www.benzinga.com/pressreleases/23/03/g31545223/abeona-therapeutics-reports-full-year-2022-financial-results-and-provides-corporate-update,2023-03-29 11:30:00,"Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atrophy",BMY,0.030408,0.028398,Neutral
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/03/29/2636554/0/en/Abeona-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html,2023-03-29 11:30:00,Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in ...,BMY,0.026213,0.059713,Neutral
Bristol Myers Squibb  ( BMY )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2071575/bristol-myers-squibb-bmy-gains-as-market-dips-what-you-should-know,2023-03-28 21:50:22,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $68.20, marking a +0.19% move from the previous day.",BMY,0.603594,0.205463,Somewhat-Bullish
Bristol Myers  ( BMY )  Gets Approval of Psoriasis Drug in EU,https://www.zacks.com/stock/news/2071518/bristol-myers-bmy-gets-approval-of-psoriasis-drug-in-eu,2023-03-28 19:22:00,Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.,BMY,0.195814,0.003079,Neutral
Why CytomX Therapeutics  ( CTMX )  Shares Are Falling Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/general/biotech/23/03/31531824/abbvie-walks-away-from-cytomx-partnership-but-garnering-attention-of-big-pharma-partners,2023-03-28 15:35:14,"CytomX Therapeutics Inc CTMX will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc ABBV decided not to advance the drug into additional studies. CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration ...",BMY,0.277433,0.0,Neutral
Healthcare Businesswomen's Association Appoints Mary Stutts as Chief Executive Officer,https://www.prnewswire.com/news-releases/healthcare-businesswomens-association-appoints-mary-stutts-as-chief-executive-officer-301782587.html,2023-03-28 15:10:00,Healthcare Businesswomen's Association Appoints Mary Stutts as ... PR ...,BMY,0.091162,0.14576,Neutral
Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?,https://www.fool.com/investing/2023/03/28/is-eli-lilly-or-bristol-myers-squibb-the-better-va/,2023-03-28 14:15:00,One of these big pharma stocks is considerably more attractive as a pure-play value investment.,BMY,0.078482,0.362597,Bullish
Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?,https://www.fool.com/investing/2023/03/28/could-this-drug-candidate-be-a-winner-for-these-2/,2023-03-28 14:15:00,These titans of big pharma just enrolled patients into phase 3 clinical trials for this promising blood thinner.,BMY,0.130926,0.107177,Neutral
"Bristol Myers Squibb Receives European Commission Approval of Sotyktu , a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis",https://investingnews.com/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-a-once-daily-oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis/,2023-03-28 11:33:17,"Bristol Myers Squibb ( NYSE:BMY ) today announced that the European Commission has approved Sotyktu ( deucravacitinib ) , a first-in-class, selective tyrosine kinase 2 ( TYK2 ) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic ...",BMY,0.139192,0.072034,Neutral
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/03/27/2635245/37704/en/CytomX-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,2023-03-27 20:15:00,- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 ( EGFRxCD3 ) and anticipated IND filings for CX-2051 ( EpCAM-directed ADC ) and CX-801 ( Interferon alpha-2b ) in the second half of ...,BMY,0.063341,0.01913,Neutral
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2070736/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks,2023-03-27 13:10:04,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.207127,0.117462,Neutral
Business Coach Angeline Gillings: 4 Ways Transportation Executives Can Feel Comfortable Delegating,https://www.prnewswire.com/news-releases/business-coach-angeline-gillings-4-ways-transportation-executives-can-feel-comfortable-delegating-301781398.html,2023-03-27 12:51:00,Business Coach Angeline Gillings: 4 Ways Transportation ... PR ...,BMY,0.055751,0.178937,Somewhat-Bullish
"Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors",https://www.prnewswire.com/news-releases/aadi-bioscience-appoints-mohammad-hirmand-md-to-board-of-directors-301781997.html,2023-03-27 12:00:00,"Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of ... PR ...",BMY,0.043579,-0.00491,Neutral
"Non-hodgkin lymphoma therapeutics market size to increase by USD 5,427.51 million between 2022 and 2027; Growing awareness about cancer as a key trend - Technavio",https://www.prnewswire.com/news-releases/non-hodgkin-lymphoma-therapeutics-market-size-to-increase-by-usd-5-427-51-million-between-2022-and-2027-growing-awareness-about-cancer-as-a-key-trend---technavio-301779830.html,2023-03-24 18:00:00,Non-hodgkin lymphoma therapeutics market size to increase by ... PR ...,BMY,0.037387,-0.019406,Neutral
US FDA moots more rigorous trials for accelerated nod of cancer therapy,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-seeks-more-rigorous-trials-cancer-drugs-accelerated-nod-2023-03-24/,2023-03-24 15:58:00,US FDA moots more rigorous trials for accelerated nod of cancer ... ...,BMY,0.118647,0.005056,Neutral
JNJ: 3 Large-Cap Pharma Stocks to Protect Your Portfolio Through 2023,https://stocknews.com/news/jnj-mrk-bmy-3-large-cap-pharma-stocks-to-protect-your-portfolio-through-2023/,2023-03-24 13:06:18,JNJ: 3 Large-Cap Pharma Stocks to Protect Your Portfolio Through ... ...,BMY,0.167904,0.117745,Neutral
JNJ: 4 Best Pharma Stocks to Buy for the Long Haul,https://stocknews.com/news/jnj-azn-nvs-bmy-abmd-cinc-4-best-pharma-stocks-to-buy-for-the-long-haul/,2023-03-24 12:33:33,"Despite the banking crisis, the Fed raised interest rates by a quarter of a percentage point, bringing the benchmark funds rate to a range of 4.75% to 5%, the highest since October 2007.",BMY,0.156606,0.187877,Somewhat-Bullish
Incyte  ( INCY )  Gets CRL for Jakafi Extended-Release Tablets,https://www.zacks.com/stock/news/2070048/incyte-incy-gets-crl-for-jakafi-extended-release-tablets,2023-03-24 11:14:00,"The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.",BMY,0.153961,0.087511,Neutral
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron,https://www.globenewswire.com/news-release/2023/03/24/2633882/0/en/Purple-Biotech-Reports-Temporary-Medical-Leave-of-CEO-Gil-Efron.html,2023-03-24 11:00:00,"Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany's business plan and clinical development programs continue as planned ...",BMY,0.033328,0.031169,Neutral
"Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director",https://www.prnewswire.com/in/news-releases/clarivate-announces-gordon-samson-as-president-intellectual-property-and-nominates-dr-saurabh-saha-as-new-independent-director-301780131.html,2023-03-23 20:30:00,"Clarivate Announces Gordon Samson as President, Intellectual ... PR ...",BMY,0.062761,-0.00502,Neutral
"Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director",https://www.prnewswire.com/news-releases/clarivate-announces-gordon-samson-as-president-intellectual-property-and-nominates-dr-saurabh-saha-as-new-independent-director-301780121.html,2023-03-23 20:30:00,"Clarivate Announces Gordon Samson as President, Intellectual ... PR ...",BMY,0.062761,-0.00502,Neutral
"Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director",https://www.newswire.ca/news-releases/clarivate-announces-gordon-samson-as-president-intellectual-property-and-nominates-dr-saurabh-saha-as-new-independent-director-895100555.html,2023-03-23 20:30:00,"Clarivate Announces Gordon Samson as President, Intellectual ... Canada ...",BMY,0.062761,-0.00502,Neutral
JNJ: The Strongest Pharma Stock This Week,https://stocknews.com/news/jnj-nvo-bmy-nvs-the-strongest-pharma-stock-this-week/,2023-03-23 17:31:12,"Despite the current banking crisis, the Federal Reserve went ahead with a 25-basis-point interest rate hike, bringing the federal funds rate to a new range of 4.75% to 5%, the highest since October 2007.",BMY,0.056808,0.135954,Neutral
Biopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight Partners,https://www.benzinga.com/pressreleases/23/03/g31473568/biopharmaceuticals-market-growth-worth-700bn-by-2028-led-by-monoclonal-antibodies-held-market-shar,2023-03-23 12:46:11,"New York, March 23, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Biopharmaceuticals Market Size, Share, Trends, Growth and Report Forecasts to 2028 - COVID-19 Impact and Global Analysis By Product Type ( Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, ...",BMY,0.072326,0.089567,Neutral
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO®  ( nivolumab ) ,https://www.globenewswire.com/news-release/2023/03/23/2633012/0/en/BridgeBio-Pharma-Announces-First-Lung-Cancer-Patient-Dosed-in-Phase-1-Trial-for-SHP2-Inhibitor-BBP-398-in-Combination-with-Bristol-Myers-Squibb-s-OPDIVO-nivolumab.html,2023-03-23 11:30:00,"- BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven by KRAS ...",BMY,0.190954,0.084898,Neutral
Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders' Meeting,https://www.globenewswire.com/news-release/2023/03/23/2632841/0/en/Sosei-Heptares-Confirms-Changes-to-its-Board-and-Executive-Management-Team-at-Annual-Shareholders-Meeting.html,2023-03-23 07:00:00,"Tokyo, Japan and Cambridge, UK, 23 March 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) , the world leader in G protein-coupled receptor ( GPCR ) focused structure-based drug design ( SBDD ) and development, announces the election of Ms. Eiko Tomita to the Board of Directors as an ...",BMY,0.116536,-0.095172,Neutral
Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders' Meeting,https://www.benzinga.com/pressreleases/23/03/g31469178/sosei-heptares-confirms-changes-to-its-board-and-executive-management-team-at-annual-shareholders-,2023-03-23 07:00:00,"Eiko Tomita, Vice President, Global Regulatory Affairs at Bristol Myers Squibb, elected to the Company's Board of Directors Candelle Chong promoted to Executive Vice President and Chief of Staff, previously Senior Vice President, Corporate Strategy",BMY,0.112532,-0.077139,Neutral
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",https://www.benzinga.com/pressreleases/23/03/g31466980/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-27-2023,2023-03-22 23:23:33,"SOUTH SAN FRANCISCO, Calif., March 22, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets.",BMY,0.172097,-0.036731,Neutral
"CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023",https://www.globenewswire.com/news-release/2023/03/22/2632792/37704/en/CytomX-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-27-2023.html,2023-03-22 23:23:00,"SOUTH SAN FRANCISCO, Calif., March 22, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of ...",BMY,0.184598,-0.041876,Neutral
Bristol Myers Squibb  ( BMY )  Stock Moves -0.4%: What You Should Know,https://www.zacks.com/stock/news/2069304/bristol-myers-squibb-bmy-stock-moves--04-what-you-should-know,2023-03-22 21:50:24,"Bristol Myers Squibb (BMY) closed at $67.24 in the latest trading session, marking a -0.4% move from the prior day.",BMY,0.653175,0.206804,Somewhat-Bullish
Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?,https://www.forbes.com/sites/greatspeculations/2023/03/22/is-bristol-myers-squibb-stock-a-better-pick-over-its-industry-peer/,2023-03-22 11:00:25,"Investors have assigned a higher multiple to LLY stock due to its robust pipeline and better profitability, as discussed below If we look at stock returns, Eli Lilly, with 15% returns in the last twelve months, has fared better than BMS, down 5%, and the broader S&P 500 index, down 11%.",BMY,0.495015,0.315124,Somewhat-Bullish
Four Elements Of Healthcare Industry Leadership: China Summit,https://www.forbes.com/sites/forbeschina/2023/03/22/four-elements-of-healthcare-industry-leadership-forbes-china-summit/,2023-03-22 04:56:00,"""Healthcare can often be a very conservative industry because it's an industry that deals with very long timetables. However, playing it too safe and too careful can leave you behind competitors,"" Forbes Senior Editor Alex Knapp believes.",BMY,0.042876,-0.06925,Neutral
"U.S.-China Collaboration Could Cut Development Time, Cost For New Cancer Treatments",https://www.forbes.com/sites/forbeschina/2023/03/22/us-china-collaboration-could-cut-development-time-cost-for-new-cancer-treatments/,2023-03-22 04:10:51,"The world's current system for developing cancer drugs is unsustainable, Memorial Sloan Kettering oncologist Dr. Bob Li believes.",BMY,0.053153,0.0,Neutral
Harness Uncertainty To Overcome It In Today's Business World: China Summit,https://www.forbes.com/sites/forbeschina/2023/03/21/harness-uncertainty-to-overcome-it-in-todays-business-world-forbes-china-summit/,2023-03-22 00:54:42,"In today's uncertain times, business leaders should focus on what is certain in their environment as a key approach to success, University of Michigan Business Professor told a Forbes China gathering last week ...",BMY,0.06697,0.0,Neutral
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income,https://www.zacks.com/stock/news/2076193/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income,2023-04-10 13:10:04,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.205807,0.113719,Neutral
2 Top Stocks to Buy in April and Hold Forever,https://www.fool.com/investing/2023/04/08/2-top-stocks-to-buy-in-april-and-hold-forever/,2023-04-08 11:39:00,The need for healthcare goods and/or services is here to stay.,BMY,0.186259,0.173,Somewhat-Bullish
Phototherapy Global Market Report 2022: Rise in Adoption of LED-Based Phototherapy Boosts Sector,https://www.prnewswire.com/news-releases/phototherapy-global-market-report-2022-rise-in-adoption-of-led-based-phototherapy-boosts-sector-301791921.html,2023-04-07 00:45:00,Phototherapy Global Market Report 2022: Rise in Adoption of LED ... PR ...,BMY,0.021199,0.114828,Neutral
Penny Stocks To Buy Now? 4 To Watch In April,https://pennystocks.com/featured/2023/04/06/penny-stocks-to-buy-now-4-to-watch-in-april/,2023-04-06 19:53:22,"Whether you're trading penny stocks or higher-priced names, you can't ignore what's happening in the stock market today. Traders have remained cautiously optimistic following a week's worth of data and more still to come on Friday when markets will be closed.",BMY,0.043499,0.039941,Neutral
Prothena  ( PRTA )  Gains 29% in One Year: Will the Momentum Continue?,https://www.zacks.com/stock/news/2075748/prothena-prta-gains-29-in-one-year-will-the-momentum-continue,2023-04-06 17:49:00,Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.,BMY,0.067158,-0.05727,Neutral
Will Bristol Myers  ( BMY )  Gain From New Drugs' Label Expansion?,https://www.zacks.com/stock/news/2075733/will-bristol-myers-bmy-gain-from-new-drugs-label-expansion,2023-04-06 16:44:00,Label expansion of Bristol Myers' (BMY) new drugs should help it somewhat combat the decline in Revlimid sales due to generic competition.,BMY,0.265089,0.099382,Neutral
JNJ: Investors Are Keeping This Healthcare Stock Long-Term,https://stocknews.com/news/jnj-nvo-nvs-bmy-abmd-investors-are-keeping-this-healthcare-stock-long-term/,2023-04-05 19:25:40,JNJ: Investors Are Keeping This Healthcare Stock ...,BMY,0.069697,0.07528,Neutral
Will Bristol Myers  ( BMY )  Beat Estimates Again in Its Next Earnings Report?,https://www.zacks.com/stock/news/2075032/will-bristol-myers-bmy-beat-estimates-again-in-its-next-earnings-report,2023-04-05 16:10:14,Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,BMY,0.167904,0.206001,Somewhat-Bullish
2 Ultra-Cheap Dividend Stocks to Buy in April,https://www.fool.com/investing/2023/04/04/2-ultra-cheap-dividend-stocks-to-buy-in-april/,2023-04-04 15:00:00,These two big pharma stocks are trading at steep discounts.,BMY,0.129168,-0.08894,Neutral
Overhaul Partners with MCA Connect to Create a More Agile Global Supply Chain,https://www.prnewswire.com/news-releases/overhaul-partners-with-mca-connect-to-create-a-more-agile-global-supply-chain-301789448.html,2023-04-04 13:00:00,Overhaul Partners with MCA Connect to Create a More Agile Global ... PR ...,BMY,0.053153,0.036998,Neutral
Bristol Myers Squibb  ( BMY )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2073999/bristol-myers-squibb-bmy-outpaces-stock-market-gains-what-you-should-know,2023-04-03 21:50:19,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $69.69, marking a +0.55% move from the previous day.",BMY,0.588876,0.283945,Somewhat-Bullish
Bristol Myers'  ( BMY )  Breyanzi Gets Positive CHMP Opinion,https://www.zacks.com/stock/news/2073865/bristol-myers-bmy-breyanzi-gets-positive-chmp-opinion,2023-04-03 16:03:00,Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed or refractory large B-cell lymphoma after one prior treatment.,BMY,0.197816,0.098035,Neutral
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2073658/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks,2023-04-03 13:10:02,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.217346,0.121966,Neutral
Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors,https://www.globenewswire.com/news-release/2023/04/03/2639431/0/en/Reunion-Neuroscience-Appoints-Dr-Fred-Grossman-to-Board-of-Directors.html,2023-04-03 11:30:00,"- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals ...",BMY,0.074576,0.001012,Neutral
Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors - Reunion Neuroscience  ( NASDAQ:REUN ) ,https://www.benzinga.com/pressreleases/23/04/g31629773/reunion-neuroscience-appoints-dr-fred-grossman-to-board-of-directors,2023-04-03 11:30:00,"- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals TORONTO, April 03, 2023 ( GLOBE NEWSWIRE ) -- Reunion Neuroscience Inc.",BMY,0.07157,0.001008,Neutral
Engine Sputtering: Tesla's Disappointing Quarter Weighs On Market As Recession Fears Grow - Tesla  ( NASDAQ:TSLA ) ,https://www.benzinga.com/markets/23/04/31921533/engine-sputtering-teslas-disappointing-quarter-weighs-on-market-as-recession-fears-grow,2023-04-20 17:53:49,"( Thursday market open ) Disappointing earnings from Tesla TSLA set the tone this morning, helping send major indexes lower overnight. Overall, the hot start to earnings season cooled over the last few days, though there have been some positive highlights.",BMY,0.039977,-0.066672,Neutral
Bristol Myers Squibb  ( BMY )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release,https://www.zacks.com/stock/news/2082128/bristol-myers-squibb-bmy-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release,2023-04-20 14:02:55,Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.101582,0.080071,Neutral
WBA: Just In: WBA Named the Top Dividend Stock With Insider Buying. Is It a Buy?,https://stocknews.com/news/wba-jnj-bmy-cvs-opch-just-in-wba-named-the-top-dividend-stock-with-insider/,2023-04-20 14:00:35,WBA: Just In: WBA Named the Top Dividend Stock With Insider ... ...,BMY,0.077593,0.03172,Neutral
Bristol Myers Squibb  ( BMY )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2081642/bristol-myers-squibb-bmy-dips-more-than-broader-markets-what-you-should-know,2023-04-19 21:50:18,"Bristol Myers Squibb (BMY) closed the most recent trading day at $69.86, moving -0.53% from the previous trading session.",BMY,0.524949,0.194645,Somewhat-Bullish
Synthetic Biology Market is Poised to Thrive at CAGR of 21.4 % CAGR During 2023 to 2031 | TMR Report,https://www.benzinga.com/pressreleases/23/04/g31900326/synthetic-biology-market-is-poised-to-thrive-at-cagr-of-21-4-cagr-during-2023-to-2031-tmr-report,2023-04-19 19:30:00,"Wilmington, Delaware, United States, April 20, 2023 ( GLOBE NEWSWIRE ) -- The global synthetic biology market is anticipated to grow at a 21.4% CAGR from 2023 to 2031. A market valuation of US$ 74.7 billion is expected by end of the forecast period.",BMY,0.084275,0.0,Neutral
How A Data Leak Pushed This Biotech To Break Out,https://www.investors.com/news/technology/legn-stock-breaks-out-on-an-unexpectedly-positive-data-leak/,2023-04-19 14:22:00,LEGN Stock Breaks Out On An Unexpectedly Positive Dats Leak ... Investor's Business Daily ...,BMY,0.166743,-0.193753,Somewhat-Bearish
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors,https://www.globenewswire.com/news-release/2023/04/19/2650015/0/en/Purple-Biotech-Reports-New-Preclinical-Data-on-Potential-of-NT219-to-Re-sensitize-Resistant-Tumors-to-Immune-Checkpoint-Inhibitors.html,2023-04-19 12:15:00,"New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April ...",BMY,0.025166,0.030188,Neutral
Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients - Evaxion Biotech  ( NASDAQ:EVAX ) ,https://www.benzinga.com/general/biotech/23/04/31864308/evaxion-biotech-says-personalized-cancer-immunotherapy-meets-primary-endpoint-in-melanoma-patient,2023-04-18 19:08:10,"Evaxion Biotech A/S EVAX presented clinical data from its Phase 1/2a first-in-human study of its DNA-based personalized cancer immunotherapy, EVX-02, in combination with the checkpoint inhibitor Bristol Myers Squibb Co Inc's BMY Opdivo ( nivolumab ) .",BMY,0.306963,-0.232433,Somewhat-Bearish
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023,https://www.globenewswire.com/news-release/2023/04/18/2649473/0/en/Sutro-Biopharma-Presents-Preclinical-Data-for-its-ROR1-Targeting-Antibody-Drug-Conjugate-STRO-003-at-the-AACR-Annual-Meeting-2023.html,2023-04-18 17:30:00,"ORLANDO, Fla., April 18, 2023 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) ( NASDAQ: STRO ) , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced expanded preclinical data for STRO-003, its ROR1 ...",BMY,0.037329,0.073306,Neutral
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023 - Sutro Biopharma  ( NASDAQ:STRO ) ,https://www.benzinga.com/pressreleases/23/04/g31865094/sutro-biopharma-presents-preclinical-data-for-its-ror1-targeting-antibody-drug-conjugate-stro-003-,2023-04-18 17:30:00,"ORLANDO, Fla., April 18, 2023 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) STRO, a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced expanded preclinical data for STRO-003, its ROR1 targeting ADC, ...",BMY,0.0362,0.068126,Neutral
This House of Representative Just Sold Up To $265K In Bristol-Myers Squibb Stock - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/government/23/04/31860298/this-house-of-representative-just-sold-up-to-265k-in-bristol-myers-squibb-stock,2023-04-18 15:05:51,"The Office of New York Representative Daniel Goldman has reported a sale of Bristol-Myers Squibb BMY stock on April 17, 2023. According to the Periodic Transaction Report the transaction was placed on April 17, 2023.",BMY,0.580018,0.075109,Neutral
BioNJ Releases New Report: Health Equity in Clinical Trials MBA Business Case Competition: Identifying Innovative Approaches to Strengthening Diversity Within Clinical Trials,https://www.prnewswire.com/news-releases/bionj-releases-new-report-health-equity-in-clinical-trials-mba-business-case-competition-identifying-innovative-approaches-to-strengthening-diversity-within-clinical-trials-301798331.html,2023-04-18 13:00:00,BioNJ Releases New Report: Health Equity in Clinical Trials MBA ... PR ...,BMY,0.085936,0.163451,Somewhat-Bullish
"With 13.87% CAGR, Atopic Dermatitis Market Size to Surpass USD 16.23 Billion by 2028 Says Brandessence Market Research",https://www.prnewswire.com/news-releases/with-13-87-cagr-atopic-dermatitis-market-size-to-surpass-usd-16-23-billion-by-2028-says-brandessence-market-research-301799955.html,2023-04-18 07:07:00,"With 13.87% CAGR, Atopic Dermatitis Market Size to Surpass USD ... PR ...",BMY,0.029654,0.080721,Neutral
"Bristol Myers  ( BMY ) , TSVT Application for Abecma Accepted",https://www.zacks.com/stock/news/2079904/bristol-myers-bmy-tsvt-application-for-abecma-accepted,2023-04-17 17:13:00,Bristol Myers (BMY) and partner TSVTs sBLA for CAR T cell therapy is accepted by the FDA for earlier lines of treatment in multiple myeloma.,BMY,0.255641,0.123918,Neutral
Merck's takeover of Prometheus gives it a foothold in immunology,https://www.marketwatch.com/story/mercks-10-8-billion-takeover-of-prometheus-is-a-good-strategic-move-that-gives-it-a-foothold-in-immunology-2f922a41,2023-04-17 16:19:00,Merck's acquisition of Prometheus Biosciences will help the drug company diversify and reduce the risk of overreliance on its cancer drug Keytruda.,BMY,0.118064,0.0,Neutral
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income,https://www.zacks.com/stock/news/2079547/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income,2023-04-17 13:10:05,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.217834,0.118879,Neutral
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma,https://investingnews.com/regulatory-applications-accepted-across-three-regions-globally-for-abecma-for-earlier-use-in-adults-with-triple-class-exposed-relapsed-and-or-refractory-multiple-myeloma/,2023-04-17 11:50:09,"Bristol Myers Squibb ( NYSE: BMY ) and 2seventy bio, Inc. ( Nasdaq: TSVT ) today announced that the U.S.",BMY,0.1952,0.038181,Neutral
2 Best Biotech Stocks to Buy for the Long Haul,https://www.fool.com/investing/2023/04/17/2-best-biotech-stocks-to-buy-for-the-long-haul/,2023-04-17 09:10:00,These two are among the largest pharma companies in the world.,BMY,0.07157,0.099916,Neutral
Editas  ( EDIT )  Soars 20.3%: Is Further Upside Left in the Stock?,https://www.zacks.com/stock/news/2078647/editas-edit-soars-203-is-further-upside-left-in-the-stock,2023-04-14 08:06:00,Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.,BMY,0.088147,0.0,Neutral
Bristol Myers Squibb  ( BMY )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2078564/bristol-myers-squibb-bmy-gains-but-lags-market-what-you-should-know,2023-04-13 21:50:26,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $70.69, marking a +0.68% move from the previous day.",BMY,0.605266,0.299676,Somewhat-Bullish
Congestive Heart Failure Drugs Market Size to Cross USD 13.5 Bn Revenue by 2031 | TMR Study,https://www.benzinga.com/pressreleases/23/04/g31798962/congestive-heart-failure-drugs-market-size-to-cross-usd-13-5-bn-revenue-by-2031-tmr-study,2023-04-13 21:30:00,"Wilmington, Delaware, United States, April 14, 2023 ( GLOBE NEWSWIRE ) -- The global congestive heart failure drugs market was valued at USD 6.7 Bn in 2022 and is estimated to reach USD 13.5 Bn by 2031, expanding at a CAGR of 7.6% between 2023 and 2031.",BMY,0.041466,0.0,Neutral
Jordan Altman Joins Ropes & Gray in New York,https://www.prnewswire.com/news-releases/jordan-altman-joins-ropes--gray-in-new-york-301797123.html,2023-04-13 18:05:00,"NEW YORK, April 13, 2023 /PRNewswire/ -- Ropes & Gray announced today that Jordan Altman, a highly regarded IP transactions lawyer, has joined the firm as a partner, bringing his broad deal experience to the firm's award-winning IP transactions, M&A and private equity practices.",BMY,0.043658,0.09827,Neutral
Jordan Altman Joins Ropes & Gray in New York,https://markets.businessinsider.com/news/stocks/jordan-altman-joins-ropes-gray-in-new-york-1032231071,2023-04-13 18:05:00,"NEW YORK, April 13, 2023 /PRNewswire/ -- Ropes & Gray announced today that Jordan Altman, a highly regarded IP transactions lawyer, has joined the firm as a partner, bringing his broad deal experience to the firm's award-winning IP transactions, M&A and private equity practices.",BMY,0.043658,0.09827,Neutral
"Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials - BeiGene  ( NASDAQ:BGNE ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/04/31785059/analysts-at-h-c-wainwright-co-set-12-month-target-of-15-per-share-for-enlv-thanks-to-high-profile,2023-04-13 11:55:43,"This month, H.C. Wainwright & Co. reiterated its buy rating for Enlivex Therapeutics Ltd. ENLV with a 12-month price target of $15 per share, based on a valuation estimated at $320 million.",BMY,0.117486,-0.119792,Neutral
Aon Appoints Sarah E. Smith to Board of Directors,https://www.prnewswire.com/news-releases/aon-appoints-sarah-e-smith-to-board-of-directors-301795500.html,2023-04-12 12:30:00,"DUBLIN, April 12, 2023 /PRNewswire/ -- Aon plc ( NYSE: AON ) , a leading global professional services firm, today announced that Sarah E. Smith, a former member of the Management Committee of The Goldman Sachs Group, Inc., has been appointed to its Board of Directors, effective April 15, 2023.",BMY,0.081552,0.012248,Neutral
"Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow - BeiGene  ( NASDAQ:BGNE ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/04/31741766/hillstream-biopharmas-drug-candidate-hsb-1216-could-be-one-to-watch-as-global-oncology-market-con,2023-04-11 12:28:09,"A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global oncology market has been growing at an unprecedented pace over the past few years.",BMY,0.104683,0.05909,Neutral
"Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow - BeiGene  ( NASDAQ:BGNE ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/04/31741764/hillstream-biopharmas-drug-candidate-hsb-1216-could-be-one-to-watch-as-global-oncology-market-con,2023-04-11 12:28:08,"A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global oncology market has been growing at an unprecedented pace over the past few years.",BMY,0.104683,0.05909,Neutral
Market Rally Volatile And Tight Amid Big Earnings Moves,https://www.investors.com/news/market-rally-wobbles-amid-big-earnings-moves-from-microsoft-meta-crocs-cloudflare/,2023-04-28 16:36:00,Market Rally Wobbles Amid Big Earnings Moves From Microsoft ... Investor's Business Daily ...,BMY,0.036532,-0.067681,Neutral
Government Drug Price Curbs Could Sound A Death Knell For Industry,https://www.investors.com/news/technology/biotech-stocks-brace-for-the-worst-as-government-drug-price-negotiations-loom/,2023-04-28 12:00:00,Biotech Stocks Brace For The Worst As Government Drug Price ... Investor's Business Daily ...,BMY,0.027118,0.044929,Neutral
5 Brand-Name Safe Stocks I Wouldn't Touch With a 10-Foot Pole Right Now,https://moneymorning.com/investing/5-brand-name-safe-stocks-i-wouldnt-touch-with-a-10-foot-pole-right-now/,2023-04-28 09:21:00,"There's no two ways about it, the last 16 months have been challenging for investors. All three major U.S. stock indexes entered a bear market in 2022, with growth stocks getting hit especially hard. But the volatility equities experienced last year may be about to ramp up once again.",BMY,0.083735,-0.067109,Neutral
5 Brand-Name Safe Stocks I Wouldn't Touch With a 10-Foot Pole Right Now,https://www.fool.com/investing/2023/04/28/5-safe-stocks-i-wouldnt-touch-with-a-10-foot-pole/,2023-04-28 09:21:00,"These well-known, time-tested businesses are exceptionally pricey given the current economic outlook.",BMY,0.061315,0.176076,Somewhat-Bullish
"Bristol-Myers  ( BMY )  Q1 Earnings Beat, Revlimid Generics Hurt Sales",https://www.zacks.com/stock/news/2086348/bristol-myers-bmy-q1-earnings-beat-revlimid-generics-hurt-sales,2023-04-27 16:16:00,"Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.",BMY,0.317138,0.227011,Somewhat-Bullish
"Bristol Myers Squibb Posts Lower Q1 Sales As Revlimid Generic Erosion Bites, Chairman & CEO Giovanni Caforio To Step Down - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/04/32046488/bristol-myers-squibb-posts-lower-q1-sales-as-revlimid-generic-erosion-bites-chairman-ceo-giovanni,2023-04-27 15:45:41,"Bristol Myers Squibb & Co BMY said that its Q1 sales of $11.34 billion fell 3% Y/Y due to Revlimid generic erosion and foreign exchange impacts, partially offset by in-line products ( primarily Opdivo and Eliquis ) and new product portfolio ( primarily Opdualag, Abecma and Reblozyl ) .",BMY,0.499789,0.0064,Neutral
"Stocks making the biggest moves premarket: Meta, Teladoc, Harley-Davidson, Southwest Airlines and more",https://www.cnbc.com/2023/04/27/stocks-making-big-premarket-moves-meta-teladoc-southwest-and-more.html,2023-04-27 12:45:42,These are some of the stocks posting the largest moves in early trading.,BMY,0.045054,0.170435,Somewhat-Bullish
Bristol Myers Squibb  ( BMY )  Surpasses Q1 Earnings Estimates,https://www.zacks.com/stock/news/2085724/bristol-myers-squibb-bmy-surpasses-q1-earnings-estimates,2023-04-27 12:15:15,"Bristol Myers (BMY) delivered earnings and revenue surprises of 3.54% and 2.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",BMY,0.138066,0.095608,Neutral
"A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US - GSK  ( NYSE:GSK ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/04/32043721/a-new-depression-drug-being-developed-by-tonix-may-side-step-treatment-limiting-effects-of-nearly,2023-04-27 12:00:00,The following post was written and/or published as a collaboration between Benzinga's in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure that all information contained within is true and accurate to the best of their knowledge and ...,BMY,0.062191,0.154085,Somewhat-Bullish
Bristol Myers Squibb Reports First Quarter Financial Results for 2023,https://investingnews.com/bristol-myers-squibb-reports-first-quarter-financial-results-for-2023/,2023-04-27 11:26:37,"Bristol Myers Squibb ( NYSE:BMY ) today reports results for the first quarter of 2023, which reflect robust in-line and new product portfolio growth, strong commercial execution and continued advancement of the product pipeline.",BMY,0.070369,0.115119,Neutral
Bristol Myers looks to new CEO as competition from generic drugs heats up,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-posts-lower-q1-sales-revlimid-falls-2023-04-27/,2023-04-27 11:07:00,Bristol Myers posts lower Q1 sales as Revlimid falls ...,BMY,0.108466,0.0,Neutral
Morning Bid: Fresh spur from Meta and Europe's banks,https://www.reuters.com/markets/europe/global-markets-view-usa-2023-04-27/,2023-04-27 10:05:38,"A look at the day ahead in U.S. and global markets from Mike Dolan The Big Tech earnings season is going some way to justifying the striking outperformance of its mega cap shares this year, with Meta Platforms the latest to impress overnight and Amazon ( AMZN.O ) advancing ahead of its readout on ...",BMY,0.048919,0.035546,Neutral
Bristol Myers CEO Caforio to step down,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-ceo-caforio-steps-down-2023-04-26/,2023-04-26 22:41:00,"[1/2] A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo April 26 ( Reuters ) - Bristol Myers Squibb Co ( BMY.N ) said on Wednesday CEO Giovanni Caforio will step down in November and be succeeded by Chief ...",BMY,0.33628,0.144879,Neutral
Bristol Myers Squibb Announces Leadership Transition Plan - Investing News Network,https://investingnews.com/bristol-myers-squibb-announces-leadership-transition-plan/,2023-04-26 20:54:17,Bristol Myers Squibb Announces Leadership Transition Plan Investing News Network ...,BMY,0.500159,0.612789,Bullish
Bristol-Myers CEO Giovanni Caforio to Step Down,https://www.wsj.com/articles/bristol-myers-ceo-giovanni-caforio-to-leave-drugmaker-5de94f38,2023-04-26 20:35:00,"Chief Commercialization Officer Christopher Boerner will take over after Giovanni Caforio retires, the company said.",BMY,0.846873,0.0,Neutral
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy,https://investingnews.com/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-for-camzyos-r-for-the-treatment-of-symptomatic-obstructive-hypertrophic-cardiomyopathy/,2023-04-26 19:23:25,"Bristol Myers Squibb ( NYSE: BMY ) today announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has recommended approval of CAMZYOS ® ( mavacamten ) for the treatment of symptomatic ( New York Heart Association, NYHA, class II-III ) ...",BMY,0.149863,0.034325,Neutral
"Pharmacovigilance Market to Exhibit USD 11.5 Bn by 2028, Expanding at an 8.8% CAGR, Says Transparency Market Research",https://www.benzinga.com/pressreleases/23/04/g32018551/pharmacovigilance-market-to-exhibit-usd-11-5-bn-by-2028-expanding-at-an-8-8-cagr-says-transparency,2023-04-26 18:30:00,"Wilmington, Delaware, United States, April 27, 2023 ( GLOBE NEWSWIRE ) -- According to the recent study published by Transparency Market Research, the global pharmacovigilance market was estimated at a market value of USD 6.1 Bn in 2020.",BMY,0.042953,0.164278,Somewhat-Bullish
LianBio Touts Positive Data From Bristol Myers-Partnered Heart Drug In Chinese Patients - LianBio  ( NASDAQ:LIAN ) ,https://www.benzinga.com/general/biotech/23/04/32014241/lianbio-touts-positive-data-from-bristol-myers-partnered-heart-drug-in-chinese-patients,2023-04-26 17:56:10,LianBio LIAN announced topline results from the Phase 3 EXPLORER-CN trial investigating mavacamten for Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy ( oHCM ) .,BMY,0.33628,0.0,Neutral
"Microsoft's Strong Quarter Lifts Tech, But Banking Worries Keep Market Mainly On Defensive - Alphabet  ( NASDAQ:GOOGL ) , Chipotle Mexican Grill  ( NYSE:CMG ) ",https://www.benzinga.com/markets/23/04/32014643/microsofts-strong-quarter-lifts-tech-but-banking-worries-keep-market-mainly-on-defensive,2023-04-26 15:42:38,"( Wednesday market open ) When it's earnings season, the trading day seldom ends with the closing bell. If you shut down your screens at 4 p.m. ET yesterday, you might have felt gloomy after the S&P 500® index ( SPX ) posted its lowest close since March 30.",BMY,0.03777,-0.066143,Neutral
"Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More",https://www.zacks.com/stock/news/2084870/drugbiotech-stocks-q1-earnings-due-apr-27-lly-abbv-more,2023-04-26 13:28:00,Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.,BMY,0.227361,0.046608,Neutral
Should You Buy Bristol Myers Squibb  ( BMY )  Ahead of Earnings?,https://www.zacks.com/stock/news/2084782/should-you-buy-bristol-myers-squibb-bmy-ahead-of-earnings,2023-04-26 12:46:00,Bristol Myers Squibb (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,BMY,0.889454,0.707816,Bullish
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients - LianBio  ( NASDAQ:LIAN ) ,https://www.benzinga.com/pressreleases/23/04/g32007911/lianbio-announces-positive-topline-results-from-phase-3-explorer-cn-trial-evaluating-mavacamten-in,2023-04-26 12:00:00,• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies,BMY,0.018327,0.097007,Neutral
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production,https://investingnews.com/bristol-myers-squibb-strengthens-cell-therapy-capabilities-by-adding-new-u-s-manufacturing-facility-for-viral-vector-production/,2023-04-26 11:23:02,"Bristol Myers Squibb ( NYSE: BMY ) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.-based manufacturing facility and its operations in Libertyville, Illinois, following the company's execution of an agreement ...",BMY,0.462953,0.070133,Neutral
Will Bristol Myers Squibb Stock Rise Post Q1?,https://www.forbes.com/sites/greatspeculations/2023/04/26/will-bristol-myers-squibb-stock-rise-post-q1/,2023-04-26 10:30:38,"We expect BMY stock to trade higher, with its revenue and earnings coming in marginally above the street estimates.",BMY,0.70554,0.141545,Neutral
USD 12.6 Bn Cancer Biomarkers Market to Grow at a CAGR of 9.9% During 2022 to 2031 - Global Analysis by Transparency Market Research,https://www.benzinga.com/pressreleases/23/04/g32005604/usd-12-6-bn-cancer-biomarkers-market-to-grow-at-a-cagr-of-9-9-during-2022-to-2031-global-analysis-,2023-04-26 10:30:00,"Wilmington, Delaware, United States, April 26, 2023 ( GLOBE NEWSWIRE ) -- According to Transparency Market Research, tThe global cancer biomarkers market size stood at USD 12.6 Bn in 2021. The market value is likely to surpass USD 31.4 Bn by 2031 and expand at a CAGR of 9.9% between 2022 and 2031.",BMY,0.045569,0.0,Neutral
"The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx",https://www.zacks.com/stock/news/2084671/the-zacks-analyst-blog-highlights-bristol-myers-squibb-medtronic-altria-group-target-and-fedex,2023-04-26 09:56:00,"Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx are included in this Analyst Blog.",BMY,0.215894,0.077707,Neutral
"Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group",https://www.zacks.com/research-daily/2084284/q1-earnings-scorecard-and-fresh-analyst-reports-for-bristol-myers-medtronic-altria-group,2023-04-25 17:47:00,"Q1 Earnings Season Scorecard is included in today's Research Daily in addition to new research reports on Bristol-Myers (BMY), Medtronic(MDT) and Altria Group (MO).",BMY,0.195419,0.09072,Neutral
"Risk-Off Rerun: Banking Concerns, Nerves Ahead of Microsoft, Alphabet Earnings Bring Pressure - First Republic Bank  ( NYSE:FRC ) , General Electric  ( NYSE:GE ) ",https://www.benzinga.com/markets/23/04/31993957/risk-off-rerun-banking-concerns-nerves-ahead-of-microsoft-alphabet-earnings-bring-pressure,2023-04-25 16:25:43,( Tuesday market open ) The rubber hits the road for info tech earnings starting later today when Microsoft MSFT and Alphabet GOOGL open their quarterly books.,BMY,0.037416,-0.066054,Neutral
This Supercharged Dividend King Stock Might Soon Run Out of Steam,https://www.fool.com/investing/2023/04/25/this-supercharged-dividend-king-stock-may-soon-run/,2023-04-25 13:45:00,"Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.",BMY,0.038223,0.056664,Neutral
Here's Why Bristol Myers Squibb  ( BMY )  is a Strong Value Stock,https://www.zacks.com/stock/news/2084069/heres-why-bristol-myers-squibb-bmy-is-a-strong-value-stock,2023-04-25 13:40:04,"Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",BMY,0.388879,0.392038,Bullish
Want Consistently Growing Passive Income? Buy Johnson & Johnson Stock,https://www.fool.com/investing/2023/04/25/want-consistently-growing-passive-income-buy-johns/,2023-04-25 10:50:00,The healthcare juggernaut recently extended its illustrious dividend growth streak.,BMY,0.064449,0.0,Neutral
Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma,https://www.globenewswire.com/news-release/2023/04/25/2653490/0/en/Ultimovacs-provides-updated-guidance-on-timeline-for-readout-of-INITIUM-Phase-II-clinical-trial-of-UV1-in-malignant-melanoma.html,2023-04-25 05:00:00,"Oslo, 25 April, 2023 -- Ultimovacs ASA ( OSE: ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced today that it has adjusted guidance from the first half of 2023 to the second half of 2023 for communication of topline progression free survival ( ...",BMY,0.039353,0.036114,Neutral
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday - Aurinia Pharmaceuticals  ( NASDAQ:AUPH ) ,https://www.benzinga.com/general/biotech/23/04/31960063/is-aurinia-pharmaceuticals-up-for-grabs-shareholder-suggests-a-quick-sale-for-a-bigger-payday,2023-04-24 19:10:58,"MKT Capital Ltd, a shareholder with a 4.2% stake in Aurinia Pharmaceuticals Inc AUPH, has issued a letter to Aurinia shareholders with plans to withhold support for three directors at the 2023 annual meeting.",BMY,0.246582,0.444106,Bullish
Bristol-Myers  ( BMY )  to Report Q1 Earnings: What+'s in Store?,https://www.zacks.com/stock/news/2083607/bristol-myers-bmy-to-report-q1-earnings-what-s-in-store,2023-04-24 15:57:00,Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.,BMY,0.250386,0.209747,Somewhat-Bullish
"Setting the Bar: After Shares Rallied in Q1, Big-Tech Companies Ready to Share Results This Week",https://www.benzinga.com/markets/23/04/31961561/setting-the-bar-after-shares-rallied-in-q1-big-tech-companies-ready-to-share-results-this-week,2023-04-24 15:51:49,"( Monday market open ) Earnings season is nearly 20% complete, but this week is when company reports could start having a more dramatic impact on major indexes. That's because ""mega-cap"" companies like Microsoft ( MSFT ) , Alphabet ( GOOGL ) , Amazon ( AMZN ) , and Meta ( META ) are among the ...",BMY,0.04161,-0.067029,Neutral
Earnings Preview: Vertex Pharmaceuticals  ( VRTX )  Q1 Earnings Expected to Decline,https://www.zacks.com/stock/news/2083428/earnings-preview-vertex-pharmaceuticals-vrtx-q1-earnings-expected-to-decline,2023-04-24 14:00:46,Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.088309,0.038104,Neutral
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income,https://www.zacks.com/stock/news/2083317/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income,2023-04-24 13:10:03,"The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",BMY,0.215415,0.119475,Neutral
"Alexandria Real Estate Equities, Inc. Named One of Most Trustworthy Companies in America by Newsweek",https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-named-one-of-most-trustworthy-companies-in-america-by-newsweek-301804795.html,2023-04-24 12:30:00,"Alexandria Real Estate Equities, Inc. Named One of Most ... PR ...",BMY,0.025034,0.326814,Somewhat-Bullish
Cancer Immunotherapy Market Size Worth USD 388.25 Billion in 2030 - Emergen Research,https://markets.businessinsider.com/news/stocks/cancer-immunotherapy-market-size-worth-usd-388-25-billion-in-2030-%E2%80%93-emergen-research-1032251605,2023-04-23 13:22:00,"The global Cancer Immunotherapy Market size was USD 119.39 Billion in 2021 and is expected to register a revenue CAGR of 14.0% during the forecast period, according to latest analysis by Emergen Research Cancer immunotherapy, also known as immuno-oncology, is a fast expanding specialty in cancer ...",BMY,0.034282,-0.109525,Neutral
This Is What Whales Are Betting On Bristol-Myers Squibb - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/04/31943939/this-is-what-whales-are-betting-on-bristol-myers-squibb,2023-04-21 20:45:47,"Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.82082,0.379178,Bullish
Earnings Round One Ends With Banks A Clear Winner But Uncertain Results Overall As Market Sags,https://www.benzinga.com/news/earnings/23/04/31939743/earnings-round-one-ends-with-banks-a-clear-winner-but-uncertain-results-overall-as-market-sags,2023-04-21 16:59:11,( Friday market open ) Bulls and bears touch gloves and go to their separate corners at the end of the week before the bell rings to signal another heavy bout of earnings and economic data starting Monday.,BMY,0.07654,0.019245,Neutral
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology  ( AAN )  Annual Meeting And The British Pain Society  ( BPS )  56th Annual Scientific Meeting 2023,https://www.globenewswire.com/news-release/2023/04/21/2651959/0/en/Lexicon-To-Present-Results-From-LX9211-Phase-2-Trial-In-Postherpetic-Neuralgia-At-The-2023-American-Academy-Of-Neurology-AAN-Annual-Meeting-And-The-British-Pain-Society-BPS-56th-An.html,2023-04-21 13:00:00,Data accepted as AAN Late-Breaking Abstract Data accepted as AAN Late-Breaking Abstract ...,BMY,0.039483,-0.067125,Neutral
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology  ( AAN )  Annual Meeting And The British Pain Society  ( BPS )  56th Annual Scientific Meeting 2023 - Lexicon Pharmaceuticals  ( NASDAQ:LXRX ) ,https://www.benzinga.com/pressreleases/23/04/g31934015/lexicon-to-present-results-from-lx9211-phase-2-trial-in-postherpetic-neuralgia-at-the-2023-america,2023-04-21 13:00:00,"THE WOODLANDS Texas, April 21, 2023 ( GLOBE NEWSWIRE ) -- Lexicon Pharmaceuticals, Inc.",BMY,0.038468,-0.065966,Neutral
LianBio Announces China National Medical Products Administration  ( NMPA )  Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy - LianBio  ( NASDAQ:LIAN ) ,https://www.benzinga.com/pressreleases/23/04/g31932573/lianbio-announces-china-national-medical-products-administration-nmpa-acceptance-with-priority-rev,2023-04-21 12:00:00,"SHANGHAI, China and PRINCETON, N.J., April 21, 2023 ( GLOBE NEWSWIRE ) -- LianBio LIAN, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that China's National Medical Products Administration ( NMPA ) has ...",BMY,0.023838,0.100398,Neutral
3 Things About Bristol-Myers Squibb That Smart Investors Know,https://www.fool.com/investing/2023/05/10/3-things-about-bristol-myers-squibb-that-smart-inv/,2023-05-10 12:45:00,Its medium-term performance is going to rest on the acquisitions it makes today.,BMY,0.114682,0.061227,Neutral
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference,https://www.globenewswire.com/news-release/2023/05/08/2663222/0/en/Sutro-Biopharma-to-Present-at-the-JMP-Securities-Life-Sciences-Conference.html,2023-05-08 12:00:00,"SOUTH SAN FRANCISCO, Calif., May 08, 2023 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) ( NASDAQ: STRO ) , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced that Bill Newell, Chief Executive ...",BMY,0.126784,0.088816,Neutral
Prothena  ( PRTA )  Q1 Earnings and Revenues Miss Estimates,https://www.zacks.com/stock/news/2091108/prothena-prta-q1-earnings-and-revenues-miss-estimates,2023-05-05 16:27:00,Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.,BMY,0.11894,0.025114,Neutral
"Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?",https://www.fool.com/investing/2023/05/05/which-is-the-better-passive-income-stock-eli-lilly/,2023-05-05 14:15:00,"One offers more income today, and the other aims to offer more in the future.",BMY,0.143131,0.110672,Neutral
Should Income Investors Buy This Blue Chip Dividend Stock?,https://www.fool.com/investing/2023/05/05/should-income-investors-buy-this-blue-chip-stock/,2023-05-05 14:00:00,This pharmaceutical company has an exceptional drug portfolio and pipeline.,BMY,0.131284,0.17149,Somewhat-Bullish
"Insiders Selling Zoom Video Communications, Bristol-Myers Squibb And This Footwear Manufacturer - Skechers USA  ( NYSE:SKX ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/23/05/32236640/insiders-selling-zoom-video-communications-bristol-myers-squibb-and-this-footwear-manufacturer,2023-05-05 12:02:05,"The Nasdaq closed lower on Thursday after the Fed increased rates by 25 basis points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced.",BMY,0.372912,0.021479,Neutral
Editas Medicine Announces First Quarter 2023 Results and Business Updates,https://www.globenewswire.com/news-release/2023/05/05/2662412/0/en/Editas-Medicine-Announces-First-Quarter-2023-Results-and-Business-Updates.html,2023-05-05 11:00:00,Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress ( EHA ) and in a ...,BMY,0.025734,0.107118,Neutral
Curis Provides First Quarter 2023 Business Update,https://www.prnewswire.com/news-releases/curis-provides-first-quarter-2023-business-update-301816505.html,2023-05-04 20:01:00,"Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3 Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief Development Officer Strong balance sheet with $71.8 million in cash and investments; cash runway into 2025",BMY,0.019731,0.027452,Neutral
5 Large-Cap Value Mutual Funds to Invest in a Choppy Market,https://www.zacks.com/stock/news/2090059/5-large-cap-value-mutual-funds-to-invest-in-a-choppy-market,2023-05-04 12:50:00,"Invest in large-cap value funds like DRGVX, JLVRX, ACSDX, TGDIX and VWNDX to preserve your capital and earn returns in such economic mayhem.",BMY,0.035293,0.051119,Neutral
Best Dividend Stocks To Buy In 2023? 2 To Know,https://stockmarket.com/featured/best-dividend-stocks-to-buy-in-2023-2-to-know-2023-05-04,2023-05-04 10:54:43,"Dividends are payments made by companies to their shareholders, usually every three months. These payments come from the company's profits and are a way to share the success of the business with the people who own its stock.",BMY,0.437261,0.234343,Somewhat-Bullish
Want Passive Income at a Fair Price? Consider Buying This Dividend Growth Stock,https://www.fool.com/investing/2023/05/03/want-passive-income-at-a-fair-price-consider-buyin/,2023-05-03 12:20:00,It's in the sweet spot for the right kind of investor.,BMY,0.129866,0.18543,Somewhat-Bullish
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/05/03/2660120/0/en/Cerevel-Therapeutics-Appoints-Ron-Renaud-as-President-and-Chief-Executive-Officer-and-Reports-First-Quarter-2023-Financial-Results.html,2023-05-03 10:30:00,"Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023. Dr. Coles will continue as chairperson of the board ...",BMY,0.014541,-0.024664,Neutral
Why Immatics Stock Is Soaring Today,https://www.fool.com/investing/2023/05/02/why-immatics-stock-is-soaring-today/,2023-05-02 15:21:15,Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.,BMY,0.118064,0.171451,Somewhat-Bullish
SunPower Announces Chief Operating Officer,https://www.prnewswire.com/news-releases/sunpower-announces-chief-operating-officer-301812302.html,2023-05-01 20:10:00,"RICHMOND, Calif., May 1, 2023 /PRNewswire/ -- SunPower Corp. ( NASDAQ:SPWR ) , a leading solar technology and energy services company, today announced Jennifer Johnston as its new Executive Vice President and Chief Operating Officer, effective May 8, 2023.",BMY,0.067158,0.086527,Neutral
"Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/05/32120905/bristol-myers-squibbs-breyanzi-aces-two-lymphoma-studies-on-overall-response-rate-endpoint-plus-n,2023-05-01 15:57:17,"Bristol-Myers Squibb Co BMY announced topline results from two Breyanzi ( lisocabtagene maraleucel ) studies: TRANSCEND FL Phase 2 trial in relapsed or refractory follicular lymphoma ( FL ) , and TRANSCEND NHL 001 Phase 1 study relapsed or refractory B-cell non-Hodgkin lymphoma, including mantle ...",BMY,0.320279,0.081119,Neutral
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration,https://www.globenewswire.com/news-release/2023/05/01/2658166/0/en/Immatics-Announces-First-Bristol-Myers-Squibb-Opt-in-of-TCR-T-Candidate-from-Ongoing-Multi-target-Strategic-Collaboration.html,2023-05-01 11:00:00,"Tuebingen, Germany & Houston, May 1, 2023 - Immatics N.V. ( NASDAQ: IMTX, ""Immatics"" ) , a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that Bristol Myers Squibb ( NYSE:BMY ) has exercised its ...",BMY,0.238133,0.179364,Somewhat-Bullish
Galera Expands Commercial Leadership Team,https://www.globenewswire.com/news-release/2023/05/01/2658164/0/en/Galera-Expands-Commercial-Leadership-Team.html,2023-05-01 11:00:00,"Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products ...",BMY,0.019193,-0.011309,Neutral
"Autoimmune Drugs Market size to grow by USD 29,314.5 million between 2022 and 2027; AbbVie Inc., and AdvaCare Pharma among others, identified as key vendors - Technavio",https://www.prnewswire.com/news-releases/autoimmune-drugs-market-size-to-grow-by-usd-29-314-5-million-between-2022-and-2027-abbvie-inc-and-advacare-pharma-among-others-identified-as-key-vendors--technavio-301828870.html,2023-05-19 23:15:00,"Autoimmune Drugs Market size to grow by USD 29,314.5 million ... PR ...",BMY,0.075161,0.137715,Neutral
RDY: Dr. Reddy's Laboratories  ( RDY )  Is the Pharmaceutical Stock to Buy,https://stocknews.com/news/rdy-abbv-nvs-bmy-dr-reddys-laboratories-rdy-is-the-pharmaceutical-stock-to-buy/,2023-05-19 16:27:32,RDY: Dr. Reddy's Laboratories ( RDY ) Is the Pharmaceutical Stock to ... ...,BMY,0.070207,0.133694,Neutral
1 Dirt Cheap Dividend Stock to Buy in May,https://www.fool.com/investing/2023/05/19/1-dirt-cheap-dividend-stock-to-buy-in-may/,2023-05-19 14:07:00,Don't wait too long before getting in on this excellent drugmaker.,BMY,0.247838,0.403904,Bullish
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/19/2672401/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html,2023-05-19 09:00:00,"• Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 • Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® ( golimumab ) initiated, marking the fifth internally developed portfolio ...",BMY,0.012545,0.051698,Neutral
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/19/2672402/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html,2023-05-19 09:00:00,"REYKJAVIK, Iceland, May 19, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of ...",BMY,0.012512,0.051684,Neutral
"Global Cytotoxic Drug Market Expected to Garner $21,644.10 Million in Revenue and Rise at a CAGR of 5.7% during the Estimated Period 2022-2031 [290-Pages] | Explicated by Research Dive",https://www.benzinga.com/pressreleases/23/05/g32465499/global-cytotoxic-drug-market-expected-to-garner-21-644-10-million-in-revenue-and-rise-at-a-cagr-of,2023-05-18 13:04:00,"New York, USA, May 18, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research Dive, the global cytotoxic drug market is projected to generate a revenue of $21,644.10 million and rise at a CAGR of 5.7% over the estimated timeframe from 2022 to 2031.",BMY,0.054483,0.0,Neutral
Zai Lab Announces That Repotrectinib Granted Priority Review by China's NMPA,https://www.globenewswire.com/news-release/2023/05/18/2671789/0/en/Zai-Lab-Announces-That-Repotrectinib-Granted-Priority-Review-by-China-s-NMPA.html,2023-05-18 11:30:00,"SHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 ( GLOBE NEWSWIRE ) -- Zai Lab Limited ( NASDAQ: ZLAB. HKEX: 9688 ) today announced that the Center for Drug Evaluation ( CDE ) of China's National Medical Products Administration ( NMPA ) has granted priority review to repotrectinib for the ...",BMY,0.03178,0.051036,Neutral
Looking Into Bristol-Myers Squibb's Recent Short Interest - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/23/05/32445246/looking-into-bristol-myers-squibbs-recent-short-interest,2023-05-17 13:30:52,"Bristol-Myers Squibb's BMY short percent of float has risen 4.94% since its last report. The company recently reported that it has 17.88 million shares sold short, which is 0.85% of all regular shares that are available for trading.",BMY,0.221819,0.155473,Somewhat-Bullish
Which Pharmaceuticals Stock Is A Better Pick: Johnson & Johnson Or Eliquis' Maker?,https://www.forbes.com/sites/greatspeculations/2023/05/17/which-pharmaceuticals-stock-is-a-better-pick-johnson--johnson-or-eliquis-maker/,2023-05-17 12:00:00,"There is more to the comparison, and in the sections below, we discuss why we believe BMY stock will offer higher returns than JNJ stock in the next three years.",BMY,0.333107,0.244088,Somewhat-Bullish
"Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer",https://www.globenewswire.com/news-release/2023/05/16/2669956/0/en/Recursion-Appoints-David-Mauro-M-D-Ph-D-as-Chief-Medical-Officer.html,2023-05-16 12:30:00,"SALT LAKE CITY, May 16, 2023 ( GLOBE NEWSWIRE ) -- Recursion ( NASDAQ: RXRX ) , a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer.",BMY,0.049221,0.0,Neutral
"Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer - Recursion Pharmaceuticals  ( NASDAQ:RXRX ) ",https://www.benzinga.com/pressreleases/23/05/g32420018/recursion-appoints-david-mauro-m-d-ph-d-as-chief-medical-officer,2023-05-16 12:30:00,"SALT LAKE CITY, May 16, 2023 ( GLOBE NEWSWIRE ) -- Recursion RXRX, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer.",BMY,0.048425,0.0,Neutral
Aspergillosis Treatment Market is to reach USD 3569.72 Mn by 2029 at a growth rate of 5.4 percent over the forecast period,https://www.benzinga.com/pressreleases/23/05/g32416515/aspergillosis-treatment-market-is-to-reach-usd-3569-72-mn-by-2029-at-a-growth-rate-of-5-4-percent-,2023-05-16 10:16:55,"Pune, May 16, 2023 ( GLOBE NEWSWIRE ) -- Maximize Market Research, a global Healthcare market research firm has published a competitive intelligence and market research report on the ""Aspergillosis Treatment Market"". The Aspergillosis Treatment Market size was valued at USD 2470.30 Mn in 2022.",BMY,0.031159,0.133497,Neutral
Accumulus Synergy Announces the Appointment of New Leadership Team Members,https://www.benzinga.com/pressreleases/23/05/g32393385/accumulus-synergy-announces-the-appointment-of-new-leadership-team-members,2023-05-15 13:22:00,"BURLINGAME, Calif., May 15, 2023 ( GLOBE NEWSWIRE ) -- Accumulus Synergy ( ""Accumulus"" ) , a nonprofit trade association working to address the global need for digital transformation within the life sciences - health authority ecosystem, today announced the appointment of two new executive ...",BMY,0.070517,0.292523,Somewhat-Bullish
"Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones",https://www.globenewswire.com/news-release/2023/05/15/2668697/0/en/Sutro-Biopharma-Reports-First-Quarter-2023-Financial-Results-Business-Highlights-and-Select-Anticipated-Milestones.html,2023-05-15 12:00:00,"- Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ...",BMY,0.017048,0.065831,Neutral
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline,https://www.globenewswire.com/news-release/2023/05/15/2668682/0/en/Ikena-Oncology-Reports-First-Quarter-2023-Financial-Results-and-Highlights-Advancements-Across-Targeted-Oncology-Pipeline.html,2023-05-15 11:50:00,"Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed ...",BMY,0.045743,0.018954,Neutral
Ikena Oncology Announces $40 Million Underwritten Offering,https://www.globenewswire.com/news-release/2023/05/15/2668679/0/en/Ikena-Oncology-Announces-40-Million-Underwritten-Offering.html,2023-05-15 11:45:00,"BOSTON, May 15, 2023 ( GLOBE NEWSWIRE ) -- Ikena Oncology, Inc. ( Nasdaq: IKNA, ""Ikena"", ""Company"" ) , a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock ( the ...",BMY,0.04531,0.054982,Neutral
Ikena Oncology Announces $40 Million Underwritten Offering - Ikena Oncology  ( NASDAQ:IKNA ) ,https://www.benzinga.com/pressreleases/23/05/g32389648/ikena-oncology-announces-40-million-underwritten-offering,2023-05-15 11:45:00,"BOSTON, May 15, 2023 ( GLOBE NEWSWIRE ) -- Ikena Oncology, Inc. IKNA ""Ikena"", ""Company"" ) ) ) , a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock ( the ""Shares"" ) at ...",BMY,0.044634,0.054968,Neutral
Pfizer CEO Fires Back: US Drug Pricing Reforms - 'Negotiation with a Gun to Your Head' - Pfizer  ( NYSE:PFE ) ,https://www.benzinga.com/general/biotech/23/05/32368106/pfizer-ceo-fires-back-us-drug-pricing-reforms-negotiation-with-a-gun-to-your-head,2023-05-12 17:28:26,"Pfizer Inc's PFE CEO Albert Bourla called U.S. plans to negotiate drug prices for its Medicare health program ""negotiation with a gun to your head."" Bristol Myers Squibb & Co's BMY Eliquis, Pfizer Inc's PFE Ibrance, and AbbVie Inc's ABBV Imbruvica are expected to be among the ten top-selling ...",BMY,0.297661,0.0,Neutral
"CAGR of 5.6%, Red Biotechnology Market Expected to Surpass USD 609.6 Billion by 2031 - Exclusive Study by TMR",https://www.benzinga.com/pressreleases/23/05/g32362861/cagr-of-5-6-red-biotechnology-market-expected-to-surpass-usd-609-6-billion-by-2031-exclusive-study,2023-05-12 12:30:00,"Wilmington, Delaware, United States, May 12, 2023 ( GLOBE NEWSWIRE ) -- The global red biotechnology market size stood at USD 357.2 Bn in 2021 and is anticipated to surpass value of USD 609.6 Bn by 2031. The global industry is anticipated to expand at a CAGR of 5.6% between 2022 and 2031.",BMY,0.044551,-0.157838,Somewhat-Bearish
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023,https://www.globenewswire.com/news-release/2023/05/12/2667534/0/en/Sosei-Heptares-Operational-Highlights-and-Consolidated-Results-for-the-First-Quarter-2023.html,2023-05-12 06:30:00,"Tokyo, Japan and Cambridge, UK, 12 May 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023. The full report can be found here.",BMY,0.030446,0.081978,Neutral
"GOP law cut Big Pharma tax rates by 40%, Senate report says",https://www.cnbc.com/2023/05/11/gop-law-cut-big-pharma-tax-rates-by-40percent-senate-report-says.html,2023-05-11 17:07:41,Senate Finance Committee Democrats said the Republican bill resulted in billion of dollars in tax savings for pharmaceutical companies.,BMY,0.078354,0.0,Neutral
Is Bristol-Myers Squibb Stock a Buy Now?,https://www.fool.com/investing/2023/05/11/is-bristol-myers-squibb-stock-a-buy-now/,2023-05-11 13:17:56,"The stock faces risks, but are they outweighed by its low valuation?",BMY,0.174587,0.249018,Somewhat-Bullish
3 High-Yielding Dividend Stocks That Could Pay You Forever,https://www.fool.com/investing/2023/05/11/3-high-yielding-dividend-stocks-that-could-pay-you/,2023-05-11 13:00:00,These are stocks that you can buy and forget about.,BMY,0.179343,0.208417,Somewhat-Bullish
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2023/05/11/2666592/0/en/Century-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html,2023-05-11 11:30:00,- Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting ...,BMY,0.053212,0.08985,Neutral
LianBio Announces Marketing Approval of CAMZYOS®  ( mavacamten )  in the Macau Special Administrative Region  ( SAR )  of China - LianBio  ( NASDAQ:LIAN ) ,https://www.benzinga.com/pressreleases/23/05/g32336253/lianbio-announces-marketing-approval-of-camzyos-mavacamten-in-the-macau-special-administrative-reg,2023-05-11 11:00:00,"SHANGHAI, China and PRINCETON, N.J., May 11, 2023 ( GLOBE NEWSWIRE ) -- LianBio LIAN, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that CAMZYOS® ( mavacamten ) has received marketing approval for the ...",BMY,0.028023,0.102697,Neutral
"Materials and Life Science Payloads, CubeSats Flying on Next Resupply Mission to International Space Station",https://markets.businessinsider.com/news/stocks/materials-and-life-science-payloads-cubesats-flying-on-next-resupply-mission-to-international-space-station-1032359087,2023-05-30 18:08:00,"KENNEDY SPACE CENTER, Fla. , May 30, 2023 /PRNewswire/ -- A student-led genetics investigation, six small satellites called CubeSats, a technology demonstration, and life and materials science payloads are set to fly on SpaceX's 28th Commercial Resupply Services ( CRS ) mission to the ...",BMY,0.075995,0.128831,Neutral
2 Tech Stocks You Can Still Buy as the Nasdaq Soars,https://www.fool.com/investing/2023/05/30/2-tech-stocks-you-can-still-buy-as-the-nasdaq-soar/,2023-05-30 12:55:00,These stocks are at bargain prices despite the market spiking higher.,BMY,0.05257,0.105988,Neutral
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors - Catalyst Pharmaceuticals  ( NASDAQ:CPRX ) ,https://www.benzinga.com/pressreleases/23/05/g32621970/catalyst-pharmaceuticals-appoints-tamar-thompson-to-its-board-of-directors,2023-05-30 12:03:00,"CORAL GABLES, Fla., May 30, 2023 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( ""Catalyst"" or ""Company"" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced ...",BMY,0.127119,0.070522,Neutral
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors,https://www.globenewswire.com/news-release/2023/05/30/2678311/13009/en/Catalyst-Pharmaceuticals-Appoints-Tamar-Thompson-to-its-Board-of-Directors.html,2023-05-30 12:03:00,"CORAL GABLES, Fla., May 30, 2023 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( ""Catalyst"" or ""Company"" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today ...",BMY,0.109705,0.066259,Neutral
Pain Relief Therapeutics Market to Grow Significantly by 2029- Brandessence Market Research,https://www.prnewswire.com/news-releases/pain-relief-therapeutics-market-to-grow-significantly-by-2029--brandessence-market-research-301836608.html,2023-05-29 15:15:00,Pain Relief Therapeutics Market to Grow Significantly by 2029 ... PR ...,BMY,0.023487,0.099264,Neutral
"CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held",https://www.prnewswire.com/news-releases/cell-world---aiming-at-internationalization-starting-from-regulation---the-1st-global-cell-therapy-summit-and-hillgene-biopharma-anniversary-celebration-successfully-held-301836480.html,2023-05-29 12:03:00,"CELL WORLD - Aiming at Internationalization, Starting from ... PR ...",BMY,0.043979,-0.061939,Neutral
Lung Cancer Therapies Market to Amplify Significantly over 2022-2029 - Brandessence Market Research,https://www.prnewswire.com/news-releases/lung-cancer-therapies-market-to-amplify-significantly-over-2022-2029---brandessence-market-research-301836472.html,2023-05-29 10:26:00,Lung Cancer Therapies Market to Amplify Significantly over 2022 ... PR ...,BMY,0.023579,0.074359,Neutral
Spend Less Time In Meetings This Summer,https://www.forbes.com/sites/lisabodell/2023/05/26/spend-less-time-in-meetings-this-summer/,2023-05-26 17:28:21,"If your schedule looks more like a Tetris game than a calendar belonging to a human person, you need this in your life.",BMY,0.064449,0.10284,Neutral
"Bristol Myers' CAR T Cell Therapy Shows Deep, Durable Efficacy In Blood Cancer Patients - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/05/32590076/bristol-myers-car-t-cell-therapy-shows-deep-durable-efficacy-in-blood-cancer-patients,2023-05-26 11:56:44,"Bristol Myers Squibb Co BMY announced the first disclosure of results from the primary analysis of the pivotal TRANSCEND CLL 004 Phase 1/2 study of Breyanzi ( lisocabtagene maraleucel, liso-cel ) in adults with relapsed or refractory chronic lymphocytic leukemia ( CLL ) or small lymphocytic ...",BMY,0.357293,0.007486,Neutral
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,https://www.globenewswire.com/news-release/2023/05/25/2676773/0/en/Ayala-Pharmaceuticals-Announces-Updated-RINGSIDE-Phase-2-Results-at-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html,2023-05-25 21:05:00,ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily ( the selected Phase 3 dose ...,BMY,0.019862,-0.031433,Neutral
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology  ( ASCO )  Annual Meeting - Advaxis  ( OTC:ADXS ) ,https://www.benzinga.com/pressreleases/23/05/g32585995/ayala-pharmaceuticals-announces-updated-ringside-phase-2-results-at-2023-american-society-of-clini,2023-05-25 21:05:00,"ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily ( the selected Phase 3 dose ) Tumor response, volume and T2 signal reduction were observed earlier in the 1.2 mg once daily group, with deeper ...",BMY,0.019618,-0.030455,Neutral
Bristol-Myers Squibb Unusual Options Activity - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/05/32583613/bristol-myers-squibb-unusual-options-activity,2023-05-25 20:03:23,A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 10 strange trades.,BMY,0.786325,0.295536,Somewhat-Bullish
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting - Mirati Therapeutics  ( NASDAQ:MRTX ) ,https://www.benzinga.com/general/biotech/23/05/32569349/miratis-sitravatinib-flunks-phase-3-combo-therapy-study-in-type-of-lung-cancer-setting,2023-05-25 12:15:40,Mirati Therapeutics Inc's MRTX SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis.,BMY,0.355588,-0.153019,Somewhat-Bearish
Agios Appoints Catherine Owen to Board of Directors,https://www.globenewswire.com/news-release/2023/05/25/2675968/31990/en/Agios-Appoints-Catherine-Owen-to-Board-of-Directors.html,2023-05-25 11:00:00,- John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service ...,BMY,0.057698,-0.038041,Neutral
Agios Appoints Catherine Owen to Board of Directors - Agios Pharmaceuticals  ( NASDAQ:AGIO ) ,https://www.benzinga.com/pressreleases/23/05/g32569894/agios-appoints-catherine-owen-to-board-of-directors,2023-05-25 11:00:00,"- John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service - - Kaye Foster to Be Appointed Lead Independent Director - CAMBRIDGE, Mass., May 25, 2023 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc.",BMY,0.055881,-0.038016,Neutral
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®,https://www.prnewswire.com/news-releases/mirati-therapeutics-provides-update-on-the-phase-3-sapphire-study-evaluating-sitravatinib-in-combination-with-opdivo-301833958.html,2023-05-24 20:01:00,Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE ... PR ...,BMY,0.050786,0.0,Neutral
Bristol Myers  ( BMY )  Reports Pulmonary Fibrosis Study Results,https://www.zacks.com/stock/news/2098701/bristol-myers-bmy-reports-pulmonary-fibrosis-study-results,2023-05-23 16:30:00,Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.,BMY,0.143843,0.166223,Somewhat-Bullish
"Sickle Cell Disease Market to Observe Impressive Growth, Predicts DelveInsight | Key Companies Active in the Domain - Sanofi, Novartis, Vertex, CRISPR, Vifor, Pfizer, GlaxoSmithKline, Alexion, Global Blood",https://www.prnewswire.com/news-releases/sickle-cell-disease-market-to-observe-impressive-growth-predicts-delveinsight--key-companies-active-in-the-domain---sanofi-novartis-vertex-crispr-vifor-pfizer-glaxosmithkline-alexion-global-blood-301830486.html,2023-05-22 15:00:00,"Sickle Cell Disease Market to Observe Impressive Growth, Predicts ... PR ...",BMY,0.029043,0.040283,Neutral
Should Income Investors Buy This Big Pharma Stock?,https://www.fool.com/investing/2023/05/21/should-income-investors-buy-this-big-pharma-stock/,2023-05-21 16:42:07,This company is prepared to lead the pharmaceutical industry beyond the COVID-19 pandemic.,BMY,0.064276,0.12145,Neutral
Bristol Myers Squibb  ( BMY )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2105392/bristol-myers-squibb-bmy-dips-more-than-broader-markets-what-you-should-know,2023-06-07 21:45:17,"Bristol Myers Squibb (BMY) closed at $65.16 in the latest trading session, marking a -0.49% move from the prior day.",BMY,0.635085,0.227269,Somewhat-Bullish
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/06/32765277/looking-at-bristol-myers-squibbs-recent-unusual-options-activity,2023-06-07 18:17:23,"Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.781591,0.28462,Somewhat-Bullish
"Organ Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market Research",https://www.benzinga.com/pressreleases/23/06/g32764419/organ-transplant-rejection-medication-market-to-surpass-usd-7-0-billion-by-2031-propelled-by-remar,2023-06-07 17:30:00,"Wilmington, Delaware, United States, June 07, 2023 ( GLOBE NEWSWIRE ) -- The global organ transplant rejection medication market is estimated to flourish at a CAGR of 3.9% from 2023 to 2031.",BMY,0.03916,0.0,Neutral
Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma,https://www.globenewswire.com/news-release/2023/06/07/2684120/0/en/Ultimovacs-provides-update-on-Phase-II-NIPU-trial-evaluating-UV1-in-second-line-patients-with-malignant-pleural-mesothelioma.html,2023-06-07 17:08:00,"Webcast to take place tomorrow, 8 June 2023 at 10:00 am ( CET ) . Webcast link ...",BMY,0.036615,-0.015662,Neutral
"Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion' - Merck & Co  ( NYSE:MRK ) ",https://www.benzinga.com/general/biotech/23/06/32743949/pharmaceutical-giant-merck-challenges-inflation-reduction-act-over-medicare-drug-pricing-calls-it,2023-06-06 19:03:23,Merck & Co Inc MRK has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act ( IRA ) .,BMY,0.301315,0.0,Neutral
"Chipotle, Bristol-Myers Squibb, Corteva And A Healthcare Giant On CNBC's 'Final Trades' - Chipotle Mexican Grill  ( NYSE:CMG ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/06/32731171/chipotle-bristol-myers-squibb-corteva-and-a-healthcare-giant-on-cnbcs-final-trades,2023-06-06 12:30:27,"On CNBC's ""Halftime Report Final Trades,"" Brenda Vingiello of Sand Hill Global Advisors named CVS Health Corporation CVS as her final trade. Analysts have a consensus Buy rating on CVS, according to Benzinga's analyst ratings data.",BMY,0.598621,0.257488,Somewhat-Bullish
Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.,https://www.marketwatch.com/story/biotech-stocks-could-soon-get-a-m-a-boost-here-are-3-likely-takeover-plays-206b79c3,2023-06-05 19:05:00,Big pharma will be looking to acquire companies with promsing new medicines.,BMY,0.129342,-0.065386,Neutral
Monoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,https://www.prnewswire.com/news-releases/monoclonal-antibodies-clinical-trial-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301842025.html,2023-06-05 15:00:00,Monoclonal Antibodies Clinical Trial Experiences Momentum ... PR ...,BMY,0.069495,0.050238,Neutral
Bristol Myers  ( BMY )  Announces Upbeat Data From NSCLC Study,https://www.zacks.com/stock/news/2103890/bristol-myers-bmy-announces-upbeat-data-from-nsclc-study,2023-06-05 14:22:00,Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.,BMY,0.197413,0.071039,Neutral
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting,https://www.newswire.ca/news-releases/dragonfly-therapeutics-announces-the-presentation-of-phase-1-df1001-trinket-r-dose-escalation-results-at-asco-2023-annual-meeting-859454173.html,2023-06-05 14:00:00,Dragonfly Therapeutics Announces the Presentation of Phase 1 ... Canada ...,BMY,0.043421,0.183294,Somewhat-Bullish
NVO: 3 Pharmaceutical Stocks to Watch,https://stocknews.com/news/nvo-nvs-bmy-3-pharmaceutical-stocks-to-watch/,2023-06-05 13:33:24,"The pharmaceutical industry tends to perform steadily amid economic downturns, as it enjoys inelastic demand for its products and services. So, amid the possibility of a recession later this year or early next year, quality pharma stocks Novo Nordisk A/S ( NVO ) , Novartis AG ( NVS ) , and ...",BMY,0.192081,0.021973,Neutral
Bristol Myers' Opdivo/Chemo Shows Durable Results At Four Years In Lung Cancer Patients - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/06/32710622/bristol-myers-opdivochemo-shows-durable-results-at-four-years-in-lung-cancer-patients,2023-06-05 10:10:17,Bristol Myers Squibb & Co BMY released four-year follow-up data from the Phase 3 CheckMate -9LA trial to be presented in a late-breaking poster presentation at the 2023 American Society of Clinical Oncology ( ASCO ) annual meeting.,BMY,0.456884,0.11691,Neutral
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1,https://www.globenewswire.com/news-release/2023/06/03/2681539/0/en/Sutro-Biopharma-Announces-Oral-Presentation-at-ASCO-2023-Featuring-Data-for-Luveltamab-Tazevibulin-from-the-Phase-1-Dose-Expansion-Study-in-Ovarian-Cancer-and-the-Initiation-of-the.html,2023-06-03 20:00:00,"- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient population, experienced ...",BMY,0.03072,0.074215,Neutral
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1 - Sutro Biopharma  ( NASDAQ:STRO ) ,https://www.benzinga.com/pressreleases/23/06/g32704501/sutro-biopharma-announces-oral-presentation-at-asco-2023-featuring-data-for-luveltamab-tazevibulin,2023-06-03 20:00:00,"- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient population, experienced ...",BMY,0.029839,0.067215,Neutral
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,https://www.globenewswire.com/news-release/2023/06/03/2681534/0/en/Replimune-Presents-RP1-Data-from-the-IGNYTE-anti-PD1-Failed-Melanoma-Cohort-and-RP2-Data-in-Uveal-Melanoma-at-the-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html,2023-06-03 18:15:00,Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile. no progression in responding patients since the data snapshot presented in December ...,BMY,0.054857,-0.003,Neutral
"Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas",https://www.prnewswire.com/news-releases/intensity-therapeutics-int230-6-prolongs-survival-alone-or-in-combination-with-ipilimumab-in-adult-patients-with-relapsed-refractory-metastatic-sarcomas-301841753.html,2023-06-03 12:00:00,Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in ... PR ...,BMY,0.030563,0.055173,Neutral
3 Dividend Stocks You Can Buy Without Any Hesitation,https://www.fool.com/investing/2023/06/03/3-dividend-stocks-you-can-buy-without-hesitation/,2023-06-03 10:14:00,The choices are easy with these stocks.,BMY,0.263467,0.479562,Bullish
Why The Biotech Buying Bonanza Will Likely Continue,https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/,2023-06-02 17:17:00,Biotech Stocks Are In A 'Blistering' M&A Climate. The FTC Could ... Investor's Business Daily ...,BMY,0.031529,0.012717,Neutral
"'Millions of women suffering in silence': Female workers want menopause benefits, so why are they so rare?",https://www.marketwatch.com/story/millions-of-women-suffering-in-silence-female-workers-want-menopause-benefits-so-why-are-they-so-rare-d06a1e6e,2023-06-02 17:04:00,A new report reveals a stigma of talking about menopause in the workplace and a disconnect between employers and employees.,BMY,0.072987,0.051317,Neutral
Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting,https://www.newswire.ca/news-releases/dragonfly-therapeutics-to-present-phase-1-df1001-monotherapy-dose-escalation-results-at-asco-2023-annual-meeting-843394787.html,2023-06-02 11:00:00,Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy ... Canada ...,BMY,0.079392,0.189431,Somewhat-Bullish
"The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance",https://www.zacks.com/stock/news/2102930/the-zacks-analyst-blog-highlights-nvidia-bristol-myers-squibb-icici-bank-palo-alto-and-walgreens-boots-alliance,2023-06-02 08:59:00,"NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.",BMY,0.690822,0.0,Neutral
Bristol Myers Squibb  ( BMY )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2102847/bristol-myers-squibb-bmy-gains-but-lags-market-what-you-should-know,2023-06-01 21:45:18,"Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.",BMY,0.565003,0.270673,Somewhat-Bullish
"Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank",https://www.zacks.com/research-daily/2102608/top-analyst-reports-for-nvidia-bristol-myers-squibb-icici-bank,2023-06-01 20:52:00,"Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).",BMY,0.188683,0.113861,Neutral
"Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc",https://www.prnewswire.com/news-releases/alkermes-appoints-caroline-j-loew-phd-as-chief-executive-officer-designate-of-mural-oncology-plc-301840322.html,2023-06-01 20:01:00,"Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive ... PR ...",BMY,0.027445,0.070509,Neutral
"Mix Talent Launches Contract Talent Organization Solution, Mix CTO",https://www.prnewswire.com/news-releases/mix-talent-launches-contract-talent-organization-solution-mix-cto-301840598.html,2023-06-01 19:08:00,The life sciences talent leader has assembled a team of industry veterans to provide greater flexibility through their new contract talent solutions.,BMY,0.060541,0.082,Neutral
Bristol Myers  ( BMY )  Loses 10.5% Year-to-Date: What Lies Ahead?,https://www.zacks.com/stock/news/2102795/bristol-myers-bmy-loses-105-year-to-date-what-lies-ahead,2023-06-01 16:46:00,"Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.",BMY,0.219809,-0.081683,Neutral
"Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More",https://www.zacks.com/stock/news/2102778/biotech-stock-roundup-mrtx-falls-on-study-failure-lxrx-drug-wins-approval-more,2023-06-01 15:35:00,Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.,BMY,0.147516,0.030134,Neutral
Physician's Weekly Announces Digital Healthcare Veteran Kaushal Patel as Chief Information Officer,https://www.prnewswire.com/news-releases/physicians-weekly-announces-digital-healthcare-veteran-kaushal-patel-as-chief-information-officer-301839519.html,2023-06-01 12:41:00,Physician's Weekly Announces Digital Healthcare Veteran Kaushal ... PR ...,BMY,0.076602,0.163174,Somewhat-Bullish
Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co.  ( MRK ) ,https://www.forbes.com/sites/johnbuckingham/2023/06/19/big-pharma-vs-washingtonan-opportunity-to-buy-merck--co-mrk/,2023-06-19 23:34:34,"Warren Buffett states, ""Uncertainty is the friend of the buyer of long-term values,"" and Washington represents a big question mark these days for the pharma sector.",BMY,0.051886,-0.232646,Somewhat-Bearish
Bristol Myers  ( BMY )  Announces CAR T Cell Therapy Breyanzi Data,https://www.zacks.com/stock/news/2110217/bristol-myers-bmy-announces-car-t-cell-therapy-breyanzi-data,2023-06-19 15:27:00,Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma.,BMY,0.100518,0.0,Neutral
3 Bargain Stocks to Buy on the Dip,https://www.fool.com/investing/2023/06/17/3-bargain-stocks-to-buy-on-the-dip/,2023-06-17 10:10:00,These stocks should be poised to rebound.,BMY,0.29689,0.146447,Neutral
Bristol Myers sues US government over Medicare drug price negotiation plan,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-sues-us-government-over-medicare-drug-price-negotiation-plan-2023-06-16/,2023-06-16 22:06:00,"June 16 ( Reuters ) - Bristol Myers Squibb Co ( BMY.N ) on Friday sued the U.S. government in an attempt to halt the Medicare drug price negotiation program that analysts believe will involve one of its top-selling medicines, saying it violates the Fifth and First Amendments to the U.S.",BMY,0.090134,-0.13497,Neutral
Bristol Myers Squibb sues Biden administration over Medicare drug negotiations,https://www.cnbc.com/2023/06/16/bristol-myers-squibb-sues-biden-administration-over-medicare-drug-negotiations.html,2023-06-16 20:44:08,Bristol Myers Squibb said its blood thinner Eliquis will be subject to the negotiations this year. Eliquis is used to prevent blood clots and strokes.,BMY,0.463792,-0.036778,Neutral
Bristol Myers  ( BMY )  Gets FDA Nod for Data Addition to Camzyos,https://www.zacks.com/stock/news/2109627/bristol-myers-bmy-gets-fda-nod-for-data-addition-to-camzyos,2023-06-16 17:38:00,Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos.,BMY,0.174587,0.237922,Somewhat-Bullish
2 Short-Squeeze Candidates That Could Go Parabolic,https://www.fool.com/investing/2023/06/15/2-short-squeeze-candidates-that-could-go-parabolic/,2023-06-15 14:00:00,Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.,BMY,0.050148,0.0,Neutral
Bristol Myers Squibb  ( BMY )  Flat As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2107872/bristol-myers-squibb-bmy-flat-as-market-gains-what-you-should-know,2023-06-13 21:50:21,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.76, marking no change from the previous day.",BMY,0.526455,0.250095,Somewhat-Bullish
"Cancer Biologics Market Set to Surpass USD 185.0 Bn by 2031 Driven by Increasing Cancer Prevalence and Biotechnology Innovations, Reveals TMR Study",https://www.benzinga.com/pressreleases/23/06/g32831132/cancer-biologics-market-set-to-surpass-usd-185-0-bn-by-2031-driven-by-increasing-cancer-prevalence,2023-06-13 10:30:00,"Wilmington, Delaware, United States, June 13, 2023 ( GLOBE NEWSWIRE ) -- The global cancer biologics market was valued at US$ 94.5 Bn in 2022. It is projected to expand at a CAGR of 7.7% from 2023 to 2031.",BMY,0.043264,0.0,Neutral
The stock market is in a bull market? What bull market?,https://www.marketwatch.com/story/the-stock-market-is-in-a-bull-market-what-bull-market-52b36828,2023-06-13 09:01:00,Most of the S&P 500 isn't in a bull market. Far from it.,BMY,0.107495,-0.089093,Neutral
Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices - Merck & Co  ( NYSE:MRK ) ,https://www.benzinga.com/general/biotech/23/06/32818125/negotiation-or-coercion-big-pharma-and-us-chamber-of-commerce-tackle-government-on-drug-prices,2023-06-12 16:06:31,"The U.S. Chamber of Commerce has filed a lawsuit against the federal government, challenging a recent law that grants Medicare the authority to negotiate drug prices with pharmaceutical companies. In the complaint, the chamber argued that the pricing program violated the due process rights of ...",BMY,0.2872,0.0,Neutral
Forget space tourism. This company wants to make drug manufacturing the next big extraterrestrial business | Business,https://edition.cnn.com/2023/06/12/business/spacex-launch-varda-drug-pharma-space-industry-scn/index.html,2023-06-12 15:03:00,Forget space tourism. This company wants to make drug manufacturing the next big extraterrestrial business CNN International ...,BMY,0.015373,0.069401,Neutral
Forget space tourism. This company wants to make drug manufacturing the next big extraterrestrial business | Business,https://www.cnn.com/2023/06/12/business/spacex-launch-varda-drug-pharma-space-industry-scn/index.html,2023-06-12 15:03:00,Forget space tourism. This company wants to make drug manufacturing the next big extraterrestrial business ...,BMY,0.015373,0.069401,Neutral
Forget space tourism. This company wants to make drug manufacturing the next big extraterrestrial business | Business,https://www.cnn.com/2023/06/12/business/spacex-launch-varda-drug-pharma-space-industry-scn,2023-06-12 15:03:00,Forget space tourism. This company wants to make drug manufacturing the next big extraterrestrial business ...,BMY,0.015373,0.069401,Neutral
"Melanoma Market to Witness Promising Growth, Predicts DelveInsight | Key Companies To Watch - IO Biotech, Merck, Eisai, Regeneron, Genentech, Seagen, Amgen, Astellas, Galectin, MedImmune, Aivita, Linnaeus, Checkmate, OnKure",https://www.prnewswire.com/news-releases/melanoma-market-to-witness-promising-growth-predicts-delveinsight--key-companies-to-watch---io-biotech-merck-eisai-regeneron-genentech-seagen-amgen-astellas-galectin-medimmune-aivita-linnaeus-checkmate-onkure-301846881.html,2023-06-12 15:00:00,"Melanoma Market to Witness Promising Growth, Predicts ... PR ...",BMY,0.057721,0.04696,Neutral
This Drug Candidate Could Be a Winner for Bristol Myers,https://www.fool.com/investing/2023/06/12/this-drug-candidate-could-be-a-winner-for-bristol/,2023-06-12 11:45:00,Bristol Myers' lung cancer drug candidate could be just months away from U.S. Food and Drug Administration approval.,BMY,0.117486,0.066898,Neutral
"Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns",https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-rises-fda-panel-backs-alzheimers-drug-easing-safety-concerns-2023-06-12/,2023-06-12 10:26:14,"Biogen rises as FDA panel backs Alzheimer's drug, easing safety ... ...",BMY,0.155451,0.00944,Neutral
"Liver Cancer Market to Proliferate Positively, Assesses DelveInsight | Key Companies Active in the Domain - SOTIO, GlaxoSmithKline, Pfizer, Merck, Takeda, Genentech, Boehringer Ingelheim, DNAtrix, Celldex",https://www.prnewswire.com/news-releases/liver-cancer-market-to-proliferate-positively-assesses-delveinsight--key-companies-active-in-the-domain---sotio-glaxosmithkline-pfizer-merck-takeda-genentech-boehringer-ingelheim-dnatrix-celldex-301867060.html,2023-06-29 21:01:00,"Liver Cancer Market to Proliferate Positively, Assesses DelveInsight | Key Companies Active in the Domain - SOTIO ... PR ...",BMY,0.027828,-0.110448,Neutral
5 High-Yielding Dividend Stocks That Are Bargain Buys,https://www.fool.com/investing/2023/06/29/5-high-yielding-dividend-stocks-that-are-bargain/,2023-06-29 14:00:00,This is a good time for investors to load up on healthcare companies.,BMY,0.210092,0.060321,Neutral
"Geriatric Care Services Market to Grow at a 7.3% CAGR from 2023 to 2028, reaching US$ 0.7 billion: TMR Report",https://www.benzinga.com/pressreleases/23/06/g33059266/geriatric-care-services-market-to-grow-at-a-7-3-cagr-from-2023-to-2028-reaching-us-0-7-billion-tmr,2023-06-29 13:30:00,"Wilmington, Delaware, United States, June 29, 2023 ( GLOBE NEWSWIRE ) -- The global geriatric care services market is anticipated to grow at a 7.3% CAGR from 2023 to 2028. A market valuation of US$ 0.7 billion is expected by end of the forecast period.",BMY,0.036812,0.052088,Neutral
"Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates",https://www.zacks.com/stock/news/2114811/biotech-stock-roundup-srpts-dmd-therapy-approval-icpts-setback-more-updates,2023-06-29 13:02:00,Regulatory updates from Sarepta (SRPT) and Intercept (ICPT) are in focus in the biotech sector.,BMY,0.070935,0.187768,Somewhat-Bullish
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO,https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-focus-on-metabolic-diseases-with-avexitide-david-apelian-takes-helm-as-ceo-301866674.html,2023-06-29 12:00:00,Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide. David Apelian Takes Helm as CEO PR ...,BMY,0.02683,0.011073,Neutral
Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update,https://www.globenewswire.com/news-release/2023/06/29/2696901/0/en/Reunion-Neuroscience-Reports-Fiscal-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-a-Corporate-Update.html,2023-06-29 11:30:00,Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact. Special Shareholder Meeting Scheduled July ...,BMY,0.022947,0.022298,Neutral
Big Pharma Vs. Washington - An Opportunity To Buy Pfizer,https://www.forbes.com/sites/johnbuckingham/2023/06/28/big-pharma-vs-washingtonan-opportunity-to-buy-pfizer/,2023-06-28 23:32:50,"As I mentioned on my last Blog Post, blood clot drug Eliquis, sold by both Bristol Myers and Pfizer, is likely to face price controls under the Inflation Reduction Act.",BMY,0.049526,-0.204165,Somewhat-Bearish
Bristol-Myers Squibb Unusual Options Activity - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/06/33048350/bristol-myers-squibb-unusual-options-activity,2023-06-28 18:18:37,"Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.684999,0.162866,Somewhat-Bullish
"Survival Rates Improve with SELLAS's New Treatment for Severe Lung Cancer, Phase 1 Study Shows - SELLAS Life Sciences Gr  ( NASDAQ:SLS ) ",https://www.benzinga.com/general/biotech/23/06/33046388/survival-rates-improve-with-sellass-new-treatment-for-severe-lung-cancer-phase-1-study-shows,2023-06-28 18:00:34,"SELLAS Life Sciences Group Inc SLS released topline data from a Phase 1 trial of its lead clinical candidate, galinpepimut-S ( GPS ) , combined with Bristol Myers Squibb Co BMY nivolumab ( Opdivo ) in patients with malignant pleural mesothelioma ( MPM ) who were either refractory to or relapsed ...",BMY,0.316846,0.046465,Neutral
Bristol Myers Squibb Enters Oversold Territory,https://www.forbes.com/sites/dividendchannel/2023/06/28/bristol-myers-squibb-enters-oversold-territory/,2023-06-28 15:32:36,"making Bristol Myers Squibb even more interesting is the fact that in trading on Wednesday, shares of BMY entered into oversold territory ...",BMY,0.520773,0.395245,Bullish
Is Editas Medicine Stock a Buy Now?,https://www.fool.com/investing/2023/06/28/is-editas-medicine-stock-a-buy-now/,2023-06-28 14:15:00,The fortunes of this once-promising biotech company have changed in the past year.,BMY,0.059935,0.137006,Neutral
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2114121/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks,2023-06-28 13:10:03,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.212115,0.118038,Neutral
"K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation  ( 4;14 ) ",https://www.prnewswire.com/news-releases/k36-therapeutics-announces-70-million-series-b-financing-to-fund-clinical-proof-of-concept-of-ktx-1001-first-in-class-inhibitor-of-mmset-for-treatment-of-multiple-myeloma-patients-with-genetic-translocation-414-301865147.html,2023-06-28 12:00:00,"K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in ... PR ...",BMY,0.060085,0.006005,Neutral
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China's NMPA,https://www.globenewswire.com/news-release/2023/06/28/2696084/0/en/Zai-Lab-Announces-NDA-Acceptance-of-Repotrectinib-for-Patients-with-ROS1-positive-NSCLC-by-China-s-NMPA.html,2023-06-28 11:30:00,"SHANGHAI, China and CAMBRIDGE, Mass., June 28, 2023 ( GLOBE NEWSWIRE ) -- Zai Lab Limited ( NASDAQ: ZLAB. HKEX: 9688 ) today announced that the National Medical Products Administration ( NMPA ) in China has accepted the New Drug Application ( NDA ) for repotrectinib for the treatment of adult ...",BMY,0.065061,0.103847,Neutral
Winners announced for the EuroFinance Treasury Excellence Awards 2023,https://www.prnewswire.com/news-releases/winners-announced-for-the-eurofinance-treasury-excellence-awards-2023-301865498.html,2023-06-28 07:49:00,"Unilever, Africa Airtel, Bristol Myers Squibb and Siemens Gamesa named as the winners and IATA Pay were given a special commendation for the annual awards recognised as the benchmark for treasury excellence globally.",BMY,0.084127,0.316218,Somewhat-Bullish
Platelet-Rich Plasma Global Market to Grow Substantially at a CAGR of ~11% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/platelet-rich-plasma-global-market-to-grow-substantially-at-a-cagr-of-11-by-2028--delveinsight-301863904.html,2023-06-27 21:01:00,"Platelet-rich plasma ( PRP ) demand is being driven primarily by an increase in the number of patients suffering from orthopedic diseases, sports injuries, acute and chronic wounds, gynecological diseases, and urological diseases, among other conditions.",BMY,0.050679,0.050567,Neutral
Bristol Myers  ( BMY )  Heart Drug Camzyos Wins EC Approval,https://www.zacks.com/stock/news/2113718/bristol-myers-bmy-heart-drug-camzyos-wins-ec-approval,2023-06-27 15:45:00,"Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.",BMY,0.183895,0.256575,Somewhat-Bullish
"Questex's Fierce Clinical Summit Returns to Discuss All Things Clinical, Brings the Clinical Research and Trial Management Ecosystem Together September 26-28 in Philadelphia",https://www.benzinga.com/pressreleases/23/06/g33025104/questexs-fierce-clinical-summit-returns-to-discuss-all-things-clinical-brings-the-clinical-researc,2023-06-27 14:00:00,"NEW YORK, June 27, 2023 ( GLOBE NEWSWIRE ) -- Questex's Fierce Pharma today announces the Fierce Clinical Summit will take place September 26-28 in Philadelphia. The Summit is Fierce Pharma's flagship event for the clinical research and trial management ecosystem.",BMY,0.044885,0.0,Neutral
Bristol Myers Camzyos Gets European Commission Approval,https://markets.businessinsider.com/news/stocks/bristol-myers-camzyos-gets-european-commission-approval-1032410780,2023-06-26 21:00:39,( RTTNews ) - Bristol Myers Squibb ( BMY ) Monday announced that the European Commission ( EC ) has approved Camzyos for the treatment of symptomatic obstructive hypertrophic cardiomyopathy ( HCM ) in adult patients.,BMY,0.495015,0.456752,Bullish
2 Low-Priced Stocks That Could Make You Richer,https://www.fool.com/investing/2023/06/26/2-low-priced-stocks-that-could-make-you-richer/,2023-06-26 14:15:00,These two low-priced healthcare stocks could skyrocket within the next 12 months.,BMY,0.051774,0.066592,Neutral
Icertis Announces 2023 Icertis Connect Events to Enable AI-Driven Transformation with Contract Intelligence,https://www.prnewswire.com/news-releases/icertis-announces-2023-icertis-connect-events-to-enable-ai-driven-transformation-with-contract-intelligence-301863132.html,2023-06-26 13:00:00,"Customers Gather Across Seven Cities to Unlock Value from Business Relationships and Define the Future of AI in Contracting BELLEVUE, Wash., June 26, 2023 /PRNewswire/ -- Icertis today announced its 2023 Icertis Connect event series to help customers optimize their use of contract intelligence ...",BMY,0.078354,0.178924,Somewhat-Bullish
3 Healthcare Stocks That Are Too Cheap to Ignore,https://www.fool.com/investing/2023/06/25/3-healthcare-stocks-that-are-too-cheap-to-ignore/,2023-06-25 12:45:00,Each of these companies is trading at a valuation well below those of its industry peers.,BMY,0.118064,0.0,Neutral
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development,https://www.globenewswire.com/news-release/2023/06/24/2693952/0/en/Lexicon-Announces-Planned-Advancement-of-LX9211-Into-Late-Stage-Development.html,2023-06-24 00:45:00,"First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies ...",BMY,0.047465,-0.06789,Neutral
Big Pharma Vs. Washington-An Opportunity To Buy Bristol Myers,https://www.forbes.com/sites/johnbuckingham/2023/06/23/big-pharma-vs-washington-an-opportunity-to-buy-bristol-myers/,2023-06-23 22:27:12,"After all, news broke on Friday that Bristol Myers Squibb has sued Uncle Sam over a Medicare price renegotiation program in the Inflation Reduction Act (IRA) that was ...",BMY,0.257895,-0.060428,Neutral
Bristol Myers Squibb  ( BMY )  Stock Moves -0.4%: What You Should Know,https://www.zacks.com/stock/news/2112633/bristol-myers-squibb-bmy-stock-moves--04-what-you-should-know,2023-06-23 21:50:23,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $65.04, marking a -0.4% move from the previous day.",BMY,0.5341,0.151016,Somewhat-Bullish
"Psoriatic Arthritis Therapeutics Market to Grow at a CAGR of 8.0% from 2022 to 2031, reaching USD 24.2 Billion: As per TMR Study",https://www.benzinga.com/pressreleases/23/06/g32992593/psoriatic-arthritis-therapeutics-market-to-grow-at-a-cagr-of-8-0-from-2022-to-2031-reaching-usd-24,2023-06-23 20:30:00,"Wilmington, Delaware, United States, June 24, 2023 ( GLOBE NEWSWIRE ) -- The global psoriatic arthritis therapeutics market stood at USD 10.8 billion in 2021, and the global market is projected to reach USD 24.2 billion by 2031. The global industry is anticipated to record a CAGR of 8.0% between ...",BMY,0.039353,0.0,Neutral
"Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director",https://www.prnewswire.com/news-releases/mirati-therapeutics-appoints-industry-veteran-carol-gallagher-pharmd-as-new-independent-director-301861168.html,2023-06-23 20:00:00,"SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® ( NASDAQ: MRTX ) , a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.",BMY,0.054483,0.016926,Neutral
2 Stocks to Buy With $100 and Hold Forever,https://www.fool.com/investing/2023/06/23/2-stocks-to-buy-with-100-and-hold-forever/,2023-06-23 11:45:00,Both companies are leaders in industries that have excellent growth prospects.,BMY,0.160633,0.292439,Somewhat-Bullish
Is AstraZeneca a Top Stock to Buy Right Now?,https://www.fool.com/investing/2023/06/22/is-astrazeneca-a-top-stock-to-buy-right-now/,2023-06-22 18:00:00,The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead.,BMY,0.068306,0.032202,Neutral
I'm Buying These 3 Resilient Stocks During a Bear Market,https://www.fool.com/investing/2023/06/22/im-buying-these-3-resilient-stocks-during-a-bear/,2023-06-22 14:23:00,Be ready for the next bear market with stocks that bounce back fast.,BMY,0.11324,0.020306,Neutral
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2111725/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks,2023-06-22 13:10:03,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.204072,0.11455,Neutral
Will Johnson & Johnson Be a Trillion-Dollar Stock by 2038?,https://www.fool.com/investing/2023/06/22/will-jnj-be-a-trillion-dollar-stock-by-2038/,2023-06-22 12:10:00,The healthcare company is already almost halfway there.,BMY,0.136499,0.188243,Somewhat-Bullish
PhRMA lawsuit challenges Biden's drug law in friendly territory,https://www.axios.com/2023/06/22/phrma-lawsuit-medicare-negotiations-biden,2023-06-22 09:32:47,"The top lobbying organization for the pharmaceutical industry yesterday filed the fourth lawsuit challenging Democrats' law that gives Medicare the power to negotiate the prices of certain drugs, this time in a Texas district court. Why it matters: More lawsuits give the industry more ...",BMY,0.078099,0.093501,Neutral
Pharmaceutical trade group sues Biden administration over Medicare drug price negotiations,https://www.cnbc.com/2023/06/21/phrma-sues-biden-administration-over-medicare-drug-negotiations-.html,2023-06-21 21:08:48,"PhRMA's lawsuit is the fourth legal challenge to the law after separate suits from Merck, Bristol Myers Squibb and the U.S. Chamber of Commerce.",BMY,0.096283,0.088423,Neutral
Drugmaker industry group sues to stop Medicare drug price negotiation | Politics,https://www.cnn.com/2023/06/21/politics/medicare-drug-price-negotiation-lawsuit-phrma/index.html,2023-06-21 17:25:00,Drugmaker industry group sues to stop Medicare drug price negotiation ...,BMY,0.045655,-0.158766,Somewhat-Bearish
PhRMA sues over Medicare drug pricing provisions,https://www.axios.com/2023/06/21/phrma-sues-medicare-drug-prices,2023-06-21 13:49:52,"Pharmaceutical Research and Manufacturers of America announced Wednesday it is suing the Biden administration over its signature measure to lower drug prices, calling it unconstitutional.",BMY,0.136113,-0.095208,Neutral
Alexandria  ( ARE )  Divests 5 Non-Core Properties for $365M,https://www.zacks.com/stock/news/2111229/alexandria-are-divests-5-non-core-properties-for-365m,2023-06-21 12:58:00,"Keeping up with its capital-recycling strategy, Alexandria (ARE) announces the disposition of five non-core assets in Greater Boston, spanning 428,663 rentable square feet, for $365 million.",BMY,0.054983,0.124913,Neutral
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis,https://www.prnewswire.com/news-releases/halozyme-announces-argenx-receives-fda-approval-for-vyvgart-hytrulo-with-enhanze-for-subcutaneous-use-in-generalized-myasthenia-gravis-301855994.html,2023-06-20 22:30:00,Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use ... PR ...,BMY,0.04406,0.083547,Neutral
Don't Judge The Tax Cuts And Jobs Act's Anti-Profit-Shifting Measures Yet,https://www.forbes.com/sites/taxnotes/2023/06/20/dont-judge-the-tax-cuts-and-jobs-acts-anti-profit-shifting-measures-yet/,2023-06-20 13:42:11,Ryan Finley explains that casting the 2017 Tax Cuts and Jobs Act's anti-base-erosion measures as a failure is premature.,BMY,0.031119,0.109032,Neutral
"Alexandria Real Estate Equities, Inc.'s Unique, Highly Sought-After Labspace Assets in High-Barrier-to-Entry Markets Continue to Generate Strong Financial Returns",https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-incs-unique-highly-sought-after-labspace-assets-in-high-barrier-to-entry-markets-continue-to-generate-strong-financial-returns-301854913.html,2023-06-20 12:30:00,"Alexandria Real Estate Equities, Inc.'s Unique, Highly Sought-After Labspace Assets in High-Barrier-to-Entry Markets ... PR ...",BMY,0.020113,0.09184,Neutral
Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform,https://www.benzinga.com/pressreleases/23/06/g32919682/attovia-therapeutics-launches-with-60-million-series-a-financing-to-unlock-potential-of-novel-bipa,2023-06-20 11:30:00,Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets,BMY,0.038717,-0.004871,Neutral
Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court,https://www.cnbc.com/2023/06/20/drug-prices-drugmakers-aim-to-fight-medicare-negotiations-at-scotus.html,2023-06-20 11:00:02,The lawsuits are the opening salvo in a historic and potentially decisive battle over Medicare's efforts to bring rising drug prices under control.,BMY,0.184951,-0.087298,Neutral
Veralox Names Jonathan Mow as Chief Executive Officer as the Company Advances Development of First-in-Class Therapies for Immune-Mediated Diseases in Conjunction with Financing,https://www.benzinga.com/pressreleases/23/06/g32918968/veralox-names-jonathan-mow-as-chief-executive-officer-as-the-company-advances-development-of-first,2023-06-20 11:00:00,-- New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX-1005 -- Company Prepares to Evaluate VLX-1005 in Heparin-Induced Thrombocytopenia ( HIT ),BMY,0.1331,-0.068716,Neutral
Bristol Myers Squibb  ( BMY )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2118342/bristol-myers-squibb-bmy-dips-more-than-broader-markets-what-you-should-know,2023-07-07 21:50:17,"Bristol Myers Squibb (BMY) closed the most recent trading day at $62.65, moving -1.25% from the previous trading session.",BMY,0.5341,0.146845,Neutral
Global 2000 List 2023: The Top 200,https://www.forbes.com/sites/forbesstaff/2023/07/07/forbes-global-2000-list-2023-the-top-200/,2023-07-07 15:45:31,"Two years after the start of the pandemic, Covid casualties like airlines and oil producers have reclaimed top spots among the largest companies in the world.",BMY,0.010247,0.103567,Neutral
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial,https://www.globenewswire.com/news-release/2023/07/07/2701007/25359/en/CytoSorbents-Completes-Enrollment-of-the-STAR-T-Pivotal-Trial.html,2023-07-07 11:07:00,"PRINCETON, N.J., July 07, 2023 ( GLOBE NEWSWIRE ) -- CytoSorbents Corporation ( NASDAQ: CTSO ) , a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has ...",BMY,0.028056,0.047159,Neutral
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial - CytoSorbents  ( NASDAQ:CTSO ) ,https://www.benzinga.com/pressreleases/23/07/g33145457/cytosorbents-completes-enrollment-of-the-star-t-pivotal-trial,2023-07-07 11:07:00,"PRINCETON, N.J., July 07, 2023 ( GLOBE NEWSWIRE ) -- CytoSorbents Corporation CTSO, a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has completed ...",BMY,0.027288,0.046015,Neutral
Which Stock Is A Better Healthcare Pick - Bristol Myers Squibb Or HCA?,https://www.forbes.com/sites/greatspeculations/2023/07/06/which-stock-is-a-better-healthcare-pick--bristol-myers-squibb-or-hca/,2023-07-06 13:00:32,"There is more to the comparison, and in the sections below, we discuss why we believe BMY stock will offer higher returns than HCA stock in the next three years.",BMY,0.526455,0.224775,Somewhat-Bullish
Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/prostate-cancer-global-market-to-witness-upsurge-in-growth-at-a-cagr-of-5-by-2028--delveinsight-301869890.html,2023-07-05 21:01:00,"The prostate cancer market is anticipated to propel owing to the increasing incidence of prostate cancer around the world, the rising number of risk factors for prostate cancer, growing technological advancements in prostate cancer diagnostics, government, and non-government awareness ...",BMY,0.027195,-0.093078,Neutral
Looking Into Bristol-Myers Squibb's Recent Short Interest - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/23/07/33122025/looking-into-bristol-myers-squibbs-recent-short-interest,2023-07-05 19:46:11,"Bristol-Myers Squibb's BMY short percent of float has fallen 3.33% since its last report. The company recently reported that it has 18.34 million shares sold short, which is 0.87% of all regular shares that are available for trading.",BMY,0.221819,0.083071,Neutral
AZN: Secure Your Portfolio With These 3 Pharma Stocks,https://stocknews.com/news/azn-bmy-alpmy-secure-your-portfolio-with-these-3-pharma-stocks/,2023-07-05 17:52:56,"The pharmaceutical industry is known for its relative stability and resilience, even during economic downturns. This is due to the consistent demand for medications and healthcare, regardless of market conditions.",BMY,0.176779,0.238376,Somewhat-Bullish
Allarity Says Initial Data Show Improved Clinical Benefit In Breast Cancer Patients Selected Via Companion Diagnostic - Allarity Therapeutics  ( NASDAQ:ALLR ) ,https://www.benzinga.com/general/biotech/23/07/33116790/allarity-says-initial-data-show-improved-clinical-benefit-in-breast-cancer-patients-selected-via-,2023-07-05 16:53:19,Allarity Therapeutics Inc ALLR announced initial results from its European Phase 2 clinical trial evaluating the efficacy of Ixempra in metastatic breast cancer ( mBC ) patients selected with the DRP-Ixempra companion diagnostic ( CDx ) candidate.,BMY,0.247838,-0.099141,Neutral
Will Bristol Myers  ( BMY )  Beat Estimates Again in Its Next Earnings Report?,https://www.zacks.com/stock/news/2117120/will-bristol-myers-bmy-beat-estimates-again-in-its-next-earnings-report,2023-07-05 16:10:10,Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,BMY,0.171485,0.208947,Somewhat-Bullish
Initial Data from Allarity's Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients,https://www.globenewswire.com/news-release/2023/07/05/2699631/0/en/Initial-Data-from-Allarity-s-Phase-2-Trial-of-IXEMPRA-Indicate-Potential-for-Improved-Clinical-Benefit-in-DRP-Selected-Metastatic-Breast-Cancer-Patients.html,2023-07-05 13:45:00,"Boston, MA ( July 5, 2023 ) - Allarity Therapeutics, Inc. ( ""Allarity"" or the ""Company"" ) ( Nasdaq: ALLR ) , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced initial ...",BMY,0.023743,-0.00187,Neutral
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick,https://www.zacks.com/stock/news/2116939/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick,2023-07-05 13:40:08,The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.,BMY,0.305058,0.329405,Somewhat-Bullish
Evotec Secures US Government Contract For Orthopoxvirus Antibody - Evotec  ( NASDAQ:EVO ) ,https://www.benzinga.com/general/biotech/23/07/33112669/evotec-secures-us-government-contract-for-orthopoxvirus-antibody,2023-07-05 11:45:43,"The U.S. Department of Defense ( DOD ) has awarded Evotec SE's EVOTF EVO Seattle-based subsidiary, Just - Evotec Biologics Inc a contract valued up to $74 million for the rapid development of monoclonal antibody ( mAb ) -based drug product prototypes targeting orthopoxviruses.",BMY,0.261117,0.0,Neutral
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income,https://www.zacks.com/stock/news/2116448/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income,2023-07-04 13:10:03,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.205807,0.1153,Neutral
3 Spectacular Dividend Stocks to Buy in July,https://www.fool.com/investing/2023/07/04/3-spectacular-dividend-stocks-to-buy-in-july/,2023-07-04 12:14:00,Heat up your portfolio this month with these dividend stocks.,BMY,0.241924,0.122634,Neutral
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,2023-07-03 21:01:00,Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...,BMY,0.020404,0.078882,Neutral
1 Green Flag and 1 Red Flag for Pfizer,https://www.fool.com/investing/2023/07/01/1-green-flag-and-1-red-flag-for-pfizer/,2023-07-01 13:15:00,"Pfizer's long-term potential shows promise, but concerns exist.",BMY,0.047278,-0.040933,Neutral
Bristol Myers Squibb  ( BMY )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2115605/bristol-myers-squibb-bmy-stock-sinks-as-market-gains-what-you-should-know,2023-06-30 21:50:20,"Bristol Myers Squibb (BMY) closed the most recent trading day at $63.95, moving -0.08% from the previous trading session.",BMY,0.695767,0.340498,Somewhat-Bullish
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday,https://www.fool.com/investing/2023/06/30/why-aurinia-pharmaceuticals-stock-is-marching-high/,2023-06-30 18:49:03,The biotech's board is exploring strategic alternatives to boost shareholder value.,BMY,0.128135,-0.046848,Neutral
Medicare will allow pharmaceutical companies to publicly discuss drug price negotiations,https://www.cnbc.com/2023/06/30/medicare-pharma-drug-price-negotiations.html,2023-06-30 17:02:36,"Drugmakers had sued the federal government, arguing that the ""gag order"" violated the First Amendment.",BMY,0.175859,-0.32416,Somewhat-Bearish
Check Out What Whales Are Doing With BMY - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/06/33081720/check-out-what-whales-are-doing-with-bmy,2023-06-30 16:31:55,"Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.765213,0.430706,Bullish
"Biotech Surges As It Explores 'Strategic Alternatives,' Including A Buyout",https://www.investors.com/news/technology/auph-stock-soars-as-aurinia-explores-strategic-alternatives-including-a-buyout/,2023-06-30 13:38:00,AUPH Stock Soars As Aurinia Explores 'Strategic Alternatives ... Investor's Business Daily ...,BMY,0.088799,0.073307,Neutral
Bristol Myers'  ( BMY )  Opdivo With Chemo Gets EC Nod for NSCLC,https://www.zacks.com/stock/news/2115347/bristol-myers-bmy-opdivo-with-chemo-gets-ec-nod-for-nsclc,2023-06-30 13:34:00,"Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.",BMY,0.257805,0.218327,Somewhat-Bullish
Biden administration moves ahead with Medicare drug price negotiations amid industry lawsuits | Politics,https://www.cnn.com/2023/06/30/politics/medicare-drug-price-negotiations-new-guidance/index.html,2023-06-30 12:45:00,Biden administration moves ahead with Medicare drug price negotiations amid industry lawsuits ...,BMY,0.127795,-0.12845,Neutral
Bristol Myers Squibb  ( BMY )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2124096/bristol-myers-squibb-bmy-gains-but-lags-market-what-you-should-know,2023-07-19 21:50:22,"Bristol Myers Squibb (BMY) closed the most recent trading day at $62.06, moving +0.1% from the previous trading session.",BMY,0.651499,0.335048,Somewhat-Bullish
Pharmaceutical Industry Overview: Top Regions  ( Updated 2023 ) ,https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/top-pharmaceutical-regions/,2023-07-19 21:15:00,"The pharmaceutical industry has a global presence, but the world's biggest markets are the US and Europe. Regions such as China and India have seen growth in recent years, but when it comes to the life science space - particularly the pharma industry - the US and Europe remain on top for ...",BMY,0.043499,0.117759,Neutral
Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government - Johnson & Johnson  ( NYSE:JNJ ) ,https://www.benzinga.com/general/biotech/23/07/33280064/drug-pricing-negotiation-program-johnson-johnson-joins-legal-battle-against-us-government,2023-07-19 11:48:29,"Johnson & Johnson JNJ has reportedly taken legal action against the U.S. government, following the lead of other pharmaceutical companies aiming to obstruct a program that empowers the Medicare government health insurance plan to negotiate lower prices for medication.",BMY,0.185306,0.083125,Neutral
"Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D",https://www.benzinga.com/pressreleases/23/07/g33281406/jnana-therapeutics-appoints-george-vratsanos-m-d-as-chief-medical-officer-and-head-of-r-d,2023-07-19 11:00:00,"BOSTON, July 19, 2023 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced the appointment of George Vratsanos, M.D., F.A.C.R., to chief ...",BMY,0.065685,0.070083,Neutral
The Fight Against Alzheimer Goes Beyond Plaque. Tangles Are a Target Too.,https://www.barrons.com/articles/alzheimer-prothea-plaque-tau-tangles-1ab2626a,2023-07-18 21:36:00,"Keep your eyes on tau, not just amyloid-beta, as the world of medical research takes on Alzheimer's disease. A rivalry between Eli Lilly and the team of Biogen and Eisai Pharmaceuticals was the main event at this week's international conference of the Alzheimer's Association in Amsterdam.",BMY,0.058903,0.079989,Neutral
Johnson & Johnson sues Biden administration over drug-pricing policies - .com,https://www.upi.com/Top_News/US/2023/07/18/johnson-and-johnson-sues-biden-administration-inflation-reduction-act/7411689709051/,2023-07-18 21:32:09,Johnson & Johnson sues Biden administration over drug-pricing policies UPI News ...,BMY,0.08183,-0.165582,Somewhat-Bearish
Johnson & Johnson sues Biden administration over Medicare drug price negotiations,https://www.cnbc.com/2023/07/18/jj-sues-biden-administration-over-medicare-drug-negotiations.html,2023-07-18 17:07:47,"Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA filed separate lawsuits against the provision last month.",BMY,0.207571,-0.261022,Somewhat-Bearish
Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals,https://www.fool.com/investing/2023/07/18/better-ai-biotech-stock-schrodinger-vs-recursion/,2023-07-18 14:00:00,Both companies could tap into huge growth from the AI revolution in a few years.,BMY,0.058188,0.089978,Neutral
Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States,https://www.prnewswire.com/apac/news-releases/antengene-announces-first-patient-dosed-in-the-nivolumab-combination-portion-of-the-clinical-study-evaluating-the-erk12-inhibitor-atg-017-in-patients-with-advanced-solid-tumors-in-the-united-states-301878587.html,2023-07-18 00:30:00,Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ... PR ...,BMY,0.041975,-0.010943,Neutral
"This Artificial Intelligence Biotech Stock Is Crushing the Market, but Is It a Buy?",https://www.fool.com/investing/2023/07/17/this-artificial-intelligence-biotech-stock-is-crus/,2023-07-17 14:15:00,Its software platform could become a core tool for many businesses in biopharma.,BMY,0.055492,0.095861,Neutral
3 Top Dividend Stocks to Maximize Your Retirement Income,https://www.zacks.com/stock/news/2122018/3-top-dividend-stocks-to-maximize-your-retirement-income,2023-07-17 13:10:04,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.216376,0.119894,Neutral
Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference,https://www.prnewswire.com/news-releases/cumulus-neuroscience-presents-data-at-aaic-2023-annual-meeting-and-technology-and-dementia-preconference-301878093.html,2023-07-17 13:00:00,"• Interim analysis of first-in-class CNS-101 study suggests that patients with mild Alzheimer's dementia are capable and willing to participate in intensive home-based functional neurophysiology studies. BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- ( Cumulus.",BMY,0.038843,0.0,Neutral
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings,https://www.zacks.com/stock/news/2121978/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings,2023-07-17 12:50:07,Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.,BMY,0.320557,0.338867,Somewhat-Bullish
"The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/07/33246335/the-acute-hospital-care-market-is-worth-over-3-trillion-and-windtree-therapeutics-brings-a-first-,2023-07-17 12:15:09,The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate ( CAGR ) of 5.62% from 2023 to 2030.,BMY,0.108712,0.10646,Neutral
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023,https://www.globenewswire.com/news-release/2023/07/17/2705214/0/en/LianBio-Announces-Phase-3-EXPLORER-CN-Data-Accepted-for-Late-Breaking-Presentation-at-the-European-Society-of-Cardiology-Congress-2023.html,2023-07-17 10:00:00,"SHANGHAI, China and PRINCETON, N.J., July 17, 2023 ( GLOBE NEWSWIRE ) -- LianBio ( Nasdaq: LIAN ) , a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced data from the Phase 3 EXPLORER-CN trial of mavacamten in ...",BMY,0.050679,0.110348,Neutral
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023 - LianBio  ( NASDAQ:LIAN ) ,https://www.benzinga.com/pressreleases/23/07/g33244089/lianbio-announces-phase-3-explorer-cn-data-accepted-for-late-breaking-presentation-at-the-european,2023-07-17 10:00:00,"SHANGHAI, China and PRINCETON, N.J., July 17, 2023 ( GLOBE NEWSWIRE ) -- LianBio LIAN, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese ...",BMY,0.046543,0.10959,Neutral
Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101,https://www.globenewswire.com/news-release/2023/07/17/2705231/37414/en/Panbela-Announces-Issuance-of-New-Patent-in-Australia-Patent-is-for-Claims-of-a-Novel-Process-for-the-Production-of-SBP-101.html,2023-07-17 10:00:00,Patent developed in collaboration with Syngene International Ltd. Patent developed in collaboration with Syngene International Ltd.,BMY,0.02668,0.12784,Neutral
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy,https://www.prnewswire.com/news-releases/positive-topline-data-reported-from-argenxs-adhere-study-of-vyvgart-hytrulo-with-halozymes-enhanze-drug-delivery-technology-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-301878178.html,2023-07-17 05:15:00,Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE ... PR ...,BMY,0.037155,0.082445,Neutral
"Congratulations, Medicare Part D Beneficiaries: You Could Soon Save a Lot of Money.",https://www.fool.com/retirement/2023/07/16/congratulations-medicare-part-d-beneficiaries-you/,2023-07-16 10:00:00,Major legislation passed in 2022 could help reduce out-of-pocket costs for many seniors.,BMY,0.067536,-0.029239,Neutral
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings,https://www.zacks.com/stock/news/2121179/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings,2023-07-14 12:50:07,Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.,BMY,0.320557,0.342996,Somewhat-Bullish
Bristol Myers Squibb  ( BMY )  Flat As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2120926/bristol-myers-squibb-bmy-flat-as-market-gains-what-you-should-know,2023-07-13 21:50:22,"Bristol Myers Squibb (BMY) closed at $62.28 in the latest trading session, marking no change from the prior day.",BMY,0.635085,0.285009,Somewhat-Bullish
What Does Bristol-Myers Squibb's Debt Look Like? - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/news/23/07/33219171/what-does-bristol-myers-squibbs-debt-look-like,2023-07-13 16:15:19,"Shares of Bristol-Myers Squibb Inc. BMY decreased by 11.11% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.",BMY,0.371523,0.095494,Neutral
"Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment",https://www.zacks.com/stock/news/2120702/biotech-stock-roundup-biib-eisais-drug-update-nvax-gains-on-deal-amendment,2023-07-13 13:22:00,Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.,BMY,0.19117,0.079032,Neutral
Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies,https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/,2023-07-13 12:06:00,"One minute Dow Jones industrial average component Merck ( MRK ) might be doing battle with fellow drugmaker Bristol Myers Squibb ( BMY ) over drugs that can ward off cancer. The next, biotech giants like Amgen ( AMGN ) and Sanofi ( SNY ) are tussling in court over the fate of ...",BMY,0.366061,-0.549433,Bearish
10 drugs drove a big share of Medicare spending in 2021,https://www.axios.com/2023/07/13/drugs-drive-medicare-spending,2023-07-13 10:56:24,10 drugs drove a big share of Medicare spending in ...,BMY,0.122269,-0.019961,Neutral
Why Shares of Exscientia Jumped on Wednesday,https://www.fool.com/investing/2023/07/12/why-shares-of-exscientia-jumped-on-wednesday/,2023-07-12 20:51:00,The company may be riding the wave of an AI healthcare boom.,BMY,0.137671,0.142787,Neutral
Bristol Myers  ( BMY )  Reports Positive Data From Urothelial Cancer Study,https://www.zacks.com/stock/news/2119995/bristol-myers-bmy-reports-positive-data-from-urothelial-cancer-study,2023-07-12 13:47:00,Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable or metastatic urothelial carcinoma.,BMY,0.345674,0.364429,Bullish
"Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge - Windtree Therapeutics  ( NASDAQ: WINT )  Is Helping Change That - Novartis  ( NYSE:NVS ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/07/33197114/medical-management-of-deadly-urgent-cardiogenic-shock-largely-remains-a-challenge-windtree-therap,2023-07-12 12:25:10,"Windtree Therapeutics, Inc. WINT, a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions.",BMY,0.106778,0.0,Neutral
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations,https://www.globenewswire.com/news-release/2023/07/12/2703463/0/en/LianBio-Announces-Clinical-Supply-Agreement-with-AstraZeneca-in-China-to-Evaluate-BBP-398-in-Combination-with-Osimertinib-in-Patients-with-Non-Small-Cell-Lung-Cancer-with-EGFR-Muta.html,2023-07-12 12:00:00,"SHANGHAI, China and PRINCETON, N.J., July 12, 2023 ( GLOBE NEWSWIRE ) -- LianBio ( Nasdaq: LIAN ) , a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced a clinical supply agreement with AstraZeneca in China to ...",BMY,0.045139,-0.013958,Neutral
Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the Market Entry,https://www.prnewswire.com/news-releases/sickle-cell-disease-clinical-trial-pipeline-accelerates-as-40-pharma-companies-rigorously-developing-drugs-for-the-market-entry-301873885.html,2023-07-11 21:01:00,Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the ... PR ...,BMY,0.022284,0.038612,Neutral
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors,https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-appointment-of-christine-a-poon-to-board-of-directors-301874728.html,2023-07-11 20:05:00,"SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. ( Nasdaq: NBIX ) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors.",BMY,0.07913,0.032424,Neutral
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2119070/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks,2023-07-11 13:10:04,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.217346,0.120318,Neutral
Prothena  ( PRTA )  Alzheimer's Disease Drug Licensed by BMY,https://www.zacks.com/stock/news/2119204/prothena-prta-alzheimers-disease-drug-licensed-by-bmy,2023-07-11 12:59:00,"Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.",BMY,0.414559,0.163005,Somewhat-Bullish
Bristol Myers' bladder cancer drug extends survival in late-stage study,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-bladder-cancer-drug-meets-goal-late-stage-sub-study-2023-07-11/,2023-07-11 11:46:00,"July 11 ( Reuters ) - Bristol Myers Squibb Co ( BMY.N ) said on Tuesday its blockbuster cancer immunotherapy, Opdivo, in combination with chemotherapy extended survival and helped patients with a type of bladder cancer live disease-free in a late-stage trial.",BMY,0.299478,-0.047419,Neutral
"Arbutus Appoints Two New Executives - Arbutus Biopharma  ( NASDAQ:ABUS ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/23/07/g33172748/arbutus-appoints-two-new-executives,2023-07-10 20:01:00,"WARMINSTER, Pa., July 10, 2023 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS ( ""Arbutus"" or the ""Company"" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the ...",BMY,0.049732,0.029839,Neutral
"Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",https://www.benzinga.com/general/biotech/23/07/33447281/johnson-johnson-other-pharma-makers-anticipate-reformulated-injectable-drugs-may-exclude-price-ne,2023-07-28 17:47:18,"Cancer drug manufacturers, including Johnson & Johnson JNJ, anticipate that injectable versions of some popular treatments will not be included in U.S. government price negotiations for several years, thereby safeguarding substantial revenue.",BMY,0.29234,-0.330285,Somewhat-Bearish
2 Surefire Stocks to Buy With $500,https://www.fool.com/investing/2023/07/28/2-surefire-stocks-to-buy-with-500/,2023-07-28 13:53:00,A little can go a long way in equity markets.,BMY,0.047654,0.099871,Neutral
"Roku To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Friday - BJ's Restaurants  ( NASDAQ:BJRI ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/23/07/33440261/roku-to-rally-around-25-here-are-10-other-analyst-forecasts-for-friday,2023-07-28 11:48:11,"JP Morgan boosted the price target for Intel Corporation INTC from $30 to $35. JP Morgan analyst Harlan Sur maintained an Underweight rating. Intel shares rose 6.8% to $36.91 in pre-market trading. Baird raised BJ's Restaurants, Inc. BJRI price target from $28 to $36.",BMY,0.288893,-0.327594,Somewhat-Bearish
"Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations",https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-go-under-skin-skirting-early-us-medicare-price-negotiations-2023-07-28/,2023-07-28 10:14:00,"[1/5] Pharmaceutical tablets and capsules are arranged in the shape of a U.S. dollar sign on a table in this picture illustration taken in Ljubljana August 20, 2014. REUTERS/Srdjan Zivulovic/File Photo",BMY,0.054483,-0.063039,Neutral
"Multiple Sclerosis Market Size and Share to Grow Significantly, Assesses DelveInsight | Leading Companies - Roche, Atara, Immunic, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Genzyme, ImStem, Rho, Bristol-Myers Squibb",https://www.prnewswire.com/news-releases/multiple-sclerosis-market-size-and-share-to-grow-significantly-assesses-delveinsight--leading-companies---roche-atara-immunic-celgene-anokion-sa-sanofi-actelion-biogen-genzyme-imstem-rho-bristol-myers-squibb-301887032.html,2023-07-27 21:01:00,"Multiple Sclerosis Market Size and Share to Grow Significantly, Assesses DelveInsight | Leading Companies - Roche ... PR ...",BMY,0.044182,0.088537,Neutral
"Cutera taps serial dealmaker Harris as CEO, stock price surges",https://www.reuters.com/business/healthcare-pharmaceuticals/cutera-taps-serial-dealmaker-harris-ceo-stock-price-surges-2023-07-27/,2023-07-27 20:49:00,"July 27 ( Reuters ) - Aesthetics device maker Cutera Inc ( CUTR.O ) said on Thursday it has appointed Taylor Harris, who previously helped lead three companies which ended up getting acquired, as its new chief executive, driving its shares up 23% on dealmaking hopes.",BMY,0.095138,0.061263,Neutral
Bristol Myers Squibb  ( BMY )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/07/27/bristol-myers-squibb-bmy-q2-2023-earnings-call-tra/,2023-07-27 19:00:28,"BMY earnings call for the period ending June 30, 2023.",BMY,0.007308,0.141514,Neutral
"Bristol-Myers  ( BMY )  Q2 Earnings, Sales Miss, '23 View Lowered",https://www.zacks.com/stock/news/2129009/bristol-myers-bmy-q2-earnings-sales-miss-23-view-lowered,2023-07-27 17:55:00,Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.,BMY,0.361407,0.224115,Somewhat-Bullish
Why Bristol Myers Squibb's  ( BMY )  Shares Are Falling Today - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/07/33417810/bristol-myers-squibbs-stocks-falls-on-q2-miss-fy23-forecast-cut-as-two-of-its-top-drugs-face-gene,2023-07-27 14:19:15,"Bristol Myers Squibb & Co BMY said that its Q2 revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and our new product portfolio. Analysts estimated sales of $11.81 billion.",BMY,0.595343,0.057413,Neutral
2 Dirt Cheap Dividend Stocks to Buy Right Now,https://www.fool.com/investing/2023/07/27/2-dirt-cheap-dividend-stocks-to-buy-right-now/,2023-07-27 13:37:00,Business never sleeps for these companies.,BMY,0.325924,0.145551,Neutral
"Bristol Myers sales fall, cuts 2023 forecast as drugs face competition",https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-sales-fall-cuts-2023-forecast-drugs-face-competition-2023-07-27/,2023-07-27 13:09:00,"July 27 ( Reuters ) - Drugmaker Bristol Myers Squibb ( BMY.N ) on Thursday said its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.",BMY,0.091509,-0.132113,Neutral
FDA Grants Clearance for UltraSight's AI-Powered Cardiac Ultrasound Technology,https://www.prnewswire.com/news-releases/fda-grants-clearance-for-ultrasights-ai-powered-cardiac-ultrasound-technology-301886516.html,2023-07-27 13:00:00,New AI guidance software will allow more medical professionals to conduct cardiac ultrasound in multiple care settings expanding patient access to cardiac imaging,BMY,0.052226,0.308852,Somewhat-Bullish
Bristol Myers Squibb  ( BMY )  Misses Q2 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2128638/bristol-myers-squibb-bmy-misses-q2-earnings-and-revenue-estimates,2023-07-27 12:25:14,"Bristol Myers (BMY) delivered earnings and revenue surprises of -12.06% and 4.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",BMY,0.138464,0.117364,Neutral
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement,https://www.globenewswire.com/news-release/2023/07/27/2712158/0/en/Ayala-Pharmaceuticals-and-Biosight-Enter-into-Definitive-Merger-Agreement.html,2023-07-27 12:10:00,"Combined company to operate as Ayala Pharmaceuticals, Inc.",BMY,0.020079,-0.030561,Neutral
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement - Ayala Pharmaceuticals  ( OTC:ADXS ) ,https://www.benzinga.com/pressreleases/23/07/g33417811/ayala-pharmaceuticals-and-biosight-enter-into-definitive-merger-agreement,2023-07-27 12:10:00,"Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala's portfolio with data anticipated in the first half of 2024 REHOVOT and TEL AVIV, Israel and MONMOUTH JUNCTION, N.J., July 27, 2023 ( GLOBE NEWSWIRE ) -- Ayala Pharmaceuticals, Inc.",BMY,0.019829,-0.029584,Neutral
"US Stocks Buckle Up For Solid Open: What Futures Market Shows - KLA  ( NASDAQ:KLAC ) , Alphabet  ( NASDAQ:GOOG ) , Alphabet  ( NASDAQ:GOOGL ) , Meta Platforms  ( NASDAQ:META ) , Roku  ( NASDAQ:ROKU ) , Ford Motor  ( NYSE:F ) , Bristol-Myers Squibb  ( NYSE:BMY ) , McDonald's  ( NYSE:MCD ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Edwards Lifesciences  ( NYSE:EW ) , First Solar  ( NASDAQ:FSLR ) , Mastercard  ( NYSE:MA ) , Lam Research  ( NASDAQ:LRCX ) , Chipotle Mexican Grill  ( NYSE:CMG ) , SPDR S&P 500  ( ARCA:SPY ) , Western Union  ( NYSE:WU ) ",https://www.benzinga.com/news/earnings/23/07/33416950/us-stocks-buckle-up-for-solid-open-on-metas-earnings-boost-fed-relief-but-analyst-advises-some-valu,2023-07-27 11:48:22,"U.S. stocks could get off to a solid start on Thursday as a Federal Reserve relief rally appears to be in the works. Strong earnings from social media giant Meta Platforms, Inc. META will likely perk up risk appetite further.",BMY,0.087824,0.0,Neutral
"Investor Sentiment Declines After Fed Raises Interest Rates By 0.25% - Boeing  ( NYSE:BA ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/earnings/23/07/33411576/investor-sentiment-declines-after-fed-raises-interest-rates-by-0-25,2023-07-27 07:58:58,"The CNN Money Fear and Greed index showed further decline in overall sentiment among U.S. investors on Wednesday. The Dow Jones closed higher on Wednesday, recording its longest winning streak since 1987 following interest-rate decision from the U.S. Federal Reserve.",BMY,0.299478,0.0,Neutral
These 7 momentum stocks ignited the market. Look out when they start to fall.,https://www.marketwatch.com/story/the-algos-are-the-enemy-machines-created-this-stock-market-rally-eventually-they-will-end-it-9bd77277,2023-07-26 15:22:00,TheoTrade's Jeffrey Bierman on algorithmic trading: 'Nothing matters except what the algos can chase higher.' Beware the 'Magnificent Seven' stocks.,BMY,0.058976,0.169204,Somewhat-Bullish
Bristol-Myers Squibb Unusual Options Activity - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/07/33375165/bristol-myers-squibb-unusual-options-activity,2023-07-25 17:31:27,"Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.747404,0.250539,Somewhat-Bullish
Bristol-Myers  ( BMY )  to Report Q2 Earnings: What's in Store?,https://www.zacks.com/stock/news/2127153/bristol-myers-bmy-to-report-q2-earnings-whats-in-store,2023-07-25 15:57:00,Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results.,BMY,0.244846,0.245128,Somewhat-Bullish
2 Cheap High-Yield Dividend Stocks to Buy Now,https://www.fool.com/investing/2023/07/25/2-cheap-high-yield-dividend-stocks-to-buy-now/,2023-07-25 15:15:00,These two pharma stocks are top-notch passive income vehicles.,BMY,0.175433,0.168718,Somewhat-Bullish
Exact Sciences  ( EXAS )  May Report Negative Earnings: Know the Trend Ahead of Next Week's Release,https://www.zacks.com/stock/news/2126980/exact-sciences-exas-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release,2023-07-25 14:01:29,Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.08687,0.039023,Neutral
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,2023-07-24 21:01:00,"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies ... PR ...",BMY,0.080638,0.047754,Neutral
"Why Immatics  ( IMTX )  Shares Are Rising Today - Immatics  ( NASDAQ:IMTX ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/markets/equities/23/07/33345193/why-immatics-shares-are-rising-today,2023-07-24 14:05:16,Immatics N.V. IMTX shares are trading higher after the company announced a $35 million equity investment from Bristol-Myers Squibb Company BMY. Bristol Myers Squibb purchased 2.42 million ordinary shares in a private placement transaction at a subscription price per share of $14.46.,BMY,0.644033,0.553534,Bullish
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks,https://www.zacks.com/stock/news/2126022/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks,2023-07-24 13:10:03,"The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",BMY,0.213048,0.118444,Neutral
"Johnson & Johnson Bankruptcy Talk: Q2 Earnings Soar, But Litigation Looms On Horizon",https://www.forbes.com/sites/qai/2023/07/24/johnson--johnson-bankruptcy-talk-q2-earnings-soar-but-litigation-looms-on-horizon/,2023-07-24 12:36:48,The company has proposed a $8.9 billion settlement to end tens of thousands of cases and stop new ones from coming through ...,BMY,0.064104,-0.034382,Neutral
Drugmakers Are 'Throwing the Kitchen Sink' to Halt Medicare Price Negotiations,https://www.nytimes.com/2023/07/23/us/politics/medicare-drug-price-negotiations-lawsuits.html,2023-07-23 07:00:17,The government will soon announce the first 10 medications that will be subject to price negotiations with Medicare under a new law. Drugmakers are fighting the measure in court.,BMY,0.024053,-0.025632,Neutral
3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other,https://www.fool.com/investing/2023/07/21/3-cutting-edge-biotech-stocks-that-are-riding-the/,2023-07-21 14:07:00,"They're not guaranteed to keep soaring, but they are right now.",BMY,0.05339,0.161718,Somewhat-Bullish
Johnson & Johnson  ( JNJ )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/07/20/johnson-johnson-jnj-q2-2023-earnings-call-transcri/,2023-07-20 18:30:22,"JNJ earnings call for the period ending June 30, 2023.",BMY,0.008766,0.002549,Neutral
Bristol Myers Squibb  ( BMY )  Earnings Expected to Grow: Should You Buy?,https://www.zacks.com/stock/news/2124681/bristol-myers-squibb-bmy-earnings-expected-to-grow-should-you-buy,2023-07-20 14:02:08,Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.088147,0.077155,Neutral
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339,https://www.prnewswire.com/news-releases/casi-pharmaceuticals-acquires-global-intellectual-property-rights-to-cleave-therapeutics-vcpp97-inhibitor-cb-5339-301881595.html,2023-07-20 12:00:00,"BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. ( Nasdaq: CASI ) , a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement ( the ""Agreement"" ) with ...",BMY,0.034882,0.064414,Neutral
"Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines DelveInsight | Key Companies Working in Market - Roche, Acticor Biotech, Genentech, Mallinckrodt, AbbVie, Janssen, Bristol Myers Squibb, Bayer",https://www.prnewswire.com/news-releases/ischemic-stroke-market-is-likely-to-increase-at-a-steady-growth-rate-examines-delveinsight--key-companies-working-in-market---roche-acticor-biotech-genentech-mallinckrodt-abbvie-janssen-bristol-myers-squibb-bayer-301895355.html,2023-08-08 21:01:00,"Ischemic Stroke Market is Likely to Increase at a Steady Growth Rate, Examines DelveInsight | Key Companies ... PR ...",BMY,0.073773,0.045349,Neutral
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/08/2721181/37704/en/CytomX-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-08-08 20:15:00,- CX-904 ( EGFRxCD3 ) initial Phase 1 dose escalation data anticipated first half of ...,BMY,0.05383,0.008003,Neutral
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates,https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-second-quarter-2023-financial-results-and-recent-corporate-updates-301896156.html,2023-08-08 20:01:00,"SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® ( NASDAQ: MRTX ) , a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.",BMY,0.051221,0.0,Neutral
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS,https://www.prnewswire.com/news-releases/halozyme-reports-second-quarter-2023-financial-and-operating-results-301896108.html,2023-08-08 20:01:00,Revenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.741 Royalty Revenue Increased 31% YOY to Record $111.7 million Raised 2023 Non-GAAP Diluted EPS Guidance to $2.65-$2.75,BMY,0.021937,0.077737,Neutral
Zoetis  ( ZTS )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/08/08/zoetis-zts-q2-2023-earnings-call-transcript/,2023-08-08 18:30:25,"ZTS earnings call for the period ending June 30, 2023.",BMY,0.005052,0.131921,Neutral
China drug-price negotiations offers glimpse into future for companies in US,https://www.financialexpress.com/healthcare/pharma-healthcare/china-drug-price-negotiations-offers-glimpse-into-future-for-companies-in-us/3202789/,2023-08-08 04:30:00,"As drugmakers in the US steel for price negotiations ushered in by President Joe Biden's Inflation Reduction Act, their experience in China, where such talks started almost a decade ago, could offer some insight into just how low costs may go.",BMY,0.038906,-0.058591,Neutral
"Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring",https://www.prnewswire.com/news-releases/bladder-cancer-market-likely-to-exhibit-substantial-growth-assesses-delveinsight--leading-companies---ciclomed-bristol-myers-squibb-cg-oncology-merck-eli-lilly-and-company-urogen-ferring-301894332.html,2023-08-07 21:01:00,"Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed ... PR ...",BMY,0.045439,-0.031842,Neutral
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction - Ikena Oncology  ( NASDAQ:IKNA ) ,https://www.benzinga.com/pressreleases/23/08/g33596881/ikena-oncology-acquires-pionyr-immunotherapeutics-in-all-stock-transaction,2023-08-07 11:00:00,"Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 ( GLOBE NEWSWIRE ) -- Ikena Oncology, Inc.",BMY,0.038843,0.054649,Neutral
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction,https://www.globenewswire.com/news-release/2023/08/07/2719566/0/en/Ikena-Oncology-Acquires-Pionyr-Immunotherapeutics-in-All-Stock-Transaction.html,2023-08-07 11:00:00,Ikena receives approximately $43 million in net cash at closing ...,BMY,0.028798,0.053363,Neutral
Should Dividend Investors Buy Bristol Myers Stock?,https://www.fool.com/investing/2023/08/06/should-dividend-investors-buy-bristol-myers-stock/,2023-08-06 12:45:00,"The drugmaker's near future may be bumpy, but it has a brighter future on the horizon.",BMY,0.109956,0.091592,Neutral
"Acute Lymphoblastic Leukemia Market Size to Surpass USD 4.5 billion by 2031, globally, expanding at a CAGR of 7.6%: TMR Report",https://www.benzinga.com/pressreleases/23/08/g33574927/acute-lymphoblastic-leukemia-market-size-to-surpass-usd-4-5-billion-by-2031-globally-expanding-at-,2023-08-04 14:00:00,"Wilmington, Delaware, United States, Aug. 04, 2023 ( GLOBE NEWSWIRE ) -- The global acute lymphoblastic leukemia market is projected to flourish at a CAGR of 7.6% from 2022 to 2031. As per the report published by TMR, a valuation of more than US$ 4.5 billion is anticipated for the market in 2031.",BMY,0.080188,0.110901,Neutral
Prothena  ( PRTA )  Q2 Earnings and Revenues Miss Estimates,https://www.zacks.com/stock/news/2132735/prothena-prta-q2-earnings-and-revenues-miss-estimates,2023-08-04 13:13:00,Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.,BMY,0.349857,-0.044707,Neutral
The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... - PR Newswire,https://www.prnewswire.com/news-releases/the-pulmonary-embolism-therapeutics-market-size-to-grow-at-a-cagr-of-9-52-from-2022-to-2027the-advancement-in-the-healthcare-and-medical-sector-is-a-major-trend-technavio-301892623.html,2023-08-04 09:30:00,The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... PR ...,BMY,0.045569,0.139204,Neutral
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023,https://www.globenewswire.com/news-release/2023/08/04/2718743/0/en/Sosei-Heptares-Operational-Highlights-and-Consolidated-Results-for-the-Second-Quarter-and-First-Half-of-2023.html,2023-08-04 06:37:00,"Tokyo, Japan and Cambridge, UK, 4 August 2023 - Sosei Group Corporation ( ""the Company"". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023. The full report can be found by clicking here.",BMY,0.02118,0.108005,Neutral
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,2023-08-03 21:01:00,"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight ... PR ...",BMY,0.041466,-0.038518,Neutral
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations - LianBio  ( NASDAQ:LIAN ) ,https://www.benzinga.com/pressreleases/23/08/g33558833/lianbio-announces-first-patient-treated-in-phase-1-trial-of-shp2-inhibitor-bbp-398-in-combination-,2023-08-03 20:05:00,"SHANGHAI, China and PRINCETON, N.J., Aug. 03, 2023 ( GLOBE NEWSWIRE ) -- LianBio LIAN, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in its Phase 1 clinical trial of BBP-398, ...",BMY,0.080323,-0.005165,Neutral
AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS,https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-financial-results-301893066.html,2023-08-03 20:01:00,"Positive Top-Line Results for LUMAKRAS® ( Sotorasib ) Plus Vectibix® ( Panitumumab ) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Aug. 3, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the second quarter of 2023.",BMY,0.014941,-0.017107,Neutral
Is Pfizer Stock A Buy Or A Sell With Covid Revenue In The Rearview?,https://www.investors.com/news/technology/pfizer-stock-buy-now/,2023-08-03 12:00:00,"Pfizer ( PFE ) stock has tumbled this year as demand for Covid products wanes and amid a fresh challenge in the obesity treatment space. During the second quarter, Pfizer's sales plummeted by half and missed forecasts. Adjusted earnings also tumbled, but beat forecasts by a penny.",BMY,0.057011,-0.014054,Neutral
Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients,https://www.globenewswire.com/news-release/2023/08/03/2717615/0/en/Ultimovacs-Announces-Completed-Enrollment-in-FOCUS-Phase-II-Clinical-Trial-of-UV1-in-Head-and-Neck-Cancer-Patients.html,2023-08-03 06:00:00,"Oslo, 3 August 2023 - Ultimovacs ASA ( ""Ultimovacs"" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced the completion of enrollment of 75 patients and that the last patient has received the first dose in the FOCUS study ( ...",BMY,0.021031,-0.0074,Neutral
Here's Why Investors Should Buy These 2 Medical Stocks After Earnings,https://www.zacks.com/stock/news/2131624/heres-why-investors-should-buy-these-2-medical-stocks-after-earnings,2023-08-03 05:31:00,Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.,BMY,0.142989,-0.061512,Neutral
"Analysts' Top Healthcare Picks: Tenet Healthcare  ( THC ) , Vertex Pharmaceuticals  ( VRTX ) ",https://markets.businessinsider.com/news/stocks/analysts-top-healthcare-picks-tenet-healthcare-thc-vertex-pharmaceuticals-vrtx-1032509298,2023-08-03 02:30:40,"Analysts' Top Healthcare Picks: Tenet Healthcare (THC), Vertex Pharmaceuticals (VRTX) - Markets Insider ...",BMY,0.100308,0.110656,Neutral
JNJ: Is Johnson & Johnson  ( JNJ )  a Must-Buy Stability Stock?,https://stocknews.com/news/jnj-nvo-abbv-bmy-is-johnson-johnson-jnj-a-must-buy-stability-stock/,2023-08-01 17:30:14,"Johnson & Johnson ( JNJ ) is one of the world's largest pharmaceutical and medical device manufacturers, making it appealing because of its safety. Being a well-established pharmaceutical company, it could resist unfavorable headwinds.",BMY,0.09402,0.097183,Neutral
Drugmakers Want to Crush Medicare's Pricing Power,https://www.barrons.com/articles/drug-price-negotiation-lawsuits-medicare-ffd4cb95,2023-08-01 01:52:08,Pharma Companies Want to Crush Medicare's Ability to Negotiate Costs ...,BMY,0.294093,-0.020378,Neutral
"Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - MedPacto, AstraZeneca, EMD Serono, Bayer, Merck, Bristol-Myers Squibb, Inovio, Seagen, Incyte",https://www.prnewswire.com/news-releases/urothelial-carcinoma-market-is-expected-to-showcase-a-significant-growth-by-2032-assesses-delveinsight--key-companies-to-look-out---medpacto-astrazeneca-emd-serono-bayer-merck-bristol-myers-squibb-inovio-seagen-incyte-301889003.html,2023-07-31 09:01:00,"Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by 2032, Assesses DelveInsight | Key ... PR ...",BMY,0.024053,0.084259,Neutral
Bristol-Myers Squibb  ( NYSE:BMY )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/07/30/bristol-myers-squibb-nysebmy-stock-rating-lowered-by-stocknews-com.html,2023-07-30 08:57:00,"Bristol-Myers Squibb ( NYSE:BMY - Get Free Report ) was downgraded by research analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a report issued on Friday. Several other research firms have also commented on BMY. HSBC began coverage on shares of Bristol-Myers Squibb in a ...",BMY,0.790705,0.361115,Bullish
Check Out What Whales Are Doing With BMY - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/08/33899980/check-out-what-whales-are-doing-with-bmy,2023-08-17 18:46:17,A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 10 strange trades.,BMY,0.819522,0.176248,Somewhat-Bullish
Bristol Myers  ( BMY )  Announces Positive Updated NSCLC Data,https://www.zacks.com/stock/news/2137737/bristol-myers-bmy-announces-positive-updated-nsclc-data,2023-08-17 15:52:00,Bristol Myers' (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.,BMY,0.182047,0.017737,Neutral
"Anticoagulants Market to Exceed USD 56.6 billion by 2031, Expanding at a CAGR of 6.2%: TMR Report",https://www.benzinga.com/pressreleases/23/08/g33890025/anticoagulants-market-to-exceed-usd-56-6-billion-by-2031-expanding-at-a-cagr-of-6-2-tmr-report,2023-08-17 08:35:08,"Wilmington, Delaware, United States, Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global anticoagulants market is projected to flourish at a CAGR of 6.2% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 56.6 billion is anticipated for the ...",BMY,0.041901,0.0,Neutral
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%,https://www.fool.com/investing/2023/08/16/wall-street-thinks-this-cathie-wood-stock-could-ju/,2023-08-16 18:54:00,This small-cap biotech stock holds enormous growth potential.,BMY,0.067536,-0.066139,Neutral
Bristol Myers' Investigational Lung Cancer Candidate Shows High Response Rates - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/08/33877772/bristol-myers-investigational-lung-cancer-candidate-shows-high-response-rates-durable-responses,2023-08-16 16:13:11,"Bristol Myers Squibb & Co BMY announced updated results from a TRIDENT-1 study, demonstrating that repotrectinib - a next-generation ROS1/TRK tyrosine kinase inhibitor ( TKI ) - continued to show high response rates and durable responses in patients with metastatic non-small cell lung cancer.",BMY,0.357293,-0.061187,Neutral
2 Dividend Stocks to Buy Hand Over Fist,https://www.fool.com/investing/2023/08/16/2-dividend-stocks-to-buy-hand-over-fist/,2023-08-16 13:53:00,Both of these companies offer more than consistent income.,BMY,0.138997,0.163763,Somewhat-Bullish
 ( BMY )  - Analyzing Bristol-Myers Squibb's Short Interest - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/23/08/33864405/bmy-analyzing-bristol-myers-squibbs-short-interest,2023-08-15 18:00:23,"Bristol-Myers Squibb's BMY short percent of float has fallen 8.05% since its last report. The company recently reported that it has 16.64 million shares sold short, which is 0.8% of all regular shares that are available for trading.",BMY,0.221819,0.083071,Neutral
Next Billion-Dollar Startups 2023,https://www.forbes.com/sites/amyfeldman/2023/08/15/next-billion-dollar-startups-2023/,2023-08-15 10:30:00,"There are more than 50,000 venture-backed startups in the U.S., and only the tiniest fraction will ever reach a $1 billion valuation. Here are the 25 we think most likely to succeed.",BMY,0.014729,0.121754,Neutral
2 Blue Chip Dividend Stocks That Are Top Buys in August,https://www.fool.com/investing/2023/08/14/2-blue-chip-dividend-stocks-that-are-top-buys-in-a/,2023-08-14 18:36:00,These two dividend-paying healthcare stocks stand out as top buys right now.,BMY,0.129866,0.120204,Neutral
"Biotechnology Market to Worth Around USD 3,995.22 Billion by 2032",https://www.benzinga.com/pressreleases/23/08/g33835844/biotechnology-market-to-worth-around-usd-3-995-22-billion-by-2032,2023-08-14 15:00:00,"Ottawa, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- The global biotechnology market size accounted for USD 1,224.31 billion in 2022, a study published by Towards Healthcare a sister firm of Precedence Research.",BMY,0.013202,0.172021,Somewhat-Bullish
"Up 970-Fold Since Its IPO, Amgen Stock Could Be Overvalued",https://www.forbes.com/sites/petercohan/2023/08/14/up-970-fold-since-its-ipo-amgen-stock-could-be-overvalued/,2023-08-14 14:37:38,Amgen's established products declined while some of its best-selling drugs enjoyed growth.,BMY,0.030026,-0.050194,Neutral
"Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management - Medicenna Therapeutics  ( NASDAQ:MDNA ) ",https://www.benzinga.com/pressreleases/23/08/g33825888/medicenna-establishes-boston-presence-appoints-brent-meadows-as-chief-business-officer-and-bolster,2023-08-14 11:00:25,"Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent. Brent Meadows, MBA, joins as Chief Business Officer ( CBO ) , bringing over 25 years of large pharma and biotech experience and a track record of multiple high-value transactions in ...",BMY,0.059415,0.022992,Neutral
"Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management",https://www.globenewswire.com/news-release/2023/08/14/2724250/0/en/Medicenna-Establishes-Boston-Presence-Appoints-Brent-Meadows-as-Chief-Business-Officer-and-Bolsters-Management.html,2023-08-14 11:00:00,"TORONTO and HOUSTON, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- Medicenna Therapeutics Corp. ( ""Medicenna"" or ""the Company"" ) ( NASDAQ: MDNA TSX: MDNA ) , a clinical-stage immunotherapy company, announced today the appointment of Brent Meadows, MBA, as its Chief Business Officer ( ""CBO"" ) , as part of ...",BMY,0.071892,0.023106,Neutral
Does Pfizer Stock Belong in a Dividend Portfolio?,https://www.fool.com/investing/2023/08/11/does-pfizer-stock-belong-in-a-dividend-portfolio/,2023-08-11 14:07:00,Pfizer is a well-known name in the pharmaceutical industry.,BMY,0.067919,0.110555,Neutral
"Bristol-Myers Squibb, Toast And A Major REIT Stock: CNBC's 'Final Trades' - Bristol-Myers Squibb  ( NYSE:BMY ) , NNN REIT  ( NYSE:NNN ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/08/33741874/bristol-myers-squibb-toast-and-a-major-reit-stock-cnbcs-final-trades,2023-08-11 13:07:07,"On CNBC's ""Halftime Report Final Trades,"" Jim Lebenthal of Cerity Partners named Bristol-Myers Squibb Company BMY, which announced $4 billion aggregate accelerated share repurchase agreements.",BMY,0.576289,0.173325,Somewhat-Bullish
Up 45% This Year What's Driving The Growth For Eli Lilly Stock?,https://www.forbes.com/sites/greatspeculations/2023/08/11/up-45-this-year-whats-driving-the-growth-for-eli-lilly-stock/,2023-08-11 13:00:59,"The stock has been on a strong run for the last few years, primarily due to its pipeline potential.",BMY,0.059636,-0.010001,Neutral
"Bristol-Myers Squibb  ( NYSE:BMY )  Upgraded to ""Strong-Buy"" at StockNews.com",https://www.defenseworld.net/2023/08/11/bristol-myers-squibb-nysebmy-upgraded-to-strong-buy-at-stocknews-com.html,2023-08-11 08:54:59,StockNews.com upgraded shares of Bristol-Myers Squibb ( NYSE:BMY - Free Report ) from a buy rating to a strong-buy rating in a research note released on Monday. BMY has been the topic of a number of other reports.,BMY,0.845983,0.326247,Somewhat-Bullish
CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/pressreleases/23/08/g33723142/cytomx-therapeutics-to-present-at-the-h-c-wainwright-immune-cell-engager-virtual-conference,2023-08-10 20:05:00,"SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the H.C.",BMY,0.183895,-0.001551,Neutral
These 10 medications are likely targets for Medicare price negotiations this fall,https://www.cnbc.com/2023/08/10/10-drugs-that-are-likely-targets-for-fall-medicare-price-negotiations.html,2023-08-10 17:21:52,"It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.",BMY,0.140348,-0.089581,Neutral
"Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update",https://www.globenewswire.com/news-release/2023/08/10/2722648/0/en/Molecular-Templates-Inc-Reports-Second-Quarter-2023-Financial-Results-and-Business-Update.html,2023-08-10 12:08:00,"AUSTIN, Texas, Aug. 10, 2023 ( GLOBE NEWSWIRE ) -- Molecular Templates, Inc. ( Nasdaq: MTEM, ""Molecular Templates,"" or ""MTEM"" ) , a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ( ""ETBs"" ) ...",BMY,0.032186,0.072178,Neutral
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update,https://www.globenewswire.com/news-release/2023/08/10/2722596/0/en/Ikena-Oncology-Reports-Second-Quarter-2023-Financial-Results-and-Corporate-Update.html,2023-08-10 12:00:00,Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter ...,BMY,0.090702,0.066424,Neutral
Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies,https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/,2023-08-09 12:06:00,"One minute Dow Jones industrial average component Merck ( MRK ) might be doing battle with fellow drugmaker Bristol Myers Squibb ( BMY ) over drugs that can ward off cancer. The next, biotech giants like Amgen ( AMGN ) and Sanofi ( SNY ) are tussling in court over the fate of ...",BMY,0.366061,-0.549433,Bearish
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology,https://www.globenewswire.com/news-release/2023/08/28/2732918/0/en/LianBio-Announces-Results-from-Phase-3-EXPLORER-CN-Trial-of-Mavacamten-Presented-at-the-European-Society-of-Cardiology-Congress-and-Simultaneous-Publication-in-JAMA-Cardiology.html,2023-08-28 20:05:00,"SHANGHAI, China and PRINCETON, N.J., Aug. 28, 2023 ( GLOBE NEWSWIRE ) -- LianBio ( Nasdaq: LIAN ) , a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced data from the Phase 3 EXPLORER-CN trial of mavacamten in ...",BMY,0.020722,0.09853,Neutral
A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/08/34068232/a-step-closer-to-cheaper-drugs-for-americans-price-negotiation-and-its-implications,2023-08-28 14:05:09,Some of the most frequently prescribed medications in the U.S. might soon become more affordable. This change could result in significant taxpayer savings but may challenge the profit margins of major pharmaceutical companies.,BMY,0.177802,0.029142,Neutral
Billion-dollar pharma cos set to face their first US price negotiations,https://www.business-standard.com/world-news/billion-dollar-pharma-cos-set-to-face-their-first-us-price-negotiations-123082800893_1.html,2023-08-28 12:59:02,"Some of the most widely used drugs in the US may be heading for lower prices under Medicare, a move that could save taxpayers billions of dollars and squeeze profits for big pharmaceutical companies.",BMY,0.040416,0.059892,Neutral
A-Alpha Bio Nets $22.4M For Groundbreaking Protein Interaction Predictions,https://www.benzinga.com/news/23/08/34055486/a-alpha-bio-nets-22-4m-for-groundbreaking-protein-interaction-predictions,2023-08-26 12:00:11,"What do you get when you combine a revolutionary healthcare startup with artificial intelligence ( AI ) technology? In the case of A-Alpha Bio, the answer is simple: a $22.4 million funding round and a bright future.",BMY,0.092569,-0.040468,Neutral
Is Alexandria Real Estate Equities a Buy?,https://www.fool.com/investing/2023/08/26/is-alexandria-real-estate-equities-a-buy/,2023-08-26 09:18:00,"Great company, attractive valuation, lousy sector.",BMY,0.126784,0.045025,Neutral
Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple ... - PR Newswire,https://www.prnewswire.com/news-releases/multiple-sclerosis-market-in-the-us-to-grow-by-usd-3-95-billion-from-2021-to-2026--rising-prevalence-of-multiple-sclerosis-will-drive-growth---technavio-301909378.html,2023-08-26 00:30:00,Multiple sclerosis market in the US to Grow by USD 3.95 billion from 2021 to 2026 | Rising prevalence of multiple ... PR ...,BMY,0.059785,0.185027,Somewhat-Bullish
Biden administration expected to unveil Tuesday first drugs subject to Medicare negotiations | Politics,https://www.cnn.com/2023/08/25/politics/medicare-drug-price-negotiations/index.html,2023-08-25 22:49:00,Medicare: Biden administration expected to unveil Tuesday first drugs subject to negotiations ...,BMY,0.059049,0.008025,Neutral
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government - AstraZeneca  ( NASDAQ:AZN ) ,https://www.benzinga.com/general/biotech/23/08/34045861/pharma-giants-unite-against-drug-price-negotiation-astrazeneca-latest-to-challenge-the-government,2023-08-25 17:49:45,AstraZeneca Plc AZN announced its legal challenge against the U.S. government's Inflation Reduction Act ( IRA ) that allows the Medicare health insurance system to negotiate more competitive drug prices.,BMY,0.233556,0.0,Neutral
AstraZeneca sues US govt over Medicare drug price negotiation plans,https://www.business-standard.com/companies/news/astrazeneca-sues-us-govt-over-medicare-drug-price-negotiation-plans-123082501298_1.html,2023-08-25 16:18:42,AstraZeneca said on Friday it has sued the U.S. government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices.,BMY,0.137671,0.146465,Neutral
"As Medicare picks 10 drugs for price negotiations, 50 million people stand to benefit - even if their drugs aren't on the list",https://www.marketwatch.com/story/as-medicare-picks-10-drugs-for-price-negotiations-50-million-people-stand-to-benefit-even-if-their-drugs-arent-on-the-list-aceec7e,2023-08-25 14:54:00,Government negotiations with drugmakers are set to launch amid a growing number of legal challenges.,BMY,0.062843,-0.034042,Neutral
"Analysis of the Global AI in Clinical Trials Industry, 2023 to 2035 - Product/Technology Utilization and Integration Agreements Lead the Way in Partnerships",https://www.prnewswire.com/news-releases/analysis-of-the-global-ai-in-clinical-trials-industry-2023-to-2035---producttechnology-utilization-and-integration-agreements-lead-the-way-in-partnerships-301909941.html,2023-08-25 14:15:00,"Analysis of the Global AI in Clinical Trials Industry, 2023 to 2035 - Product/Technology Utilization and Integration ... PR ...",BMY,0.051961,0.162536,Somewhat-Bullish
Could NovoCure Stock Help You Become a Millionaire?,https://www.fool.com/investing/2023/08/25/could-novocure-stock-help-you-become-a-millionaire/,2023-08-25 12:20:00,"The stock has some significant upside, but it also comes with considerable risks and volatility.",BMY,0.050465,0.058502,Neutral
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors,https://www.benzinga.com/pressreleases/23/08/g34023394/cargo-therapeutics-appoints-biotech-life-sciences-leaders-to-board-of-directors,2023-08-24 13:05:00,"- Board of Director appointments follow the Company's recent launch and $200 million Series A financing in March 2023 - - Appointments include industry veterans John Orwin as Chairman, David Lubner as Independent Director and Strategic Finance and Audit Committee Chair, and Dr. Krishnan ...",BMY,0.043108,0.093918,Neutral
PM360 Announces 2023 Trailblazer Award Finalists,https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-finalists-301907769.html,2023-08-24 13:00:00,"Top Companies, Marketers, CEOs, Products, and Initiatives to be Honored During Gala on October 3rd NEW YORK, Aug. 24, 2023 /PRNewswire/ -- PM360 has announced the finalists for its 15th annual Trailblazer Awards.",BMY,0.027747,-0.071498,Neutral
"GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus - AstraZeneca  ( NASDAQ:AZN ) , Amgen  ( NASDAQ:AMGN ) ",https://www.benzinga.com/general/biotech/23/08/34022293/gri-bio-is-bringing-hope-to-patients-with-idiopathic-pulmonary-fibrosis-and-lupus,2023-08-24 12:23:59,"Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that are more widely known are Idiopathic Pulmonary Fibrosis ( IPF ) and Lupus.",BMY,0.110973,0.051125,Neutral
Bristol-Myers Squibb  ( NYSE:BMY )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/08/24/bristol-myers-squibb-nysebmy-stock-rating-upgraded-by-stocknews-com.html,2023-08-24 05:30:43,Bristol-Myers Squibb ( NYSE:BMY ) Stock Rating Upgraded by ... Defense World ...,BMY,0.809819,0.362678,Bullish
Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization  ( IDMO )  and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies,https://www.prnewswire.com/news-releases/cellares-raises-255m-series-c-to-launch-first-integrated-development-and-manufacturing-organization-idmo-and-pioneering-smart-factory-to-meet-global-demand-for-life-saving-cell-therapies-301908236.html,2023-08-23 15:33:00,Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization ( IDMO ) and ... PR ...,BMY,0.072876,0.094252,Neutral
Bristol Myers'  ( BMY )  Opdivo Gets EC Nod for Label Expansion,https://www.zacks.com/stock/news/2139831/bristol-myers-bmy-opdivo-gets-ec-nod-for-label-expansion,2023-08-23 15:28:00,Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.,BMY,0.355588,0.089691,Neutral
Rosie White Sees New Zealand Soccer's Bright Future,https://www.forbes.com/sites/andyfrye/2023/08/22/rosie-white-sees-new-zealand-soccers-bright-future/,2023-08-22 14:08:19,"Ex-New Zealand soccer star battled her whole career with ulcerative colitis, and shares her optimism about options for patients-and the game of soccer.",BMY,0.03399,-0.072773,Neutral
Purple Biotech Reports Second Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/08/22/2729640/0/en/Purple-Biotech-Reports-Second-Quarter-2023-Financial-Results.html,2023-08-22 13:29:00,Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway extended into ...,BMY,0.021659,0.025928,Neutral
Bryan Hanson Named CEO of 3M's Health Care Business Group - PR Newswire,https://www.prnewswire.com/news-releases/bryan-hanson-named-ceo-of-3ms-health-care-business-group-301906778.html,2023-08-22 12:23:00,Bryan Hanson Named CEO of 3M's Health Care Business Group PR ...,BMY,0.0226,0.043513,Neutral
Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?,https://www.forbes.com/sites/greatspeculations/2023/08/22/down-25-in-a-year-will-pfizer-stock-rebound-to-its-pre-inflation-shock-level/,2023-08-22 11:00:22,"Returning to the pre-inflation shock level of over $60 means that PFE stock will have to gain more than 65% from here, and we don't think this will materialize anytime...",BMY,0.045655,-0.031,Neutral
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,2023-08-21 21:01:00,"The medical second opinion market is expanding rapidly due to the increasing frequency of malignancies, infectious diseases, genetic diseases, cardiovascular diseases, hematological diseases, orthopedic diseases, and other diseases around the world.",BMY,0.048671,-0.031649,Neutral
Bristol-Myers Squibb Unusual Options Activity For August 21 - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/08/33969989/bristol-myers-squibb-unusual-options-activity-for-august-21,2023-08-21 18:45:55,A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 13 strange trades.,BMY,0.850429,0.028763,Neutral
"Lung Cancer Treatment Market Revenue to Cross USD 102 billion by 2031, Expanding at a CAGR of 9.8% Says, Transparency Market Research Inc.",https://www.benzinga.com/pressreleases/23/08/g33964549/lung-cancer-treatment-market-revenue-to-cross-usd-102-billion-by-2031-expanding-at-a-cagr-of-9-8-s,2023-08-21 14:30:00,"Wilmington, Delaware, United States, Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global lung cancer treatment market is projected to flourish at a CAGR of 9.8% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 102 billion is anticipated for ...",BMY,0.082535,0.023752,Neutral
HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... - PR Newswire,https://www.prnewswire.com/news-releases/hiv-drugs-market-size-to-grow-by-usd-10-47-biilion-from-2022-to-2027--expanding-access-to-hiv-treatment-is-a-major-trend--technavio-301905076.html,2023-08-21 11:30:00,HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... PR ...,BMY,0.064973,0.102266,Neutral
Bristol-Myers Squibb  ( NYSE:BMY )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/08/20/bristol-myers-squibb-nysebmy-stock-rating-lowered-by-stocknews-com.html,2023-08-20 10:07:41,Bristol-Myers Squibb ( NYSE:BMY ) Stock Rating Lowered by ... Defense World ...,BMY,0.82082,0.369616,Bullish
Prothena  ( PRTA )  Skyrockets 88.7% in 12 Months: Here's Why,https://www.zacks.com/stock/news/2146171/prothena-prta-skyrockets-887-in-12-months-heres-why,2023-09-07 16:00:00,Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.,BMY,0.152821,0.10643,Neutral
Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/09/34314043/bristol-myers-antitrust-allegations-lawsuit-over-alleged-patent-deception-for-blood-cancer-drug,2023-09-07 14:03:19,"Bristol Myers Squibb Co BMY faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug market with Pomalyst ( pomalidomide ) long after it should have faced competition from generic ...",BMY,0.459624,-0.388425,Bearish
"Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain  ( DPNP ) ",https://www.globenewswire.com/news-release/2023/09/07/2739406/0/en/Lexicon-Announces-Series-of-Presentations-Relating-to-LX9211-Its-Investigational-Drug-for-the-Treatment-of-Diabetic-Peripheral-Neuropathic-Pain-DPNP.html,2023-09-07 13:00:00,Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development ...,BMY,0.047371,-0.067885,Neutral
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans,https://www.reuters.com/business/healthcare-pharmaceuticals/astellas-withdraws-lawsuit-challenging-medicare-drug-price-negotiation-plans-2023-09-06/,2023-09-07 02:11:00,"Astellas Pharma's logo is pictured at its headquarters in Tokyo, Japan, December 3, 2019. REUTERS/Kim Kyung-Hoon Acquire Licensing Rights",BMY,0.150592,-0.034067,Neutral
How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low - Pfizer  ( NYSE:PFE ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34293430/how-to-earn-500-from-pfizer-stock-with-shares-trading-at-52-week-low,2023-09-06 22:37:26,"President Joe Biden's Inflation Reduction Act, which allows Medicare to negotiate the price of some prescription drugs, remains the talk of the town as investors sell off shares in pharmaceutical companies such as Pfizer Inc. PFE because drugs associated with the companies are on the negotiation ...",BMY,0.208464,0.0,Neutral
Bristol Myers Squibb  ( BMY )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2145694/bristol-myers-squibb-bmy-dips-more-than-broader-markets-what-you-should-know,2023-09-06 21:50:19,"Bristol Myers Squibb (BMY) closed the most recent trading day at $59.67, moving -1.6% from the previous trading session.",BMY,0.646507,0.167216,Somewhat-Bullish
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,2023-09-06 21:01:00,"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period ( 2023-2032 ) , Examines ... PR ...",BMY,0.022494,0.023078,Neutral
Why Is Axsome  ( AXSM )  Up 8.6% Since Last Earnings Report?,https://www.zacks.com/stock/news/2145539/why-is-axsome-axsm-up-86-since-last-earnings-report,2023-09-06 15:30:31,Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BMY,0.060694,0.06,Neutral
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer,https://www.globenewswire.com/news-release/2023/09/05/2737897/0/en/NANOBIOTIX-Strengthens-Global-Development-Capabilities-With-the-Appointment-of-Veteran-Industry-Leader-Dr-Louis-Kayitalire-as-Chief-Medical-Officer.html,2023-09-05 20:15:00,"PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO - NASDAQ: NBTX - the ""Company"" ) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the ...",BMY,0.029581,0.093963,Neutral
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer - Nanobiotix  ( NASDAQ:NBTX ) ,https://www.benzinga.com/pressreleases/23/09/g34252743/nanobiotix-strengthens-global-development-capabilities-with-the-appointment-of-veteran-industry-le,2023-09-05 20:15:00,"PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- NANOBIOTIX NBTX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical ...",BMY,0.029399,0.093879,Neutral
"Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",https://www.benzinga.com/general/biotech/23/09/34228654/legal-twist-in-drug-price-negotiation-federal-judge-quits-case-amid-allegations-of-stock-ownershi,2023-09-05 12:38:32,"On Friday, Judge Thomas Rose, serving in the U.S. District Court for the Southern District of Ohio, opted to step down from the case on the same day the Revolving Door Project, a nonprofit organization, revealed his ownership of stocks in Johnson & Johnson JNJ and AstraZeneca Plc AZN.",BMY,0.234684,-0.025921,Neutral
Analysis: US healthcare stocks roiled by investor tug of war over economy,https://www.reuters.com/business/healthcare-pharmaceuticals/us-healthcare-stocks-roiled-by-investor-tug-war-over-economy-2023-09-05/,2023-09-05 10:48:00,"Traders work on the floor of the New York Stock Exchange ( NYSE ) in New York City, U.S., July 26, 2023. REUTERS/Brendan McDermid Acquire Licensing Rights",BMY,0.04794,-0.032714,Neutral
3 No-Brainer Dividend Stocks to Buy in September,https://www.fool.com/investing/2023/09/02/3-no-brainer-dividend-stocks-to-buy-in-september/,2023-09-02 10:55:00,Income investors should really like these biopharma stocks with juicy dividends.,BMY,0.166455,-0.008488,Neutral
8 Pharma Stocks Affected by New Drug Price Negotiation Rules,https://www.fool.com/investing/2023/09/02/8-pharma-stocks-affected-by-new-drug-price-negotia/,2023-09-02 10:51:00,Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?,BMY,0.188193,0.187207,Somewhat-Bullish
"Bristol-Myers Squibb  ( NYSE:BMY )  Downgraded by StockNews.com to ""Buy""",https://www.defenseworld.net/2023/09/02/bristol-myers-squibb-nysebmy-downgraded-by-stocknews-com-to-buy.html,2023-09-02 09:02:46,Bristol-Myers Squibb ( NYSE:BMY ) Downgraded by StockNews.com ... Defense World ...,BMY,0.736142,0.3106,Somewhat-Bullish
Unlocking the Potential of TIGIT Antibodies: Market Insights and Clinical Progress in Immune Checkpoint Therapies,https://www.prnewswire.com/news-releases/unlocking-the-potential-of-tigit-antibodies-market-insights-and-clinical-progress-in-immune-checkpoint-therapies-301915993.html,2023-09-02 00:30:00,"DUBLIN, Sept. 1, 2023 /PRNewswire/ -- The ""Anti TIGIT Antibody Market Opportunity and Clinical Trials Insight 2024"" report has been added to ResearchAndMarkets.com's offering. The report provides insights into the clinical trials and market dynamics of anti TIGIT antibodies.",BMY,0.096283,-0.07113,Neutral
Global Vitiligo Treatment Market 2023 - 2028: Ongoing Research and Advocacy Drive Progress,https://www.prnewswire.com/news-releases/global-vitiligo-treatment-market-2023---2028-ongoing-research-and-advocacy-drive-progress-301915850.html,2023-09-01 23:15:00,"DUBLIN, Sept. 1, 2023 /PRNewswire/ -- The ""Vitiligo Treatment Market, Size, Share, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis"" report has been added to ResearchAndMarkets.com's offering.",BMY,0.058615,0.0,Neutral
Why Is Repligen  ( RGEN )  Up 2.9% Since Last Earnings Report?,https://www.zacks.com/stock/news/2143824/why-is-repligen-rgen-up-29-since-last-earnings-report,2023-09-01 15:31:34,Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BMY,0.041682,0.058241,Neutral
Anti-rheumatic Market to Grow Exponentially by 2029- Brandessence Market Research,https://www.prnewswire.com/news-releases/anti-rheumatic-market-to-grow-exponentially-by-2029--brandessence-market-research-301915970.html,2023-09-01 14:34:00,"LONDON, Sept. 1, 2023 /PRNewswire/ -- Rheumatoid arthritis ( RA ) is a highly prevalent auto-immune ailment. This disease predominantly affects our joints, mainly that of hands and feet. It occurs when the immune system begins attacking the healthy tissues.",BMY,0.027382,0.060193,Neutral
Warren Buffett and Vivek Ramaswamy are miles apart politically. But the investing icon and Republican upstart have these 3 things in common.,https://markets.businessinsider.com/news/stocks/warren-buffett-vivek-ramaswammy-berkshire-hathaway-president-value-investing-pharma-2023-8,2023-09-01 11:19:00,Warren Buffett and Vivek Ramaswamy Have These 3 Things in Common - Markets Insider ...,BMY,0.067158,0.059106,Neutral
Will Medicare drug price controls save lives?,https://theweek.com/science/health/1026188/medicare-drug-price-controls,2023-09-01 09:01:06,Medicare starts negotiating lower drug prices over Big Pharma protests The Week ...,BMY,0.051003,0.000999,Neutral
Bristol Myers Squibb  ( BMY )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2143286/bristol-myers-squibb-bmy-dips-more-than-broader-markets-what-you-should-know,2023-08-31 21:45:16,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.65, marking a -1.17% move from the previous day.",BMY,0.5341,0.138036,Neutral
Why Big Pharma is Suing the Biden Administration: What the Legal Showdown Means for Your Wallet - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/08/34149438/biden-administration-vs-big-pharma-what-the-legal-showdown-means-for-your-wallet,2023-08-31 17:35:16,"The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. While legal experts acknowledge the lack of a clear legal precedent, signs suggest that the drugmakers might find a sympathetic audience within the U.S. Supreme Court.",BMY,0.208464,0.213719,Somewhat-Bullish
Vertex  ( VRTX )  Down 2.1% Since Last Earnings Report: Can It Rebound?,https://www.zacks.com/stock/news/2143104/vertex-vrtx-down-21-since-last-earnings-report-can-it-rebound,2023-08-31 15:31:29,Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,BMY,0.04406,0.058655,Neutral
"Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More",https://www.zacks.com/stock/news/2143072/biotech-stock-roundup-fgen-down-on-study-failure-bmy-drugs-label-expansion-more,2023-08-31 14:15:00,Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.,BMY,0.169378,0.030895,Neutral
 ( BMY )  - Analyzing Bristol-Myers Squibb's Short Interest - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/23/08/34144452/bmy-analyzing-bristol-myers-squibbs-short-interest,2023-08-31 13:45:21,"Bristol-Myers Squibb's BMY short percent of float has risen 220.0% since its last report. The company recently reported that it has 53.51 million shares sold short, which is 2.56% of all regular shares that are available for trading.",BMY,0.221819,0.155473,Somewhat-Bullish
Zai Lab  ( ZLAB )  Up on Breakthrough Therapy Tag for Oncology Drug,https://www.zacks.com/stock/news/2143034/zai-lab-zlab-up-on-breakthrough-therapy-tag-for-oncology-drug,2023-08-31 13:16:00,Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.,BMY,0.067536,0.287584,Somewhat-Bullish
Christina Ackermann Joins Verona Pharma as Non-Executive Director,https://www.globenewswire.com/news-release/2023/08/31/2734896/0/en/Christina-Ackermann-Joins-Verona-Pharma-as-Non-Executive-Director.html,2023-08-31 06:00:00,"LONDON and RALEIGH, N.C., Aug. 31, 2023 ( GLOBE NEWSWIRE ) -- Verona Pharma plc ( Nasdaq: VRNA ) ( ""Verona Pharma"" ) , announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director.",BMY,0.064623,0.064153,Neutral
Christina Ackermann Joins Verona Pharma as Non-Executive Director - Verona Pharma  ( NASDAQ:VRNA ) ,https://www.benzinga.com/pressreleases/23/08/g34131488/christina-ackermann-joins-verona-pharma-as-non-executive-director,2023-08-31 06:00:00,"LONDON and RALEIGH, N.C., Aug. 31, 2023 ( GLOBE NEWSWIRE ) -- Verona Pharma plc VRNA ( ""Verona Pharma"" ) , announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director.",BMY,0.063258,0.064102,Neutral
Bristol Myers Squibb  ( BMY )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2142676/bristol-myers-squibb-bmy-stock-sinks-as-market-gains-what-you-should-know,2023-08-30 21:50:17,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.38, marking a -0.75% move from the previous day.",BMY,0.646507,0.263366,Somewhat-Bullish
"Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology",https://www.prnewswire.com/news-releases/essential-thrombocythemia-market-to-witness-upsurge-in-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---imago-biosciences-incyte-karyopharm-novartis-pharmaessentia-celgene-kartos-sierra-oncology-301912007.html,2023-08-30 21:01:00,"Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to ... PR ...",BMY,0.029113,0.040299,Neutral
Medicare wants to cut the price on an Eli Lilly drug. What is means for LLY shares,https://www.cnbc.com/2023/08/30/medicare-wants-to-cut-the-price-on-an-eli-lilly-drug-what-is-means-for-lly-shares.html,2023-08-30 18:23:19,"Lilly's Jardiance is among the first 10 prescription drugs subject a new, contentious negotiation process between Medicare and drugmakers.",BMY,0.097062,0.028923,Neutral
Medicare drug price negotiations may have a muted impact on drugmakers in the near term,https://www.cnbc.com/2023/08/30/medicare-drug-price-negotiations-may-have-muted-impact-on-drugmakers.html,2023-08-30 17:48:18,Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.,BMY,0.104379,-0.020727,Neutral
"Apellis Pharmaceuticals, Inc.  ( APLS )  Up 67.8% Since Last Earnings Report: Can It Continue?",https://www.zacks.com/stock/news/2142494/apellis-pharmaceuticals-inc-apls-up-678-since-last-earnings-report-can-it-continue,2023-08-30 15:30:10,"Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",BMY,0.066414,0.060085,Neutral
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China,https://www.globenewswire.com/news-release/2023/08/30/2734220/0/en/Zai-Lab-Announces-Breakthrough-Therapy-Designation-Granted-for-Repotrectinib-for-Treatment-of-Patients-with-NTRK-positive-TKI-pretreated-advanced-solid-tumors-in-China.html,2023-08-30 11:30:00,Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors ...,BMY,0.0312,0.073284,Neutral
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China - Zai Lab  ( NASDAQ:ZLAB ) ,https://www.benzinga.com/pressreleases/23/08/g34111114/zai-lab-announces-breakthrough-therapy-designation-granted-for-repotrectinib-for-treatment-of-pati,2023-08-30 11:30:00,"SHANGHAI, China and CAMBRIDGE, Mass., Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Zai Lab Limited ZLAB HKEX: 9688 ) ) ) today announced that the Center for Drug Evaluation ( CDE ) of the National Medical Products Administration ( NMPA ) granted Breakthrough Therapy Designation for investigational ...",BMY,0.030563,0.070157,Neutral
"10 things you need to know today: August 30, 2023",https://theweek.com/briefing/daily-briefing/1026151/10-things-you-need-to-know-today-august-30-2023,2023-08-30 11:22:31,"Christian Monterrosa / Bloomberg via Getty Images Hurricane Idalia rapidly strengthened over the Gulf of Mexico early Wednesday, becoming an ""extremely dangerous"" Category 4 storm with top sustained winds of 130 miles per hour as it headed toward northwest Florida.",BMY,0.033515,0.022318,Neutral
US to negotiate price of 10 prescription drugs: What you need to know,https://www.aljazeera.com/news/2023/8/30/us-negotiating-price-of-10-prescription-drugs-what-you-need-to-know,2023-08-30 09:38:53,"Under President Joe Biden's Inflation Reduction Act, the government will negotiate the prices of select medicines. The United States government on Tuesday released a list of 10 prescription medicines that will be subject to the first-ever price negotiations by the Medicare health program that ...",BMY,0.073546,0.091703,Neutral
"Morning Bid: US jobs data and China bring cheer, for now",https://www.reuters.com/markets/europe/global-markets-view-europe-2023-08-30/,2023-08-30 04:07:30,"EUROPE US jobs data and China bring cheer, for now ...",BMY,0.072217,0.0,Neutral
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?,https://www.fool.com/investing/2023/08/29/medicare-price-negotiations-big-pharma-stocks/,2023-08-29 21:00:00,Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations.,BMY,0.157483,0.158342,Somewhat-Bullish
How This Manufacturer Turned Big Pharma's Commercialization Model Upside Down,https://www.forbes.com/sites/chasefeiger/2023/08/29/how-this-manufacturer-turned-big-pharmas-commercialization-model-upside-down/,2023-08-29 20:59:21,"When Pfizer﻿ acquired Biohaven for $11.6 billion, many big Pharma executives began to question their own beliefs and commercial tactics.",BMY,0.064797,0.034158,Neutral
America's plan to cut drug prices comes with unpleasant side-effects,https://www.economist.com/business/2023/08/29/americas-plan-to-cut-drug-prices-comes-with-unpleasant-side-effects,2023-08-29 19:28:58,"""A piggy-bank of the pharma world,"" gripes David Mitchell of Patients for Affordable Drugs, a consumer lobbying group. There is some truth to this. America is the world's largest pharmaceutical market, with $630bn in sales in 2022, or 42% of the worldwide total.",BMY,0.045918,-0.038835,Neutral
"Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations",https://www.marketwatch.com/story/merck-amgen-abbvie-products-among-first-10-drugs-selected-for-medicare-price-negotiations-556c2484,2023-08-29 19:22:00,"Merck, Johnson & Johnson and Amgen are among the first drugmakers to have products chosen for a contentious initiative to rein in prescription-drug costs.",BMY,0.116067,-0.026232,Neutral
"Bristol Myers' Expanded Approval For Anemia Drug, Shows Superior Efficacy Over Concurrent Blood Transfusion - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/08/34097054/bristol-myers-expanded-approval-for-anemia-drug-shows-superior-efficacy-over-concur,2023-08-29 17:40:53,"On Monday, the FDA approved Bristol Myers Squibb Co's BMY Reblozyl ( luspatercept-aamt ) for anemia without previous erythropoiesis-stimulating agent use ( ESA-naïve ) in adult patients with very low-to-intermediate-risk myelodysplastic syndromes ( MDS ) who may require regular red blood cell ...",BMY,0.419153,0.234559,Somewhat-Bullish
"At U.S. Open, Michelle Obama Calls For Equal Pay For Female Athletes",https://www.forbes.com/sites/adamzagoria/2023/08/29/at-us-open-michelle-obama-calls-for-equal-pay-for-female-athletes/,2023-08-29 17:20:34,"Barack and Michelle Obama were in the house at the U.S. Open on opening night to watch and support Coco Gauff, and the former First Lady also used the occasion to advo...",BMY,0.082677,0.135879,Neutral
Biden admin names first 10 drugs subject to Medicare price negotiation,https://www.foxbusiness.com/economy/biden-administration-names-first-10-drugs-subject-medicare-price-negotiation,2023-08-29 14:53:52,"The Biden administration on Tuesday released a list of the first 10 prescription medications that will be subject to price negotiations with Medicare, in an effort to lower the cost of pharmaceutical drugs for older Americans.",BMY,0.105604,0.0,Neutral
"Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle - Wants To Cut Billions In Costs. Here Are The Stocks Affected - Johnson & Johnson  ( NYSE:JNJ ) ",https://www.benzinga.com/general/biotech/23/08/34087337/biden-targets-cancer-diabetes-drugs-in-controversial-medicare-price-battle-wants-to-cut-billions-,2023-08-29 13:30:50,"The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: Bristol Myers Squibb Co's BMS blood thinner, Eliquis Eli Lilly And Co's LLY diabetes treatment, Jardiance.",BMY,0.114682,0.320043,Somewhat-Bullish
"AbbVie, Merck, Lilly Highlight Biden List For Price Cuts",https://www.investors.com/news/technology/pharmaceutical-stocks-biden-administration-unveils-10-drugs-subject-to-price-cuts/,2023-08-29 13:28:00,Pharmaceutical Stocks: Biden Administration Unveils 10 Drugs ... Investor's Business Daily ...,BMY,0.290607,0.311341,Somewhat-Bullish
US names 10 prescription drugs subject to price negotiations,https://www.aljazeera.com/news/2023/8/29/us-names-10-prescription-drugs-subject-to-price-negotiations,2023-08-29 12:55:17,Move is expected to cut costs for some patients but faces lawsuits from drugmakers and heavy criticism from Republicans.,BMY,0.067919,-0.196851,Somewhat-Bearish
Bristol Myers  ( BMY )  Gets FDA Nod for Reblozyl Label Expansion,https://www.zacks.com/stock/news/2141767/bristol-myers-bmy-gets-fda-nod-for-reblozyl-label-expansion,2023-08-29 12:54:00,Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia in adults with lower-risk MDS who may require transfusions.,BMY,0.242285,0.063477,Neutral
"Coinbase Global, Bristol-Myers Squibb And 2 Other Stocks Insiders Are Selling - Andersons  ( NASDAQ:ANDE ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/23/08/34087260/coinbase-global-bristol-myers-squibb-and-2-other-stocks-insiders-are-selling,2023-08-29 12:32:53,"The Nasdaq 100 closed higher by over 100 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.",BMY,0.322023,0.019266,Neutral
Explainer: Why the US is negotiating the price of 10 drugs,https://www.reuters.com/business/healthcare-pharmaceuticals/why-us-is-negotiating-price-10-drugs-2023-08-29/,2023-08-29 12:08:00,"[1/2] U.S. President Joe Biden convenes the fourth virtual leader-level meeting of the Major Economies Forum ( MEF ) on Energy and Climate at the White House in Washington, U.S., April 20, 2023. REUTERS/Kevin Lamarque/File Photo Acquire Licensing Rights",BMY,0.069697,0.083321,Neutral
U.S. Announces First Drugs Picked for Medicare Price Negotiations,https://www.nytimes.com/2023/08/29/us/politics/medicare-drug-pricing-negotiations.html,2023-08-29 11:39:43,"The Biden administration's announcement was an important moment for Democrats, who have campaigned on a promise to lower the cost of prescription drugs.",BMY,0.108222,-0.074995,Neutral
Biden administration unveils first 10 drugs subject to Medicare price negotiations,https://www.cnbc.com/2023/08/29/10-drugs-to-face-medicare-price-negotiations-see-the-list.html,2023-08-29 11:37:25,The announcement of the 10 drugs kicks off a Medicare negotiation process that aims to make costly medications more affordable for older Americans.,BMY,0.075279,-0.11972,Neutral
Omega Therapeutics Announces Updates to its Board of Directors - Omega Therapeutics  ( NASDAQ:OMGA ) ,https://www.benzinga.com/pressreleases/23/08/g34085062/omega-therapeutics-announces-updates-to-its-board-of-directors,2023-08-29 11:00:52,"Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D. Michelle C. Werner, CEO of Alltrna, Appointed to Board of Directors CAMBRIDGE, Mass., Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Omega Therapeutics, Inc.",BMY,0.051886,0.078568,Neutral
Omega Therapeutics Announces Updates to its Board of Directors,https://www.globenewswire.com/news-release/2023/08/29/2733258/0/en/Omega-Therapeutics-Announces-Updates-to-its-Board-of-Directors.html,2023-08-29 11:00:00,"CAMBRIDGE, Mass., Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Omega Therapeutics, Inc. ( Nasdaq: OMGA ) ( ""Omega"" ) , a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that Chris Schade has been appointed as ...",BMY,0.031822,0.074906,Neutral
US to name first 10 drugs for Medicare price negotiation,https://www.reuters.com/business/healthcare-pharmaceuticals/us-name-first-10-drugs-medicare-price-negotiation-2023-08-29/,2023-08-29 10:20:00,"[1/3] U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. REUTERS/Jonathan Ernst Acquire Licensing Rights",BMY,0.068306,0.069181,Neutral
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous  ( SC )  with ENHANZE® in Great Britain,https://www.prnewswire.com/news-releases/halozyme-announces-approval-of-roches-tecentriq-subcutaneous-sc-with-enhanze-in-great-britain-301911904.html,2023-08-29 08:50:00,First subcutaneous anti-PD- ( L ) 1 cancer immunotherapy available to patients in Great Britain Tecentriq® subcutaneous formulation with ENHANZE® reduces treatment time to seven minutes compared to 30-60 minutes for standard intravenous infusion,BMY,0.029618,0.080493,Neutral
Biden administration to target drugs for price negotiations to lower Medicare costs,https://apnews.com/article/medicare-prescription-drug-negotiations-biden-inflation-2bf6775c3431111a2cd03fd033caefa7,2023-08-29 04:04:00,WASHINGTON ( AP ) - President administration will announce on Tuesday the first prescription drugs being targeted by the U.S. government for price negotiations as part of an effort to lower costs. The announcement is a significant step under the which was signed by Biden last year.,BMY,0.059636,-0.18102,Somewhat-Bearish
"Faron Reports Half-Year Financial Results, January 1 - June 30, 2023",https://www.globenewswire.com/news-release/2023/08/29/2733033/0/en/Faron-Reports-Half-Year-Financial-Results-January-1-June-30-2023.html,2023-08-29 04:01:00,Summary Highlights ( including post-period events ...,BMY,0.019201,0.043799,Neutral
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/pressreleases/23/09/n34669152/samsung-biologics-announces-expanded-strategic-agreement-with-bristol-myers-squibb-to-manufacture-,2023-09-17 23:57:00,"INCHEON, South Korea, Sept. 17, 2023 /PRNewswire/ -- Samsung Biologics ( KRX: 207940.KS ) announced today a new agreement with Bristol Myers Squibb BMY for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.",BMY,0.535653,0.294065,Somewhat-Bullish
3 AI Drug Discovery Stocks to Watch,https://www.fool.com/investing/2023/09/15/3-ai-drug-discovery-stocks-to-watch/,2023-09-15 12:45:00,The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies.,BMY,0.071251,0.079156,Neutral
Repairon Appoints Co-Founder Dr. Lothar Germeroth as Chief Executive Officer,https://www.benzinga.com/pressreleases/23/09/g34599848/repairon-appoints-co-founder-dr-lothar-germeroth-as-chief-executive-officer,2023-09-15 05:00:00,"GÖTTINGEN, Germany, Sept. 15, 2023 ( GLOBE NEWSWIRE ) -- Repairon, a clinical-stage German biotech company focused on developing a novel reparative treatment for heart failure, today announced Dr. Lothar Germeroth, Executive Chairman of Repairon GmbH, has been appointed to the role of Chief ...",BMY,0.140896,0.037764,Neutral
Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/09/34587529/bristol-myers-squibb-plans-to-double-clinical-pipeline-platforms-to-support-long-term-sustainable,2023-09-14 17:53:32,"Bristol-Myers Squibb & Co BMY announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted protein degradation and cell therapies.",BMY,0.719473,0.316072,Somewhat-Bullish
"Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates",https://www.zacks.com/stock/news/2148988/biotech-stock-roundup-mrnas-pipeline-news-rckt-bcyc-rally-on-study-updates,2023-09-14 14:12:00,Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.,BMY,0.057628,0.117973,Neutral
Bristol Myers plans to double experimental treatments to expand research pipeline,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-plans-double-experimental-treatments-expand-research-pipeline-2023-09-14/,2023-09-14 12:48:00,"A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights",BMY,0.294093,0.042072,Neutral
2 Undervalued Dividend Stocks to Buy Now,https://www.fool.com/investing/2023/09/13/2-undervalued-dividend-stocks-to-buy-now/,2023-09-13 13:30:00,These two pharma titans are proven income vehicles.,BMY,0.28305,0.43175,Bullish
"The Zacks Analyst Blog Highlights Mastercard, SAP, Texas Instruments, Bristol-Myers Squibb and AT&T",https://www.zacks.com/stock/news/2148108/the-zacks-analyst-blog-highlights-mastercard-sap-texas-instruments-bristol-myers-squibb-and-att,2023-09-13 09:12:00,"Mastercard, SAP, Texas Instruments, Bristol-Myers Squibb and AT&T are included in this Analyst Blog.",BMY,0.146469,0.041101,Neutral
Bristol Myers Squibb  ( BMY )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2148020/bristol-myers-squibb-bmy-dips-more-than-broader-markets-what-you-should-know,2023-09-12 21:45:17,"Bristol Myers Squibb (BMY) closed at $60.24 in the latest trading session, marking a -0.94% move from the prior day.",BMY,0.648164,0.188556,Somewhat-Bullish
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs - Geron  ( NASDAQ:GERN ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34495981/recent-pullback-buying-opportunity-for-blood-cancer-firm-geron-goldman-sachs,2023-09-12 18:43:53,"Goldman Sachs has upgraded Geron Corporation GERN to Buy from Neutral, with a price target of $4. Recently, the FDA assigned a standard review and a Prescription Drug User Fee Act ( PDUFA ) action date of June 16, 2024, for Geron's New Drug Application ( NDA ) for imetelstat for ...",BMY,0.240489,0.202346,Somewhat-Bullish
"CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer",https://www.benzinga.com/pressreleases/23/09/g34487555/cargo-therapeutics-announces-appointment-of-michael-ports-phd-as-chief-scientific-officer,2023-09-12 13:05:51,- Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development -,BMY,0.051999,0.058896,Neutral
"Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer - Abeona Therapeutics  ( NASDAQ:ABEO ) ",https://www.benzinga.com/pressreleases/23/09/g34481776/abeona-therapeutics-appoints-madhav-vasanthavada-ph-d-m-b-a-as-chief-commercial-officer,2023-09-12 11:30:00,"CLEVELAND, Sept. 12, 2023 ( GLOBE NEWSWIRE ) -- Abeona Therapeutics Inc. ABEO today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer ( CCO ) and Head of Business Development ( BD ) , effective immediately.",BMY,0.067347,0.061118,Neutral
"Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/09/34451546/bristol-myers-squibbs-opdivo-plus-yervoy-combo-shows-durable-long-term-survival-in-lung-cancer-pa,2023-09-11 18:10:01,"Bristol Myers Squibb & Co BMY announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo ( nivolumab ) plus Yervoy ( ipilimumab ) compared to chemotherapy in the first-line treatment of patients with ...",BMY,0.327366,0.127686,Neutral
Bristol Myers'  ( BMY )  Pulmonary Fibrosis Drug Positive in Phase II,https://www.zacks.com/stock/news/2147370/bristol-myers-bmy-pulmonary-fibrosis-drug-positive-in-phase-ii,2023-09-11 16:02:00,Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis.,BMY,0.144275,0.091664,Neutral
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/news/23/09/34357229/how-a-small-indian-firm-firm-was-pulled-into-a-legal-battle-with-big-pharma-over-a-cancer-drug,2023-09-11 13:18:42,"This story was first published on the Benzinga India portal. It's not uncommon to see headlines about large pharmaceutical companies being sued in the U.S. - after all, the healthcare industry walks the tightrope between profit and saving lives.",BMY,0.374312,-0.108907,Neutral
Could This Issue Sink Johnson & Johnson's Stock Price?,https://www.fool.com/investing/2023/09/11/could-this-issue-sink-johnson-johnson-stock/,2023-09-11 10:49:00,Don't be too quick to press the sell button.,BMY,0.059341,0.164265,Somewhat-Bullish
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer,https://www.globenewswire.com/news-release/2023/09/11/2740616/0/en/SpringWorks-Therapeutics-Appoints-Dr-Tai-An-Lin-as-Chief-Scientific-Officer.html,2023-09-11 10:30:00,"STAMFORD, Conn., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc. ( Nasdaq: SWTX ) , a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, ...",BMY,0.038717,0.010654,Neutral
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - SpringWorks Therapeutics  ( NASDAQ:SWTX ) ,https://www.benzinga.com/pressreleases/23/09/g34432690/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer,2023-09-11 10:30:00,"STAMFORD, Conn., Sept. 11, 2023 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc. SWTX, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief ...",BMY,0.037098,0.010592,Neutral
Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities,https://www.prnewswire.com/news-releases/oral-antiviral-market-report-2023-demand-for-novel-therapeutics-boosts-opportunities-301921979.html,2023-09-09 01:15:00,"DUBLIN, Sept. 8, 2023 /PRNewswire/ -- The ""Oral Antiviral Market by Indication, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031"" report has been added to ResearchAndMarkets.com's offering.",BMY,0.085022,0.079948,Neutral
"Natco Pharma, Celgene Corp, others sued in US for generic cancer drug",https://www.business-standard.com/companies/news/natco-pharma-celgene-corp-others-sued-in-us-for-generic-cancer-drug-123090800520_1.html,2023-09-08 09:49:19,Natco Pharma on Friday said the company and other drug makers have been named defendants in an antitrust lawsuit regarding a generic cancer treatment drug in the US.,BMY,0.279015,0.0,Neutral
"Natco Pharma, others sued in US for generic cancer drug",https://www.moneycontrol.com/news/business/natco-pharma-others-sued-in-us-for-generic-cancer-drug-11334751.html,2023-09-08 09:18:46,"The company believes this matter is without merit, Natco Pharma said in a statement.",BMY,0.279015,0.0,Neutral
Natco Pharma slumps 3% over US anti-trust lawsuit,https://www.moneycontrol.com/news/business/stocks/natco-pharma-slumps-3-over-us-anti-trust-lawsuit-11334451.html,2023-09-08 08:32:16,"The other defendants named in the lawsuit were Celgene Corporation, Bristol Myers Squibb, and Breckenridge Pharmaceutical.",BMY,0.19117,-0.191205,Somewhat-Bearish
Bristol-Myers Squibb Unusual Options Activity For September 27 - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/09/34959541/bristol-myers-squibb-unusual-options-activity-for-september-27,2023-09-27 20:16:08,"Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.778186,0.387204,Bullish
"AstraZeneca, Boehringer Ingelheim to participate in Medicare drug price negotiations",https://www.cnbc.com/2023/09/27/diabetes-medicare-drug-price-negotiations.html,2023-09-27 19:55:22,"AstraZeneca, Boehringer Ingelheim and other drugmakers have filed at least eight lawsuits seeking to declare the Medicare price talks unconstitutional.",BMY,0.088799,-0.182524,Somewhat-Bearish
Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023,https://www.globenewswire.com/news-release/2023/09/27/2750581/0/en/Ultimovacs-Announces-that-the-Results-from-UV1-Phase-II-Clinical-Trial-NIPU-in-Malignant-Mesothelioma-will-be-Presented-at-the-ESMO-Congress-2023.html,2023-09-27 14:31:00,"Oslo, September 27, 2023 - Ultimovacs ASA ( ""Ultimovacs"" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced today that the results from the UV1 Phase II clinical trial NIPU will be presented at the ESMO Congress 2023 in Madrid, Spain, ...",BMY,0.079392,-0.026761,Neutral
Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80?,https://www.forbes.com/sites/greatspeculations/2023/09/27/will-bristol-myers-squibb-stock-rebound-to-its-pre-inflation-shock-level-of-80/,2023-09-27 13:00:00,"Returning to the pre-inflation shock level of over $80 means that BMY stock will have to gain more than 35% from here, and we think it will likely materialize over time.",BMY,0.568148,-0.079948,Neutral
Black Health Matters Summit & Expo Returns to Los Angeles,https://www.benzinga.com/pressreleases/23/09/n34910644/black-health-matters-summit-expo-returns-to-los-angeles,2023-09-26 14:02:00,"""Empowering Our Communities from Coast to Coast"" FREE HEALTH SCREENINGS AND EDUCATIONAL SESSIONS NEW YORK, Sept. 26, 2023 /PRNewswire/ -- After a triumphant debut in Los Angeles in 2022, Black Health Matters ( BHM ) is once again bringing its nationally acclaimed health summit series to the west ...",BMY,0.056407,0.017061,Neutral
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101,https://www.globenewswire.com/news-release/2023/09/26/2749484/37414/en/Panbela-Announces-Issuance-of-New-Patent-in-China-for-Claims-of-a-Novel-Process-for-the-Production-of-SBP-101.html,2023-09-26 12:15:00,Patent developed in collaboration with Syngene International Ltd. Patent developed in collaboration with Syngene International Ltd.,BMY,0.02695,0.131864,Neutral
Bristol Myers Squibb  ( BMY )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2155118/bristol-myers-squibb-bmy-outpaces-stock-market-gains-what-you-should-know,2023-09-25 21:50:18,"Bristol Myers Squibb (BMY) closed at $59.16 in the latest trading session, marking a +0.44% move from the prior day.",BMY,0.610329,0.320252,Somewhat-Bullish
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,2023-09-25 21:01:00,"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key ... PR ...",BMY,0.130723,0.049466,Neutral
"3 Artificial Intelligence  ( AI )  Stocks That Could Soar More Than Nvidia, According to Wall Street",https://www.fool.com/investing/2023/09/25/artificial-intelligence-ai-stocks-soar-nvidia/,2023-09-25 09:50:00,None of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story.,BMY,0.05833,0.0,Neutral
Baby Food Market size to hit USD 122.81 Bn by 2029 at a CAGR 6.2 percent - says Maximize Market Research,https://www.benzinga.com/pressreleases/23/09/g34850149/baby-food-market-size-to-hit-usd-122-81-bn-by-2029-at-a-cagr-6-2-percent-says-maximize-market-rese,2023-09-25 07:14:56,"Pune, Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- As per the report published by Maximize Market Research, the global Baby Food Market was USD 80.60 Bn in 2022 and is expected to reach USD 122.81 Bn with a CAGR of 6.2 percent by the end of 2029.",BMY,0.060161,0.0,Neutral
Top Wall Street analysts are bullish on these dividend stocks,https://www.cnbc.com/2023/09/24/top-wall-street-analysts-are-bullish-on-dividend-stocks.html,2023-09-24 12:32:16,"TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Chevron and Broadcom.",BMY,0.120431,0.053112,Neutral
Innovative Gelatin Capsules Transforming Pharmaceutical Industry: A Look into the Future,https://www.prnewswire.com/news-releases/innovative-gelatin-capsules-transforming-pharmaceutical-industry-a-look-into-the-future-301936082.html,2023-09-22 21:45:00,"DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The ""Pharmaceutical Gelatin Market Share, Size, Trends, Industry Analysis Report, By Source, By Function, By End Use, By Regions, Segment Forecast, 2023-2032"" report has been added to ResearchAndMarkets.com's offering.",BMY,0.060236,-0.055999,Neutral
"Global Dermatology Drugs Market Set to Skyrocket, Anticipated Valuation of $50.47 Billion by 2032",https://www.prnewswire.com/news-releases/global-dermatology-drugs-market-set-to-skyrocket-anticipated-valuation-of-50-47-billion-by-2032--301936081.html,2023-09-22 21:30:00,"DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The ""Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Segment Forecast, 2023-2032"" report has been added to ResearchAndMarkets.com's ...",BMY,0.060541,-0.056,Neutral
Bristol Myers'  ( BMY )  Opdivo Positive in Late-Stage NSCLC Study,https://www.zacks.com/stock/news/2154403/bristol-myers-bmy-opdivo-positive-in-late-stage-nsclc-study,2023-09-22 16:08:00,"Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.",BMY,0.252332,-0.243721,Somewhat-Bearish
The Executive Leadership Council to Award More Than $3M in Scholarships During its Annual Recognition and Fundraising Gala,https://www.prnewswire.com/news-releases/the-executive-leadership-council-to-award-more-than-3m-in-scholarships-during-its-annual-recognition-and-fundraising-gala-301936374.html,2023-09-22 16:05:00,The Executive Leadership Council to Award More Than $3M in Scholarships During its Annual Recognition and ... PR ...,BMY,0.053992,0.043822,Neutral
Biopharma Co. Adds CTO to Team,https://www.investorideas.com/news/2023/biotech/09221DiaMedica-Therapeutics.asp,2023-09-22 15:48:58,"September 22, 2023 ( Investorideas.com Newswire ) This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.",BMY,0.102449,0.140431,Neutral
Faron Pharmaceuticals Announces Board Changes,https://www.globenewswire.com/news-release/2023/09/22/2748072/0/en/Faron-Pharmaceuticals-Announces-Board-Changes.html,2023-09-22 15:00:00,"TURKU, Finland and BOSTON, Sept. 22, 2023 ( GLOBE NEWSWIRE ) -- Faron Pharmaceuticals Ltd. ( AIM: FARN, First North: FARON ) , a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, is pleased to announce the appointment of Ms. Christine Roth and Dr. ...",BMY,0.032078,0.041391,Neutral
Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/09/34820936/bristol-myers-lead-cancer-drug-opdivo-regime-meets-primary-goal-in-phase-3-lung-cancer-study,2023-09-22 14:18:24,Bristol Myers Squibb & Co BMY announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant ( before surgery ) Opdivo ( nivolumab ) with chemotherapy followed by surgery and adjuvant Opdivo.,BMY,0.485711,0.142736,Neutral
"FORTUNE CEO INITIATIVE RETURNS TO WASHINGTON, D.C. OCTOBER 3, 2023",https://www.prnewswire.com/news-releases/fortune-ceo-initiative-returns-to-washington-dc-october-3-2023-301936220.html,2023-09-22 14:00:00,"Navigating the New Frontier of Leadership: Fortune's annual meeting of the CEO Initiative will assemble top leaders in business, public affairs and government to examine crucial issues of AI, ESG, culture wars, geopolitical tensions, and other industry headwinds Confirmed speakers include U.S.",BMY,0.073098,0.213124,Somewhat-Bullish
Big pharma can't get enough of one class of cancer drugs,https://www.economist.com/business/2023/09/21/big-pharma-cant-get-enough-of-one-class-of-cancer-drugs,2023-09-21 12:51:46,A spate of dealmaking suggests high expectations for antibody-drug conjugates ...,BMY,0.0699,0.099427,Neutral
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023,https://www.globenewswire.com/news-release/2023/09/20/2746360/0/en/Oxford-Biomedica-Plc-INTERIM-RESULTS-FOR-THE-SIX-MONTHS-ENDED-30-JUNE-2023.html,2023-09-20 11:41:00,The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation ( EU ) No. 596/2014 ( as it forms part of domestic law by virtue of the European Union ( Withdrawal ) Act 2018 ) .,BMY,0.002888,0.0,Neutral
Chasing Breakthrough Innovation in a Time of Uncertainty With Insights from McKinsey & Company,https://www.prnewswire.com/news-releases/chasing-breakthrough-innovation-in-a-time-of-uncertainty-with-insights-from-mckinsey--company-301932360.html,2023-09-19 18:00:00,"TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott.",BMY,0.115232,0.159345,Somewhat-Bullish
BeiGene to go solo with cancer drug after Novartis deal termination,https://www.reuters.com/business/healthcare-pharmaceuticals/beigene-regains-rights-cancer-drug-after-novartis-deal-termination-2023-09-19/,2023-09-19 14:05:14,"Sept 19 ( Reuters ) - BeiGene ( 6160.HK ) and Swiss drugmaker Novartis ( NOVN.S ) have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such discontinuation in just over two months.",BMY,0.122894,-0.051161,Neutral
Bristol Myers Squibb  ( BMY )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2152142/bristol-myers-squibb-bmy-stock-sinks-as-market-gains-what-you-should-know,2023-09-18 21:50:20,"Bristol Myers Squibb (BMY) closed at $58.58 in the latest trading session, marking a -0.76% move from the prior day.",BMY,0.538782,0.223768,Somewhat-Bullish
"Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison - Incyte  ( NASDAQ:INCY ) , GSK  ( NYSE:GSK ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34699111/anemia-advantage-for-gsks-blood-cancer-therapy-could-influence-market-share-despite,2023-09-18 17:59:46,"Friday, the FDA approved GSK plc's GSK Ojjaara ( momelotinib ) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis ( post-polycythemia vera and post-essential thrombocythaemia ) , in adults with anemia.",BMY,0.28387,0.250826,Somewhat-Bullish
Looking Into Bristol-Myers Squibb's Recent Short Interest - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/23/09/34691981/looking-into-bristol-myers-squibbs-recent-short-interest,2023-09-18 14:00:34,"Bristol-Myers Squibb's BMY short percent of float has fallen 17.97% since its last report. The company recently reported that it has 43.76 million shares sold short, which is 2.1% of all regular shares that are available for trading.",BMY,0.221819,0.083071,Neutral
"Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer",https://www.globenewswire.com/news-release/2023/09/18/2744572/0/en/Verve-Expands-Leadership-Team-with-Appointment-of-Frederick-T-Fiedorek-M-D-as-Chief-Medical-Officer.html,2023-09-18 10:30:00,"BOSTON, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick ""Fred"" T.",BMY,0.033656,0.017988,Neutral
"Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer - Verve Therapeutics  ( NASDAQ:VERV ) ",https://www.benzinga.com/pressreleases/23/09/g34681785/verve-expands-leadership-team-with-appointment-of-frederick-t-fiedorek-m-d-as-chief-medical-office,2023-09-18 10:30:00,"BOSTON, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick ""Fred"" T.",BMY,0.03319,0.016986,Neutral
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,2023-09-18 09:15:00,"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... PR ...",BMY,0.043108,0.0,Neutral
Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire,https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html,2023-09-18 08:35:00,Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...,BMY,0.052685,0.0,Neutral
Is Editas Stock a Buy Now?,https://www.fool.com/investing/2023/10/07/is-editas-stock-a-buy-now/,2023-10-07 14:07:00,Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now?,BMY,0.052112,0.23869,Somewhat-Bullish
The Executive Leadership Council's Symposium and Recognition Gala Week Wraps Up with $1M Community Impact ... - PR Newswire,https://www.prnewswire.com/news-releases/the-executive-leadership-councils-symposium-and-recognition-gala-week-wraps-up-with-1m-community-impact-investment-301949944.html,2023-10-06 20:40:00,The Executive Leadership Council's Symposium and Recognition Gala Week Wraps Up with $1M Community Impact ... PR ...,BMY,0.07157,0.055272,Neutral
Bristol-Myers Squibb Unusual Options Activity For October 06 - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/10/35128575/bristol-myers-squibb-unusual-options-activity-for-october-06,2023-10-06 15:45:54,A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 10 strange trades.,BMY,0.720958,0.046027,Neutral
Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action,https://www.globenewswire.com/news-release/2023/10/06/2756032/0/en/Purple-Biotech-Reports-Potential-Biomarker-Data-Support-CM24-s-Mechanism-of-Action.html,2023-10-06 11:50:00,"REHOVOT, Israel, Oct. 06, 2023 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( ""Purple Biotech"" or ""the Company"" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug ...",BMY,0.02922,0.026866,Neutral
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials,https://www.prnewswire.com/news-releases/paradigm-and-bristol-myers-squibb-collaborate-to-build-a-new-model-for-clinical-trials-301949038.html,2023-10-06 10:30:00,"COLUMBUS, Ohio, Oct. 6, 2023 /PRNewswire/ -- Paradigm announced today a collaboration with Bristol Myers Squibb ( NYSE: BMY ) to build a new end-to-end clinical trial operating model across design, recruitment, and data collection.",BMY,0.406526,0.375775,Bullish
"Diffuse Cutaneous Systemic Sclerosis Market to Proliferate at a Considerable Growth Rate by 2032, Estimates DelveInsight | Leading Companies in the Market - Kyowa Kirin Acceleron, Cumberland, Horizon, CSL Behring, Seagen, Janssen",https://www.prnewswire.com/news-releases/diffuse-cutaneous-systemic-sclerosis-market-to-proliferate-at-a-considerable-growth-rate-by-2032-estimates-delveinsight--leading-companies-in-the-market---kyowa-kirin-acceleron-cumberland-horizon-csl-behring-seagen-janssen-301947923.html,2023-10-05 21:01:00,"Diffuse Cutaneous Systemic Sclerosis Market to Proliferate at a Considerable Growth Rate by 2032, Estimates ... PR ...",BMY,0.025679,0.015133,Neutral
"Stocks That Hit 52-Week Lows On Thursday - PRA Group  ( NASDAQ:PRAA ) , Perimeter Solutions  ( NYSE:PRM ) ",https://www.benzinga.com/news/23/10/35111787/stocks-that-hit-52-week-lows-on-thursday,2023-10-05 17:22:02,"On Thursday, 369 companies hit new 52-week lows. The largest company in terms of market cap to set a new 52-week low was Coca-Cola KO. The smallest company by market cap to hit a new 52-week low was Neptune Wellness Solns NEPT.",BMY,0.013047,0.004444,Neutral
"Acute Lymphoblastic Leukemia Market to Surpass USD 4.5 billion with CAGR 7.6% by 2031,TMR Report",https://www.benzinga.com/pressreleases/23/10/g35104896/acute-lymphoblastic-leukemia-market-to-surpass-usd-4-5-billion-with-cagr-7-6-by-2031-tmr-report,2023-10-05 11:30:00,"Wilmington, Delaware, United States, Oct. 05, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The acute lymphoblastic leukemia market was estimated to have acquired US$ 2.2 billion in 2021. It is anticipated to register a 7.6% CAGR from 2022 to 2031 and by 2031.",BMY,0.080865,0.094061,Neutral
Precede Biosciences Emerges from Stealth to Dramatically Impact Precision Medicine with a First-in-Class Liquid Biopsy Platform,https://www.benzinga.com/pressreleases/23/10/g35103795/precede-biosciences-emerges-from-stealth-to-dramatically-impact-precision-medicine-with-a-first-in,2023-10-05 11:00:00,Unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activation of individual genes and pathways in diseased tissues from just 1mL of plasma,BMY,0.031949,-0.012406,Neutral
Medicare Price Talks to Include All 10 Drugmakers,https://www.kiplinger.com/retirement/medicare/medicare-price-talks-to-include-all-10-drugmakers,2023-10-04 23:13:26,"The 10 pharmaceutical companies whose drugs will be part of the first cycle of the upcoming Medicare Drug Price Negotiation Program have agreed to participate in the talks, the White House announced on October 3. The drugmakers slated to take part in the discussions with Medicare are: AstraZeneca ...",BMY,0.090134,0.0,Neutral
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,2023-10-04 21:01:00,"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Assesses ... PR ...",BMY,0.086948,-0.040696,Neutral
"Stocks That Hit 52-Week Lows On Wednesday - Bristol-Myers Squibb Company Common Stock  ( NYSE:BMY ) , SenesTech, Inc. - Common Stock  ( NASDAQ:SNES ) ",https://www.benzinga.com/markets/options/23/10/35092508/stocks-that-hit-52-week-lows-on-wednesday,2023-10-04 16:01:17,"On Wednesday, 311 stocks hit new 52-week lows. Bristol-Myers Squibb Company Common Stock BMY is the largest company in terms of market cap to set a new 52-week low this morning. SenesTech, Inc. - Common Stock SNES was the smallest company by market cap to set a new 52-week low. A10 Networks, ...",BMY,0.025413,-0.094732,Neutral
PM360 Announces 2023 Trailblazer Award Winners,https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-winners-301943290.html,2023-10-04 12:00:00,"Top Companies, Marketers, CEOs, Products, and Initiatives Were Honored During Gala on October 3rd NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Last night at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 15th annual Trailblazer Awards.",BMY,0.020615,0.0,Neutral
"Fusion Inhibitors Market Revenue to Cross USD 7.2 billion by 2031, Exhibiting a 14.2% CAGR: TMR Report",https://www.benzinga.com/pressreleases/23/10/g35081060/fusion-inhibitors-market-revenue-to-cross-usd-7-2-billion-by-2031-exhibiting-a-14-2-cagr-tmr-repor,2023-10-04 07:52:11,"Wilmington, Delaware, United States, Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The fusion inhibitors market attained US$ 295.3 million in 2021. The market is likely to gain US$ 7.2 billion by 2031 securing a CAGR of 14.2% between 2022 and 2031.",BMY,0.07446,-0.085926,Neutral
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors - Larimar Therapeutics  ( NASDAQ:LRMR ) ,https://www.benzinga.com/pressreleases/23/10/g35072387/larimar-therapeutics-appoints-dr-jeffery-w-sherman-to-its-board-of-directors,2023-10-03 20:05:00,"BALA CYNWYD, Pa., Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( ""Larimar"" ) LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W.",BMY,0.051221,-0.008981,Neutral
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors,https://www.globenewswire.com/news-release/2023/10/03/2754158/0/en/Larimar-Therapeutics-Appoints-Dr-Jeffery-W-Sherman-to-its-Board-of-Directors.html,2023-10-03 20:05:00,"BALA CYNWYD, Pa., Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( ""Larimar"" ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W.",BMY,0.039679,-0.00879,Neutral
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration - Novo Nordisk  ( NYSE:NVO ) ,https://www.benzinga.com/general/biotech/23/10/35068559/drugmakers-agree-to-participate-for-medicare-drug-price-negotiation-with-biden-administration,2023-10-03 17:35:19,"All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration to halt the process.",BMY,0.262522,0.0,Neutral
Drugmakers agree to negotiate prices in Medicare even as they sue to stop the program | Politics,https://www.cnn.com/2023/10/03/politics/drugmakers-medicare-price-negotiations/index.html,2023-10-03 12:12:00,Drugmakers agree to negotiate prices in Medicare even as they sue to stop the program ...,BMY,0.128822,-0.014444,Neutral
"Medicare drug price negotiations move forward with all drugmakers participating, White House says",https://www.marketwatch.com/story/medicare-drug-price-negotiations-move-forward-with-all-drugmakers-participating-white-house-says-45b891dc,2023-10-03 12:00:00,Novo Nordisk is latest drugmaker to challenge negotiation program in court.,BMY,0.11983,-0.027305,Neutral
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer,https://www.globenewswire.com/news-release/2023/10/03/2753531/0/en/Purple-Biotech-Reports-Positive-Interim-and-Preliminary-Results-from-NT219-Phase-1-2-Study-in-R-M-Head-Neck-Cancer.html,2023-10-03 11:50:00,"REHOVOT, Israel, Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( ""Purple Biotech"" or ""the Company"" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug ...",BMY,0.024521,0.026314,Neutral
Bristol Myers Squibb  ( BMY )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2158865/bristol-myers-squibb-bmy-stock-sinks-as-market-gains-what-you-should-know,2023-10-02 21:50:18,"Bristol Myers Squibb (BMY) closed at $57.85 in the latest trading session, marking a -0.33% move from the prior day.",BMY,0.587278,0.23923,Somewhat-Bullish
Drugmakers opt in to Medicare drug price negotiations - here's what happens next,https://www.cnbc.com/2023/10/02/drugmakers-agree-to-medicare-price-negotiations-whats-next.html,2023-10-02 19:34:02,"The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.",BMY,0.102231,-0.114146,Neutral
Drugmakers sign on to negotiate Medicare prices under protest,https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-sign-negotiate-medicare-prices-under-protest-2023-10-02/,2023-10-02 17:12:00,"U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. REUTERS/Jonathan Ernst/File Photo Acquire Licensing Rights",BMY,0.085022,0.033017,Neutral
FDA Accepts Merck's  ( MRK )  Filing for Sotatercept in PAH Disease,https://www.zacks.com/stock/news/2158816/fda-accepts-mercks-mrk-filing-for-sotatercept-in-pah-disease,2023-10-02 15:34:00,The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.,BMY,0.234307,0.094482,Neutral
"Medicare Drug Price Negotiation - What Court's Decision Means for Americans - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/10/35030476/medicare-drug-price-negotiation-what-courts-decision-means-for-americans,2023-10-02 14:54:14,"A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices. U.S.",BMY,0.265378,0.264687,Somewhat-Bullish
Clade Therapeutics Announces the Acquisition of Gadeta B.V.,https://www.benzinga.com/pressreleases/23/10/g35029893/clade-therapeutics-announces-the-acquisition-of-gadeta-b-v,2023-10-02 12:30:03,"Expands Clade's pipeline and broadens its platform with:- proprietary gamma/delta ( g/d ) TCR universal targeting platform technology,- g/d TCR candidate integrated into Clade's solid tumor pipeline",BMY,0.042271,0.269033,Somewhat-Bullish
Federal judge declines to block Medicare price negotiations,https://www.cnbc.com/2023/09/29/medicare-price-negotiations-federal-judge-denies-injunction-request.html,2023-09-29 21:39:58,Judge Michael Newman of the Southern District of Ohio issued a ruling denying a preliminary injunction sought by the Chamber of Commerce.,BMY,0.057907,-0.117981,Neutral
"As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment",https://www.marketwatch.com/story/as-merck-astrazeneca-and-other-drugmakers-sign-on-medicare-price-negotiations-face-critical-moment-9d85879f,2023-09-29 14:20:00,A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.,BMY,0.100099,-0.006512,Neutral
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer,https://www.globenewswire.com/news-release/2023/09/28/2751637/0/en/Molecular-Templates-Announces-the-Appointment-of-Dr-Maurizio-Voi-to-the-Role-of-Chief-Medical-Officer.html,2023-09-28 20:11:00,"AUSTIN, Texas, Sept. 28, 2023 ( GLOBE NEWSWIRE ) -- Molecular Templates, Inc. ( Nasdaq: MTEM, ""Molecular Templates,"" or ""MTEM"" ) , a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the ...",BMY,0.04823,0.03378,Neutral
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer - Molecular Templates  ( NASDAQ:MTEM ) ,https://www.benzinga.com/pressreleases/23/09/g34986881/molecular-templates-announces-the-appointment-of-dr-maurizio-voi-to-the-role-of-chief-medical-offi,2023-09-28 20:11:00,"AUSTIN, Texas, Sept. 28, 2023 ( GLOBE NEWSWIRE ) -- Molecular Templates, Inc. MTEM ""Molecular Templates, "" or ""MTEM"" ) ) ) , a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of ...",BMY,0.047465,0.03374,Neutral
"Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs - AstraZeneca  ( NASDAQ:AZN ) ",https://www.benzinga.com/general/biotech/23/09/34977352/pharma-giants-shift-stance-embrace-medicare-negotiations-amid-rising-drug-costs,2023-09-28 14:19:56,"AstraZeneca Plc AZN, Bristol Myers Squibb & Co BMY, and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiations despite having previously sued to halt the process.",BMY,0.303175,0.293044,Somewhat-Bullish
3 Dividend Stocks to Buy and Hold Until Retirement,https://www.fool.com/investing/2023/09/28/3-dividend-stocks-to-buy-and-hold-until-retirement/,2023-09-28 12:45:00,"Together, these stocks can also help diversify your portfolio by giving you exposure to different industries.",BMY,0.227007,0.035132,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, OLK, ORTX, MRTX - Mirati Therapeutics  ( NASDAQ:MRTX ) , Olink Holding  ( NASDAQ:OLK ) ",https://www.benzinga.com/pressreleases/23/10/g35300244/shareholder-investigation-halper-sadeh-llc-investigates-sp-olk-ortx-mrtx,2023-10-17 23:59:57,"NEW YORK, Oct. 17, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",BMY,0.092927,0.113562,Neutral
"Moore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law Firm - Orchard Therapeutics  ( NASDAQ:ORTX ) , Mirati Therapeutics  ( NASDAQ:MRTX ) ",https://www.benzinga.com/pressreleases/23/10/g35299453/moore-kuehn-encourages-sp-ortx-mrtx-and-srt-investors-to-contact-law-firm,2023-10-17 22:03:23,"NEW YORK, Oct. 17, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.",BMY,0.101582,0.157313,Somewhat-Bullish
Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma,https://www.globenewswire.com/news-release/2023/10/17/2761776/0/en/Ultimovacs-Announces-NIPU-Results-Presented-at-ESMO-2023-Significant-and-Clinically-Meaningful-Improvement-in-Overall-Survival-for-Patients-Receiving-UV1-Cancer-Vaccine-in-Phase-II.html,2023-10-17 16:01:00,"• UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, demonstrated a clinically meaningful overall survival benefit with no added toxicities, compared to ipilimumab and nivolumab alone, in the second-line treatment of patients with malignant ...",BMY,0.063341,-0.041314,Neutral
2 Biotech Stocks That Could Make You Richer,https://www.fool.com/investing/2023/10/17/2-biotech-stocks-that-could-make-you-richer/,2023-10-17 14:07:00,These two well-known drugmakers still have some growth fuel in their seemingly empty tanks.,BMY,0.165031,0.238045,Somewhat-Bullish
"FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication - Merck & Co  ( NYSE:MRK ) ",https://www.benzinga.com/general/biotech/23/10/35282353/fda-approves-mercks-top-selling-drug-keytruda-for-expanded-use-in-lung-cancer-indication,2023-10-17 11:28:25,The FDA approved Merck & Co Inc's MRK Keytruda for resectable ( tumors ≥4 centimeters [cm] or node-positive ) non-small cell lung cancer ( NSCLC ) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after ...,BMY,0.272788,-0.171685,Somewhat-Bearish
Bristol Myers Squibb  ( BMY )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2166760/bristol-myers-squibb-bmy-outpaces-stock-market-gains-what-you-should-know,2023-10-16 21:50:18,"Bristol Myers Squibb (BMY) reachead $57.17 at the closing of the latest trading day, reflecting a +1.24% change compared to its last close.",BMY,0.598621,0.293986,Somewhat-Bullish
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,2023-10-16 21:01:00,"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period ( 2019-2032 ) , Assesses ... PR ...",BMY,0.025845,-0.026539,Neutral
Why Is Alzheimer's Player Prothena Stock Trading Higher Today? - Prothena Corp  ( NASDAQ:PRTA ) ,https://www.benzinga.com/general/biotech/23/10/35269372/why-is-alzheimers-player-prothena-stock-trading-higher-today,2023-10-16 15:28:00,"Prothena Corporation plc PRTA is reportedly talking to advisors, potentially preparing for a sale. The closely watched Alzheimer's player is due to report key data expected in the coming months.",BMY,0.407844,0.115093,Neutral
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery,https://www.prnewswire.com/news-releases/halozyme-announces-positive-clinical-data-of-its-high-volume-auto-injector-demonstrating-successful-rapid-subcutaneous-drug-delivery-301957079.html,2023-10-16 12:00:00,Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid ... PR ...,BMY,0.03792,0.081581,Neutral
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html,2023-10-16 11:50:00,"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... PR ...",BMY,0.044386,-0.047896,Neutral
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html,2023-10-16 11:50:00,"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... Canada ...",BMY,0.044386,-0.047896,Neutral
"FDA OKs Pfizer's New Bowel Disease Drug, Analysts Predict Peak Sales Of $3B A Year - Pfizer  ( NYSE:PFE ) ",https://www.benzinga.com/general/biotech/23/10/35243580/fda-oks-pfizers-new-bowel-disease-drug-analysts-predict-peak-sales-of-3b-a-year,2023-10-13 16:26:56,"The Food and Drug Administration ( FDA ) approved Pfizer Inc's PFE Velsipity ( etrasimod ) , an oral, once-daily, selective sphingosine-1-phosphate ( S1P ) receptor modulator for adults with moderately to severely active ulcerative colitis ( UC ) .",BMY,0.308891,0.399009,Bullish
Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics,https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html,2023-10-13 15:45:00,Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...,BMY,0.036643,0.067285,Neutral
Is Bristol Myers Squibb Stock a Buy Now?,https://www.fool.com/investing/2023/10/13/is-bristol-myers-squibb-stock-a-buy-now/,2023-10-13 11:00:00,Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio.,BMY,0.175009,0.073746,Neutral
3 Top-Ranked Goldman Sachs Mutual Funds for 2023 & Beyond,https://www.zacks.com/stock/news/2165377/3-top-ranked-goldman-sachs-mutual-funds-for-2023-beyond,2023-10-13 10:00:00,"Invest in Goldman Sachs mutual funds like GGYPX, GMPPX and GGZPX that have given positive returns amid uncertain market conditions and are expected to perform well in the future.",BMY,0.050894,0.049591,Neutral
Is Amgen Stock a Buy Now?,https://www.fool.com/investing/2023/10/13/is-amgen-stock-a-buy-now/,2023-10-13 09:25:00,The company recently closed its acquisition of Horizon Therapeutics.,BMY,0.04823,0.082354,Neutral
"Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields - Pfizer  ( NYSE:PFE ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/23/10/35219939/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields,2023-10-12 13:19:23,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",BMY,0.104228,0.0,Neutral
Attention Medicare Recipients: You Could See Lower Costs for These 10 Drugs in the Not-Too-Distant Future,https://www.fool.com/retirement/2023/10/12/medicare-recipients-could-see-lower-costs-for-thes/,2023-10-12 09:15:00,Medicare will soon begin negotiations with drugmakers for the first time ever.,BMY,0.08687,-0.129312,Neutral
"Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade",https://www.investors.com/news/technology/amgen-stock-surges-to-10-month-high-after-snagging-an-unexpected-upgrade/,2023-10-11 19:49:00,"Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected ... Investor's Business Daily ...",BMY,0.149192,-0.121467,Neutral
"The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer",https://www.zacks.com/stock/news/2164151/the-zacks-analyst-blog-highlights-bristol-myers-squibb-mirati-therapeutics-eli-lilly-point-biopharma-and-pfizer,2023-10-11 11:56:00,"Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.",BMY,0.17715,0.092045,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, NWLI, PWFL - National Western Life  ( NASDAQ:NWLI ) , Mirati Therapeutics  ( NASDAQ:MRTX ) ",https://www.benzinga.com/pressreleases/23/10/g35188433/shareholder-investigation-halper-sadeh-llc-investigates-mrtx-nwli-pwfl,2023-10-11 11:08:02,"NEW YORK, Oct. 11, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mirati Therapeutics, Inc.",BMY,0.114682,0.121395,Neutral
Why Shares of Ventyx Biosciences Are Dropping Tuesday,https://www.fool.com/investing/2023/10/10/why-shares-of-ventyx-biosciences-are-dropping-tues/,2023-10-10 16:55:00,Investors were unimpressed by the company's trial results for an ulcerative colitis therapy.,BMY,0.130926,0.074484,Neutral
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus,https://www.zacks.com/stock/news/2163363/cancer-biotechs-pique-buyout-interest-recent-deals-in-focus,2023-10-10 15:37:00,The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.,BMY,0.130926,0.134455,Neutral
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday,https://www.fool.com/investing/2023/10/10/why-shares-of-lexicon-pharmaceuticals-are-up-tuesd/,2023-10-10 15:25:34,Express Scripts will give its clients access to Lexicon's first approved therapy.,BMY,0.136888,0.040792,Neutral
How Is The Market Feeling About Bristol-Myers Squibb? - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/23/10/35165144/how-is-the-market-feeling-about-bristol-myers-squibb,2023-10-10 15:00:32,"Bristol-Myers Squibb's BMY short percent of float has fallen 15.71% since its last report. The company recently reported that it has 36.98 million shares sold short, which is 1.77% of all regular shares that are available for trading.",BMY,0.221819,0.083071,Neutral
"Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors",https://www.newswire.ca/news-releases/specific-biologics-announces-additional-investment-and-appointment-of-experienced-biotechnology-leader-steven-kanner-phd-to-the-board-of-directors-800596496.html,2023-10-10 13:30:00,Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven ... Canada ...,BMY,0.072765,0.019286,Neutral
Bristol Myers Squibb  ( BMY )  Stock Declines While Market Improves: Some Information for Investors,https://www.zacks.com/stock/news/2162964/bristol-myers-squibb-bmy-stock-declines-while-market-improves-some-information-for-investors,2023-10-09 21:50:20,"In the most recent trading session, Bristol Myers Squibb (BMY) closed at $56.61, indicating a -0.09% shift from the previous trading day.",BMY,0.570165,0.240945,Somewhat-Bullish
"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight",https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html,2023-10-09 21:01:00,"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand ... PR ...",BMY,0.054483,0.032874,Neutral
"Stocks making the biggest moves midday: General Dynamics, United Airlines, Spotify and more",https://www.cnbc.com/2023/10/09/stocks-making-the-biggest-moves-midday-general-dynamics-united-airlines-spotify-and-more.html,2023-10-09 16:52:28,These are the stocks posting the largest moves in midday trading.,BMY,0.093653,0.150526,Somewhat-Bullish
Why Shares of Tango Therapeutics Are Dropping Monday,https://www.fool.com/investing/2023/10/09/why-shares-of-tango-therapeutics-are-dropping-mond/,2023-10-09 15:53:07,"Another company's buyout helped drive up the price last week. This week, investors started out by selling the stock.",BMY,0.147818,0.0363,Neutral
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal,https://www.foxbusiness.com/markets/bristol-myers-squibb-buy-cancer-drugmaker-mirati-therapeutics-billion-deal,2023-10-09 15:23:49,"Bristol Myers Squibb said Sunday it will acquire drugmaker Mirati Therapeutics in a deal worth up to $5.8 billion, adding to its oncology business portfolio. The company said it will pay $58 per share in cash.",BMY,0.392948,0.204216,Somewhat-Bullish
Stock Market Reacts To Brutal Attacks On Israel; Defense Stocks Benefit,https://www.investors.com/market-trend/stock-market-today/stock-market-sinks-after-attacks-on-israel-defense-stocks-benefit/,2023-10-09 14:54:00,Stock Market Reacts To Brutal Attacks On Israel. Defense Stocks ... Investor's Business Daily ...,BMY,0.154785,-0.137786,Neutral
Bristol Myers  ( BMY )  to Acquire Mirati Therapeutics for $5.8 B,https://www.zacks.com/stock/news/2162756/bristol-myers-bmy-to-acquire-mirati-therapeutics-for-58-b,2023-10-09 14:24:00,"Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.",BMY,0.354952,0.335439,Somewhat-Bullish
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.®  ( Nasdaq - MRTX ) , LiveVox Holdings, Inc.  ( Nasdaq - LVOX ) , SP® Plus Corporation  ( Nasdaq - SP ) , Summit Materials  ( NYSE - SUM ) ",https://www.benzinga.com/pressreleases/23/10/g35146266/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-mirati-therap,2023-10-09 14:08:34,"BALA CYNWYD, Pa., Oct. 09, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BMY,0.237358,0.245244,Somewhat-Bullish
Mirati  ( MRTX )  Gets Buyout Offer From Bristol Myers for $4.8B,https://www.zacks.com/stock/news/2162730/mirati-mrtx-gets-buyout-offer-from-bristol-myers-for-48b,2023-10-09 14:01:00,"Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.",BMY,0.116631,0.207933,Somewhat-Bullish
Here's Why Mirati Stock Tumbled On A $5.8 Billion Takeover Bid,https://www.investors.com/news/technology/mrtx-stock-takes-a-hit-after-receiving-a-lowball-takeover-bid/,2023-10-09 13:52:00,MRTX Stock Takes A Hit After Receiving A Lowball Takeover Bid Investor's Business Daily ...,BMY,0.235823,-0.452244,Bearish
War Could Bring Added Volatility To Markets,https://www.forbes.com/sites/jjkinahan/2023/10/09/war-could-bring-added-volatility-to-markets/,2023-10-09 13:43:53,"In premarket activity, the S&P futures are down just over 0.5% and Nasdaq futures are off by 0.8%.",BMY,0.045396,0.061644,Neutral
"Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal - Mirati Therapeutics  ( NASDAQ:MRTX ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/10/35141493/bristol-myers-squibb-strengthens-oncology-portfolio-with-mirati-therapeutics-5b-deal,2023-10-09 13:07:22,"Bristol Myers Squibb & Co BMY has agreed to acquire Mirati Therapeutics Inc MRTX for $58.00 per share in cash, for a total equity value of $4.8 billion.",BMY,0.421485,0.317928,Somewhat-Bullish
"Alexandria Real Estate Equities, Inc. Awarded GRESB 4 Star Ratings and Seventh Consecutive Green Star Designation in the 2023 GRESB Real Estate Assessment, Reinforcing Its Sustained ESG Leadership and Performance",https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-awarded-gresb-4-star-ratings-and-seventh-consecutive-green-star-designation-in-the-2023-gresb-real-estate-assessment-reinforcing-its-sustained-esg-leadership-and-performance-301950270.html,2023-10-09 12:30:00,"Alexandria Real Estate Equities, Inc. Awarded GRESB 4 Star Ratings and Seventh Consecutive Green Star ... PR ...",BMY,0.031282,0.13679,Neutral
"Stocks making the biggest moves premarket: Exxon Mobil, Lockheed Martin, Walt Disney and more",https://www.cnbc.com/2023/10/09/stocks-making-the-biggest-moves-premarket-exxon-mobil-lockheed-martin-walt-disney-and-more.html,2023-10-09 12:04:17,These are the stocks posting the largest moves in early trading.,BMY,0.172713,0.067171,Neutral
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer,https://www.globenewswire.com/news-release/2023/10/09/2756623/0/en/Tom-Garner-Joins-Lexicon-as-Senior-Vice-President-and-Chief-Commercial-Officer.html,2023-10-09 12:00:00,Mr. Garner brings over 25 years of pharmaceutical industry experience Mr. Garner brings over 25 years of pharmaceutical industry experience ...,BMY,0.056943,0.02301,Neutral
"Why S&P 500, Nasdaq Are Set To Open Lower Today - Microsoft  ( NASDAQ:MSFT ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , NVIDIA  ( NASDAQ:NVDA ) , Lockheed Martin  ( NYSE:LMT ) ",https://www.benzinga.com/markets/equities/23/10/35143020/s-p-500-nasdaq-set-for-bleak-start-to-week-as-middle-east-tensions-dampen-risk-on-mood-earnings-,2023-10-09 11:28:11,The market may open the week on a cautious note due to escalating tensions in the Middle East caused by violent rocket attacks from the Palestinian militant group Hamas on Israel. Israel's determination to respond to these attacks has dented risk appetite.,BMY,0.090645,0.250524,Somewhat-Bullish
From $150 oil to no impact at all: What the surprise attack on Israel means to markets,https://www.marketwatch.com/story/from-150-oil-to-no-impact-at-all-what-the-surprise-attack-on-israel-means-to-markets-6190fd77,2023-10-09 10:50:00,Trying to map out all the possibilities from the surprise attack on Israel yields results ranging from a surge in oil prices to no change at all.,BMY,0.082963,0.163865,Somewhat-Bullish
"Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Camtek  ( NASDAQ:CAMT ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/23/10/35141651/tesla-mirati-therapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session,2023-10-09 09:57:24,"U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording losses in today's pre-market trading session. TPG RE Finance Trust, Inc. TRTX shares tumbled 8.1% to $5.64 in pre-market trading. InMode Ltd. INMD shares declined 7% to $26.70 in pre-market trading.",BMY,0.306963,0.239663,Somewhat-Bullish
"Shares in weapons makers Lockheed Martin, RTX surge following surprise attack on Israel and other stocks on the move",https://www.marketwatch.com/story/shares-in-weapons-makers-lockheed-martin-rtx-surge-following-surprise-attack-on-israel-and-other-stocks-on-the-move-e2f2d866,2023-10-09 09:57:00,"Shares in RTX, Lockheed Martin, Marathon Oil, Occidental Petroleum, Mirati Therapeutics, and Bristol Myers Squibb Co. were on the move ...",BMY,0.499789,0.343111,Somewhat-Bullish
Futures down as Middle East conflict sparks run for safe-haven assets,https://www.reuters.com/markets/us/futures-down-middle-east-conflict-sparks-run-safe-haven-assets-2023-10-09/,2023-10-09 09:45:00,"Traders work on the floor of the New York Stock Exchange ( NYSE ) in New York City, U.S., September 28, 2023. REUTERS/Brendan McDermid Acquire Licensing Rights",BMY,0.072876,-0.076583,Neutral
Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma,https://www.globenewswire.com/news-release/2023/10/09/2756420/0/en/Ultimovacs-Receives-FDA-Orphan-Drug-Designation-for-the-UV1-Cancer-Vaccine-for-Treatment-of-Mesothelioma.html,2023-10-09 05:00:00,"• The orphan drug designation was granted based on data from the randomized Phase II clinical trial NIPU • The results from the NIPU study will be presented at the ESMO Congress being held October 20-24, 2023 in Madrid • UV1 also received FDA orphan drug designation for treatment of patients ...",BMY,0.067536,-0.03938,Neutral
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion,https://www.marketwatch.com/story/bristol-myers-squibb-to-buy-mirati-therapeutics-in-deal-worth-up-to-5-8-billion-491f4a89,2023-10-08 23:34:00,"Mirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its portfolio.",BMY,0.576289,0.46381,Bullish
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion,https://www.wsj.com/health/pharma/bristol-myers-squibb-to-acquire-mirati-therapeutics-in-deal-worth-up-to-5-8-billion-7d83106,2023-10-08 22:12:00,The deal expands the pharmaceutical company's portfolio of cancer drugs.,BMY,0.930964,0.225709,Somewhat-Bullish
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal,https://www.reuters.com/markets/deals/bristol-myers-squibb-acquire-mirati-48-billion-deal-2023-10-08/,2023-10-08 21:55:49,"Oct 8 ( Reuters ) - Bristol-Myers Squibb ( BMY.N ) is set to acquire cancer drugmaker Mirati Therapeutics ( MRTX.O ) for $58 per share in cash, representing $4.8 billion equity value. Bristol-Myers Squibb will finance the transaction with a combination of cash and debt.",BMY,0.827318,-0.221516,Somewhat-Bearish
2 Growth Stocks That Could Rocket Higher Before the End of 2023,https://www.fool.com/investing/2023/10/08/2-growth-stocks-that-could-rocket-higher-before-th/,2023-10-08 10:29:00,Potential approvals of new medicines expected soon could push these stocks through the roof.,BMY,0.1789,0.070638,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - MRTX, FAZE, HES, TGH",https://www.benzinga.com/pressreleases/23/10/g35476187/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-mrtx-faze-hes-tgh,2023-10-27 22:00:10,"NEW YORK, Oct. 27, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and headquartered ...",BMY,0.069697,0.141441,Neutral
Pharma Giant Bristol-Myers Stock At 52-Week Low: Analyst Sees Uncertainty In Near-Term Outlook - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/10/35469919/pharma-giant-bristol-myers-stock-at-52-week-low-analyst-sees-uncertainty-in-near-term-outlook,2023-10-27 18:13:44,Bristol-Myers Squibb Co BMY shares are trading lower on continuous weakness following the disappointing Q3 earnings and a downward revision to the medium-term outlook. The company reported that sales of the drug maker's popular Revlimid blood cancer treatment plunged due to competition from ...,BMY,0.397098,-0.351904,Bearish
Bristol Myers Squibb Analysts Slash Their Forecasts Following Q3 Results - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/news/earnings/23/10/35470452/bristol-myers-squibb-analysts-slash-their-forecasts-following-q3-results,2023-10-27 17:47:57,"Bristol Myers Squibb & Co BMY reported better-than-expected earnings for its third quarter. Bristol Myers Squibb said revenues came in at $10.966 billion, due to lower sales of Revlimid, partially offset by in-line products and its new product portfolio. Analysts were expecting sales of $10.965 ...",BMY,0.913524,-0.126384,Neutral
Correction Intensifies Amid Earnings Wave: Weekly Review,https://www.investors.com/news/stock-market-correction-intensifies-google-meta-microsoft-amazon-are-big-earnings-movers-weekly-review/,2023-10-27 16:19:00,Correction Intensifies. Google Tops On Earnings Investor's Business Daily ...,BMY,0.034831,0.059766,Neutral
Why LianBio Stock Is Shooting Through the Roof This Week,https://www.fool.com/investing/2023/10/27/why-lianbio-stock-is-shooting-through-the-roof-thi/,2023-10-27 12:32:43,"LianBio stock is seeing explosive gains, and it's one of this week's biggest winners.",BMY,0.176502,0.169349,Somewhat-Bullish
"3 Penny Stocks To Buy For Under $5, Are They Worth It?",https://pennystocks.com/featured/2023/10/26/3-penny-stocks-to-buy-for-under-5-are-they-worth-it/,2023-10-26 19:06:14,Penny stocks are defined as stocks trading for under $5. They typically include start-up or emerging-growth stage companies starting from the grassroots. There are also companies that may have previously been market leaders but have fallen on hard times.,BMY,0.046452,0.027471,Neutral
Bristol Myers Squibb  ( BMY )  Q3 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/10/26/bristol-myers-squibb-bmy-q3-2023-earnings-call-tra/,2023-10-26 18:00:24,"BMY earnings call for the period ending September 30, 2023.",BMY,0.004501,0.195184,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PNT, MRTX, ORTX - Orchard Therapeutics  ( NASDAQ:ORTX ) , Mirati Therapeutics  ( NASDAQ:MRTX ) ",https://www.benzinga.com/pressreleases/23/10/g35446978/shareholder-investigation-halper-sadeh-llc-investigates-pnt-mrtx-ortx,2023-10-26 17:23:58,"NEW YORK, Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: POINT Biopharma Global, Inc.",BMY,0.101582,0.11634,Neutral
"Bristol-Myers  ( BMY )  Q3 Earnings & Sales Beat, Opdivo Sales Grow",https://www.zacks.com/stock/news/2173090/bristol-myers-bmy-q3-earnings-sales-beat-opdivo-sales-grow,2023-10-26 16:13:00,Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.,BMY,0.300854,0.245968,Somewhat-Bullish
Bristol Myers says it needs another year to hit target for new drugs,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-says-it-needs-another-year-hit-target-new-drugs-2023-10-26/,2023-10-26 15:07:00,"A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights",BMY,0.193465,0.0,Neutral
Advance GDP Estimate Comes in Higher Than Expectations,https://www.zacks.com/stock/news/2172937/advance-gdp-estimate-comes-in-higher-than-expectations,2023-10-26 14:54:00,"We got out first look at Q3 Gross Domestic Product ( GDP ) this morning - an advanced look, subject to two revisions in the coming months - with a headline of +4.9%, 20 basis points ( bps ) ahead of consensus estimates. Consumer spending jumped to +4.0% from +0.8% the previous quarter.",BMY,0.11983,0.043853,Neutral
"Q3 GDP +4.9%, Earnings Beats for UPS, Bristol Myers and Honeywell",https://www.zacks.com/stock/news/2172908/q3-gdp-49-earnings-beats-for-ups-bristol-myers-and-honeywell,2023-10-26 14:25:00,"In the preliminary Q3 GDP print, consumer spending jumped to +4.0% while private domestic investment roared ahead +8.4%.",BMY,0.114682,0.076052,Neutral
"US Stocks Mixed; Bristol Myers Posts Upbeat Earnings - ABVC BioPharma  ( NASDAQ:ABVC ) , Bit Brother  ( NASDAQ:BETS ) ",https://www.benzinga.com/news/earnings/23/10/35440369/us-stocks-mixed-bristol-myers-posts-upbeat-earnings,2023-10-26 13:44:11,"U.S. stocks traded mixed this morning, following the release of several economic reports. Following the market opening Thursday, the Dow traded up 0.10% to 33,069.66 while the NASDAQ fell 0.24% to 12,790.71. The S&P 500 also fell, dropping, 0.13% to 4,181.15. Real estate shares rose by 1% on ...",BMY,0.200134,-0.032297,Neutral
Bristol Myers Squibb shares drop as key product sales fall short of expectations,https://www.marketwatch.com/story/bristol-myers-squibb-earnings-top-estimates-0a9519c8,2023-10-26 13:32:00,"IRS an ""unlikely savior"" of quarterly results, analysts say.",BMY,0.359014,0.01288,Neutral
"Bristol Myers Squibb's Revlimid Sales Plunge 41%, but Opdivo and Eliquis Boost Q3, Stock Dips - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/earnings/23/10/35438868/bristol-myers-squibbs-revlimid-sales-plunge-41-but-opdivo-and-eliquis-boost-q3-stock-dips,2023-10-26 13:27:57,"Bristol Myers Squibb & Co BMY said that its Q3 revenues of $10.966 billion declined 2% Y/Y, or 3% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and its new product portfolio. Analysts estimated sales of $10.965 billion.",BMY,0.702434,-0.011652,Neutral
Bristol Myers Skids 5% After Pushing Back A Key Sales Goal By A Year,https://www.investors.com/news/technology/bmy-stock-bristol-myers-earnings-q3-2023/,2023-10-26 13:04:00,Bristol Myers Skids 5% After Pushing Back A Key Sales Goal By A ... Investor's Business Daily ...,BMY,0.587597,0.373585,Bullish
Bristol Myers Squibb  ( BMY )  Surpasses Q3 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2172451/bristol-myers-squibb-bmy-surpasses-q3-earnings-and-revenue-estimates,2023-10-26 12:15:17,"Bristol Myers (BMY) delivered earnings and revenue surprises of 13.64% and 0.28%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?",BMY,0.137278,0.095302,Neutral
"Why Nasdaq, S&P 500 Futures Are Sliding Today - Alphabet  ( NASDAQ:GOOGL ) , Mattel  ( NASDAQ:MAT ) , Ford Motor  ( NYSE:F ) , Merck & Co  ( NYSE:MRK ) ",https://www.benzinga.com/markets/equities/23/10/35436214/nasdaq-futures-plunge-as-meta-warns-of-q4-softness-gdp-data-amazon-earnings-on-investors-radar-a,2023-10-26 11:38:30,"A somber mood looms over Wall Street, stirred by lackluster earnings reports and relentless bond yield increases. Stock futures dipped early Thursday, with Meta Platforms, Inc.'s META impressive results failing to satisfy investors.",BMY,0.066877,0.0,Neutral
Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition,https://www.cnbc.com/2023/10/26/bristol-myers-squibb-bmy-q3-earnings-report-2023.html,2023-10-26 11:05:39,"Bristol Myers Squibb's revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Revlimid.",BMY,0.142144,-0.030176,Neutral
2 Absurdly Cheap Healthcare Stocks to Buy and Hold for Decades,https://www.fool.com/investing/2023/10/26/2-absurdly-cheap-healthcare-stocks-to-buy-and-hold/,2023-10-26 11:00:00,You won't have to worry about paying a premium for either one of these stocks -- and they both pay a solid dividend.,BMY,0.194763,0.258379,Somewhat-Bullish
"Morning Bid: Haunted by 5% ahead of ECB, GDP and Amazon",https://www.reuters.com/markets/us/global-markets-view-usa-2023-10-26/,2023-10-26 10:01:00,"Traders work on the floor at the New York Stock Exchange ( NYSE ) in New York City, U.S., October 23, 2023. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights A look at the day ahead in U.S. and global markets from Mike Dolan",BMY,0.051551,0.105477,Neutral
"Cell Therapy Market Revenue to Cross USD 54.6 million by 2032; Registering at a CAGR of 18.7% - Says, Transparency Market Research",https://www.benzinga.com/pressreleases/23/10/g35433363/cell-therapy-market-revenue-to-cross-usd-54-6-million-by-2032-registering-at-a-cagr-of-18-7-says-t,2023-10-26 09:33:32,"Wilmington, Delaware, United States, Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The market for cell therapy was valued at US$ 10 million US$ 10 million in 2022. The CAGR between 2022 and 2032 is expected to reach 18.7%. By 2032, the market is expected to reach US$ ...",BMY,0.037622,0.0,Neutral
"Meta, Amazon And 3 Stocks To Watch Heading Into Thursday - Amazon.com  ( NASDAQ:AMZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/earnings/23/10/35431828/meta-amazon-and-3-stocks-to-watch-heading-into-thursday,2023-10-26 09:31:58,"With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Amazon.com, Inc. AMZN to report quarterly earnings at 58 cents per share on revenue of $141.44 billion after the closing bell.",BMY,0.498188,0.131823,Neutral
"Fear Continues To Grip Markets As S&P 500 Settles Below 4,200 - Amazon.com  ( NASDAQ:AMZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/earnings/23/10/35431932/fear-continues-to-grip-markets-as-s-p-500-settles-below-4-200,2023-10-26 08:16:51,"The CNN Money Fear and Greed index showed growth easing in the overall fear level, remaining in the ""Fear"" zone on Wednesday. U.S. stocks closed lower on Wednesday, with the S&P 500 closing the session below the 4,200 level. Alphabet Inc.",BMY,0.234684,0.0,Neutral
META Up +4% on +23% Revenue Growth; IBM and NOW Also Beat,https://www.zacks.com/stock/news/2172157/meta-up-4-on-23-revenue-growth-ibm-and-now-also-beat,2023-10-25 22:22:00,The social media leader posted a big beat on earnings -- $4.39 per share versus expectations of $3.62 and the year-ago number of $1.64 per share.,BMY,0.151064,0.033733,Neutral
"Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC",https://www.zacks.com/stock/news/2171776/drug-biotech-stocks-q3-earnings-due-on-oct-26-bmy-mrk-bpmc,2023-10-25 14:15:00,"Let's look at three biotech/drug companies, BMY, MRK and BPMC, slated to release quarterly results on Oct 26.",BMY,0.201523,0.0,Neutral
This Artificial Intelligence  ( AI )  Stock Is Powering the Biotech Revolution: Should You Invest?,https://www.fool.com/investing/2023/10/25/this-ai-stock-is-powering-the-biotech-revolution-s/,2023-10-25 10:50:00,There's more to the AI boom than Microsoft and ChatGPT.,BMY,0.052226,0.12377,Neutral
"Nasdaq Gains 100 Points; Coca-Cola Earnings Top Expectations - InMed Pharmaceuticals  ( NASDAQ:INM ) , Agilysys  ( NASDAQ:AGYS ) ",https://www.benzinga.com/news/earnings/23/10/35401536/nasdaq-gains-100-points-coca-cola-earnings-top-expectations,2023-10-24 18:34:11,"U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 200 points on Tuesday. The Dow traded up 0.67% to 33,155.68 while the NASDAQ rose 0.78% to 13,120.31. The S&P 500 also rose, gaining, 0.72% to 4,247.52. Utilities shares rose by 2.6% on Tuesday.",BMY,0.068896,0.241441,Somewhat-Bullish
"Crude Oil Down Over 2%; General Motors Posts Upbeat Earnings - General Motors  ( NYSE:GM ) , Ascent Solar Technologies  ( NASDAQ:ASTI ) ",https://www.benzinga.com/news/earnings/23/10/35399768/crude-oil-down-over-2-general-motors-posts-upbeat-earnings,2023-10-24 16:59:40,"U.S. stocks traded slightly higher midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.17% to 32,992.95 while the NASDAQ rose 0.06% to 13,023.65. The S&P 500 also rose, gaining, 0.07% to 4,220.02. Utilities shares rose by 2.3% on Tuesday.",BMY,0.0699,0.241685,Somewhat-Bullish
Why LianBio Stock Is Skyrocketing Today,https://www.fool.com/investing/2023/10/24/why-lianbio-stock-is-skyrocketing-today/,2023-10-24 16:40:16,Investors are loving LianBio's new deal with Bristol Myers Squibb.,BMY,0.478494,0.381382,Bullish
"Alopecia Areata Market Overview 2023-2027: Projected Market Size, Major Driver And Lucrative Segments As Per The Business Research Company's Alopecia Areata Global Market Report 2023",https://www.benzinga.com/pressreleases/23/10/g35397742/alopecia-areata-market-overview-2023-2027-projected-market-size-major-driver-and-lucrative-segment,2023-10-24 15:30:00,"LONDON, Oct. 24, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Alopecia Areata Global Market Report 2023, the global alopecia areata market is on a steady growth trajectory, with expectations to increase from $3.08 billion in 2022 to $3.31 billion in 2023, marking a ...",BMY,0.056011,0.143223,Neutral
Why LianBio Stock Is Ripping Higher Today - LianBio  ( NASDAQ:LIAN ) ,https://www.benzinga.com/news/23/10/35395537/why-lianbio-stock-is-ripping-higher-today,2023-10-24 14:24:40,"LianBio LIAN shares are trading higher Tuesday after the company announced an agreement with Bristol Myers Squibb BMY to purchase LianBio's exclusive rights to develop and commercialize mavacamten in mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand.",BMY,0.479683,0.490533,Bullish
"Dow Surges 250 Points; US Manufacturing PMI Tops Expectations - ReAlpha Tech Corp  ( NASDAQ:AIRE ) , Ascent Solar Technologies  ( NASDAQ:ASTI ) ",https://www.benzinga.com/news/earnings/23/10/35395378/dow-surges-250-points-us-manufacturing-pmi-tops-expectations,2023-10-24 14:14:23,"U.S. stocks traded higher this morning, with the Dow Jones index gaining over 250 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.80% to 33,200.75 while the NASDAQ rose 0.88% to 13,132.62. The S&P 500 also rose, gaining, 0.79% to 4,250.15. Utilities shares rose by ...",BMY,0.074926,0.266627,Somewhat-Bullish
"Earnings Preview: Harmony Biosciences Holdings, Inc.  ( HRMY )  Q3 Earnings Expected to Decline",https://www.zacks.com/stock/news/2170871/earnings-preview-harmony-biosciences-holdings-inc-hrmy-q3-earnings-expected-to-decline,2023-10-24 14:00:47,"Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",BMY,0.085476,0.037893,Neutral
4 Hot Penny Stocks To Watch With Big News This Week,https://pennystocks.com/featured/2023/10/24/4-hot-penny-stocks-to-watch-with-big-news-this-week/,2023-10-24 13:02:45,"Whether you're trading penny stocks or stocks over $100, the goal is the same. You want to find opportunities as early as possible and capitalize. In the stock market today, there are plenty of factors affecting the way investors approach both long-term and short-term opportunities.",BMY,0.039033,0.026811,Neutral
"'Never Buy A Drug Stock Just For The Yield': Jim Cramer On This Big Pharma Company - AutoNation  ( NYSE:AN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/10/35387533/never-buy-a-drug-stock-just-for-the-yield-jim-cramer-on-this-big-pharma-company,2023-10-24 12:47:18,"On CNBC's ""Mad Money Lightning Round,"" Jim Cramer recommended selling Petróleo Brasileiro S.A. - Petrobras PBR. ""This stock has run too much for me, even though it sells at six times earnings,"" he noted. When asked about Fisker Inc. FSR, he said, ""Like the car, sell the stock.""",BMY,0.441059,-0.152484,Somewhat-Bearish
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets,https://www.globenewswire.com/news-release/2023/10/24/2765435/0/en/LianBio-Enters-into-Agreement-with-Bristol-Myers-Squibb-for-Mavacamten-in-China-and-Other-Asian-Markets.html,2023-10-24 10:59:00,"SHANGHAI and PRINCETON, N.J., Oct. 24, 2023 ( GLOBE NEWSWIRE ) -- LianBio ( Nasdaq: LIAN ) , a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the company has entered into an agreement with Bristol Myers ...",BMY,0.066047,0.103764,Neutral
What's in Store for Bristol-Myers  ( BMY )  in Q3 Earnings?,https://www.zacks.com/stock/news/2170140/whats-in-store-for-bristol-myers-bmy-in-q3-earnings,2023-10-23 12:47:00,Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.,BMY,0.22421,0.260342,Somewhat-Bullish
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 - Ayala Pharmaceuticals  ( OTC:ADXS ) ,https://www.benzinga.com/pressreleases/23/10/g35369503/ayala-pharmaceuticals-presents-updated-al102-results-from-phase-2-clinical-trial-in-desmoid-tumors,2023-10-23 11:00:00,"AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Oct. 23, 2023 ( GLOBE NEWSWIRE ) ...",BMY,0.017096,-0.029945,Neutral
"Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market? - Alphabet  ( NASDAQ:GOOGL ) , Logitech International  ( NASDAQ:LOGI ) , Archer-Daniels Midland  ( NYSE:ADM ) , Novartis  ( NYSE:NVS ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35367409/amazon-alphabet-meta-intel-q3-earnings-this-week-will-mega-caps-shatter-forecasts-a,2023-10-23 07:15:17,"After the first week of earnings, analysts have tempered their expectations for profit growth, anticipating a continuation of the profit-declining trend.",BMY,0.104228,0.0,Neutral
Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients with Malignant Mesothelioma Receiving UV1 Cancer Vaccine,https://www.globenewswire.com/news-release/2023/10/23/2764362/0/en/Ultimovacs-Provides-Complete-Phase-II-NIPU-Results-Presented-at-ESMO-2023-Significant-and-Clinically-Meaningful-Improvement-in-Overall-Survival-for-Patients-with-Malignant-Mesothel.html,2023-10-23 05:00:00,"Oslo, October 23, 2023: Ultimovacs ASA ( ""Ultimovacs"" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced the full dataset from the NIPU clinical trial ( NCT04300244 ) presented at the ESMO Congress 2023 in Madrid.",BMY,0.067823,-0.028368,Neutral
Bladder cancer studies suggest new ways to treat the disease and improve survival,https://www.cnn.com/2023/10/22/health/bladder-cancer-treatment-studies/index.html,2023-10-22 14:30:00,A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care.,BMY,0.027699,0.0,Neutral
"After a robust third quarter, US economic growth will likely slow. That bodes well for rate cuts next year. | Business",https://www.cnn.com/2023/10/22/economy/stocks-week-ahead-q3-gdp/index.html,2023-10-22 12:04:00,"After a robust third quarter, US economic growth will likely slow. That bodes well for rate cuts next year. ...",BMY,0.032207,-0.005755,Neutral
Top Wall Street analysts favor these five dividend stocks during tumultuous times,https://www.cnbc.com/2023/10/22/top-wall-street-analysts-favor-these-five-dividend-stocks-during.html,2023-10-22 11:02:53,"TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Cisco and Chesapeake Energy.",BMY,0.245959,0.195455,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, MRTX, ICPT - Intercept Pharma  ( NASDAQ:ICPT ) , Mirati Therapeutics  ( NASDAQ:MRTX ) ",https://www.benzinga.com/pressreleases/23/10/g35364344/shareholder-investigation-halper-sadeh-llc-investigates-sp-mrtx-icpt,2023-10-22 01:28:15,"NEW YORK, Oct. 21, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",BMY,0.11983,0.12363,Neutral
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?,https://www.fool.com/investing/2023/10/21/which-is-the-better-long-term-hold-for-investors-p/,2023-10-21 10:00:00,The venerable pharmaceutical companies' shares have slumped this year.,BMY,0.03786,0.041488,Neutral
"Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets - Alphabet  ( NASDAQ:GOOGL ) , Chevron  ( NYSE:CVX ) , Verizon Communications  ( NYSE:VZ ) , Merck & Co  ( NYSE:MRK ) ",https://www.benzinga.com/markets/asia/23/10/35358005/investor-risk-sentiment-wavers-amid-war-interest-rate-concerns-tesla-earnings-disappoint-the-week-in,2023-10-20 20:08:03,"Volatility notably returned to the markets this week as investors navigated the escalating conflict between Israel and Hamas, remarks from Federal Reserve Chair Jerome Powell and mixed earning reports from leading U.S. corporations.",BMY,0.097854,0.0,Neutral
"MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb - Mirati Therapeutics  ( NASDAQ:MRTX ) ",https://www.benzinga.com/pressreleases/23/10/g35349181/mrtx-alert-monsey-firm-of-wohl-fruchter-investigating-fairness-of-the-proposed-sale-of-mirati-ther,2023-10-20 13:01:00,"MONSEY, N.Y., Oct. 20, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Mirati Therapeutics, Inc.",BMY,0.115787,0.192675,Somewhat-Bullish
Bristol Myers'  ( BMY )  Opdivo SC Meets Kidney Cancer Study Goals,https://www.zacks.com/stock/news/2169376/bristol-myers-bmy-opdivo-sc-meets-kidney-cancer-study-goals,2023-10-20 09:36:00,"Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.",BMY,0.308504,0.092044,Neutral
Purple Biotech Announces Closing of $5 Million Registered Direct Offering - Purple Biotech  ( NASDAQ:PPBT ) ,https://www.benzinga.com/pressreleases/23/10/g35338635/purple-biotech-announces-closing-of-5-million-registered-direct-offering,2023-10-19 19:55:53,"REHOVOT, Israel, Oct. 19, 2023 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( ""Purple Biotech"" or ""the Company"" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug ...",BMY,0.026213,0.025543,Neutral
Purple Biotech Announces Closing of $5 Million Registered Direct Offering,https://www.globenewswire.com/news-release/2023/10/19/2763632/0/en/Purple-Biotech-Announces-Closing-of-5-Million-Registered-Direct-Offering.html,2023-10-19 19:55:00,"REHOVOT, Israel, Oct. 19, 2023 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( ""Purple Biotech"" or ""the Company"" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug ...",BMY,0.026444,0.026552,Neutral
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/10/35328430/opdivos-subcutaneous-formulation-shows-promise-in-advanced-kidney-cancer-bristol-myers-squibbs-la,2023-10-19 14:25:13,Bristol Myers Squibb Co BMY released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo ( nivolumab ) compared to intravenous ( IV ) Opdivo for advanced or metastatic clear cell renal cell carcinoma ( ccRCC ) who have received prior systemic therapy.,BMY,0.337811,0.250885,Somewhat-Bullish
Earnings Preview: Bristol Myers Squibb  ( BMY )  Q3 Earnings Expected to Decline,https://www.zacks.com/stock/news/2168854/earnings-preview-bristol-myers-squibb-bmy-q3-earnings-expected-to-decline,2023-10-19 14:01:59,Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.101367,-0.010951,Neutral
3 Things About Bristol Myers Squibb That Smart Investors Know,https://www.fool.com/investing/2023/10/19/3-things-about-bristol-myers-that-smart-investors/,2023-10-19 13:53:00,"The stock is down this year, but will its struggles fade into the rearview mirror?",BMY,0.131403,-0.010972,Neutral
Could Bristol Myers Squibb Stock Help You Become a Millionaire?,https://www.fool.com/investing/2023/10/19/could-bristol-myers-squibb-stock-help-you-become-a/,2023-10-19 13:15:00,"Bristol Myers has been investing in growth, but will it be enough to get investors bullish on its struggling stock?",BMY,0.111747,-0.013654,Neutral
Bristol Myers' injectable kidney cancer drug found non-inferior to IV form,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myerss-injectable-kindey-cancer-drug-found-non-inferior-iv-form-2023-10-19/,2023-10-19 11:23:50,"Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights",BMY,0.751437,-0.115161,Neutral
CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference,https://www.globenewswire.com/news-release/2023/10/18/2762767/37704/en/CytomX-Therapeutics-Presents-Preclinical-Profile-of-EpCAM-directed-Antibody-Drug-Conjugate-CX-2051-at-2023-World-ADC-Conference.html,2023-10-18 20:30:00,- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload ...,BMY,0.073773,-0.00924,Neutral
Bristol Myers Squibb Highlights Opdivo Regime Data In Lung Cancer Settings - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/10/35311374/bristol-myers-squibb-highlights-opdivo-regime-data-in-lung-cancer-settings,2023-10-18 15:15:46,Bristol Myers Squibb & Co BMY announced the first disclosure of data from the Phase 3 CheckMate -77T trial of the perioperative regimen of neoadjuvant Opdivo ( nivolumab ) with chemotherapy followed by surgery and adjuvant Opdivo in patients with resectable stage IIA to IIIB non-small cell lung ...,BMY,0.386875,-0.084784,Neutral
2 High-Yield Dividend Stocks to Buy Now,https://www.fool.com/investing/2023/10/18/2-high-yield-dividend-stocks-to-buy-now/,2023-10-18 12:00:00,These two blue-chip stocks sport generous yields.,BMY,0.206392,0.049367,Neutral
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS,https://www.prnewswire.com/news-releases/halozyme-reports-third-quarter-2023-financial-and-operating-results-301979106.html,2023-11-06 21:01:00,Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted EPS of $0.61 and Non-GAAP Diluted EPS of $0.751 Maintained Revenue Guidance and Raised 2023 EBITDA Guidance to $430-$445 million and Non-GAAP ...,BMY,0.020526,0.076156,Neutral
"Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More",https://www.zacks.com/stock/news/2179006/biotechdrug-stocks-q3-earnings-due-nov-7-gild-prgo-vtrs-more,2023-11-06 13:26:00,"Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.",BMY,0.073321,0.120064,Neutral
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates,https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-third-quarter-2023-financial-results-and-recent-corporate-updates-301977680.html,2023-11-06 13:00:00,"SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® ( NASDAQ: MRTX ) , a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.",BMY,0.063174,0.017096,Neutral
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors - Ayala Pharmaceuticals  ( OTC:ADXS ) ,https://www.benzinga.com/pressreleases/23/11/g35617921/ayala-pharmaceuticals-announces-al102-receives-orphan-drug-designation-for-desmoid-tumors,2023-11-06 13:00:00,"REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 ( GLOBE NEWSWIRE ) -- Ayala Pharmaceuticals, Inc. ADXS, a clinical-stage oncology company, today announced that the U.S.",BMY,0.029256,-0.032121,Neutral
Bristol Myers buys Orum's blood cancer therapy for up to $180 mln,https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buys-orums-blood-cancer-therapy-up-180-mln-2023-11-06/,2023-11-06 12:54:00,Bristol Myers buys Orum's blood cancer therapy for up to ...,BMY,0.588876,0.059898,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLGC, SP, MRTX - SomaLogic  ( NASDAQ:SLGC ) , Mirati Therapeutics  ( NASDAQ:MRTX ) ",https://www.benzinga.com/pressreleases/23/11/g35604903/shareholder-investigation-halper-sadeh-llc-investigates-slgc-sp-mrtx,2023-11-04 04:00:00,"NEW YORK, Nov. 04, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SomaLogic, Inc.",BMY,0.116348,0.122104,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - SIX, MRTX, FAZE, TGH",https://www.benzinga.com/pressreleases/23/11/g35603805/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-six-mrtx-faze-tgh,2023-11-03 21:40:29,"NEW YORK, Nov. 03, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and ...",BMY,0.068896,0.141299,Neutral
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI  ( adagrasib )  as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer  ( NSCLC )  with a KRASG12C Mutation,https://www.prnewswire.com/news-releases/mirati-therapeutics-receives-approval-from-the-mhra-for-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-with-a-krasg12c-mutation-301977569.html,2023-11-03 21:19:00,Mirati Therapeutics Receives Approval from the MHRA for KRAZATI ( adagrasib ) as a Targeted Treatment Option for ... PR ...,BMY,0.036926,0.012705,Neutral
Prothena  ( PRTA )  Q3 Earnings Beat on Collaboration Revenue Hike,https://www.zacks.com/stock/news/2178331/prothena-prta-q3-earnings-beat-on-collaboration-revenue-hike,2023-11-03 15:34:00,"Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.",BMY,0.336934,0.131142,Neutral
Which Corporations Pay The Most Federal Income Tax?,https://www.forbes.com/sites/taxnotes/2023/11/03/which-corporations-pay-the-most-federal-income-tax/,2023-11-03 14:31:05,"Corporations report their total cash payments of income tax - federal, state, and foreign combined - but they don't identify, nor does the IRS reveal, how much federal income tax they pay. We believe, however, that we can make reasonable estimates from information reported by publicly traded ...",BMY,0.0367,0.036094,Neutral
JNJ: 3 Pharma Stocks to Capitalize on With Potential Upside,https://stocknews.com/news/jnj-bmy-gsk-me-3-pharma-stocks-to-capitalize-on-with-potential-upside/,2023-11-02 18:05:15,"The pharmaceutical sector is poised for robust growth, propelled by the rapidly expanding market for medications and vaccines. Moreover, the consistent demand for its products upholds the industry's resilience, rendering it less vulnerable to economic fluctuations.",BMY,0.165484,0.149924,Neutral
Ovarian Cancer Treatment Market To Reach USD 18.3 Billion By 2031. By TMR,https://www.benzinga.com/pressreleases/23/11/g35564549/ovarian-cancer-treatment-market-to-reach-usd-18-3-billion-by-2031-by-tmr,2023-11-02 14:00:00,"Wilmington, Delaware, United States, Nov. 02, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global ovarian cancer treatment market was estimated to have acquired US$ 5.1 billion in 2022. It is anticipated to register a 15.4% CAGR from 2023 to 2031 and by 2031, the market is ...",BMY,0.042876,-0.48572,Bearish
Is Schrödinger Stock a Buy Now?,https://www.fool.com/investing/2023/11/02/is-schrodinger-stock-a-buy-now/,2023-11-02 12:15:00,"Its groundbreaking work is winning it some powerful fans, but it's still risky.",BMY,0.052112,0.171568,Somewhat-Bullish
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC,https://www.globenewswire.com/news-release/2023/11/02/2772156/35186/en/Kura-Oncology-and-Mirati-Therapeutics-Enter-into-Clinical-Collaboration-and-Supply-Agreement-to-Evaluate-KO-2806-and-Adagrasib-in-KRAS%E1%B4%B3-%E1%B6%9C-Mutated-NSCLC.html,2023-11-02 11:30:00,- Ongoing Phase 1 dose-escalation trial of KO-2806 ( FIT-001 ) expected to begin dosing patients in combination with adagrasib by mid-2024 - - Ongoing Phase 1 dose-escalation trial of KO-2806 ( FIT-001 ) expected to begin dosing patients in combination with adagrasib by ...,BMY,0.020421,0.011782,Neutral
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress,https://www.prnewswire.com/news-releases/karyopharm-reports-third-quarter-2023-financial-results-and-highlights-recent-company-progress-301975084.html,2023-11-02 11:30:00,"- Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® ( selinexor ) Net Product Revenue of $30.2 Million - - Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $160 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $125 ...",BMY,0.019333,0.059828,Neutral
"Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma",https://www.globenewswire.com/news-release/2023/11/02/2771871/0/en/Ultimovacs-Announces-Completion-of-Patient-Enrollment-in-Supplementary-Study-to-INITIUM-UV1-Phase-II-Trial-in-Malignant-Melanoma.html,2023-11-02 06:00:00,"• The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of development • Enrollment of 21 patients with unresectable or metastatic malignant melanoma completed • All ...",BMY,0.032078,-0.01357,Neutral
"Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/23/10/35528502/christopher-boerner-to-take-the-helm-at-bristol-myers-squibb-as-chair-of-the-board-ceo,2023-11-01 01:09:27,"Bristol Myers Squibb BMY has named Christopher Boerner as their new Chair of the Board of Directors and CEO. Boerner, who is set to take over as Chair in April 2024, will assume the role of CEO from November 1.",BMY,0.619618,0.67374,Bullish
"Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer",https://www.globenewswire.com/news-release/2023/10/31/2770478/18362/en/Amarin-Appoints-Jonathan-Provoost-Executive-Vice-President-Chief-Legal-Compliance-Officer.html,2023-10-31 16:00:00,"-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 ( GLOBE NEWSWIRE ) -- Amarin Corporation plc ( NASDAQ:AMRN ) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, ...",BMY,0.047185,0.04462,Neutral
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS,https://investingnews.com/amgen-reports-third-quarter-financial-results/,2023-10-31 11:39:17,"Amgen ( NASDAQ:AMGN ) today announced financial results for the third quarter of 2023 1 . References in this release to ""non-GAAP"" measures, measures presented ""on a non-GAAP basis"" and ""free cash flow"" ( computed by subtracting capital expenditures from operating cash flow ) refer to ...",BMY,0.01615,0.020913,Neutral
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS,https://www.prnewswire.com/news-releases/amgen-reports-third-quarter-financial-results-301972231.html,2023-10-31 11:00:00,"THOUSAND OAKS, Calif., Oct. 31, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the third quarter of 20231.",BMY,0.016053,0.021825,Neutral
Coalition calls on Congress to repeal Biden's prescription drug price controls,https://www.foxbusiness.com/politics/coalition-calls-congress-repeal-bidens-prescription-drug-price-controls,2023-10-31 09:00:50,"EXCLUSIVE - A coalition of more than 40 groups is calling on Congress to repeal the Drug Price Negotiation Program included in the Inflation Reduction Act ( IRA ) that passed last year, arguing that the price control scheme run by the Biden administration will ultimately lead to shortages of ...",BMY,0.064797,0.0,Neutral
"Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024",https://www.globenewswire.com/news-release/2023/10/31/2769813/0/en/Ultimovacs-Announces-Protocol-Amendment-in-UV1-Phase-II-Study-INITIUM-in-Malignant-Melanoma-Enabling-Data-Readout-in-First-Half-of-2024.html,2023-10-31 06:00:00,"Oslo, October 31, 2023: Ultimovacs ASA ( ""Ultimovacs"" ) ( OSE ULTI ) , a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced that the analysis of the INITIUM data will be initiated in mid-January 2024, following an amendment of the clinical trial ...",BMY,0.023281,-0.016788,Neutral
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/10/35498013/looking-at-bristol-myers-squibbs-recent-unusual-options-activity,2023-10-30 18:30:50,"Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb BMY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",BMY,0.703874,0.164871,Somewhat-Bullish
"Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults",https://www.benzinga.com/pressreleases/23/10/g35488556/allyx-therapeutics-lead-compound-alx-001-is-safe-and-tolerable-at-doses-achieving-full-brain-targe,2023-10-30 12:30:00,"NEW HAVEN, Conn., Oct. 30, 2023 ( GLOBE NEWSWIRE ) -- Allyx Therapeutics, a clinical-stage biotechnology company which is developing ALX-001, a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy for neurodegenerative diseases, presented Phase 1a single ascending ...",BMY,0.128822,0.025408,Neutral
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/pressreleases/23/10/g35487786/cytomx-therapeutics-to-present-preclinical-data-for-conditionally-activated-interferon-alpha-2b-at,2023-10-30 12:00:00,"- IND filing for CX-801 anticipated by the end of 2023 - SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc.",BMY,0.087027,-0.009532,Neutral
Panacea Biotec arm launches cancer drug in Canadian market; shares trade higher,https://www.moneycontrol.com/news/business/stocks/panacea-biotec-arm-launches-cancer-drug-in-canadian-market-shares-trade-higher-11618711.html,2023-10-30 04:04:35,"Paclitaxel Protein-Bound Particles is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and adenocarcinoma of the pancreas.",BMY,0.148731,0.0,Neutral
"StockNews.com Upgrades Bristol-Myers Squibb  ( NYSE:BMY )  to ""Strong-Buy""",https://www.defenseworld.net/2023/10/29/stocknews-com-upgrades-bristol-myers-squibb-nysebmy-to-strong-buy.html,2023-10-29 06:56:44,StockNews.com Upgrades Bristol-Myers Squibb ( NYSE:BMY ) to ... Defense World ...,BMY,0.688669,0.438324,Bullish
Bristol Myers  ( BMY )  Receives FDA Approval for NSCLC Drug,https://www.zacks.com/stock/news/2185457/bristol-myers-bmy-receives-fda-approval-for-nsclc-drug,2023-11-16 16:17:00,"Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA???s approval for NSCLC.",BMY,0.212425,0.013654,Neutral
"Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod",https://www.zacks.com/stock/news/2185428/biotech-stock-roundup-bmys-drug-approval-vrtx-crsp-gene-therapy-get-mhra-nod,2023-11-16 15:30:00,Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.,BMY,0.107016,0.043076,Neutral
Q32 Bio and Homology Medicines Announce Merger Agreement,https://www.globenewswire.com/news-release/2023/11/16/2781720/0/en/Q32-Bio-and-Homology-Medicines-Announce-Merger-Agreement.html,2023-11-16 12:05:00,"--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart ( ADX-914 ) in Phase 2 for the treatment of atopic dermatitis ( AD ) and alopecia areata ( AA ) , and ADX-097 entering Phase 2 for the treatment of ...",BMY,0.012428,0.176405,Somewhat-Bullish
Q32 Bio and Homology Medicines Announce Merger Agreement - PR Newswire,https://www.prnewswire.com/news-releases/q32-bio-and-homology-medicines-announce-merger-agreement-301990064.html,2023-11-16 12:05:00,Q32 Bio and Homology Medicines Announce Merger Agreement PR ...,BMY,0.012107,0.166736,Somewhat-Bullish
Q32 Bio and Homology Medicines Announce Merger Agreement - Homology Medicines  ( NASDAQ:FIXX ) ,https://www.benzinga.com/pressreleases/23/11/g35823756/q32-bio-and-homology-medicines-announce-merger-agreement,2023-11-16 12:05:00,"--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart ( ADX-914 ) in Phase 2 for the treatment of atopic dermatitis ( AD ) and alopecia areata ( AA ) , and ADX-097 entering Phase 2 for the treatment of ...",BMY,0.012089,0.166716,Somewhat-Bullish
"FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/11/35822094/fda-approves-bristol-myers-lung-cancer-drug-acquired-via-4b-turning-point-deal-competes-with-roch,2023-11-16 11:48:33,The FDA approved Bristol Myers Squibb And Co's BMY Augtyro ( repotrectinib ) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer ( NSCLC ) . The pharma giant added the drug via a $4.1 billion buyout of Turning Point Therapeutics ...,BMY,0.401331,0.156825,Somewhat-Bullish
Could Bristol-Myers Squibb Stock Help You Retire A Millionaire?,https://www.fool.com/investing/2023/11/16/could-bristol-myers-squibb-stock-help-you-retire-a/,2023-11-16 10:59:00,"It isn't exactly a growth stock, but it has a few features that could make you richer.",BMY,0.25726,0.320393,Somewhat-Bullish
US FDA approves Bristol-Myers' lung cancer drug,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-bristol-myers-lung-cancer-drug-2023-11-15/,2023-11-15 22:43:00,"A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo/File Photo Acquire Licensing Rights Nov 15 ( Reuters ) - The U.S.",BMY,0.158519,0.0,Neutral
"PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors - PepGen  ( NASDAQ:PEPG ) ",https://www.benzinga.com/pressreleases/23/11/g35802158/pepgen-announces-appointment-of-howard-mayer-m-d-to-board-of-directors,2023-11-15 13:00:00,"BOSTON, Nov. 15, 2023 ( GLOBE NEWSWIRE ) -- PepGen Inc. PEPG, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Howard ...",BMY,0.052455,-0.060901,Neutral
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies,https://www.benzinga.com/pressreleases/23/11/g35800745/mural-oncology-launches-to-advance-pipeline-of-novel-engineered-cytokine-immunotherapies,2023-11-15 12:00:00,"Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company's lead product candidate - nemvaleukin alfa - being developed to treat a wide range of solid tumors - is currently in two potentially registrational ...",BMY,0.033515,0.020122,Neutral
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment,https://www.fool.com/investing/2023/11/14/bristol-myers-squibb-diverse-portfolio/,2023-11-14 15:01:49,The stock isn't nearly as risky as its low valuation suggests.,BMY,0.124809,-0.064323,Neutral
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - XBiotech  ( NASDAQ:XBIT ) ,https://www.benzinga.com/pressreleases/23/11/g35776284/dr-alan-kivitz-to-chair-xbiotechs-natrunix-program-in-rheumatoid-arthritis,2023-11-14 14:00:00,"AUSTIN, Texas, Nov. 14, 2023 ( GLOBE NEWSWIRE ) -- XBiotech XBIT today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for ...",BMY,0.039614,0.037048,Neutral
RHHBY: 3 Booming Pharma Stocks Making Waves in November,https://stocknews.com/news/rhhby-azn-bmy-3-booming-pharma-stocks-making-waves-in-november/,2023-11-13 17:18:41,"Due to rising medical requirements and technical improvements, the pharmaceutical industry's long-term growth prospects remain promising. Also, the growing global population and rising number of chronic diseases are adding to the industry's positive outlook.",BMY,0.10087,0.212812,Somewhat-Bullish
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update,https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-third-quarter-financial-results-and-provides-corporate-update-301985474.html,2023-11-13 13:01:00,"Presented positive Phase 1/2 clinical data for INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue Oncology Society ( ""CTOS"" ) , demonstrating 93% disease control rate in patients on monotherapy and survival extension of nearly 15 months vs. synthetic control group",BMY,0.025219,0.043587,Neutral
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments,https://www.globenewswire.com/news-release/2023/11/13/2778937/0/en/Abeona-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Corporate-Developments.html,2023-11-13 12:30:00,Abeona's first-ever U.S. Biologics License Application ( BLA ) submission completed in September ...,BMY,0.035035,0.10574,Neutral
Active Pharmaceutical Ingredients  ( API )  Market to Hit USD 331.3 billion by 2031 | Says Transparency Market Research Inc.,https://www.benzinga.com/pressreleases/23/11/g35742297/active-pharmaceutical-ingredients-api-market-to-hit-usd-331-3-billion-by-2031-says-transparency-ma,2023-11-13 07:24:41,"Wilmington, Delaware, United States, Nov. 13, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. -The global active pharmaceutical ingredients ( API ) market is projected to flourish at a CAGR of 6.4% from 2023 to 2031.",BMY,0.045054,-0.006946,Neutral
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?,https://www.fool.com/investing/2023/11/11/merck-and-bristol-myers-squibb-will-face-off-in-th/,2023-11-11 12:25:00,There's a lot more at stake than bragging rights.,BMY,0.275867,0.106749,Neutral
Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research,https://www.prnewswire.com/news-releases/oncology-drugs-market-worth-520-billion-by-2033---exclusive-report-by-we-market-research-301984776.html,2023-11-10 15:01:00,"CHICAGO, Nov. 10, 2023 /PRNewswire/ -- According to the latest findings from We Market Research, the oncology drug market is on track to achieve a value of USD 205 billion by the year 2023.",BMY,0.040622,0.059987,Neutral
Mirati's lung cancer drug gets EU's regulatory backing,https://www.reuters.com/business/healthcare-pharmaceuticals/miratis-lung-cancer-drug-gets-eus-regulatory-backing-2023-11-10/,2023-11-10 14:07:00,"The exterior of EMA, European Medicines Agency is seen in Amsterdam, Netherlands December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo Acquire Licensing Rights Nov 10 ( Reuters ) - Mirati Therapeutics ( MRTX.O ) said on Friday the European medicines regulator's panel has recommended ...",BMY,0.181137,0.055871,Neutral
Is Bristol Myers Squibb Stock Undervalued At $50?,https://www.forbes.com/sites/greatspeculations/2023/11/10/is-bristol-myers-squibb-stock-undervalued-at-50/,2023-11-10 13:00:00,"Bristol Myers Squibb ( NYSE: BMY ) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is undervalued, as discussed below.",BMY,0.644603,0.176956,Somewhat-Bullish
"As The Regulatory Landscape Shifts Globally, So, Too, Must The Pharma Commercial Model",https://www.forbes.com/sites/ritanumerof/2023/11/09/as-the-regulatory-landscape-shifts-globally-so-too-must-the-pharma-commercial-model/,2023-11-09 21:43:57,"In my previous column, I discussed how pharmaceutical and medical device companies are adapting their commercial model approaches in critical areas to address growing economic, market and other competitive pressures.",BMY,0.038592,-0.032661,Neutral
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/11/35708448/decoding-bristol-myers-squibbs-options-activity-whats-the-big-picture,2023-11-09 18:32:42,"Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb BMY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",BMY,0.664882,0.215535,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, GAN - GAN  ( NASDAQ:GAN ) , Mirati Therapeutics  ( NASDAQ:MRTX ) ",https://www.benzinga.com/pressreleases/23/11/g35699366/shareholder-investigation-halper-sadeh-llc-investigates-mrtx-gan,2023-11-09 13:44:32,"NEW YORK, Nov. 09, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mirati Therapeutics, Inc.",BMY,0.132368,0.129574,Neutral
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates,https://www.globenewswire.com/news-release/2023/11/09/2777199/0/en/Century-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html,2023-11-09 12:01:00,"- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics ...",BMY,0.024126,0.03453,Neutral
"Issy Perez Joins Boyden United States as Managing Partner, Dallas, and Global Practice Leader, Consumer & Retail",https://www.benzinga.com/pressreleases/23/11/g35694121/issy-perez-joins-boyden-united-states-as-managing-partner-dallas-and-global-practice-leader-consum,2023-11-09 10:00:00,"Dallas, Nov. 09, 2023 ( GLOBE NEWSWIRE ) -- Boyden, a premier global leadership and talent advisory firm, is delighted to welcome new Managing Partner Issy Perez, head of the Dallas office and leader of the firm's global consumer & retail practice, effective immediately.",BMY,0.069495,0.073519,Neutral
Overhaul Ranked #407 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™,https://www.prnewswire.com/news-releases/overhaul-ranked-407-fastest-growing-company-in-north-america-on-the-2023-deloitte-technology-fast-500-301981839.html,2023-11-08 15:24:00,"AUSTIN, Texas, Nov. 8, 2023 /PRNewswire/ -- today announced it ranked #407 on the ™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.",BMY,0.051441,0.036979,Neutral
"Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role - Illumina  ( NASDAQ:ILMN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/23/11/g35674541/global-precision-medicine-market-size-demonstrates-consistent-growth-with-a-cagr-of-11-12-with-nor,2023-11-08 14:50:00,"New York, United States, Nov. 08, 2023 ( GLOBE NEWSWIRE ) -- Precision medicine is a new approach to treating and preventing disease that considers each individual's genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal ...",BMY,0.156461,0.115839,Neutral
HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS,https://www.prnewswire.com/news-releases/harmony-biosciences-appoints-peter-anastasiou-to-its-board-of-directors-301980887.html,2023-11-08 13:05:00,"PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ( ""Harmony"" or the ""Company"" ) ( Nasdaq: HRMY ) , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the ...",BMY,0.092569,0.254854,Somewhat-Bullish
3 No-Brainer Stocks to Buy With $500 Right Now,https://www.fool.com/investing/2023/11/08/3-no-brainer-stocks-to-buy-with-500-right-now/,2023-11-08 10:21:00,A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts.,BMY,0.156664,-0.01107,Neutral
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/07/2775653/37704/en/CytomX-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,2023-11-07 21:15:00,- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1 dose escalation data anticipated in the first half of ...,BMY,0.089729,0.013733,Neutral
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/pressreleases/23/11/g35658764/cytomx-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-update,2023-11-07 21:15:00,- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 ( EpCAM-directed ADC ) comprehensive preclinical profile presented at 14th Annual World ADC Conference; IND filing on track for year-end -,BMY,0.104911,0.04202,Neutral
Scopus BioPharma's Subsidiary - Duet BioTherapeutics - Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer,https://www.globenewswire.com/news-release/2023/11/07/2775232/0/en/Scopus-BioPharma-s-Subsidiary-Duet-BioTherapeutics-Presents-Compelling-New-Data-for-a-Novel-Treatment-for-Malignant-Glioma-at-38th-Annual-Meeting-of-the-Society-for-Immunotherapy-o.html,2023-11-07 14:15:00,DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma ...,BMY,0.035661,0.062328,Neutral
"Arbutus Announces CEO, William Collier, to Retire December 31, 2023 - Arbutus Biopharma  ( NASDAQ:ABUS ) ",https://www.benzinga.com/pressreleases/23/11/g35640675/arbutus-announces-ceo-william-collier-to-retire-december-31-2023,2023-11-07 12:15:00,"WARMINSTER, Pa., Nov. 07, 2023 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS ( ""Arbutus"" or the ""Company"" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus ( cHBV ) infection, today ...",BMY,0.061473,-0.018,Neutral
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale,https://www.fool.com/investing/2023/11/24/dont-wait-for-a-market-crash-these-2-top-stocks-ar/,2023-11-24 10:30:00,Sometimes the stock market offers its own version of Black Friday deals.,BMY,0.284972,0.159484,Somewhat-Bullish
"Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates",https://www.zacks.com/stock/news/2188386/biotech-stock-roundup-bmy-tsvt-down-on-setback-trda-mor-offer-updates,2023-11-23 14:32:00,Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.,BMY,0.316846,0.112048,Neutral
"Pulmonary Drug Delivery Devices Market to Exceed Value of USD 49.5 Billion by 2031, TMR Study",https://www.benzinga.com/pressreleases/23/11/g35930486/pulmonary-drug-delivery-devices-market-to-exceed-value-of-usd-49-5-billion-by-2031-tmr-study,2023-11-23 13:30:00,"Wilmington, Delaware, United States, Nov. 23, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. -The global pulmonary drug delivery devices market is projected to flourish at a CAGR of 4.7% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 49.5 billion is ...",BMY,0.037329,0.069901,Neutral
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,2023-11-22 22:01:00,"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic ... PR ...",BMY,0.052656,0.017928,Neutral
Need a path to your dream profession? Rutgers Business School offers a roadmap to success,https://www.prnewswire.com/news-releases/need-a-path-to-your-dream-profession-rutgers-business-school-offers-a-roadmap-to-success-301995139.html,2023-11-22 14:15:00,"NEW BRUNSWICK, N.J., Nov. 22, 2023 /PRNewswire/ -- For Eric Yao, a high school student in Rockville, Maryland, Rutgers Business School offered proximity to New York City ( ""the capital of the world,"" as he put it ) , an extremely large alumni network and the opportunity to study at a tier-one ...",BMY,0.021013,0.135909,Neutral
"$1M Bet On Iridium Communications? Check Out These 3 Stocks Insiders Are Buying - Iridium Comms  ( NASDAQ:IRDM ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/11/35915699/1m-bet-on-iridium-communications-check-out-these-3-stocks-insiders-are-buying,2023-11-22 13:43:03,"Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.",BMY,0.41627,0.12856,Neutral
How Viz.ai Uses Artificial Intelligence To Treat Stroke Patients Faster,https://www.forbes.com/sites/amyfeldman/2023/11/22/how-vizai-uses-artificial-intelligence-to-speed-help-to-stroke-patients/,2023-11-22 11:30:00,"The startup has 12 FDA-approved algorithms to flag problems, agreements with more than 1,500 U.S. hospitals, and big plans to work with drug companies to reduce roadblocks in healthcare. October 26, while visiting New York City for a gala, Jess Allison collapsed on the street.",BMY,0.033918,0.127825,Neutral
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,2023-11-21 22:01:00,"Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, along with others, there are several emerging key players, that are expected to change the dynamics of the metastatic colorectal cancer market in the coming years owing to the positive outcomes of the ...",BMY,0.023102,-0.093525,Neutral
Looking Into Bristol-Myers Squibb's Recent Short Interest - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/23/11/35903927/looking-into-bristol-myers-squibbs-recent-short-interest,2023-11-21 19:15:23,"Bristol-Myers Squibb's BMY short percent of float has fallen 12.88% since its last report. The company recently reported that it has 23.40 million shares sold short, which is 1.15% of all regular shares that are available for trading.",BMY,0.221819,0.083071,Neutral
Bayer CEO says tougher cash outlook will be considered in overhaul,https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-ceo-says-tougher-cash-outlook-will-be-considered-overhaul-2023-11-21/,2023-11-21 15:27:00,"Logo and flags of Bayer AG are pictured outside a plant of the German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Rattay/File Photo Acquire Licensing Rights",BMY,0.128822,0.053579,Neutral
"Bristol Myers  ( BMY ) , TSVT Cell Therapy Abecma Faces Setback",https://www.zacks.com/stock/news/2187319/bristol-myers-bmy-tsvt-cell-therapy-abecma-faces-setback,2023-11-21 15:15:00,"Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.",BMY,0.697702,0.042265,Neutral
"Company News for Nov 21, 2023",https://www.zacks.com/stock/news/2187235/company-news-for-nov-21-2023,2023-11-21 14:30:00,Companies in The News Are: ...,BMY,0.742397,0.05718,Neutral
Purple Biotech Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/21/2783886/0/en/Purple-Biotech-Reports-Third-Quarter-2023-Financial-Results.html,2023-11-21 11:50:00,Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients' Enrollment in the Phase 2 Randomized CM24 Pancreatic Cancer Trial Ahead of Timelines Cash Runway Extended to 2H 2025 through Recent Financing ...,BMY,0.03387,0.039684,Neutral
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35878620/analyst-assess-implications-of-bristol-myers-investigational-blood-thinner-post-bay,2023-11-20 19:58:20,"Monday, Bayer AG BAYRY BAYZF stopped the OCEANIC-AF Phase 3 study early after asundexian showed inferiority to Bristol-Myers Squibb Company BMY and Pfizer Inc's PFE apixaban ( Eliquis ) .",BMY,0.468029,0.042977,Neutral
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details - Bayer  ( OTC:BAYRY ) ,https://www.benzinga.com/general/biotech/23/11/35878286/bayers-blood-thinner-study-stopped-early-due-to-lack-of-efficacy-details,2023-11-20 18:34:49,Bayer AG BAYRY BAYZF stopped the OCEANIC-AF Phase 3 study investigating asundexian compared to apixaban ( a direct oral anticoagulant ) in patients with atrial fibrillation at risk for stroke.,BMY,0.285526,0.0,Neutral
Why Bristol Myers Squibb Stock Is Fading Today,https://www.fool.com/investing/2023/11/20/why-bristol-myers-squibb-stock-is-fading-today/,2023-11-20 16:47:11,A high-profile clinical failure by a rival is weighing on the drugmaker's shares today.,BMY,0.299478,-0.143281,Neutral
Stock Market Holds On To Gains; Nvidia Stock Lifts As Earnings Loom,https://www.investors.com/market-trend/stock-market-today/stock-market-pulls-ahead-to-start-holiday-week-boeing-leads-the-dow/,2023-11-20 16:03:00,Stock Market Pulls Ahead To Start Holiday Week. Boeing Leads The ... Investor's Business Daily ...,BMY,0.09347,-0.072683,Neutral
"Why Is Pharma Giant Bristol-Myers Squibb  ( BMY )  Stock Trading Lower Today? - 2seventy bio  ( NASDAQ:TSVT ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/11/35873204/why-is-pharma-giant-bristol-myers-squibb-stock-trading-lower-today,2023-11-20 14:37:41,Shares of Bristol-Myers Squibb Company BMY and 2seventy Bio Inc TSVT fell after the companies' efforts to win expanded U.S. approval for its Abecma gene therapy hit a delay.,BMY,0.456884,0.310463,Somewhat-Bullish
"Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment",https://www.marketwatch.com/story/bristol-myers-squibb-2seventy-bio-shares-fall-as-fda-delays-action-on-cancer-treatment-468a8f7b,2023-11-20 13:35:00,"Shares of Bristol Myers Squibb, 2seventy bio fell early Monday as FDA said it would miss a regulatory action date on a cancer treatment ...",BMY,0.879272,0.097123,Neutral
US FDA delays decision on Bristol Myers-2seventy bio cancer therapy,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-delays-decision-bristol-myers-2seventy-bio-cancer-therapy-2023-11-20/,2023-11-20 12:27:29,"Nov 20 ( Reuters ) - The U.S. Food and Drug Administration ( FDA ) will not make a decision on Bristol Myers Squibb ( BMY.N ) and 2seventy bio's ( TSVT.O ) marketing application of their blood cancer therapy, Abecma, for earlier lines of treatment by Dec. 16.",BMY,0.570165,-0.343917,Somewhat-Bearish
"Researchers return to Alzheimer's vaccines, buoyed by recent drug success",https://www.reuters.com/business/healthcare-pharmaceuticals/researchers-return-alzheimers-vaccines-buoyed-by-recent-drug-success-2023-11-20/,2023-11-20 11:15:00,"A doctor points out evidence of Alzheimer's disease on PET scans at the Center for Alzheimer Research and Treatment ( CART ) at Brigham And Women's Hospital in Boston, Massachusetts, U.S., March 30, 2023. REUTERS/Brian Snyder/File photo Acquire Licensing Rights",BMY,0.041682,0.0,Neutral
Prothena  ( PRTA )  Pipeline Shows Promise in a Tough AD Market,https://www.zacks.com/stock/news/2186212/prothena-prta-pipeline-shows-promise-in-a-tough-ad-market,2023-11-17 18:35:00,"Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.",BMY,0.299478,0.067233,Neutral
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/11/35853992/looking-at-bristol-myers-squibbs-recent-unusual-options-activity,2023-11-17 18:15:47,"Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 10 unusual trades. Delving into the details, we found 70% of traders were bullish, while 30% showed bearish tendencies.",BMY,0.824067,0.212201,Somewhat-Bullish
"The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics",https://www.zacks.com/stock/news/2185763/the-zacks-analyst-blog-highlights-arcellx-bristol-myers-squibb-solid-biosciences-vertex-pharmaceuticals-and-crispr-therapeutics,2023-11-17 11:00:00,"Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.",BMY,0.148426,0.02062,Neutral
Best Penny Stocks To Buy? 4 To Watch With Big News This Week,https://pennystocks.com/featured/2023/12/06/best-penny-stocks-to-buy-4-to-watch-with-big-news-this-week/,2023-12-06 19:48:10,"Penny Stocks - How News Makes These Small Caps Soar or Plunge Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around ...",BMY,0.062434,-0.057007,Neutral
Bristol Myers'  ( BMY )  Opdivo sBLA Gets FDA's Priority Review,https://www.zacks.com/stock/news/2194178/bristol-myers-bmy-opdivo-sbla-gets-fdas-priority-review,2023-12-06 14:43:00,Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.,BMY,0.224072,-0.052691,Neutral
"2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains - Angi  ( NASDAQ:ANGI ) , Aptiv  ( NYSE:APTV ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36113326/2024s-potential-stock-surprises-goldman-sachs-unveils-s-p-500-laggards-for-major-ga,2023-12-06 14:26:56,"Investors are always on the lookout for untapped opportunities, especially in stocks that have been heavily discounted and now present promising opportunities for those prepared to wager on a recovery. As the new year looms, a seasoned strategy, known as the ""Laggards"" trade, is witnessing a ...",BMY,0.114409,0.0,Neutral
"Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... - PR Newswire",https://www.prnewswire.com/news-releases/fallopian-tube-cancer-therapeutics-market-size-to-grow-by-usd-832-01-million-from-2023-2028-abbvie-inc-amgen-inc-arrien-pharmaceuticals-llc-and-more-among-the-key-companies-in-the-market---technavio-302006567.html,2023-12-05 22:15:00,"Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... PR ...",BMY,0.057628,-0.003,Neutral
"UniCredit seeks new chair candidate by early 2024, sources say",https://www.reuters.com/business/finance/unicredit-seeks-new-chair-candidate-by-early-2024-sources-say-2023-12-05/,2023-12-05 19:10:00,"Unicredit bank logo is seen on a banner downtown Milan, Italy, May 23, 2016. REUTERS/Stefano Rellandini/File Photo Acquire Licensing Rights",BMY,0.079392,0.0,Neutral
3 Dirt-Cheap Stocks That Could Skyrocket,https://www.fool.com/investing/2023/12/05/3-dirt-cheap-stocks-that-could-skyrocket/,2023-12-05 16:23:49,"Low valuations don't always guarantee gains are in the offing. You need a company firing on all cylinders, too.",BMY,0.10087,-0.040749,Neutral
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors,https://www.newswire.ca/news-releases/dragonfly-therapeutics-initiates-phase-1-1b-study-of-its-il-2-immunotherapy-in-patients-with-advanced-solid-tumors-897149276.html,2023-12-05 15:00:00,"The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug to enter into clinical trials.",BMY,0.075635,0.180047,Somewhat-Bullish
"Hospital Infection Therapeutics Market to be Worth USD 14.4 billion by 2031| Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/23/12/g36087772/hospital-infection-therapeutics-market-to-be-worth-usd-14-4-billion-by-2031-transparency-market-re,2023-12-05 12:00:00,"Wilmington, Delaware, United States, Dec. 05, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global hospital infection therapeutics market was estimated to have acquired US$ 11.3 billion in 2022.",BMY,0.044551,0.0,Neutral
Blackstone explores sale of Anthos Therapeutics -sources,https://www.reuters.com/markets/deals/blackstone-explores-sale-anthos-therapeutics-sources-2023-12-04/,2023-12-04 19:26:00,Blackstone explores sale of Anthos Therapeutics ...,BMY,0.100308,0.111726,Neutral
"Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer",https://www.benzinga.com/pressreleases/23/12/g36067092/zenas-biopharma-strengthens-executive-leadership-with-appointment-of-jennifer-fox-as-chief-busines,2023-12-04 13:00:00,"WALTHAM, Mass., Dec. 04, 2023 ( GLOBE NEWSWIRE ) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology ( I&I ) directed therapies, today announced the appointment of Jennifer Fox as its Chief ...",BMY,0.052685,0.088631,Neutral
Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... - PR Newswire,https://www.prnewswire.com/news-releases/laryngeal-cancer-therapeutics-market-size-to-grow-by-usd-575-25-million-from-2022-2027-accord-healthcare-ltd-amgen-inc-astrazeneca-plc-athenex-inc-and-more-among-the-major-companies-in-the-market--technavio-302002789.html,2023-12-01 22:35:00,Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... PR ...,BMY,0.066414,-0.02104,Neutral
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium,https://www.prnewswire.com/news-releases/intensity-therapeutics-selected-for-spotlight-oral-presentation-at-the-2023-san-antonio-breast-cancer-symposium-302002672.html,2023-12-01 13:01:00,"WESTPORT, Conn., Dec. 1, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ( Nasdaq: INTS ) , a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system ...",BMY,0.058472,0.013108,Neutral
AbbVie  ( ABBV )  to Acquire ImmunoGen  ( IMGN )  for $10.1 Billion,https://www.zacks.com/stock/news/2191954/abbvie-abbv-to-acquire-immunogen-imgn-for-101-billion,2023-12-01 10:55:00,"AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.",BMY,0.138066,0.112347,Neutral
"The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie",https://www.zacks.com/stock/news/2191938/the-zacks-analyst-blog-highlights-avidity-bristol-myers-squibb-vertex-arcturus-and-biovie,2023-12-01 10:09:00,"Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.",BMY,0.238133,0.102868,Neutral
"Global Stem Cells Market to surge at a CAGR of 11.6%, targeting an estimated value of USD 31,950 Million by 2030 as per Straits Research",https://www.benzinga.com/pressreleases/23/11/g36025684/global-stem-cells-market-to-surge-at-a-cagr-of-11-6-targeting-an-estimated-value-of-usd-31-950-mil,2023-11-30 15:35:00,"New York, United States, Nov. 30, 2023 ( GLOBE NEWSWIRE ) -- Recent advancements in stem cell therapies and tissue engineering have the potential to attract interest in the treatment of a variety of ailments.",BMY,0.040348,0.071636,Neutral
"Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More",https://www.zacks.com/stock/news/2191567/biotech-stock-roundup-rna-up-on-bmy-deal-expansion-bivi-down-on-setback-more,2023-11-30 15:33:00,"Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.",BMY,0.2138,0.123296,Neutral
Biotech Stocks Facing FDA Decision In December 2023,https://markets.businessinsider.com/news/stocks/biotech-stocks-facing-fda-decision-in-december-2023-1032861195,2023-11-30 08:20:51,"( RTTNews ) - The month of November witnessed a couple of notable firsts, including the approval of the first treatment for congenital thrombotic thrombocytopenic purpura, the first chikungunya vaccine and the first treatment for progressing desmoid tumors.",BMY,0.115094,0.0,Neutral
"Company News for Nov 29, 2023",https://www.zacks.com/stock/news/2190824/company-news-for-nov-29-2023,2023-11-29 14:35:00,Companies in The News Are: ...,BMY,0.275867,0.0,Neutral
"Avidity  ( RNA )  Expands Collaboration With BMY, Shares Rise",https://www.zacks.com/stock/news/2190798/avidity-rna-expands-collaboration-with-bmy-shares-rise,2023-11-29 14:03:00,Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.,BMY,0.323078,0.338883,Somewhat-Bullish
"Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies - Johnson & Johnson  ( NYSE:JNJ ) , Novartis  ( NYSE:NVS ) ",https://www.benzinga.com/general/biotech/23/11/35996543/eyes-on-novartis-gilead-bristol-myers-as-fda-weighs-risks-vs-benefits-of-approved-car-t-cell-ther,2023-11-29 13:30:17,"Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.",BMY,0.183895,0.0,Neutral
"PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday - Clearway Energy  ( NYSE:CWEN ) , Carlyle Group  ( NASDAQ:CG ) ",https://www.benzinga.com/news/23/11/35979913/pdd-posts-upbeat-revenue-joins-avidity-biosciences-springworks-therapeutics-and-other-big-stocks-mov,2023-11-28 14:39:07,"U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday. Shares of PDD Holdings Inc. PDD shares jumped in Tuesday's session following third-quarter results.",BMY,0.143415,0.0,Neutral
"US Stocks Mixed; House Prices Rise In September - Citi Trends  ( NASDAQ:CTRN ) , ESGL Holdings  ( NASDAQ:ESGL ) ",https://www.benzinga.com/news/earnings/23/11/35979734/us-stocks-mixed-house-prices-rise-in-september,2023-11-28 14:33:13,"U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 10 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.04% to 35,345.85 while the NASDAQ fell 0.08% to 14,229.55. The S&P 500 also fell, dropping, 0.10% to 4,545.98.",BMY,0.083251,0.11765,Neutral
"Why Is RNA Therapeutics-Focused Avidity Biosciences  ( RNA )  Stock Trading Higher Today? - Avidity Biosciences  ( NASDAQ:RNA ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/11/35977661/why-is-rna-therapeutics-focused-avidity-biosciences-stock-trading-higher-today,2023-11-28 14:17:30,"Avidity Biosciences Inc RNA announced a global licensing and research collaboration with Bristol Myers Squibb & Co BMY focused on discovering, developing, and commercializing multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.",BMY,0.733479,0.203372,Somewhat-Bullish
Avidity's stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone payments,https://www.marketwatch.com/story/aviditys-stock-soars-on-news-of-expanded-collaboration-with-bristol-myers-that-includes-potential-to-receive-up-to-2-2-billion-in-milestone-payments-9ca2a762,2023-11-28 13:33:00,Avidity's stock soared 30.5% early Tuesday on news of an expanded collaboration with Bristol Myers.,BMY,0.651499,0.0,Neutral
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology,https://www.prnewswire.com/news-releases/avidity-biosciences-announces-expansion-of-cardiovascular-collaboration-with-bristol-myers-squibb-for-up-to-five-targets-utilizing-aviditys-proprietary-aoc-platform-technology-301998479.html,2023-11-28 11:30:00,Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five ... PR ...,BMY,0.349424,0.059739,Neutral
Bristol-Myers Squibb Unusual Options Activity - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/11/35967248/bristol-myers-squibb-unusual-options-activity,2023-11-27 20:15:59,"Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 12 trades. If we consider the specifics of each trade, it is accurate to state that 8% of the investors opened trades with ...",BMY,0.682689,0.082546,Neutral
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/23/12/36264236/a-closer-look-at-bristol-myers-squibbs-options-market-dynamics,2023-12-15 19:31:10,"Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 19 trades. If we consider the specifics of each trade, it is accurate to state that 15% of the investors opened trades with ...",BMY,0.718177,0.022975,Neutral
Is Bristol Myers Squibb Stock a Buy Now?,https://www.fool.com/investing/2023/12/15/is-bristol-myers-squibb-stock-a-buy-now/,2023-12-15 14:45:00,The answer might depend on the kind of investor you are.,BMY,0.159569,0.055177,Neutral
"Cancer Cachexia Market to Hit USD 3.6 billion by 2031, at a CAGR 4.7% | Says Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/23/12/g36255121/cancer-cachexia-market-to-hit-usd-3-6-billion-by-2031-at-a-cagr-4-7-says-transparency-market-resea,2023-12-15 12:30:00,"Wilmington, Delaware, United States, Dec. 15, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global cancer cachexia market was projected to attain US$ 2.2 billion in 2022. It is anticipated to garner a 4.7% CAGR from 2023 to 2031. By 2031, the market is likely to attain US$ ...",BMY,0.04076,0.0,Neutral
Bristol Myers Squibb  ( BMY )  Stock Slides as Market Rises: Facts to Know Before You Trade,https://www.zacks.com/stock/news/2198292/bristol-myers-squibb-bmy-stock-slides-as-market-rises-facts-to-know-before-you-trade,2023-12-14 22:45:18,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.47, marking a -0.75% move from the previous day.",BMY,0.579393,0.210432,Somewhat-Bullish
"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html,2023-12-14 22:15:00,"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... PR ...",BMY,0.078099,0.0,Neutral
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board,https://www.globenewswire.com/news-release/2023/12/14/2796170/0/en/Tourmaline-Bio-Appoints-Dr-Clay-Siegall-as-Chairman-of-the-Board.html,2023-12-14 12:30:00,"NEW YORK, Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( ""Tourmaline"" ) ( NASDAQ: TRML ) , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced ...",BMY,0.046095,-0.007981,Neutral
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board - Tourmaline Bio  ( NASDAQ:TRML ) ,https://www.benzinga.com/pressreleases/23/12/g36234063/tourmaline-bio-appoints-dr-clay-siegall-as-chairman-of-the-board,2023-12-14 12:30:00,"NEW YORK, Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Tourmaline Bio, Inc. ( ""Tourmaline"" ) TRML, a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay ...",BMY,0.045396,-0.007975,Neutral
Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb,https://www.prnewswire.com/news-releases/terray-therapeutics-announces-multi-target-collaboration-with-bristol-myers-squibb-302014285.html,2023-12-14 12:00:00,"Companies to leverage Terray's tNova drug discovery platform to identify small molecule therapeutics against targets of interest. The collaboration includes an upfront payment and performance-based milestone payments, as well as royalties on global net sales of products.",BMY,0.610572,0.475839,Bullish
Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/pressreleases/23/12/n36233380/terray-therapeutics-announces-multi-target-collaboration-with-bristol-myers-squibb,2023-12-14 12:00:00,"Companies to leverage Terray's tNova drug discovery platform to identify small molecule therapeutics against targets of interest. The collaboration includes an upfront payment and performance-based milestone payments, as well as royalties on global net sales of products.",BMY,0.593484,0.469833,Bullish
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial,https://www.globenewswire.com/news-release/2023/12/14/2796118/0/en/Purple-Biotech-Completes-Patient-Enrollment-in-Phase-2-Pancreatic-Cancer-Trial.html,2023-12-14 11:50:00,This acceleration of recruitment is expected to result in earlier look at overall survival of patients ...,BMY,0.065775,0.024217,Neutral
3 Penny Stocks Under $1 To Watch After December Fed Meeting,https://pennystocks.com/featured/2023/12/13/3-penny-stocks-under-1-to-watch-after-december-fed-meeting/,2023-12-13 22:30:39,"The wait is over for the results of the December 2023 FOMC Meeting and Fed press conference. If you had a Dovish Fed on your bingo card for this week, you might be ready to claim your prize. At the December Fed meeting, the central bank has caused a significant about-face in the outlook on rates ...",BMY,0.130453,0.075019,Neutral
Pfizer shares fall as 2024 revenue and profit forecast disappoints,https://www.cnbc.com/2023/12/13/pfizer-forecasts-2024-revenue-below-wall-street-expectations.html,2023-12-13 14:40:18,"After raking in billions from Covid products, Pfizer has struggled to navigate a world beyond the pandemic and reassure investors about its growth potential.",BMY,0.088472,-0.123286,Neutral
EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing,https://www.benzinga.com/pressreleases/23/12/g36213164/evolveimmune-therapeutics-provides-corporate-and-program-update-highlighted-by-closing-of-37-milli,2023-12-13 12:00:02,"Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control ( CMC ) Activities for Lead Multi-Functional T-cell Engager Program, EV-104, Following Presentation of Latest Preclinical ...",BMY,0.164656,0.051893,Neutral
Bristol to pay SystImmune up to $8.4 billion in cancer-drug deal,https://www.financialexpress.com/healthcare/news-healthcare/bristol-to-pay-systimmune-up-to-8-4-billion-in-cancer-drug-deal/3336763/,2023-12-13 03:30:00,"Bristol Myers Squibb Co. will pay SystImmune Inc. up to $8.4 billion for rights to co-develop and sell an experimental drug for lung and breast cancers, the latest in a string of large deals for a potent new class of oncology treatments.",BMY,0.163909,-0.048107,Neutral
"Head And Neck Cancer Diagnostics Market size to grow by USD 4.93 billion from 2022-2027 | AbbVie Inc., Accuray Inc ... - PR Newswire",https://www.prnewswire.com/news-releases/head-and-neck-cancer-diagnostics-market-size-to-grow-by-usd-4-93-billion-from-2022-2027--abbvie-inc-accuray-inc-addent-inc-and-more-among-the-key-companies-in-the-market---technavio-302013059.html,2023-12-12 18:30:00,"Head And Neck Cancer Diagnostics Market size to grow by USD 4.93 billion from 2022-2027 | AbbVie Inc., Accuray Inc ... PR ...",BMY,0.064797,-0.022024,Neutral
Bristol Myers  ( BMY )  Partners With SystImmune for Oncology Drug,https://www.zacks.com/stock/news/2196867/bristol-myers-bmy-partners-with-systimmune-for-oncology-drug,2023-12-12 16:04:00,Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.,BMY,0.357049,0.137178,Neutral
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36195740/bristol-myers-squibb-further-diversifies-oncology-portfolio-with-mega-8-4b-deal,2023-12-12 14:00:05,"SystImmune and Bristol Myers Squibb & Co BMY announced an exclusive license and collaboration agreement for SystImmune's BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate ( ADC ) .",BMY,0.478939,0.466145,Bullish
"Vanqua Bio Advances Clinical Candidate for Parkinson's Disease, Expands Leadership Team to Support Further Development",https://www.benzinga.com/pressreleases/23/12/g36194201/vanqua-bio-advances-clinical-candidate-for-parkinsons-disease-expands-leadership-team-to-support-f,2023-12-12 12:30:00,"CHICAGO, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase ( GCase ) , will enter clinical development in the first quarter of 2024, with an initial ...",BMY,0.047092,0.094795,Neutral
"Bristol Myers, SystImmune to collaborate for cancer drug development",https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-systimmune-collaborate-cancer-drug-development-2023-12-11/,2023-12-11 21:32:00,"Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights",BMY,0.846873,-0.15008,Somewhat-Bearish
Bristol Myers Squibb A Top Socially Responsible Dividend Stock With 4.8% Yield,https://www.forbes.com/sites/dividendchannel/2023/12/11/bristol-myers-squibb-a-top-socially-responsible-dividend-stock-with-48-yield/,2023-12-11 16:23:28,"Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.8% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, ...",BMY,0.757528,0.444906,Bullish
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks,https://www.fool.com/investing/2023/12/10/emerging-risk-problem-big-pharma-stocks/,2023-12-10 18:48:00,"Regulators are already on the case, and their findings will have financial impacts.",BMY,0.135094,0.057097,Neutral
Bristol Myers Squibb  ( BMY )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2195761/bristol-myers-squibb-bmy-gains-but-lags-market-what-you-should-know,2023-12-08 22:45:15,"Bristol Myers Squibb (BMY) closed at $50.31 in the latest trading session, marking a +0.3% move from the prior day.",BMY,0.535653,0.195985,Somewhat-Bullish
How a 75-year-old Indian-American tech entrepreneur is betting $1 billion of his own fortune on AI's future,https://www.cnbc.com/2023/12/08/75-year-old-tech-mogul-betting-1-billion-of-his-fortune-on-ai-future.html,2023-12-08 15:14:26,Romesh Wadhwani made a fortune in tech and now he is betting $1 billion of his money on three enterprise AI software technologies.,BMY,0.023673,0.02181,Neutral
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS,https://www.prnewswire.com/news-releases/intensity-therapeutics-presents-positive-int230-6-data-in-patients-with-early-stage-breast-cancer-in-a-podium-poster-spotlight-discussion-at-the-2023-sabcs-302010020.html,2023-12-08 13:30:00,Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster ... PR ...,BMY,0.021562,0.041877,Neutral
"Insiders Buying Bristol-Myers Squibb And 3 Other Stocks - DMC Glb  ( NASDAQ:BOOM ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/12/36151017/insiders-buying-bristol-myers-squibb-and-3-other-stocks,2023-12-08 12:04:58,"Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.",BMY,0.407844,-0.128433,Neutral
"Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights",https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html,2023-12-08 07:14:00,"BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.",BMY,0.028833,0.001897,Neutral
Investing in Space: Why Amazon bought rocket launches from rival SpaceX,https://www.cnbc.com/2023/12/07/investing-in-space-why-amazon-bought-rocket-launches-from-rival-spacex.html,2023-12-07 18:28:20,"Last week, Amazon was the crunch-time shopper and the dominant platform with speedy shipping was SpaceX.",BMY,0.030918,0.254042,Somewhat-Bullish
Why Bristol Myers Squibb's  ( BMY )  Shares Are Gaining Today - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/12/36136698/why-bristol-myers-squibbs-shares-are-gaining-today,2023-12-07 17:37:15,Bristol Myers Squibb & Co BMY released topline data from Phase 3 CheckMate -8HW trial of Opdivo ( nivolumab ) plus Yervoy ( ipilimumab ) compared to the investigator's choice of chemotherapy as a first-line treatment for microsatellite instability-high ( MSI-H ) or mismatch repair deficient ( ...,BMY,0.369685,-0.188478,Somewhat-Bearish
Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now,https://www.fool.com/investing/2023/12/07/looking-for-the-next-big-thing-add-this-ai-biotech/,2023-12-07 13:15:00,"Exscientia has the potential to be a star collaborator and a profitable drug developer, too.",BMY,0.05654,0.081,Neutral
Compass Pathways appoints Teri Loxam as Chief Financial Officer,https://investingnews.com/compass-pathways-appoints-teri-loxam-as-chief-financial-officer/,2023-12-07 12:43:37,"Compass Pathways plc ( Nasdaq: CMPS ) ( ""Compass"" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer ( CFO ) , effective the beginning of March 2024.",BMY,0.032513,0.118414,Neutral
"Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/12/36130073/pharma-industry-on-alert-as-biden-administration-explores-patent-seizure-powers,2023-12-07 12:33:14,The White House is endorsing a contentious power that permits the government to reclaim patents for specific high-cost medications.,BMY,0.235823,0.203533,Somewhat-Bullish
Compass Pathways appoints Teri Loxam as Chief Financial Officer - Compass Pathways  ( NASDAQ:CMPS ) ,https://www.benzinga.com/pressreleases/23/12/g36130382/compass-pathways-appoints-teri-loxam-as-chief-financial-officer,2023-12-07 12:00:00,"LONDON, Dec. 07, 2023 ( GLOBE NEWSWIRE ) -- Compass Pathways plc CMPS ( ""Compass"" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer ( CFO ) , effective ...",BMY,0.030759,0.117589,Neutral
"ALERT: Juan Monteverde Encourages the Shareholders of RYZB, GRCL, X, PGTI to Take Action",https://www.benzinga.com/pressreleases/23/12/g36392560/alert-juan-monteverde-encourages-the-shareholders-of-ryzb-grcl-x-pgti-to-take-action,2023-12-26 23:01:03,"NEW YORK, Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",BMY,0.065685,0.120703,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger - SUM, KRTX, DSKE, AYX",https://www.benzinga.com/pressreleases/23/12/g36392498/stockholder-alert-the-m-a-class-action-firm-is-investigating-the-merger-sum-krtx-dske-ayx,2023-12-26 22:49:47,"NEW YORK, Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",BMY,0.068306,0.127146,Neutral
"Yes Virginia, There Is a Santa Claus Rally",https://www.zacks.com/stock/news/2202365/yes-virginia-there-is-a-santa-claus-rally,2023-12-26 22:44:00,"The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.",BMY,0.176502,-0.07869,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRCL, RYZB, BRBS",https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-grcl-ryzb-brbs-302022425.html,2023-12-26 20:21:00,"NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to AstraZeneca.",BMY,0.139265,0.102096,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc.  ( Nasdaq - RYZB ) , Gracell Biotechnologies Inc.  ( Nasdaq - GRCL ) , Daseke, Inc.  ( Nasdaq - DSKE ) , Karuna Therapeutics, Inc.  ( Nasdaq - KRTX )  - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/23/12/g36389876/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-rayzebio-inc-,2023-12-26 19:43:38,"BALA CYNWYD, Pa., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BMY,0.422661,0.372368,Bullish
"Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher - AstraZeneca  ( NASDAQ:AZN ) , Gracell Biotechnologies  ( NASDAQ:GRCL ) ",https://www.benzinga.com/news/earnings/23/12/36389860/nasdaq-surges-75-points-inspira-technologies-shares-spike-higher,2023-12-26 19:43:36,"U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The S&P 500 also rose, gaining, 0.45% to 4,776.17. Energy shares jumped by 1.3% on Tuesday.",BMY,0.092569,0.250626,Somewhat-Bullish
"Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst - Karuna Therapeutics  ( NASDAQ:KRTX ) , Eli Lilly  ( NYSE:LLY ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/markets/equities/23/12/36388646/bristol-myers-acquisition-of-karuna-therapeutics-paves-way-for-aggressive-global-marketing-of-ka,2023-12-26 19:02:48,"H.C. Wainwright analyst Raghuram Selvaraju downgraded Karuna Therapeutics, Inc. KRTX to Neutral from Buy, raising the Price Target to $330 from $300. Bristol-Myers Squibb Company BMY agreed to acquire Karuna Therapeutics for $330.00 per share in cash, for a total equity value of $14.0 billion, or ...",BMY,0.258351,0.400572,Bullish
"In $4 billion deal, Bristol Myers Squibb to buy cancer therapeutics firm RayzeBio - .com",https://www.upi.com/Health_News/2023/12/26/bristol-myers-squibb-acquire-rayzebio-cancer-treatment/7371703614124/,2023-12-26 18:29:18,"In $4 billion deal, Bristol Myers Squibb to buy cancer therapeutics firm RayzeBio UPI News ...",BMY,0.252987,0.23878,Somewhat-Bullish
Karuna  ( KRTX )  Up 48% on $14B Buyout Offer From Bristol Myers,https://www.zacks.com/stock/news/2202260/karuna-krtx-up-48-on-14b-buyout-offer-from-bristol-myers,2023-12-26 16:20:00,Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.,BMY,0.144708,0.235477,Somewhat-Bullish
"Santa Claus Rally In Gear For Dow, Other Indexes; Tesla Eyes New Record To Wrap Up The Year",https://www.investors.com/market-trend/stock-market-today/dow-jones-gains-after-economic-data-tesla-eyes-new-record/,2023-12-26 16:06:00,Dow Jones Gains After Economic Data. Tesla Eyes New Record Investor's Business Daily ...,BMY,0.112269,0.191551,Somewhat-Bullish
BMY Stock: Bristol Myers Buying RayzeBio For $4.1 Billion; RYZB Soars,https://www.investors.com/news/technology/bmy-stock-bristol-strikes-4-1-billion-deal-for-rayzebio-ryzb-soars/,2023-12-26 15:47:00,BMY Stock: Bristol Myers Buying RayzeBio For $4.1 Billion. RYZB Soars Investor's Business Daily ...,BMY,0.560594,0.05135,Neutral
"Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio - RayzeBio  ( NASDAQ:RYZB ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/m-a/23/12/36385973/health-care-company-bristol-myers-squibb-announces-merger-with-rayzebio,2023-12-26 15:10:05,"Bristol-Myers Squibb BMY has announced a merger with RayzeBio RYZB that is expected to be completed 2024-H1. Under the terms of the agreement, Bristol-Myers Squibb has agreed to give RayzeBio $4.10 billion in cash in exchange for RYZB stock.",BMY,0.592095,0.139885,Neutral
Top 10 things to watch in the stock market Tuesday,https://www.cnbc.com/2023/12/26/top-10-things-to-watch-in-the-stock-market-tuesday.html,2023-12-26 14:30:51,Stocks edged higher to kick off last trading week of 2023.,BMY,0.073321,0.024313,Neutral
"RYZB News: Johnson Fistel Investigates Proposed Sale of RayzeBio; Is $62.50 a Fair Price? - RayzeBio  ( NASDAQ:RYZB ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/23/12/g36385225/ryzb-news-johnson-fistel-investigates-proposed-sale-of-rayzebio-is-62-50-a-fair-price,2023-12-26 14:23:23,"SAN DIEGO, Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of RayzeBio RYZB breached their fiduciary duties in connection with the proposed sale of the Company to Bristol Myers Squibb BMY.",BMY,0.399204,0.24729,Somewhat-Bullish
"Why RayzeBio  ( RYZB )  Stock Is Soaring Today - RayzeBio  ( NASDAQ:RYZB ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/12/36382899/bristol-myers-squibb-takes-on-novartis-eli-lilly-with-rayzebio-4b-deal-in-radiopharmaceuticals,2023-12-26 13:48:02,"Bristol Myers Squibb & Co BMY has agreed to acquire RayzeBio Inc RYZB for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. RayzeBio is a clinical-stage radiopharmaceutical therapeutics ( RPT ) focused on ...",BMY,0.558244,0.384657,Bullish
Bristol Myers to buy RayzeBio for about $4.1B,https://www.foxbusiness.com/healthcare/bristol-myers-to-buy-rayzebio-for-about-4-1-billion,2023-12-26 13:42:00,"Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second large deal struck by the drugmaker in less than a week.",BMY,0.172097,-0.169735,Somewhat-Bearish
"Company News for Dec 26, 2023",https://www.zacks.com/stock/news/2202100/company-news-for-dec-26-2023,2023-12-26 13:35:00,Companies In The Articles: ...,BMY,0.576289,0.22022,Somewhat-Bullish
5 Best Inverse/Leveraged ETFs of Last Week,https://www.zacks.com/stock/news/2202069/5-best-inverseleveraged-etfs-of-last-week,2023-12-26 13:00:00,"The optimism surrounding the likely Fed rate cuts in 2024 aided the rally in the market last week, barring some occasional dips.",BMY,0.063258,0.086378,Neutral
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion,https://www.barrons.com/amp/articles/bristol-myers-rayzebio-acquisition-358de5bf,2023-12-26 12:16:00,"Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. The acquisition price is more than a 100% premium over RayZeBio stock's closing price of $30.57 on Friday. In a press release on Tuesday, the companies said the total equity value of ...",BMY,0.18967,0.229959,Somewhat-Bullish
"Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio - RayzeBio  ( NASDAQ:RYZB ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/23/12/g36382591/bristol-myers-squibb-adds-premier-radiopharmaceutical-platform-with-acquisition-of-rayzebio,2023-12-26 12:13:25,"Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise",BMY,0.348788,0.19624,Somewhat-Bullish
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio,https://www.globenewswire.com/news-release/2023/12/26/2801050/0/en/Bristol-Myers-Squibb-Adds-Premier-Radiopharmaceutical-Platform-with-Acquisition-of-RayzeBio.html,2023-12-26 12:13:00,"Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise ...",BMY,0.35336,0.186159,Somewhat-Bullish
"RayzeBio, Gracell, NIO, Intel, Manchester United, Arm, FedEx, and More Stock Market Movers",https://www.barrons.com/amp/articles/stock-market-movers-cf8aacfa,2023-12-26 09:40:00,"Gracell, Ansys, NIO, Manchester United, and More Stock Market Movers ...",BMY,0.109455,0.269473,Somewhat-Bullish
"Recap 2023: From postpartum depression to Alzheimer's disease, here are some crucial USFDA approvals this year",https://www.financialexpress.com/healthcare/pharma-healthcare/recap-2023-from-postpartum-depression-to-alzheimers-disease-here-are-some-crucial-usfda-approvals-this-year/3347615/,2023-12-26 08:11:11,"The United States Food and Drug Administration ( FDA ) approves a wide range of innovative drugs and products that play a crucial role in improved patient outcomes. Based on the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new ...",BMY,0.080188,0.168534,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, AYX - Alteryx  ( NYSE:AYX ) , Daseke  ( NASDAQ:DSKE ) ",https://www.benzinga.com/pressreleases/23/12/g36379825/shareholder-investigation-halper-sadeh-llc-investigates-dske-krtx-ayx,2023-12-25 18:34:34,"NEW YORK, Dec. 25, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Daseke, Inc.",BMY,0.150592,0.0991,Neutral
"Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio",https://apnews.com/article/bristol-myers-squibb-acquires-karuna-therapeutics-bbd1c1e1b4c219fdb822c6755fc1dd79,2023-12-22 19:53:00,"NEW YORK ( AP ) - Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. Bristol Myers Squibb and Karuna announced their merger agreement on Friday.",BMY,0.466325,0.423227,Bullish
"Dow Edges Lower; Nike Sales Miss Estimates - AlloVir  ( NASDAQ:ALVR ) , Advent Technologies Hldgs  ( NASDAQ:ADN ) ",https://www.benzinga.com/news/earnings/23/12/36368931/dow-edges-lower-nike-sales-miss-estimates,2023-12-22 19:47:48,"U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also rose, gaining, 0.15% to 4,753.64. Consumer staples shares jumped by 0.9% on Friday.",BMY,0.100729,0.228022,Somewhat-Bullish
Stock Market Making Progress In Final Day Of The Week; Nike Worst In The Dow,https://www.investors.com/market-trend/stock-market-today/stock-market-making-progress-nike-worst-in-the-dow/,2023-12-22 18:53:00,Stock Market Making Progress In Final Day Of The Week. Nike Worst In The Dow Investor's Business Daily ...,BMY,0.192183,0.159013,Somewhat-Bullish
"HBM gets health boost from drug licensing deals - BeiGene  ( NASDAQ:BGNE ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/23/12/36367426/hbm-gets-health-boost-from-drug-licensing-deals,2023-12-22 18:11:47,"Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion HBM Holdings boosted its revenue by 48% in the first half of this year through licensing-out partnerships and ...",BMY,0.073209,0.005065,Neutral
Market In Merry Mood Heading Into Christmas: Weekly Review,https://www.investors.com/news/stock-market-rally-is-in-merry-mood-heading-into-christmas-weekend-weekly-review/,2023-12-22 17:30:00,"The stock market rally suffered a sharp sell-off Wednesday, but the major indexes were flat to slightly higher for the week. Micron Technology ( MU ) jumped on strong earnings and guidance, lifting key chip-gear makers and other semiconductor plays.",BMY,0.0428,0.15626,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX",https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-dske-krtx-thrx-302021835.html,2023-12-22 17:26:00,"NEW YORK, Dec. 22, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to TFI International Inc. for $8.30 in cash ...",BMY,0.179788,0.120006,Neutral
"Gold Moves Higher; US Consumer Sentiment Improves In December - AlloVir  ( NASDAQ:ALVR ) , Advent Technologies Hldgs  ( NASDAQ:ADN ) ",https://www.benzinga.com/news/earnings/23/12/36366443/gold-moves-higher-us-consumer-sentiment-improves-in-december,2023-12-22 17:18:33,"U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500 also rose, gaining, 0.28% to 4,759.82. Utilities shares jumped by 0.9% on Friday.",BMY,0.114409,0.237845,Somewhat-Bullish
Why Is Bristol Myers Squibb Stock Trading Higher Today? - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36365959/with-karuna-therapeutics-14b-deal-bristol-myers-is-serious-for-re-establishing-its-,2023-12-22 17:07:59,"Earlier Friday, Bristol Myers Squibb & Co BMY agreed to acquire Karuna Therapeutics Inc KRTX for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.",BMY,0.390904,0.437903,Bullish
"Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday - Allogene Therapeutics  ( NASDAQ:ALLO ) , Altair Engineering  ( NASDAQ:ALTR ) ",https://www.benzinga.com/news/23/12/36365167/karuna-therapeutics-jumps-following-takeover-by-bristol-myers-joins-rocket-lab-usa-altair-engineerin,2023-12-22 16:20:07,"U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. KRTX rose sharply during Friday's session following acquisition news.",BMY,0.327366,0.399429,Bullish
Bristol Myers  ( BMY )  to Buy Karuna Therapeutics for $14B,https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b,2023-12-22 16:13:00,"Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.",BMY,0.196344,0.208624,Somewhat-Bullish
"Biotech stocks set for a rebound in 2024, analysts say",https://www.marketwatch.com/story/biotech-stocks-set-for-a-rebound-in-2024-analysts-say-24df6236,2023-12-22 16:06:00,"A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.",BMY,0.089129,0.0,Neutral
"Health Care Company Bristol-Myers Squibb Announces Merger With Karuna Therapeutics - Karuna Therapeutics  ( NASDAQ:KRTX ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/m-a/23/12/36363253/health-care-company-bristol-myers-squibb-announces-merger-with-karuna-therapeutics,2023-12-22 15:10:05,"Bristol-Myers Squibb BMY has announced a merger with Karuna Therapeutics KRTX that is expected to be completed 2024-H1. Under the terms of the agreement, Bristol-Myers Squibb has agreed to give Karuna Therapeutics $14.00 billion in cash in exchange for KRTX stock.",BMY,0.532941,0.132017,Neutral
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal,https://www.cnbc.com/2023/12/22/bristol-myers-squibb-to-buy-karuna-therapeutics.html,2023-12-22 14:58:38,Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.,BMY,0.367865,0.471386,Bullish
"Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November - AlloVir  ( NASDAQ:ALVR ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/earnings/23/12/36362517/dow-rises-50-points-feds-preferred-inflation-gauge-cools-in-november,2023-12-22 14:40:18,"U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose 0.30% to 15,008.08. The S&P 500 also rose, gaining, 0.31% to 4,761.25.",BMY,0.114137,0.237631,Somewhat-Bullish
Karuna Therapeutics' stock hits record territory after Bristol Myers' $14 billion buyout deal,https://www.marketwatch.com/story/karuna-therapeutics-stock-rockets-into-record-territory-after-report-bristol-myers-14-billion-buyout-agreement-a64768b1,2023-12-22 14:20:00,"Karuna Therapeutics stock jumped 48% into record territory early Friday, after the biopharmaceutical company announced a $14 billion agreement to be bought by Bristol Myers Squibb.",BMY,0.179788,0.308697,Somewhat-Bullish
"Why Schizophrenia Player Karuna Therapeutics'  ( KRTX )  Stock Is Soaring Today - Karuna Therapeutics  ( NASDAQ:KRTX ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/12/36360205/bristol-myers-squibb-scoops-up-schizophrenia-player-karuna-therapeutics-in-massive-14b-deal,2023-12-22 14:19:55,"On Friday, Bristol Myers Squibb & Co BMY agreed to acquire Karuna Therapeutics Inc KRTX for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. Karuna is focused on developing treatments for psychiatric and neurological conditions.",BMY,0.622414,0.326207,Somewhat-Bullish
Bristol Myers Nabs Karuna For $14 Billion And Shares Catapult,https://www.investors.com/news/technology/krtx-stock-catapults-on-bristol-myers-takeover/,2023-12-22 14:06:00,KRTX Stock Soars On Bristol Myers' $14 Billion Takeover Investor's Business Daily ...,BMY,0.463792,0.0,Neutral
Bristol Myers to buy Karuna Therapeutics for $14B,https://www.foxbusiness.com/markets/bristol-myers-buy-karuna-therapeutics-14-billion,2023-12-22 13:35:00,"Under the terms, Bristol would pay $330 a share in cash for Karuna and its experimental schizophrenia drug now up for U.S. government approval. Bristol expects the deal, which includes $1.3 billion in cash that Karuna has on hand, would close in the first half of next year.",BMY,0.064104,0.0,Neutral
Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal,https://www.barrons.com/articles/bristol-myers-karuna-therapeutics-stock-595ddf2d,2023-12-22 12:05:00,Karuna Stock Surges. Bristol Myers Buying Drug Developer for $14 Billion: Report ...,BMY,0.371523,0.07329,Neutral
Bristol Myers Squibb  ( BMY )  Rises But Trails Market: What Investors Should Know,https://www.zacks.com/stock/news/2201259/bristol-myers-squibb-bmy-rises-but-trails-market-what-investors-should-know,2023-12-21 22:45:18,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.26, marking a +0.59% move from the previous day.",BMY,0.516073,0.322934,Somewhat-Bullish
These unsung stock market heroes offer 9 favorite picks for 2024,https://www.marketwatch.com/story/these-unsung-stock-market-heroes-offer-9-favorite-picks-for-2024-7eea2a49,2023-12-21 20:56:00,3 top newsletters: 'Magnificent Seven' take a pause. dividend-rich value and energy stocks take the lead.,BMY,0.118647,-0.039767,Neutral
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/21/2799945/37704/en/CytomX-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2023-12-21 13:00:00,"SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the ...",BMY,0.201523,-0.037842,Neutral
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/pressreleases/23/12/g36341721/cytomx-therapeutics-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference,2023-12-21 13:00:00,"SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 42nd Annual ...",BMY,0.186738,-0.0341,Neutral
"The Zacks Analyst Blog Highlights Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar",https://www.zacks.com/stock/news/2200841/the-zacks-analyst-blog-highlights-microsoft-booking-holdings-bristol-myers-squibb-equifax-hand-first-solar,2023-12-21 09:49:00,"Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar are included in this Analyst Blog.",BMY,0.2872,0.058947,Neutral
"Top Stock Reports for Microsoft, Booking Holdings & Bristol-Myers Squibb",https://www.zacks.com/research-daily/2200541/top-stock-reports-for-microsoft-booking-holdings-bristol-myers-squibb,2023-12-20 22:26:00,"Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Booking Holdings Inc. (BKNG) and Bristol-Myers Squibb Company (BMY).",BMY,0.102888,0.021063,Neutral
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - Eterna Therapeutics  ( NASDAQ:ERNA ) ,https://www.benzinga.com/pressreleases/23/12/g36334084/eterna-therapeutics-names-sanjeev-luther-as-president-and-chief-executive-officer,2023-12-20 21:15:31,"CAMBRIDGE, Mass., Dec. 20, 2023 ( GLOBE NEWSWIRE ) -- Eterna Therapeutics Inc.",BMY,0.08183,0.097898,Neutral
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer,https://www.globenewswire.com/news-release/2023/12/20/2799652/0/en/Eterna-Therapeutics-Names-Sanjeev-Luther-as-President-and-Chief-Executive-Officer.html,2023-12-20 21:15:00,"CAMBRIDGE, Mass., Dec. 20, 2023 ( GLOBE NEWSWIRE ) -- Eterna Therapeutics Inc. ( Nasdaq: ERNA ) ( ""Eterna"" or the ""Company"" ) , a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev ...",BMY,0.046816,0.094742,Neutral
BioMarin Announces Governance Enhancements and Value Creation Initiatives,https://www.prnewswire.com/news-releases/biomarin-announces-governance-enhancements-and-value-creation-initiatives-302020453.html,2023-12-20 21:05:00,Board Approves Appointment of Three New Independent Directors Company Establishes Strategic and Operating Review Committee of the Board BioMarin Enters into Cooperation and Information Sharing Agreements with Elliott,BMY,0.04907,0.051752,Neutral
5 Stocks to Watch on Their Recent Dividend Hike,https://www.zacks.com/stock/news/2200448/5-stocks-to-watch-on-their-recent-dividend-hike,2023-12-20 13:31:00,"Five stocks that have recently raised dividends are: BMY, PWR, CARR, AVGO, OC.",BMY,0.248924,0.109945,Neutral
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors,https://www.globenewswire.com/news-release/2023/12/20/2799235/0/en/Purple-Biotech-Appoints-Dr-Yael-Margolin-to-its-Board-of-Directors.html,2023-12-20 13:05:00,"Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital ...",BMY,0.028456,0.026783,Neutral
"Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors - Gamida Cell  ( NASDAQ:GMDA ) , POINT Biopharma Global  ( NASDAQ:PNT ) ",https://www.benzinga.com/pressreleases/23/12/g36323058/purple-biotech-appoints-dr-yael-margolin-to-its-board-of-directors,2023-12-20 13:05:00,"Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer",BMY,0.028023,0.025749,Neutral
"Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma",https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html,2023-12-20 12:00:01,"Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.",BMY,0.053992,-0.015961,Neutral
Better Dividend Stock: Bristol Myers Squibb or Merck?,https://www.fool.com/investing/2023/12/19/better-dividend-stock-bristol-myers-squibb-or-merc/,2023-12-19 14:00:00,These two pharma stocks have sizable dividend yields. Which is the better buy right now?,BMY,0.132004,0.189846,Somewhat-Bullish
Appointment of Chief Business Officer,https://www.globenewswire.com/news-release/2023/12/19/2798406/0/en/Appointment-of-Chief-Business-Officer.html,2023-12-19 12:00:00,19 December ...,BMY,0.05654,0.067917,Neutral
"Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care - Canada NewsWire",https://www.newswire.ca/news-releases/burjeel-holdings-oncology-conference-marks-10-years-focusing-on-equitable-solutions-for-cancer-care-848851777.html,2023-12-19 11:30:00,"Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care Canada ...",BMY,0.061159,0.141798,Neutral
Bristol Myers  ( BMY )  Stops Late-Stage Colorectal Cancer Study,https://www.zacks.com/stock/news/2199510/bristol-myers-bmy-stops-late-stage-colorectal-cancer-study,2023-12-18 16:40:00,Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.,BMY,0.262805,-0.135379,Neutral
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?,https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/,2023-12-18 14:15:00,2024 is going to be a sizzler in the biopharma sector.,BMY,0.049424,0.043511,Neutral
Looking Into Bristol-Myers Squibb's Recent Short Interest - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/short-sellers/24/01/36508910/looking-into-bristol-myers-squibbs-recent-short-interest,2024-01-05 13:30:22,"Bristol-Myers Squibb's BMY short percent of float has fallen 11.19% since its last report. The company recently reported that it has 24.10 million shares sold short, which is 1.19% of all regular shares that are available for trading.",BMY,0.221819,0.083071,Neutral
"GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer - PR Newswire",https://www.prnewswire.com/news-releases/glycoera-ag-announces-new-investor-appoints-industry-veteran-greg-fralish-as-chief-business-officer-302027158.html,2024-01-05 13:00:00,"GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer PR ...",BMY,0.077593,0.018317,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICVX, RYZB, CVLY, KRTX - Icosavax  ( NASDAQ:ICVX ) , Codorus Valley Bancorp  ( NASDAQ:CVLY ) ",https://www.benzinga.com/pressreleases/24/01/g36507799/shareholder-investigation-halper-sadeh-llc-investigates-icvx-ryzb-cvly-krtx,2024-01-05 12:27:46,"NEW YORK, Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Icosavax, Inc.",BMY,0.233556,0.136118,Neutral
Cancer Antibodies Combination Therapies Clinical Research Market Size Insight,https://www.benzinga.com/pressreleases/24/01/g36507666/cancer-antibodies-combination-therapies-clinical-research-market-size-insight,2024-01-05 12:09:51,"Delhi, Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Global Cancer Antibody Combinations Market Opportunity & Clinical Trials Insight 2028 Report Findings & Highlights: Global Cancer Antibody Combinations Market Opportunity: > USD 40 Billion By 2028",BMY,0.042048,0.061243,Neutral
"Oral Transmucosal Drug Market to Hit USD 27 billion by 2031, at a CAGR 6%| Says Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/01/g36506871/oral-transmucosal-drug-market-to-hit-usd-27-billion-by-2031-at-a-cagr-6-says-transparency-market-r,2024-01-05 11:30:00,"Wilmington, Delaware, United States, Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global oral transmucosal drug market is estimated to flourish at a CAGR of 6% from 2021 to 2031.",BMY,0.034136,0.058626,Neutral
Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer,https://www.globenewswire.com/news-release/2024/01/05/2804475/0/en/Sosei-Group-Announces-Appointment-of-Experienced-Pharmaceutical-Executive-Toshihiro-Maeda-as-Chief-Operating-Officer.html,2024-01-05 08:00:00,"Tokyo, Japan and Cambridge, UK, 5 January 2024 - Sosei Group Corporation ( ""Sosei Heptares"" or ""the Company"". TSE: 4565 ) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer ( ""COO"" ) . Mr. Maeda joins from Bristol Myers Squibb ( ""BMS"" ) , where he led a Business ...",BMY,0.051774,0.065596,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - ICVX, PGTI, KRTX, CSTR",https://www.benzinga.com/pressreleases/24/01/g36503737/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-icvx-pgti-krtx-cstr,2024-01-05 01:00:00,"NEW YORK, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",BMY,0.067536,0.12703,Neutral
"SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of GRCL, RYZB, CVLY, WAVD to Take Action",https://www.benzinga.com/pressreleases/24/01/g36503736/shareholder-alert-juan-monteverde-encourages-the-shareholders-of-grcl-ryzb-cvly-wavd-to-take-actio,2024-01-05 01:00:00,"NEW YORK, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",BMY,0.065327,0.120661,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc.  ( Nasdaq - RYZB ) , Gracell Biotechnologies Inc.  ( Nasdaq - GRCL ) , Daseke, Inc.  ( Nasdaq - DSKE ) , Karuna Therapeutics, Inc.  ( Nasdaq - KRTX )  - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/24/01/g36493511/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-rayzebio-inc-,2024-01-04 16:05:08,"BALA CYNWYD, Pa., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BMY,0.422661,0.372368,Bullish
"Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More",https://www.zacks.com/stock/news/2205605/biotech-stock-roundup-vygr-gains-from-nvs-deal-agio-up-on-study-data-more,2024-01-04 14:05:00,Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.,BMY,0.135094,0.063145,Neutral
Ashvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical Operations,https://www.benzinga.com/pressreleases/24/01/g36488973/ashvattha-therapeutics-announces-the-appointment-of-mehdi-paborji-as-senior-vice-president-of-tech,2024-01-04 13:30:00,"REDWOOD CITY, Calif., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Ashvattha Therapeutics ( ""Ashvattha"" ) , a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the ...",BMY,0.08183,0.036992,Neutral
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/pressreleases/24/01/g36488030/cytomx-therapeutics-outlines-2024-company-priorities-and-milestones,2024-01-04 13:00:00,- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND application filed for conditionally activated EpCAM-directed ADC ( CX-2051 ) with Phase 1 initiation in EpCAM positive tumors expected in the 1st half of 2024 -,BMY,0.180325,0.070017,Neutral
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones,https://www.globenewswire.com/news-release/2024/01/04/2803919/37704/en/CytomX-Therapeutics-Outlines-2024-Company-Priorities-and-Milestones.html,2024-01-04 13:00:00,- CX-904 ( EGFRxCD3 T-cell engager ) initial Phase 1a dose escalation data anticipated in the 2nd half of ...,BMY,0.166679,0.060408,Neutral
Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.,https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets,2024-01-04 12:30:00,"Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.",BMY,0.079392,0.0,Neutral
"""2023 DEI Employer® Awards"" Winners and the List of ""2023 Top 50 DEI Employer®"" Officially Announced in China",https://www.prnewswire.com/news-releases/2023-dei-employer-awards-winners-and-the-list-of-2023-top-50-dei-employer-officially-announced-in-china-302026117.html,2024-01-04 09:00:00,"SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- The winners of the ""2023 DEI Employer® Awards ( China ) "" hosted by the Employer Branding Institute, a leading employer brand communication organization, are grandly announced.",BMY,0.063763,0.277686,Somewhat-Bullish
Bristol Myers Squibb  ( BMY )  Dips More Than Broader Market: What You Should Know,https://www.zacks.com/stock/news/2205304/bristol-myers-squibb-bmy-dips-more-than-broader-market-what-you-should-know,2024-01-03 22:50:17,"Bristol Myers Squibb (BMY) concluded the recent trading session at $52.30, signifying a -0.87% move from its prior day's close.",BMY,0.573651,0.099364,Neutral
Bristol Myers  ( BMY )  NSCLC Drug Application Gets EMA Validation,https://www.zacks.com/stock/news/2205247/bristol-myers-bmy-nsclc-drug-application-gets-ema-validation,2024-01-03 19:05:00,Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.,BMY,0.294977,0.100323,Neutral
"This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36473452/this-analyst-downgrades-bristol-myers-squibb-cautions-amid-product-launch-and-reven,2024-01-03 17:29:30,"BofA Securities downgraded Bristol-Myers Squibb & Co BMY, noting that initially, the analyst believed that Bristol's loss of exclusivity ( LOEs ) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate for these losses and boost ...",BMY,0.56415,0.197908,Somewhat-Bullish
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program,https://www.prnewswire.com/news-releases/intensity-therapeutics-provides-business-update-reflecting-progress-in-phase-3-sarcoma-program-302024890.html,2024-01-03 13:01:00,"FDA provides ""Study May Proceed"" letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024",BMY,0.024982,-0.025049,Neutral
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones,https://www.globenewswire.com/news-release/2024/01/03/2803199/0/en/SELLAS-Provides-Corporate-Updates-and-Highlights-Key-Upcoming-Milestones.html,2024-01-03 12:30:00,"- Company to Host Corporate Update Webinar Today, January 3, 2024, at 8:30 am ...",BMY,0.021857,0.013314,Neutral
2 Biotechs That Could Get Bought Out in 2024,https://www.fool.com/investing/2024/01/03/2-biotechs-that-could-get-bought-out-in-2024/,2024-01-03 11:45:00,These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason.,BMY,0.059785,-0.076575,Neutral
Moderna's stock soars after Oppenheimer upgrades to buy,https://www.marketwatch.com/story/modernas-stock-soars-10-to-lead-s-p-500-gainers-as-oppenheimer-upgrades-to-buy-f822bb42,2024-01-02 15:46:00,Moderna's stock started the year with a bang thanks to an analyst upgrade.,BMY,0.191929,0.118352,Neutral
"Head and Neck Cancer Market Size & Share to Surpass USD 2.9 billion by 2031 | Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/01/g36450984/head-and-neck-cancer-market-size-share-to-surpass-usd-2-9-billion-by-2031-transparency-market-rese,2024-01-02 14:00:00,"Wilmington, Delaware, United States, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - Head and neck cancer market was valued at US$ 1.6 billion in 2022. A CAGR of 6.8% is predicted from 2023 to 2031. Head and neck cancer market is expected to reach US$ 2.9 billion by the ...",BMY,0.0428,0.0,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, GRCL, RYZB, BRBS - Daseke  ( NASDAQ:DSKE ) , Blue Ridge Bankshares  ( AMEX:BRBS ) ",https://www.benzinga.com/pressreleases/24/01/g36443676/shareholder-investigation-halper-sadeh-llc-investigates-dske-grcl-ryzb-brbs,2024-01-01 14:21:35,"NEW YORK, Jan. 01, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Daseke, Inc.",BMY,0.113062,0.08615,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGTI, AYX, KRTX, THRX - Alteryx  ( NYSE:AYX ) , Karuna Therapeutics  ( NASDAQ:KRTX ) ",https://www.benzinga.com/pressreleases/24/01/g36443675/shareholder-investigation-halper-sadeh-llc-investigates-pgti-ayx-krtx-thrx,2024-01-01 14:21:26,"NEW YORK, Jan. 01, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc.",BMY,0.124809,0.089734,Neutral
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/23/12/36429626/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet,2023-12-29 16:04:56,"Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks.",BMY,0.111747,0.0,Neutral
Stock Market Ending 2023 On High Note: Weekly Review,https://www.investors.com/news/stock-market-ending-2023-on-high-note-tesla-drug-ma-in-focus-weekly-review/,2023-12-29 12:33:00,"Stock Market Ending 2023 On High Note. Tesla, Drug M&A In Focus: Weekly Review Investor's Business Daily ...",BMY,0.337197,0.007167,Neutral
"Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/12/36394374/upward-trajectory-for-biotechpharma-m-a-sector-trends-towards-pre-pandemic-levels-forecasts-posit,2023-12-29 12:04:52,"According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023. PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: ...",BMY,0.459624,0.611513,Bullish
Bristol Myers Squibb  ( BMY )  Rises Yet Lags Behind Market: Some Facts Worth Knowing,https://www.zacks.com/stock/news/2203369/bristol-myers-squibb-bmy-rises-yet-lags-behind-market-some-facts-worth-knowing,2023-12-28 22:50:19,"The latest trading day saw Bristol Myers Squibb (BMY) settling at $51.22, representing a +0.02% change from its previous close.",BMY,0.574748,0.189567,Somewhat-Bullish
Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch - Cytokinetics  ( NASDAQ:CYTK ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot,2023-12-28 17:19:46,"On Wednesday, Cytokinetics Incorporated CYTK released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy ( HCM ) .",BMY,0.262522,-0.07009,Neutral
"Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024 - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/12/36410940/pharmaceutical-giants-brace-for-showdown-as-medicare-drug-price-negotiations-are-poised-for-2024,2023-12-28 14:21:24,"2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. The forthcoming year will provide the first glimpse into how much Medicare can leverage its newfound power to negotiate down drug prices.",BMY,0.239305,0.028897,Neutral
Why Is Blood Purification Focused CytoSorbents  ( CTSO )  Trading Lower Today? - CytoSorbents  ( NASDAQ:CTSO ) ,https://www.benzinga.com/markets/equities/23/12/36410011/why-is-blood-purification-focused-cytosorbents-trading-lower-today,2023-12-28 14:01:41,CytoSorbents Corporation CTSO released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the pivotal U.S. and Canadian STAR-T trial.,BMY,0.221819,0.139011,Neutral
Biden administration's Medicare drug price negotiations will face major tests in 2024,https://www.cnbc.com/2023/12/28/medicare-drug-price-negotiations-whats-ahead-in-2024.html,2023-12-28 12:00:01,"Next year could set the precedent for the Inflation Reduction Act's controversial talks, which could affect dozens of medications by the end of the decade.",BMY,0.1172,-0.026135,Neutral
Wall Street ekes out modest gains as S&P 500 hovers near all-time closing high,https://www.moneycontrol.com/news/business/markets/wall-street-ekes-out-modest-gains-as-sp-500-hovers-near-all-time-closing-high-11964991.html,2023-12-28 00:30:38,"The three major U.S. stock indexes oscillated between modest gains and losses throughout the session but finished up for the day. All are on course for monthly, quarterly, and annual gains.",BMY,0.072217,0.069147,Neutral
"Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned - Fusion Pharmaceuticals  ( NASDAQ:FUSN ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36400490/recent-m-a-bodes-well-for-targeted-cancer-therapy-player-fusion-pharmaceuticals-ana,2023-12-27 17:42:14,"With recent merger and acquisition deals in the targeted radiopharmaceutical therapy ( TRT ) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc FUSN is potentially the sole remaining clinical-stage player with a robust supply chain.",BMY,0.280615,0.354095,Bullish
Bristol Myers  ( BMY )  to Buy Cancer Drug-Maker RayzeBio for $4.1B,https://www.zacks.com/stock/news/2202691/bristol-myers-bmy-to-buy-cancer-drug-maker-rayzebio-for-41b,2023-12-27 15:35:00,Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.,BMY,0.207571,0.207277,Somewhat-Bullish
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - NWLI, ROVR, RYZB",https://markets.businessinsider.com/news/stocks/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger---nwli-rovr-ryzb-1032928360,2023-12-27 15:15:00,STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger ...,BMY,0.082677,0.132948,Neutral
THE SKIN OF COLOR SOCIETY  ( SOCS )  REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR,https://markets.businessinsider.com/news/stocks/the-skin-of-color-society-socs-reports-a-banner-year-of-progress-toward-greater-diversity-inclusion-in-dermatology-and-health-equity-for-patients-of-color-1032928334,2023-12-27 15:10:00,THE SKIN OF COLOR SOCIETY (SOCS) REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR ...,BMY,0.078269,0.264914,Somewhat-Bullish
"Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Aspen Aerogels  ( NYSE:ASPN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/23/12/36397132/meta-to-rally-over-18-here-are-10-top-analyst-forecasts-for-wednesday,2023-12-27 14:06:31,"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Raymond James raised Fusion Pharmaceuticals Inc. FUSN price target from $12 to $15.",BMY,0.251247,-0.142577,Neutral
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma,https://www.globenewswire.com/news-release/2023/12/27/2801365/0/en/SELLAS-Life-Sciences-Reports-Positive-Follow-Up-Immune-Response-and-Survival-Data-in-Completed-Phase-1-Study-of-Galinpepimut-S-Combined-with-Opdivo-in-Advanced-Malignant-Pleural-Me.html,2023-12-27 13:55:00,- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed ...,BMY,0.029327,-0.055232,Neutral
"Company News for Dec 27, 2023",https://www.zacks.com/stock/news/2202486/company-news-for-dec-27-2023,2023-12-27 13:07:00,Companies In The Article Are: ...,BMY,0.644033,0.411137,Bullish
5 Best ETF Areas of Last Week,https://www.zacks.com/stock/news/2202477/5-best-etf-areas-of-last-week,2023-12-27 13:00:00,"Wall Street was upbeat last week.The optimism surrounding the likely Fed rate cuts in 2024 aided the rally in the market, barring some occasional dips.",BMY,0.067727,0.090855,Neutral
"Three Stocks to Watch: $350 or $150 First?, Biotech's Buying Bonanza, and the $1 Billion ""I'm Sorry"" - Money Morning",https://moneymorning.com/2023/12/27/three-stocks-to-watch-350-or-150-first-biotechs-buying-bonanza-and-the-1-billion-im-sorry/,2023-12-27 12:56:21,"Three Stocks to Watch: $350 or $150 First?, Biotech's Buying Bonanza, and the $1 Billion ""I'm Sorry"" Money Morning ...",BMY,0.183895,0.0,Neutral
"Investor Sentiment Improves; Dow Jumps Over 150 Points - Bridgeline Digital  ( NASDAQ:BLIN ) , AstraZeneca  ( NASDAQ:AZN ) ",https://www.benzinga.com/news/earnings/23/12/36393433/investor-sentiment-improves-dow-jumps-over-150-points,2023-12-27 08:28:14,"The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the ""Extreme Greed"" zone on Tuesday. U.S. stocks closed higher on Tuesday, with the S&P 500 moving closer to record levels.",BMY,0.116914,0.240979,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRCL, RYZB, BRBS - Gracell Biotechnologies  ( NASDAQ:GRCL ) , Blue Ridge Bankshares  ( AMEX:BRBS ) ",https://www.benzinga.com/pressreleases/23/12/g36392938/shareholder-investigation-halper-sadeh-llc-investigates-grcl-ryzb-brbs,2023-12-27 01:13:17,"NEW YORK, Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Gracell Biotechnologies Inc.",BMY,0.126784,0.090384,Neutral
"Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight",https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html,2024-01-15 22:05:00,"The dynamics of the heart failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world.",BMY,0.093561,0.092837,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - RYZB, FGH, AMAM, CSTR",https://www.prnewswire.com/news-releases/stockholder-alert-the-ma-class-action-firm-continues-investigating-the-merger--ryzb-fgh-amam-cstr-302033994.html,2024-01-13 01:30:00,"NEW YORK, Jan. 12, 2024 /PRNewswire/ -- , founder and managing partner of the class action firm ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, ...",BMY,0.075635,0.137439,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - GRCL, KRTX, AXNX, HA",https://www.prnewswire.com/news-releases/alert-the-ma-class-action-firm-continues-investigating-the-merger--grcl-krtx-axnx-ha-302033973.html,2024-01-13 01:20:00,"NEW YORK, Jan. 12, 2024 /PRNewswire/ -- , founder and managing partner of the class action firm ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, ...",BMY,0.073773,0.134952,Neutral
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst - Cytokinetics  ( NASDAQ:CYTK ) ,https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar,2024-01-12 19:38:14,"Thursday, Novartis AG NVS decided to step back from pursuing the Cytokinetics Inc CYTK acquisition, dealing a blow to the potential deal with the promising heart drug developer. Analysts estimated Cytokinetics' cardiomyopathy drug sales of up to $3.6 billion by 2032.",BMY,0.240489,0.24173,Somewhat-Bullish
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference,https://www.globenewswire.com/news-release/2024/01/12/2808578/37704/en/CytomX-Therapeutics-to-Present-at-the-B-Riley-Securities-Virtual-Annual-Oncology-Conference.html,2024-01-12 13:00:00,"SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in ...",BMY,0.209365,0.037617,Neutral
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/pressreleases/24/01/g36609305/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-conference,2024-01-12 13:00:00,"SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a fireside ...",BMY,0.188928,0.033129,Neutral
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,2024-01-11 22:01:00,"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates ... PR ...",BMY,0.025139,0.034515,Neutral
"ConcertAI Highlights 2024 Partnerships, Strategy, Business Results, and AI Roadmap at 42nd Annual J.P. Morgan Healthcare Conference",https://www.benzinga.com/pressreleases/24/01/n36600691/concertai-highlights-2024-partnerships-strategy-business-results-and-ai-roadmap-at-42nd-annual-j-p,2024-01-11 20:00:00,"Introduced CARA™, the predictive and generative AI Platform powered by multi-modal Real-World Data, enabling precision oncology, accelerating clinical trials, increasing patient access, driving improved patient outcomes.",BMY,0.040348,0.296265,Somewhat-Bullish
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/24/01/36597401/decoding-bristol-myers-squibbs-options-activity-whats-the-big-picture,2024-01-11 16:31:07,"Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb BMY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",BMY,0.638519,0.212411,Somewhat-Bullish
"Breakthrough Properties Acquires Majority Interest in Callan Ridge, A Newly-Constructed, Fully-Leased Life Science Campus in Torrey Pines",https://www.prnewswire.com/news-releases/breakthrough-properties-acquires-majority-interest-in-callan-ridge-a-newly-constructed-fully-leased-life-science-campus-in-torrey-pines-302031868.html,2024-01-10 21:15:00,"Breakthrough Properties Acquires Majority Interest in Callan Ridge, A Newly-Constructed, Fully-Leased Life Science ... PR ...",BMY,0.12645,0.232769,Somewhat-Bullish
Bullish Continuation in '24? 3 Market Areas to Watch,https://www.zacks.com/commentary/2208464/bullish-continuation-in-24-3-market-areas-to-watch,2024-01-10 18:01:00,Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.,BMY,0.158,0.132347,Neutral
Prothena's  ( PRTA )  Update on Pipeline Progress Disappoints,https://www.zacks.com/stock/news/2208432/prothenas-prta-update-on-pipeline-progress-disappoints,2024-01-10 17:06:00,"Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.",BMY,0.169279,0.106826,Neutral
Prothena  ( PRTA )  Surges 12.3%: Is This an Indication of Further Gains?,https://www.zacks.com/stock/news/2208019/prothena-prta-surges-123-is-this-an-indication-of-further-gains,2024-01-10 10:38:00,Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.,BMY,0.085324,0.075254,Neutral
"SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates WAVD, CSTR, KRTX, BRBS - CapStar Finl Hldgs  ( NASDAQ:CSTR ) , Blue Ridge Bankshares  ( AMEX:BRBS ) ",https://www.benzinga.com/pressreleases/24/01/g36569997/shareholder-rights-investigation-halper-sadeh-llc-investigates-wavd-cstr-krtx-brbs,2024-01-10 02:08:53,"NEW YORK, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: WaveDancer, Inc.",BMY,0.122894,0.089116,Neutral
"SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates RYZB, VIA, CPE, FGH - FG Group Holdings  ( AMEX:FGH ) , Callon Petroleum  ( NYSE:CPE ) ",https://www.benzinga.com/pressreleases/24/01/g36569989/shareholder-rights-investigation-halper-sadeh-llc-investigates-ryzb-via-cpe-fgh,2024-01-10 02:05:51,"NEW YORK, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: RayzeBio, Inc.",BMY,0.10607,0.084268,Neutral
Here's Why Bristol Myers Squibb  ( BMY )  Fell More Than Broader Market,https://www.zacks.com/stock/news/2207811/heres-why-bristol-myers-squibb-bmy-fell-more-than-broader-market,2024-01-09 22:50:17,"Bristol Myers Squibb (BMY) concluded the recent trading session at $51.28, signifying a -0.98% move from its prior day's close.",BMY,0.568435,0.296457,Somewhat-Bullish
"STOCKHOLDER ALERT: Juan Monteverde Encourages the Shareholders of HARP, VIA, RYZB, FGH to Take Action",https://www.benzinga.com/pressreleases/24/01/g36567623/stockholder-alert-juan-monteverde-encourages-the-shareholders-of-harp-via-ryzb-fgh-to-take-action,2024-01-09 22:36:15,"NEW YORK, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",BMY,0.068502,0.121075,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - HA, KRTX, EAR, ICVX",https://www.benzinga.com/pressreleases/24/01/g36567547/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-ha-krtx-ear-icvx,2024-01-09 22:30:42,"NEW YORK, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered ...",BMY,0.068502,0.127176,Neutral
PRISM MarketView Honors National Biotechnology Month with a Spotlight on Emerging Biotech Innovators,https://www.benzinga.com/pressreleases/24/01/g36564507/prism-marketview-honors-national-biotechnology-month-with-a-spotlight-on-emerging-biotech-innovato,2024-01-09 20:02:03,"NEW YORK, Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- In celebration of National Biotechnology Month, PRISM MarketView acknowledges the significant advancements in biotechnology since its establishment by President Clinton in 2000.",BMY,0.064623,0.059348,Neutral
"NeuroTrauma Sciences Appoints William Fricker, CPA, MBA, as Chief Financial Officer",https://www.prnewswire.com/news-releases/neurotrauma-sciences-appoints-william-fricker-cpa-mba-as-chief-financial-officer-302029049.html,2024-01-09 13:30:00,David Lawrence Departs as CFO; Appointed to Board of Directors,BMY,0.082677,0.026635,Neutral
Bristol-Myers CEO talks new acquisitions: 'We are writing the next chapter of this company',https://www.cnbc.com/2024/01/08/bristol-myers-ceo-talks-new-acquisitions-writing-the-next-chapter.html,2024-01-09 00:03:12,Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant's slew of recent acquisitions in a Monday interview with CNBC's Jim Cramer.,BMY,0.249106,-0.043281,Neutral
How To Buy Hot And Promising - But Uncertain - Biotech Stocks,https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/xbi-etf-how-to-buy-hot-and-promising-but-uncertain-biotech-stocks/,2024-01-08 17:34:00,"A mix of choppy or nonexistent earnings alongside the promise of game-changing breakthroughs make biotech stocks a challenge for investors. The SPDR S&P Biotech ETF ( XBI ) , now on the IBD Leaderboard watchlist, offers an alternative to betting on a single biotech name.",BMY,0.166169,0.0,Neutral
"NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO",https://www.globenewswire.com/news-release/2024/01/08/2805449/32418/en/NightHawk-Biosciences-Announces-Planned-Name-Change-to-Scorpius-Holdings-Reflecting-Successful-Transition-to-a-Large-Molecule-Biomanufacturing-CDMO.html,2024-01-08 13:30:00,Announces senior leadership appointments to further support client programs and growing sales pipeline Announces senior leadership appointments to further support client programs and growing sales pipeline ...,BMY,0.031241,0.052023,Neutral
"Regenerative Medicine Market Set to Hit USD 194.9 Billion by 2032, Driven by Robust CAGR of 19.4%",https://www.benzinga.com/pressreleases/24/01/g36531197/regenerative-medicine-market-set-to-hit-usd-194-9-billion-by-2032-driven-by-robust-cagr-of-19-4,2024-01-08 12:35:33,"New York, Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- According to the market.us, the anticipated value of the Global Regenerative Medicine Market is projected to reach approximately USD 194.9 billion by the year 2032, showing a significant increase from USD 41.3 billion recorded in 2023.",BMY,0.020163,0.0,Neutral
3 Magnificent High-Yield Dividend Stocks to Buy in 2024,https://www.fool.com/investing/2024/01/06/3-high-yield-dividend-stocks-to-buy-in-2024/,2024-01-06 12:50:00,There's more than meets the eye with all three of these dividend stocks.,BMY,0.167612,0.041264,Neutral
What You Need to Know Ahead of Bristol-Myers  ( BMY )  Q4 Earnings,https://www.zacks.com/stock/news/2215936/what-you-need-to-know-ahead-of-bristol-myers-bmy-q4-earnings,2024-01-25 15:32:00,"Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.",BMY,0.279471,0.266256,Somewhat-Bullish
Is Bristol Myers Squibb Stock a Buy Now?,https://www.fool.com/investing/2024/01/25/is-bristol-myers-squibb-stock-a-buy-now/,2024-01-25 15:15:00,This healthcare stock has seen healthier days.,BMY,0.120733,0.047986,Neutral
"SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of FGH, KRTX, VIA, PGTI to Take Action",https://www.benzinga.com/pressreleases/24/01/g36770021/shareholder-alert-juan-monteverde-encourages-the-shareholders-of-fgh-krtx-via-pgti-to-take-action,2024-01-24 22:28:15,"NEW YORK, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",BMY,0.067536,0.12703,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - AMAM, CSTR, RYZB, THRX",https://www.benzinga.com/pressreleases/24/01/g36769662/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-amam-cstr-ryzb-thrx,2024-01-24 22:16:58,"NEW YORK, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",BMY,0.068502,0.121075,Neutral
"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight",https://www.prnewswire.com/news-releases/drug-eluting-balloons-global-market-is-expected-to-expand-at-a-healthy-growth-rate-of-8-by-2028-predicts-delveinsight-302042856.html,2024-01-24 22:01:00,"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts ... PR ...",BMY,0.025985,0.033663,Neutral
"Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of ""Risks Of Secondary Cancer' - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/24/01/36760938/gileads-tecartus-dropped-from-fda-list-of-car-t-therapy-with-updated-label-warning-of-risks-of-se,2024-01-24 15:36:09,"Tuesday, the FDA announced to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.",BMY,0.240489,0.0,Neutral
"Immunotherapy Drugs Market Size Anticipated to Surge to USD 237.4 billion at 7.1% CAGR by 2031 - Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/01/g36754138/immunotherapy-drugs-market-size-anticipated-to-surge-to-usd-237-4-billion-at-7-1-cagr-by-2031-tran,2024-01-24 11:14:00,"Wilmington, Delaware, United States, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global immunotherapy drugs market is estimated to flourish at a CAGR of 7.1% from 2023 to 2031.",BMY,0.03399,0.0,Neutral
"Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028, Assesses DelveInsight",https://www.prnewswire.com/news-releases/implantable-drug-delivery-devices-global-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2028-assesses-delveinsight-302041477.html,2024-01-23 22:31:00,Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028 ... PR ...,BMY,0.027103,0.027657,Neutral
"Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study - Exelixis  ( NASDAQ:EXEL ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/24/01/36741223/bristol-myers-exelixis-reveal-4-year-follow-up-results-from-cancer-treatment-study,2024-01-23 16:11:15,Bristol Myers Squibb & Co BMY and Exelixis Inc EXEL revealed four-year follow-up results from a cancer study that compared one treatment with another from Pfizer Inc PFE.,BMY,0.238913,0.0,Neutral
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/24/01/36736105/bristol-myers-squibbs-combo-therapy-shows-sustained-benefits-over-pfizers-cancer-drug-in-kidney-c,2024-01-23 13:23:15,Bristol Myers Squibb & Co BMY announced that Opdivo ( nivolumab ) plus Yervoy ( ipilimumab ) combination continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial.,BMY,0.288893,0.188095,Somewhat-Bullish
"Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment - Johnson & Johnson  ( NYSE:JNJ ) , Novartis  ( NYSE:NVS ) , Gilead Sciences  ( NASDAQ:GILD ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-,2024-01-23 13:19:18,"In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies. In its January 19 notification letters, the agency stressed that the potential risk applies to all ...",BMY,0.175859,0.007437,Neutral
Lantheus Announces CEO Succession Plan,https://www.globenewswire.com/news-release/2024/01/23/2814006/0/en/Lantheus-Announces-CEO-Succession-Plan.html,2024-01-23 12:45:00,"Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March ...",BMY,0.034233,0.074769,Neutral
Lantheus Announces CEO Succession Plan - Lantheus Holdings  ( NASDAQ:LNTH ) ,https://www.benzinga.com/pressreleases/24/01/g36735003/lantheus-announces-ceo-succession-plan,2024-01-23 12:45:00,"Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and Become Chair of the Board of Directors",BMY,0.032513,0.074195,Neutral
Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies,https://www.prnewswire.com/news-releases/accent-therapeutics-announces-75-million-series-c-financing-to-advance-small-molecule-precision-cancer-therapies-302041338.html,2024-01-23 11:00:00,"Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors Funds will support advancement of lead programs through early clinical development, including Accent's first-in-class DHX9 inhibitor and newly unveiled, potentially best-in-class KIF18A ...",BMY,0.039418,0.045323,Neutral
Bristol Myers Squibb  ( BMY )  Stock Drops Despite Market Gains: Important Facts to Note,https://www.zacks.com/stock/news/2213791/bristol-myers-squibb-bmy-stock-drops-despite-market-gains-important-facts-to-note,2024-01-22 22:50:18,"The latest trading day saw Bristol Myers Squibb (BMY) settling at $49.57, representing a -1.08% change from its previous close.",BMY,0.551622,0.239405,Somewhat-Bullish
"Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer",https://www.prnewswire.com/news-releases/non-alcoholic-fatty-liver-disease-market-to-observe-impressive-growth-by-2032-evaluates-delveinsight--key-companies---medicinova-eli-lilly-and-company-astrazeneca-madrigal-pharmaceuticals-biomarin-pharmaceutical-glaxosmithk-302040349.html,2024-01-22 22:01:00,"Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key ... PR ...",BMY,0.043381,0.059524,Neutral
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024,https://www.globenewswire.com/news-release/2024/01/22/2813509/0/en/Latest-Phase-III-trial-data-investigating-Cabometyx-in-combination-with-immunotherapy-to-be-presented-at-ASCO-GU-2024.html,2024-01-22 22:00:00,"PARIS, FRANCE, 22 January 2024 - Ipsen ( Euronext: IPN. ADR: IPSEY ) announced today new data to be presented for Cabometyx® ( cabozantinib ) in combination with immunotherapy across indications at the upcoming American Society of Clinical Oncology Genitourinary Symposium ( ASCO GU ) taking place ...",BMY,0.015851,-0.016885,Neutral
"SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates KRTX, TAST, ROVR - Karuna Therapeutics  ( NASDAQ:KRTX ) , Rover Group  ( NASDAQ:ROVR ) ",https://www.benzinga.com/pressreleases/24/01/g36718320/shareholder-notice-halper-sadeh-llc-investigates-krtx-tast-rovr,2024-01-22 15:49:36,"NEW YORK, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Karuna Therapeutics, Inc.",BMY,0.154455,0.100645,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc.  ( Nasdaq - KRTX ) , Carrols Restaurant Group, Inc.  ( Nasdaq - TAST ) , Ansys, Inc.  ( Nasdaq - ANSS ) , HomeStreet, Inc.  ( Nasdaq - HMST )  - Restaurant Brands Intl  ( NYSE:QSR ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/24/01/g36717789/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-karuna-therap,2024-01-22 15:20:28,"BALA CYNWYD, Pa., Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BMY,0.228431,0.215988,Somewhat-Bullish
ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer,https://www.prnewswire.com/news-releases/immunobrain-checkpoint-appoints-dr-sanjay-keswani-as-chief-executive-officer-302039635.html,2024-01-22 13:00:00,"NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. ( ImmunoBrain ) , a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as ...",BMY,0.065685,0.085332,Neutral
Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/24/01/36713260/bristol-myers-lead-cancer-immunotherapy-shows-progression-free-survival-versus-chemo-in-certain-t,2024-01-22 12:07:00,"Saturday, Bristol-Myers Squibb Company BMY released results from the Phase 3 CheckMate -8HW trial evaluating Opdivo ( nivolumab ) plus Yervoy ( ipilimumab ) compared to the investigator's choice of chemotherapy ( mFOLFOX-6 or FOLFIRI with or without bevacizumab or cetuximab ) as a first-line ...",BMY,0.297061,-0.142304,Neutral
"USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... - PR Newswire",https://www.prnewswire.com/news-releases/usd-10-40-billion-growth-in-vascular-endothelial-market-between-2022-and-2027--the-strategic-alliances-and-collaborations-are-notably-driving-market-growth-17-000-technavio-research-reports-302039609.html,2024-01-22 04:35:00,"USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... PR ...",BMY,0.049939,0.083583,Neutral
Could Editas Medicine Become the Next CRISPR Therapeutics?,https://www.fool.com/investing/2024/01/21/could-editas-medicine-become-the-next-crispr/,2024-01-21 14:37:00,"The similarities between the pair are striking, but it might not be enough.",BMY,0.047654,0.080991,Neutral
"SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - RYZB, THRX, AMAM, CSTR",https://www.benzinga.com/pressreleases/24/01/g36704959/shareholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-ryzb-thrx-amam-cstr,2024-01-20 01:00:00,"NEW YORK, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",BMY,0.068502,0.121075,Neutral
"ALERT: Juan Monteverde Encourages the Shareholders of VIA, PGTI, FGH, KRTX to Take Action",https://www.benzinga.com/pressreleases/24/01/g36704956/alert-juan-monteverde-encourages-the-shareholders-of-via-pgti-fgh-krtx-to-take-action,2024-01-20 01:00:00,"NEW YORK, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and ...",BMY,0.067536,0.12703,Neutral
Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes - Ikena Oncology  ( NASDAQ:IKNA ) ,https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36700913/ikena-oncology-refocuses-on-key-programs-analysts-maintain-outperform-ratings-amid-,2024-01-19 19:55:45,"Thursday, Ikena Oncology Inc IKNA announced an organizational streamlining to reallocate resources from exploratory research and discovery towards the ongoing targeted oncology clinical programs. The company says it is laser-focused on IK-930 and IK-595:",BMY,0.229149,-0.380174,Bearish
"Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering? - Eli Lilly  ( NYSE:LLY ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/markets/equities/24/01/36682926/inflation-busting-price-hikes-for-ozempic-mounjaro-and-others-are-drugmakers-profiteering,2024-01-18 17:48:42,"Diabetes treatments such as Ozempic and Mounjaro became the blockbuster drugs of 2023 thanks to their popularity as weight-loss remedies. Prices for a month's supply of these drugs were high then, and in 2024 their manufacturers have raised them higher still.",BMY,0.196877,0.190828,Somewhat-Bullish
Nivolumab Market Overview 2024-2028: Global Expansion Driven By Immunotherapy Advancements And Rising Cancer Incidence As Per The Business Research Company's Nivolumab Global Market Report 2024,https://www.benzinga.com/pressreleases/24/01/g36681451/nivolumab-market-overview-2024-2028-global-expansion-driven-by-immunotherapy-advancements-and-risi,2024-01-18 16:30:00,"LONDON, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Nivolumab Global Market Report 2024, nivolumab market has experienced remarkable growth in recent years and is set to continue its upward trajectory, with the market size projected to reach $1.69 billion in 2024, ...",BMY,0.061315,0.115659,Neutral
2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter,https://www.kiplinger.com/business/a-good-year-for-the-pharma-industry-the-kiplinger-letter,2024-01-18 13:30:15,2024: The Pharma Industry's Good Year Kiplinger's Personal Finance ...,BMY,0.099066,0.066677,Neutral
Catheter Associated Urinary Tract Infections Treatment Market Surges with a Promising CAGR of 4.0% through 2033 | Persistence Market Research,https://www.benzinga.com/pressreleases/24/01/g36673659/catheter-associated-urinary-tract-infections-treatment-market-surges-with-a-promising-cagr-of-4-0-,2024-01-18 10:15:00,"New York, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global market for treating catheter-associated urinary tract infections ( CAUTIs ) is projected to grow at a compound annual growth rate ( CAGR ) of 4.0%.",BMY,0.044359,0.123953,Neutral
"Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3%| Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/01/g36658710/protein-therapeutics-market-size-to-be-worth-usd-549-4-billion-by-2031-at-a-cagr-of-6-3-transparen,2024-01-17 13:30:00,"Wilmington, Delaware, United States, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The protein therapeutics market was valued at US$ 318.4 billion in 2022. A CAGR of 6.3% is predicted from 2023 to 2031, reaching more than US$ 549.4 billion by 2031.",BMY,0.067919,-0.075761,Neutral
"Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T  ( Treg )  and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases",https://www.prnewswire.com/news-releases/tr1x-inc-announces-75-million-series-a-financing-to-develop-best-in-class-universal-allogeneic-regulatory-t-treg-and-car-treg-cell-therapies-to-treat-and-potentially-cure-autoimmune-and-inflammatory-diseases-302036679.html,2024-01-17 13:30:00,"Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T ( Treg ... PR ...",BMY,0.044386,0.043125,Neutral
"Cell Therapy Market Global Surge to Over USD 26.8 Billion by 2033, Fueled by Growing Demand in United States",https://www.benzinga.com/pressreleases/24/01/g36658512/cell-therapy-market-global-surge-to-over-usd-26-8-billion-by-2033-fueled-by-growing-demand-in-unit,2024-01-17 13:21:47,"New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- According to Market.us, the global Cell Therapy Market size is forecasted to exceed USD 26.8 Billion by 2033, with a promising CAGR of 16.9% from 2024 to 2033.",BMY,0.037593,0.071135,Neutral
Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment,https://www.prnewswire.com/news-releases/ratio-therapeutics-announces-50m-series-b-financing-to-advance-targeted-radiotherapies-for-cancer-treatment-302036375.html,2024-01-17 13:00:00,Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90 Million Since 2021 Launch,BMY,0.062434,0.054081,Neutral
"SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates PGTI, KRTX, THRX, GRCL - Gracell Biotechnologies  ( NASDAQ:GRCL ) , Karuna Therapeutics  ( NASDAQ:KRTX ) ",https://www.benzinga.com/pressreleases/24/01/g36653979/shareholder-rights-investigation-halper-sadeh-llc-investigates-pgti-krtx-thrx-grcl,2024-01-17 05:00:00,"NEW YORK, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc.",BMY,0.112532,0.086,Neutral
"SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates BRBS, RYZB, VIA, CPE - Callon Petroleum  ( NYSE:CPE ) , Blue Ridge Bankshares  ( AMEX:BRBS ) ",https://www.benzinga.com/pressreleases/24/01/g36653977/shareholder-rights-investigation-halper-sadeh-llc-investigates-brbs-ryzb-via-cpe,2024-01-17 05:00:00,"NEW YORK, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Blue Ridge Bankshares, Inc.",BMY,0.112008,0.085853,Neutral
Bristol Myers Squibb  ( BMY )  Sees a More Significant Dip Than Broader Market: Some Facts to Know,https://www.zacks.com/stock/news/2211098/bristol-myers-squibb-bmy-sees-a-more-significant-dip-than-broader-market-some-facts-to-know,2024-01-16 22:50:17,"Bristol Myers Squibb (BMY) closed at $50 in the latest trading session, marking a -0.62% move from the prior day.",BMY,0.479683,0.098198,Neutral
Behind the Scenes of Bristol-Myers Squibb's Latest Options Trends - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/markets/options/24/01/36648552/behind-the-scenes-of-bristol-myers-squibbs-latest-options-trends,2024-01-16 19:30:57,"Whales with a lot of money to spend have taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 23 trades. If we consider the specifics of each trade, it is accurate to state that 78% of the investors opened trades with ...",BMY,0.64962,0.1345,Neutral
"3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street",https://www.fool.com/investing/2024/01/16/3-incredible-growth-stocks-that-could-soar-in-2024/,2024-01-16 14:00:00,Analysts have high hopes for these three innovation companies in 2024.,BMY,0.058047,-0.027038,Neutral
"Financial Relief For Medicare Patients: Part D Overhaul Caps Out-of-Pocket Drug Cost Limits - Pfizer  ( NYSE:PFE ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/24/01/36641146/financial-relief-for-medicare-patients-part-d-overhaul-caps-out-of-pocket-drug-cost-limits,2024-01-16 13:54:55,Medicare Part D beneficiaries facing rising drug costs received welcome news as changes brought about by the 2022 Inflation Reduction Act cap their out-of-pocket expenses in 2024.,BMY,0.218817,-0.117393,Neutral
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization,https://www.globenewswire.com/news-release/2024/01/16/2809721/0/en/HOOKIPA-Pharma-Appoints-Mark-Winderlich-as-Chief-Development-Officer-to-Lead-Clinical-Research-and-Development-Organization.html,2024-01-16 12:01:00,"NEW YORK and VIENNA, Austria, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Mark Winderlich, PhD, as Chief Development ...",BMY,0.042421,0.022639,Neutral
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization - HOOKIPA Pharma  ( NASDAQ:HOOK ) ,https://www.benzinga.com/pressreleases/24/01/g36637094/hookipa-pharma-appoints-mark-winderlich-as-chief-development-officer-to-lead-clinical-research-and,2024-01-16 12:01:00,"NEW YORK and VIENNA, Austria, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. HOOK 'HOOKIPA' ) ) ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Mark Winderlich, PhD, as Chief Development Officer, ...",BMY,0.041755,0.021612,Neutral
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD- ( L ) 1 Cancer Immunotherapy for Multiple Cancer Types,https://www.prnewswire.com/news-releases/halozyme-announces-roche-receives-european-commission-approval-of-tecentriq-sc-with-enhanze-representing-the-eus-first-subcutaneous-pd-l1-cancer-immunotherapy-for-multiple-cancer-types-302035190.html,2024-01-16 06:15:00,Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE ... PR ...,BMY,0.034984,0.080944,Neutral
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024,https://www.globenewswire.com/news-release/2024/01/16/2809492/0/en/Ultimovacs-Updates-Timeline-for-Reporting-on-Randomized-UV1-Phase-II-Trial-INITIUM-in-Malignant-Melanoma-Topline-Results-expected-in-March-2024.html,2024-01-16 06:00:00,"• Study protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, or after 70 patients have progressed or died. • As of today, the 70 events have not yet occurred, but the 18-month follow-up for the last patient has now been reached.",BMY,0.027134,-0.013297,Neutral
Bristol Myers Squibb  ( BMY )  Q4 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2024/02/02/bristol-myers-squibb-bmy-q4-2023-earnings-call-tra/,2024-02-02 20:00:20,"BMY earnings call for the period ending December 31, 2023.",BMY,0.004294,0.149585,Neutral
"Bristol-Myers  ( BMY )  Q4 Earnings & Sales Beat, Stock Gains",https://www.zacks.com/stock/news/2220491/bristol-myers-bmy-q4-earnings-sales-beat-stock-gains,2024-02-02 17:40:00,Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.,BMY,0.339978,0.345425,Somewhat-Bullish
"INVESTIGATION ALERT: Halper Sadeh LLC Investigates DSKE, RYZB, GRPH, ROVR - Graphite Bio  ( NASDAQ:GRPH ) , Daseke  ( NASDAQ:DSKE ) ",https://www.benzinga.com/pressreleases/24/02/g36913809/investigation-alert-halper-sadeh-llc-investigates-dske-ryzb-grph-rovr,2024-02-02 17:26:45,"NEW YORK, Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Daseke, Inc.",BMY,0.135347,0.093342,Neutral
"Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review",https://www.investors.com/news/stock-market-handles-huge-earnings-week-fed-powell-jobs-report-weekly-review/,2024-02-02 17:15:00,"Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review Investor's Business Daily ...",BMY,0.033236,-0.133526,Neutral
"Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm - Graphite Bio  ( NASDAQ:GRPH ) , Daseke  ( NASDAQ:DSKE ) ",https://www.benzinga.com/pressreleases/24/02/g36913256/kuehn-law-encourages-dske-ryzb-rovr-and-grph-investors-to-contact-law-firm,2024-02-02 16:58:22,"NEW YORK, Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",BMY,0.113597,0.302162,Somewhat-Bullish
What's Going On With US Pharma Giant Bristol-Myers Squibb Stock Today? - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/24/02/36910514/whats-going-on-with-us-pharma-giant-bristol-myers-squibb-stock-today,2024-02-02 14:48:49,"Bristol-Myers Squibb Company BMY said that its fourth-quarter revenues were $11.48 billion, up 1% Y/Y, beating the consensus of $11.19 billion, primarily due to higher sales of new product portfolio, as well as Eliquis and Opdivo, partially offset by lower sales of Revlimid.",BMY,0.699089,0.103617,Neutral
Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat,https://www.investors.com/news/technology/bmy-stock-bristol-myers-squibb-earnings-q4-2023/,2024-02-02 13:03:00,BMY Stock Gains On Fourth-Quarter Earnings Beat Investor's Business Daily ...,BMY,0.71032,0.349902,Somewhat-Bullish
"Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/24/02/36907360/nasdaq-futures-climb-as-meta-amazon-gains-offset-apple-slide-analyst-points-to-2-factors-reinforcin,2024-02-02 12:24:06,"Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. META, Amazon, Inc. AMZN, and Apple, Inc. AAPL. Earnings remain mixed, raising concerns about both the economy and corporate profit growth.",BMY,0.117486,0.0,Neutral
Bristol Myers Squibb results top expectations as newer drugs help fuel growth,https://www.marketwatch.com/story/bristol-myers-squibb-results-top-expectations-as-newer-drugs-help-fuel-growth-d8978299,2024-02-02 12:01:00,"Bristol Myers Squibb on Friday reported fourth-quarter results that beat analysts' expectations, helped by portfolio stalwarts as well as newer drugs.",BMY,0.366061,0.049788,Neutral
Bristol Myers Squibb results top estimates as new drugs post strong sales growth,https://www.cnbc.com/2024/02/02/bristol-myers-squibb-bmy-q4-earnings-report-2023.html,2024-02-02 11:59:57,"Bristol Myers Squibb also issued its full-year 2024 forecast, which was generally in line with expectations.",BMY,0.077845,0.241164,Somewhat-Bullish
The best trades of the last 50 years show what investors should do now,https://www.marketwatch.com/story/the-best-trades-of-the-last-50-years-show-what-investors-should-do-now-58773bf0,2024-02-02 11:24:00,"Yet again, big tech is lifting the market. A danger for investors is thinking this will always be so.",BMY,0.062843,0.0,Neutral
"Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/news/earnings/24/02/36904384/investor-optimism-improves-following-earnings-economic-reports-dow-jumps-over-350-points,2024-02-02 08:26:05,"The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the ""Greed"" zone on Thursday. U.S. stocks closed higher on Thursday, with the Dow Jones index gaining more than 350 points during the session.",BMY,0.186738,0.0,Neutral
"Amazon, Apple And 3 Stocks To Watch Heading Into Friday - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/news/earnings/24/02/36904348/amazon-apple-and-3-stocks-to-watch-heading-into-friday,2024-02-02 08:20:35,"With U.S. stock futures trading mostly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Exxon Mobil Corporation XOM to report quarterly earnings at $2.21 per share on revenue of $85.23 billion before the opening bell, ...",BMY,0.401331,0.293662,Somewhat-Bullish
Purple Biotech Reaches Recommended Phase 2 Dose for NT219,https://www.globenewswire.com/news-release/2024/02/01/2821889/0/en/Purple-Biotech-Reaches-Recommended-Phase-2-Dose-for-NT219.html,2024-02-01 12:30:00,"REHOVOT, Israel, Feb. 01, 2024 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( ""Purple Biotech"" or ""the Company"" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug ...",BMY,0.027828,0.056682,Neutral
Medicare drug price negotiations begin after Biden administration makes initial offers | Politics,https://www.cnn.com/2024/02/01/politics/medicare-drug-price-negotiations-initial-offers/index.html,2024-02-01 11:06:00,Medicare drug price negotiations start after Biden administration makes initial offers ...,BMY,0.063763,-0.042288,Neutral
Bristol Myers'  ( BMY )  sBLAs for Breyanzi Get FDA Priority Tag,https://www.zacks.com/stock/news/2218934/bristol-myers-bmy-sblas-for-breyanzi-get-fda-priority-tag,2024-01-31 16:50:00,Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.,BMY,0.100308,0.056626,Neutral
Completion of First Triage Test Clinical Validation Study - Investing News Network,https://investingnews.com/cov-december-2023-quarterly-activities-report/,2024-01-31 10:52:30,Completion of First Triage Test Clinical Validation Study Investing News Network ...,BMY,0.24289,0.089308,Neutral
"Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat",https://www.cnbc.com/2024/01/30/healthy-returns-jj-merck-and-bristol-myers-squibb-in-the-hot-seat.html,2024-01-30 18:52:54,"J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.",BMY,0.15347,-0.00411,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc.  ( Nasdaq - AVRO ) , California BanCorp  ( Nasdaq - CALB ) , Exro Technologies Inc.  ( OTC - EXROF ) , Karuna Therapeutics, Inc.  ( Nasdaq - KRTX )  - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/24/01/g36849187/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-avrobio-inc-n,2024-01-30 16:13:26,"BALA CYNWYD, Pa., Jan. 30, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BMY,0.206392,0.199954,Somewhat-Bullish
Amgen  ( AMGN )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release,https://www.zacks.com/stock/news/2218010/amgen-amgn-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release,2024-01-30 15:00:49,Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.087663,0.038054,Neutral
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers  ( BMY )  Q4 Earnings,https://www.zacks.com/stock/news/2217812/wall-streets-insights-into-key-metrics-ahead-of-bristol-myers-bmy-q4-earnings,2024-01-30 14:15:24,"Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Bristol Myers (BMY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.",BMY,0.131643,0.01577,Neutral
"Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts? - CVS Health  ( NYSE:CVS ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/news/24/01/36842103/did-you-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-most-accu,2024-01-30 12:49:37,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",BMY,0.102013,0.092927,Neutral
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures,https://www.benzinga.com/pressreleases/24/01/g36839828/cour-pharmaceuticals-secures-105-million-in-series-a-financing-co-led-by-lumira-ventures-and-alpha,2024-01-30 11:00:00,"Funds will be used to support the advancement of COUR's Myasthenia Gravis ( MG ) and Type 1 Diabetes ( T1D ) product candidates into Phase 2a clinical trials Participating investors include Roche Venture Fund, Pfizer, Bristol Myers Squibb, Angelini Ventures, and JDRF T1D Fund",BMY,0.10607,0.123417,Neutral
Bristol Myers Squibb  ( BMY )  Increases Yet Falls Behind Market: What Investors Need to Know,https://www.zacks.com/stock/news/2217453/bristol-myers-squibb-bmy-increases-yet-falls-behind-market-what-investors-need-to-know,2024-01-29 22:45:18,"In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $49.87, denoting a +0.34% change from the preceding trading day.",BMY,0.543535,0.299988,Somewhat-Bullish
"Kuehn Law Encourages SNCE, MGRC, VINE, and KRTX Investors to Contact Law Firm - Karuna Therapeutics  ( NASDAQ:KRTX ) , McGrath RentCorp  ( NASDAQ:MGRC ) ",https://www.benzinga.com/pressreleases/24/01/g36829389/kuehn-law-encourages-snce-mgrc-vine-and-krtx-investors-to-contact-law-firm,2024-01-29 17:22:36,"NEW YORK, Jan. 29, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",BMY,0.100308,0.331245,Somewhat-Bullish
"At 3.7% CAGR, Global Carboprost Tromethamine Market Size Value to be Worth USD 2,100.63 Million By 2032: Polaris Market Research",https://www.prnewswire.com/news-releases/at-3-7-cagr-global-carboprost-tromethamine-market-size-value-to-be-worth-usd-2-100-63-million-by-2032-polaris-market-research-302046762.html,2024-01-29 15:30:00,"At 3.7% CAGR, Global Carboprost Tromethamine Market Size Value to be Worth USD 2,100.63 Million By 2032 ... PR ...",BMY,0.027319,0.0,Neutral
"Corcept Appoints Roberto Vieira as President, Oncology - Corcept Therapeutics  ( NASDAQ:CORT ) ",https://www.benzinga.com/pressreleases/24/01/g36822717/corcept-appoints-roberto-vieira-as-president-oncology,2024-01-29 13:00:00,"MENLO PARK, Calif., Jan. 29, 2024 ( GLOBE NEWSWIRE ) -- Corcept Therapeutics Incorporated CORT, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the ...",BMY,0.06697,-0.030343,Neutral
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients - Bristol-Myers Squibb  ( NYSE:BMY ) ,https://www.benzinga.com/general/biotech/24/01/36822522/bristol-myers-lead-cancer-drug-opdivo-formulated-as-under-skin-injection-at-par-with-intravenous-,2024-01-29 12:43:34,"Saturday, Bristol Myers Squibb & Co BMY released the first disclosure of data from the Phase 3 CheckMate -67T trial of the subcutaneous formulation of Opdivo ( nivolumab ) compared to intravenous ( IV ) Opdivo in advanced or metastatic clear cell renal cell carcinoma ( ccRCC ) who have received ...",BMY,0.431065,0.289561,Somewhat-Bullish
"Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? - SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/24/01/36820476/tech-titans-microsoft-apple-lead-magnificent-seven-earnings-wave-this-week-can-mega-caps-ignite-mar,2024-01-29 10:51:00,"The past week's earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that would see the release of a slew of tech earnings reports. The Week That Was: Tesla, Inc. TSLA, Intel, Inc. INTC, and Texas Instruments, Inc.",BMY,0.086713,0.0,Neutral
"SoFi, iRobot, Tesla, Archer Daniels, McGrath RentCorp, ZoomInfo, and More Stock Market Movers",https://www.barrons.com/amp/articles/stock-market-movers-149f2d69,2024-01-29 09:24:00,"Boeing, Evergrande, SoFi, Microsoft, Apple, and More Stock Market Movers ...",BMY,0.06211,0.0,Neutral
"Big Tech, Boeing, and More Stocks to Watch",https://www.barrons.com/amp/articles/stocks-to-watch-apple-meta-microsoft-fed-meeting-jobs-report-8313983c,2024-01-28 19:00:00,"Apple, Meta, Amazon, Microsoft, Boeing, and More Stocks to Watch This Week ...",BMY,0.06697,0.052084,Neutral
"Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs",https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html,2024-01-28 13:00:01,Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.,BMY,0.085553,0.030376,Neutral
"RAYZEBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB",https://www.prnewswire.com/news-releases/rayzebio-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-rayzebio-inc---ryzb-302046059.html,2024-01-27 03:03:00,"RAYZEBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC ... PR ...",BMY,0.417995,0.186106,Somewhat-Bullish
"KARUNA THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX",https://www.prnewswire.com/news-releases/karuna-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-karuna-therapeutics-inc---krtx-302046043.html,2024-01-27 01:34:00,KARUNA THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick ... PR ...,BMY,0.447528,0.19486,Somewhat-Bullish
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc.  ( Nasdaq - KRTX ) , Carrols Restaurant Group, Inc.  ( Nasdaq - TAST ) , Ansys, Inc.  ( Nasdaq - ANSS ) , HomeStreet, Inc.  ( Nasdaq - HMST )  - Restaurant Brands Intl  ( NYSE:QSR ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/pressreleases/24/01/g36810687/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-karuna-therap,2024-01-26 21:49:23,"BALA CYNWYD, Pa., Jan. 26, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",BMY,0.228431,0.215988,Somewhat-Bullish
"Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices",https://www.cnbc.com/2024/01/26/merck-jj-ceos-agree-to-testify-in-senate-hearing-on-drug-prices-.html,2024-01-26 21:17:09,"The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.",BMY,0.085022,0.126295,Neutral
Analysts Estimate Bristol Myers Squibb  ( BMY )  to Report a Decline in Earnings: What to Look Out for,https://www.zacks.com/stock/news/2216537/analysts-estimate-bristol-myers-squibb-bmy-to-report-a-decline-in-earnings-what-to-look-out-for,2024-01-26 15:00:19,Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,BMY,0.088147,-0.001054,Neutral
"Urinary Tract Infections  ( UTI )  Treatment Market Projection US$ 13.7 Billion by 2030 with a 5.5% CAGR, Persistence Market Research",https://www.benzinga.com/pressreleases/24/01/g36796399/urinary-tract-infections-uti-treatment-market-projection-us-13-7-billion-by-2030-with-a-5-5-cagr-p,2024-01-26 08:31:44,"New York, Jan. 26, 2024 ( GLOBE NEWSWIRE ) -- The effective management of Urinary Tract Infections ( UTIs ) is crucial in healthcare, targeting bacterial infections affecting the entire urinary system, including the bladder, kidneys, ureters, and urethra.",BMY,0.029691,0.157375,Somewhat-Bullish
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and ... - PR Newswire,https://www.prnewswire.com/news-releases/ctla4-cytotoxic-t-lymphocyte-associated-protein-4-inhibitors-market-to-grow-by-usd-2-23-billion-between-2023-and-2028--growth-driven-by-high-target-affinity-and-specificity-of-ctla4-inhibitors---technavio-302044103.html,2024-01-26 01:15:00,CTLA4 ( Cytotoxic T-Lymphocyte-Associated Protein 4 ) Inhibitors Market to grow by USD 2.23 billion between 2023 and ... PR ...,BMY,0.085782,-0.012559,Neutral
